0001136261-12-000441.txt : 20120810 0001136261-12-000441.hdr.sgml : 20120810 20120810143610 ACCESSION NUMBER: 0001136261-12-000441 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120810 DATE AS OF CHANGE: 20120810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tiger X Medical, Inc. CENTRAL INDEX KEY: 0000925741 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 232753988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21419 FILM NUMBER: 121024144 BUSINESS ADDRESS: STREET 1: 10900 WILSHIRE BOULEVARD, SUITE #1500 CITY: LOS ANGELES STATE: CA ZIP: 90024 BUSINESS PHONE: (310) 987-7345 MAIL ADDRESS: STREET 1: 10900 WILSHIRE BOULEVARD, SUITE #1500 CITY: LOS ANGELES STATE: CA ZIP: 90024 FORMER COMPANY: FORMER CONFORMED NAME: Cardo Medical, Inc. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: CLICKNSETTLE COM INC DATE OF NAME CHANGE: 20000823 FORMER COMPANY: FORMER CONFORMED NAME: NAM CORP DATE OF NAME CHANGE: 19960802 10-Q 1 form10q.htm 10-Q Q2 2012 DOC

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

OR

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to _________

Commission file number: 0-21419

Tiger X Medical, Inc.
(Exact name of Registrant as Specified in its Charter)

 
Delaware
23-2753988
  (State or Other Jurisdiction of Incorporation or Organization) 
(I.R.S. Employer Identification Number)

10900 Wilshire Blvd, Suite #1500
Los Angeles, CA    90024
(Address of Principal Executive Offices including Zip Code)

(310) 987-7345
(Registrant's Telephone Number, Including Area Code)

          N/A          
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days.
YES    x        NO    ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     YES  x     NO  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer    ¨

Accelerated filer    ¨

Non-accelerated filer    ¨
(Do not check if a smaller reporting company)

Smaller reporting company    x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES    ¨        NO    x

As of August 10, 2012, 230,293,141 shares of the issuer's common stock, par value of $0.001 per share, were outstanding.

TIGER X MEDICAL, INC.

Table of Contents

Page

PART I — FINANCIAL INFORMATION

1

Item 1.

Financial Statements

1

 

 

Condensed Consolidated Balance Sheets at June 30, 2012 (Unaudited) and December 31, 2011

1

Condensed Consolidated Statements of Operations (Unaudited) — Three and Six Months Ended June 30, 2012 and 2011

2

 

 

Condensed Consolidated Statements of Cash Flows (Unaudited) — Six Months Ended June 30, 2012 and 2011

3

Notes to Condensed Consolidated Financial Statements (Unaudited)

4

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

8

Item 3.

Quantitative and Qualitative Dosclosures About Market Risk

12

Item 4.

Controls and Procedures

13

PART II — OTHER INFORMATION

13

Item 1.

Legal Proceedings

13

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

13

Item 3.

Defaults upon Senior Securities

13

Item 4.

Mine Safety Disclosures

13

Item 5.

Other Information

13

Item 6.

Exhibits

14

Signatures

15

Exhibit Index

 

i

PART I — FINANCIAL INFORMATION

ITEM 1 — CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

TIGER X MEDICAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
      June 30,     December 31,
      2012     2011
      (Unaudited)      
Assets
             
Current assets            
     Cash and cash equivalents   $ 12,884    $ 12,678 
     Restricted cash     -      900 
     Accounts receivable, net of allowance for doubtful accounts of $250 and $278, respectively     24      67 
     Prepaid expenses and other current assets     32      89 
          Total assets   $ 12,940    $ 13,734 
             
Liabilities and Stockholders' Equity
             
Current liabilities            
     Accounts payable and accrued expenses   $ 142    $ 756 
          Total liabilities     142      756 
             
Stockholders' equity            
     Common stock, $0.001 par value, 750,000,000 shares authorized,            
          230,293,141 issued and outstanding as of June 30, 2012 (unaudited)            
          and December 31, 2011     230      230 
     Additional paid-in capital     25,814      25,810 
     Note receivable from stockholder     (50)     (50)
     Accumulated deficit     (13,196)     (13,012)
          Total stockholders' equity     12,798      12,978 
          Total liabilities and stockholders' equity    $ 12,940    $ 13,734 

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

TIGER X MEDICAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share amounts)
(Unaudited)

      Three Months Ended     Six Months Ended
      June 30,     June 30,
      2012     2011     2012     2011
                         
                       
Revenue   $ 17    $ -     $ 28    $ -  
Cost of revenue     -       -       -       -  
Gross profit     17      -       28      -  
General and administrative expenses     149      249      218      350 
Loss from operations     (132)     (249)     (190)     (350)
Interest income (expense), net     3      2      6      (22)
Loss from continuing operations before income tax provision     (129)     (247)     (184)     (372)
Provision for income taxes     -      -      -      - 
Loss from continuing operations     (129)     (247)     (184)     (372)
Discontinued operations (Note 1)                        
Gain from sale of discontinued Reconstructive and Spine Divisions, net of income taxes     -       12,253      -      12,253 
Loss from operations of discontinued Reconstructive and Spine Divisions, net of income taxes     -      (1,170)     -      (1,366)
Net income (loss)   $ (129)   $ 10,836    $ (184)   $ 10,515 
                         
Net income (loss) per share:                        
Basic and diluted                        
     Continuing operations   $ -     $ -     $ -     $ -  
     Discontinued operations   $ -     $ 0.05    $ -     $ 0.05 
     Total   $ -     $ 0.05    $ -     $ 0.05 
                         
Weighted average shares outstanding:                        
Basic and diluted     230,293,141      230,293,141      230,293,141      230,293,141 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

TIGER X MEDICAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

    Six Months Ended
    June 30,
    2012   2011
           
Cash flows from operating activities            
     Net income (loss)   $ (184)   $ 10,515 
     Adjustments to reconcile net loss to net cash used in operating activities:            
          Loss on abandonment of property and equipment     -      44 
          Gain on sale of Reconstructive and Spine Divisions     -      (12,253)
          Allowance for doubtful accounts           184 
          Stock option compensation     4      22 
     Changes in operating assets and liabilities:            
          Accounts receivable     43      (38)
          Inventories     -      85 
          Due from Arthrex     -      (193)
          Prepaid expenses and other current assets     57      64 
          Other assets     -      31 
          Accounts payable and accrued expenses     (614)     (826)
Net cash used in operating activities     (694)     (2,365)
             
Cash flows from investing activities            
     Purchases of property and equipment     -      (137)
     Decrease (increase) in restricted cash     900      (1,459)
     Proceeds from sale of Recontructive and Spine Divisions     -      17,026 
Net cash provided by investing activities     900      15,430 
             
Cash flows from financing activities            
     Proceeds from notes payable     -      1,224 
     Payments of notes payable     -      (1,724)
Net cash used in financing activities     -      (500)
Net change in cash and cash equivalents     206      12,565 
Cash and cash equivalents, beginning of period     12,678      127 
Cash and cash equivalents, end of period   $ 12,884    $ 12,692 
             
Supplemental disclosure of cash flow information:            
     Interest paid   $ -    $ 25 
     Income taxes paid   $ 553    $ - 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

TIGER X MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
June 30, 2012
(Unaudited)

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Tiger X Medical, Inc. ("Tiger X" or the "Company"), formerly known as Cardo Medical, Inc., previously operated as an orthopedic medical device company specializing in designing, developing and marketing high performance reconstructive joint devices and spinal surgical devices.

As discussed below in the discontinued operations section, we sold our Reconstructive and Spine Divisions during the quarter ended June 30, 2011. Our continuing operations include the collection and management of our royalty income earned in connection with the Asset Purchase Agreement with Arthrex, as well as continuing to promote our former products sold to Arthrex and seek a joint venture partner or buyer for the remaining intellectual property owned by the Company. The Company will also be evaluating future investment opportunities and uses for its cash.

Basis of Presentation

The accompanying condensed consolidated balance sheet as of December 31, 2011, which has been derived from the Company's audited financial statements as of that date, and the unaudited condensed consolidated financial information of the Company as of June 30, 2012 and for the three and six months ended June 30, 2012 and 2011, has been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. In the opinion of management, such financial information includes all adjustments considered necessary for a fair presentation of the Company's financial position at such date and the operating results and cash flows for such periods. Operating results for the interim period ended June 30, 2012 are not necessarily indicative of the results that may be expected for the entire year.

Certain information and footnote disclosure normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the United States Securities and Exchange Commission ("SEC"). These unaudited financial statements should be read in conjunction with our audited financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 filed on March 29, 2012.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of Tiger X Medical, Inc., Accelerated Innovation, Inc. ("Accelerated"), Uni-Knee LLC ("Uni") and Cervical Xpand LLC ("Cervical"). All significant intercompany transactions have been eliminated in consolidation.

Discontinued Operations

On October 7, 2010, the Company's management and Board of Directors decided to put substantially all of its assets up for sale. The assets determined to be held for sale were inventories, intellectual properties, and property and equipment of its reconstructive products line (the "Reconstructive Division") and spine products line (the "Spine Division"). The Company decided to put the assets of its Reconstructive and Spine Divisions up for sale primarily because it did not have sufficient working capital, and was not able to procure such financial resources through equity or debt financing, in order to fully execute a profitable sales strategy.

4

On January 24, 2011, the Company entered into an Asset Purchase Agreement with Arthrex, Inc. ("Arthrex") (the agreement being the "Arthrex Asset Purchase Agreement"), pursuant to which the Company agreed to sell the assets of the Reconstructive Division to Arthrex. The Arthrex Asset Purchase Agreement also provides for the Company to receive royalty payments equal to 5% of net sales of the Company's products made by Arthrex on a quarterly basis for a term up to and including the 20th anniversary of the closing date. During the three and six months ended June 30, 2012, the Company received total royalty payments of $17,000 and $28,000 from Arthrex and reflected this payment as revenue on the accompanying condensed consolidated statements of operations.

The Company completed the sale of the Reconstructive Division on June 10, 2011. The total cash consideration received by the Company from Arthrex amounted to $14,586,000, which was comprised of $9,960,000 plus inventory with a value of $2,908,000 and property and equipment with a value of $1,718,000. From this amount, $1,159,000 was deposited with an escrow agent to be held for twelve months for any potential adjustments to the purchase price relating to future adjustments to the value of the inventory and property and equipment and other unasserted claims. The total gain on the sale of the Reconstructive Division assets as of June 30, 2011 amounted to $10,527,000, which represents the excess of the cash consideration over the carrying amount of the assets sold of $4,059,000.

On April 4, 2011, the Company entered into and closed an Asset Purchase Agreement with Altus Partners, LLC, a Delaware limited liability company ("Altus"), pursuant to which the Company sold substantially all of the assets of the Spine Division in exchange for cash consideration of $3,000,000 (the "Altus Asset Purchase Agreement"). Pursuant to the terms of the Altus Asset Purchase Agreement, $2,700,000 of the purchase price was paid at the closing and $300,000 was deposited into escrow with an escrow agent for a period of 90 days from the closing date (assuming there are no disputes) to be used for any adjustments to the closing value of the Company's inventory and property and equipment. The total gain on the sale of the Spine Division assets as of June 30, 2011 amounted to $2,286,000.

The total gain associated with the above sales of the assets of the Reconstructive and Spine divisions amounted to $12,253,000, which is presented net of the income tax expense effect of $560,000.

Pursuant to the sale transaction with Arthrex, the total aggregate amount remaining in escrow accounts as of December 31, 2011 was $900,000, which is reflected as restricted cash on the accompanying condensed consolidated balance sheets. As of June 30, 2012, there were no amounts remaining in the escrow accounts relating to the sales transaction with Arthrex or Altus.

Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $214,000, respectively. Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $761,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $1,170,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $1,366,000, respectively. The continuing operations reflected are expenses associated with business insurance, legal and accounting fees that the Company will continue to incur.

Use of Estimates

Financial statements prepared in accordance with U.S. GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Among other things, management makes estimates relating to allowances for doubtful accounts, share-based payments and deferred income tax assets. Given the short operating history of Tiger X, actual results could differ from those estimates.

5

Revenue Recognition

The Company's revenue consists of royalty revenue from the Arthrex Asset Purchase Agreement, which is recognized as the amount becomes known and collectability is reasonably assured.

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental common shares issuable upon exercise of stock options or warrants. No dilutive potential common shares are included in the computation of any diluted per share amount when a loss from continuing operations is reported by the Company because they are anti-dilutive.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The likelihood of realizing the tax benefits related to a potential deferred tax asset is evaluated, and a valuation allowance is recognized to reduce that deferred tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are calculated at the beginning and end of the year; the change in the sum of the deferred tax asset, valuation allowance and deferred tax liability during the year generally is recognized as a deferred tax expense or benefit. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.

The Company evaluates the accounting for uncertainty in income tax recognized in its financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its financial statements. For those tax positions where it is "not more likely than not" that a tax benefit will be sustained, no tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has not accrued for any such uncertain tax positions as of June 30, 2012 (unaudited) or December 31, 2011.

Reclassifications

Certain amounts from prior periods have been reclassified to conform to the current period presentation due to the treatment of discontinued operations.

Concentration of Credit Risk

The cash and cash equivalents held in the Company's business money market and escrow bank accounts are with local and national banking institutions and subjected to current FDIC insurance limits of $250,000 per banking institution. As of June 30, 2012, the Company bank balances in these bank accounts exceeded the insured amount by $12,582,000.

Recent Accounting Pronouncements

There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

6

NOTE 2 — SHARE BASED PAYMENT

On August 29, 2008, the Company issued options to certain employees and Board members to purchase membership units in the Company. The options give the grantees the right to purchase up to 2,398,400 shares of the Company's common stock at an exercise price of $0.23 per share. The options vest 20% each year over a five-year period and expire after ten years. The weighted average grant date fair value of options granted was $0.13 per option. Stock option compensation recognized for the three months ended June 30, 2012 and 2011 in the accompanying condensed consolidated statements of operations amounted to $2,000 and $11,000, respectively. Stock option compensation recognized for the six months ended June 30, 2012 and 2011 in the accompanying condensed consolidated statements of operations amounted to $4,000 and $22,000, respectively.

As a result of the sale of substantially all of the Company's assets in the second quarter of 2011, other than the CEO, the Company no longer has any employees. As a result, the only options expected to vest are those held by the Company's Board of Directors and CEO. As a result, the estimated forfeiture rate has been adjusted to 75.6%.

A summary of stock option activity as of June 30, 2012, and changes during the period then ended is presented below.

           

Weighted-

      
       

Weighted-

  

Average

     
       

Average

  

Remaining

   

Aggregate
       

Exercise

  

Contractual

    

Intrinsic
 

Options

    

Price

  

Life (Years)

    

Value
                   

Outstanding at December 31, 2011

385,000 

  

$

0.23 

  

6.67 

  

$

- 

Granted

- 

    

- 

  

- 

    

- 

Exercised

- 

    

- 

  

- 

    

- 

Forfeited

- 

    

- 

  

- 

    

- 

Outstanding at June 30, 2012 (unaudited)

385,000 

  

$

0.23 

  

6.17 

  

$

- 
                   

Vested and expected to vest

                  

at June 30, 2012 (unaudited)

385,000 

  

$

0.23 

  

6.17 

  

$

- 
                   

Exercisable at June 30, 2012 (unaudited)

231,000 

  

$

0.23 

  

6.17 

  

$

- 

The Company had 575,613 warrants outstanding as of June 30, 2012 which entitle the holders to immediately purchase one share of the Company's common stock at an exercise price of $0.44 per share. The warrants expire on November 13, 2014.

NOTE 3 — STOCKHOLDERS' EQUITY

Our authorized capital consists of 750,000,000 shares of common stock and 50,000,000 shares of preferred stock. Our preferred stock may be designated into series pursuant to authority granted by our Certificate of Incorporation, and on approval from our Board of Directors. As of June 30, 2012 and December 31, 2011, we did not have any preferred stock issued.

7

ITEM 2 — MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

As used in this "Management's Discussion and Analysis of Financial Condition and Results of Operation," except where the context otherwise requires, the term "we," "us," "our" or "Tiger X" refers to the business of Tiger X Medical, Inc.

The following discussion should be read together with the information contained in the unaudited condensed consolidated financial statements and related notes included in Item 1, "Financial Statements," in this Form 10-Q. All dollar amounts are in thousands unless otherwise specified.

Overview

Tiger X Medical, Inc. ("Tiger X" or the "Company"), formerly known as Cardo Medical, Inc., previously operated as an orthopedic medical device company specializing in designing, developing and marketing high performance reconstructive joint devices and spinal surgical devices. As discussed below, in January 2011 we entered into an asset purchase agreement to sell substantially all of our assets in the Reconstructive Division to Arthrex. We completed the sale of the Reconstructive Division assets during the second quarter of 2011. Additionally, we completed the sale of substantially all of the assets in the Spine Division in April 2011. Our continuing operations include the collection and management of our royalty income earned in connection with the Asset Purchase Agreement with Arthrex, as well as continuing to promote our former products sold to Arthrex and seek a joint venture partner or buyer for the remaining intellectual property owned by the Company. The Company will also be evaluating future investment opportunities and uses for its cash.

We are headquartered in Los Angeles, California. Our common stock is quoted on the National Association of Securities Dealers, Inc.'s, Over-the-Counter Bulletin Board, or the OTC Bulletin Board with a trading symbol of CDOM.OB.

Critical Accounting Policies

Use of Estimates

Financial statements prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Among other things, management makes estimates relating to allowances for doubtful accounts, share-based payments, and deferred income tax assets. Given the short operating history of Tiger X since discontinuing its operations, actual results could differ from those estimates.

8

Discontinued Operations

On October 7, 2010, the Company's management and Board of Directors decided to put substantially all of its assets up for sale. The assets determined to be held for sale were inventories, intellectual properties, and property and equipment of its reconstructive products line (the "Reconstructive Division") and spine products line (the "Spine Division"). The Company decided to put the assets of its Reconstructive and Spine Divisions up for sale primarily because it did not have sufficient working capital, and was not able to procure such financial resources through equity or debt financing, in order to fully execute a profitable sales strategy.

On January 24, 2011, the Company entered into an Asset Purchase Agreement with Arthrex, Inc. ("Arthrex") (the agreement being the "Arthrex Asset Purchase Agreement"), pursuant to which the Company agreed to sell the assets of the Reconstructive Division to Arthrex. The Arthrex Asset Purchase Agreement also provides for the Company to receive royalty payments equal to 5% of net sales of the Company's products made by Arthrex on a quarterly basis for a term up to and including the 20th anniversary of the closing date. During the three and six months ended June 30, 2012, the Company received total royalty payments of $17,000 and $28,000 from Arthrex and reflected this payment as revenue on the accompanying condensed consolidated statements of operations.

The Company completed the sale of the Reconstructive Division on June 10, 2011. The total cash consideration received by the Company from Arthrex amounted to $14,586,000, which was comprised of $9,960,000 plus inventory with a value of $2,908,000 and property and equipment with a value of $1,718,000. From this amount, $1,159,000 was deposited with an escrow agent to be held for twelve months for any potential adjustments to the purchase price relating to future adjustments to the value of the inventory and property and equipment and other unasserted claims. The total gain on the sale of the Reconstructive Division assets as of June 30, 2011 amounted to $10,527,000, which represents the excess of the cash consideration over the carrying amount of the assets sold of $4,059,000.

On April 4, 2011, the Company entered into and closed an Asset Purchase Agreement with Altus Partners, LLC, a Delaware limited liability company ("Altus"), pursuant to which the Company sold substantially all of the assets of the Spine Division in exchange for cash consideration of $3,000,000 (the "Altus Asset Purchase Agreement"). Pursuant to the terms of the Altus Asset Purchase Agreement, $2,700,000 of the purchase price was paid at the closing and $300,000 was deposited into escrow with an escrow agent for a period of 90 days from the closing date (assuming there are no disputes) to be used for any adjustments to the closing value of the Company's inventory and property and equipment. The total gain on the sale of the Spine Division assets as of June 30, 2011 amounted to $2,286,000.

The total gain associated with the above sales of the assets of the Reconstructive and Spine divisions amounted to $12,253,000, which is presented net of the income tax expense effect of $560,000.

Pursuant to the sale transaction with Arthrex, the total aggregate amount remaining in escrow accounts as of December 31, 2011 was $900,000, which is reflected as restricted cash on the accompanying condensed consolidated balance sheets. As of June 30, 2012, there were no amounts remaining in the escrow accounts relating to the sales transaction with Arthrex or Altus.

Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $214,000, respectively. Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $761,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $1,170,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $1,366,000, respectively. The continuing operations reflected are expenses associated with business insurance, legal and accounting fees that the Company will continue to incur.

9

Revenue Recognition

The Company's revenue consists of royalty revenue from the Arthrex Asset Purchase Agreement, which is recognized as the amount becomes known and collectability is reasonably assured.

Recent Accounting Updates

There are no recently issued accounting updates that we have yet to adopt that are expected to have a material effect on our financial position, results of operations, or cash flows.

Results of Operations for the Three Months Ended June 30, 2012 as Compared to the Three Months Ended June 30, 2011.

The following is a comparison of the consolidated results of operations for Tiger X for the three months ended June 30, 2012 and 2011. As discussed above, our Reconstructive Division and Spine Division were discontinued during 2011.

      Three Months Ended      
      June 30,      
      2012     2011     $ Change
                   
Revenue   $ 17    $ -     $ 17 
Cost of revenue     -       -       -  
Gross profit     17      -       17 
General and administrative expenses     149      249      (100)
Loss from operations     (132)     (249)     117 
Interest (expense) income, net     3      2      1 
Loss from continuing operations before income tax provision     (129)     (247)     118 
Provision for income taxes     -      -      -  
Loss from continuing operations     (129)     (247)     118 
Discontinued operations                  
Gain from sale of discontinued Reconstructive and Spine Divisions, net of income taxes     -      12,253      (12,253)
Loss from operations of discontinued Reconstructive and Spine Divisions, net of income taxes     -      (1,170)     1,170 
Net income (loss)   $ (129)   $ 10,836    $ (10,965)

Revenues

Revenues from continuing operations amounted to $17,000 for the quarter ended June 30, 2012 compared with $0 for the same period in 2011. Revenues from continuing operations represented royalties received from Arthrex in connection with the Arthrex Asset Purchase Agreement. In the future, we expect our primary source of revenue to be royalty payments under the Arthrex Asset Purchase Agreement.

General and Administrative Expenses

General and administrative expenses for the quarter ended June 30, 2012 decreased by $100,000 as compared to the same period in 2011. General and administrative expenses represent our continuing operating expenses associated with remaining a public company, including business insurance expense and professional fees such as legal, accounting and audit services. The primary reason for the decrease in 2012 relates to higher legal and professional fees incurred in 2011 relating to the sale of our Reconstruction and Spine Divisions. In the future, we expect our general and administrative expenses to remain at a reduced level.

10

Interest Income/(Expense)

During the quarter ended June 30, 2012, we had interest income of $3,000, as compared to $2,000 in 2011. We had no interest expense during the quarters ended June 30, 2012 or 2011, as there was no debt outstanding during this timeframe.

Results of Operations for the Six Months Ended June 30, 2012 as Compared to the Six Months Ended June 30, 2011.

The following is a comparison of the consolidated results of operations for Tiger X for the six months ended June 30, 2012 and 2011. As discussed above, our Reconstructive Division and Spine Division were discontinued during 2011.

      Six Months Ended      
      June 30,      
      2012     2011     $ Change
                   
Revenue   $ 28    $ -     $ 28 
Cost of revenue     -       -       -  
Gross profit     28      -       28 
General and administrative expenses     218      350      (132)
Loss from operations     (190)     (350)     160 
Interest (expense) income, net     6      (22)     28 
Loss from continuing operations before income tax provision     (184)     (372)     188 
Provision for income taxes     -      -      -  
Loss from continuing operations     (184)     (372)     188 
Discontinued operations                  
Gain from sale of discontinued Reconstructive and Spine Divisions, net of income taxes     -      12,253      (12,253)
Loss from operations of discontinued Reconstructive and Spine Divisions, net of income taxes     -      (1,366)     1,366 
Net income (loss)   $ (184)   $ 10,515    $ (10,699)

Revenues

Revenues from continuing operations amounted to $28,000 for the six months ended June 30, 2012 compared with $0 for the same period in 2011. Revenues from continuing operations represented royalties received from Arthrex in connection with the Arthrex Asset Purchase Agreement. In the future, we expect our primary source of revenue to be royalty payments under the Arthrex Asset Purchase Agreement.

General and Administrative Expenses

General and administrative expenses for the six months ended June 30, 2012 decreased by $132,000 as compared to the same period in 2011. General and administrative expenses represent our continuing operating expenses associated with remaining a public company, including business insurance expense and professional fees such as legal, accounting and audit services. The primary reason for the decrease in 2012 relates to higher legal and professional fees incurred in 2011 relating to the sale of our Reconstruction and Spine Divisions. In the future, we expect our general and administrative expenses to remain at a reduced level.

11

Interest Income/(Expense)

During the six months ended June 30, 2011, we had net interest expense of $24,000, which was primarily the result of $500,000 in notes payable outstanding as of December 31, 2010 which were repaid in March 2011, offset by interest income of $2,000. During the six months ended June 30, 2012, we had interest income of $6,000. We had no interest expense in 2012, as there was no debt outstanding during this timeframe.

Liquidity and Capital Resources

Net cash used in operating activities was $694,000 for the six months ended June 30, 2012 compared to $2,365,000 for the same period in 2011. Our overall operating costs were lower in 2012 due to our current operations being the collection and management of our royalty income earned in connection with the Asset Purchase Agreement with Arthrex. The Company will also be evaluating future investment opportunities and uses for its cash.

As discussed above, during the quarter ended June 30, 2011, we sold substantially all of our assets relating to the Spine and Reconstructive Divisions, which were discontinued during the fourth quarter of 2010. This resulted in net cash provided by investing activities for the six months ended June 30, 2011 of $15,430,00, which included gross proceeds from the sale of the assets of $17,026,000, less $1,459,000 of the funds placed in restricted cash escrow accounts, less purchases of equipment of $137,000. During the six months ended June 30, 2012, we had cash provided by investing activities of $900,000, which represented a decrease in restricted cash from the restrictions being removed on the cash held in escrow associated with the sale of the Reconstructive Division.

Net cash used in financing activities was $0 for the six months ended June 30, 2012 compared to $500,000 for the six months ended June 30, 2011. The net cash used in 2011 consisted of $1,224,000 in short-term borrowings related to the sale of the Reconstructive Division, offset by the repayment of these borrowings, as well as $500,000 in previously outstanding notes payable. There was no cash provided by or used in financing activities during the six months ended June 30, 2012, as we have no further debt outstanding.

We believe our cash and cash equivalents as of June 30, 2012 are adequate to meet our cash needs for the next twelve months and beyond.

Forward-Looking Statements

Some of the statements in this Quarterly Report on Form 10-Q are "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "may," "will," "should," "anticipate," "estimate," "expect," "plan," "believe," "predict," "potential," "project," "target," "forecast," "intend," "assume," "guide," "seek" and similar expressions. Forward-looking statements do not relate strictly to historical or current matters. Rather, forward-looking statements are predictive in nature and may depend upon or refer to future events, activities or conditions. Although we believe that these statements are based upon reasonable assumptions, we cannot provide any assurances regarding future results. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. Information regarding our risk factors appears in Part I, Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2011 filed on March 29, 2012.

ITEM 3 — QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable for smaller reporting companies.

12

ITEM 4 — CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our principal executive officer and principal financial officer are responsible for establishing and maintaining disclosure controls and procedures. We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our interim principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

We carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and interim principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of June 30, 2012.

The determination that our disclosure controls and procedures were not effective as of June 30, 2012 are a result of:

  • the departure of the former Chief Financial Officer in late June 2011;
  • the fact that we no longer have significant operations and as a result have eliminated our internal accounting and financial department; and
  • insufficient segregation of duties.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1 — LEGAL PROCEEDINGS

We know of no material, existing or pending legal proceeding against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

ITEM 2 — UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3 — DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4 — MINE SAFETY DISCLOSURES

Not applicable

ITEM 5 — OTHER INFORMATION

None

13

ITEM 6 — EXHIBITS

The following exhibits are filed as part of, or incorporated by reference into this Report:

Exhibit
Number

Exhibit Title

31.1

Certification of Chief Executive Officer of Tiger X Medical, Inc., as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *

31.2

Certification of Chief Financial Officer of Tiger X Medical, Inc., as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *

32.1

Certification of Chief Executive Officer of Tiger X Medical, Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **

32.2

Certification of Chief Financial Officer of Tiger X Medical, Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **

101.INS***

XBRL Instance Document

101.SCH***

XBRL Taxonomy Extension Schema Document

101.CAL***

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF***

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB***

XBRL Taxonomy Extension Label Linkbase Document

101.PRE***

XBRL Taxonomy Extension Presentation Linkbase Document

*

Filed herewith

**

Furnished herewith

***

Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Act of 1934 and otherwise not subject to liability.

14

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TIGER X MEDICAL, INC.

August 10, 2012

By:

/s/ Andrew A. Brooks

Andrew A. Brooks

Chief Executive Officer and Interim Chief Financial Officer
(Principal Executive Officer)

(Principal Financial and Accounting Officer)

15

INDEX TO EXHIBITS

Exhibit
Number

Exhibit Title

31.1

Certification of Chief Executive Officer of Tiger X Medical, Inc., as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*     PDF

31.2

Certification of Interim Chief Financial Officer of Tiger X Medical, Inc., as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*     PDF

32.1

Certification of Chief Executive Officer of Tiger X Medical, Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**     PDF

32.2

Certification of Interim Chief Financial Officer of Tiger X Medical, Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**     PDF

101.INS***

XBRL Instance Document

101.SCH***

XBRL Taxonomy Extension Schema Document

101.CAL***

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF***

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB***

XBRL Taxonomy Extension Label Linkbase Document

101.PRE***

XBRL Taxonomy Extension Presentation Linkbase Document

*

Filed herewith

**

Furnished herewith

***

Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.

 

 

 

 

EX-31.1 2 exh31-1.htm CEO 302 CERTIFICATE Q2 2012 Exhibit 31.1

Exhibit 31.1

CERTIFICATION

I, Andrew A. Brooks, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Tiger X Medical, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 10, 2012

/s/ Andrew A. Brooks

Andrew A. Brooks
Chief Executive Officer

EX-31.2 3 exh31-2.htm CFO 302 CERTIFICATE Q2 2012 Exhibit 31.2

Exhibit 31.2

CERTIFICATION

I, Andrew A. Brooks, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Tiger X Medical, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 10, 2012

/s/ Andrew A. Brooks

Andrew A. Brooks
Interim Chief Financial Officer

EX-32.1 4 exh32-1.htm CEO 906 CERTIFICATE Q2 2012 Exhibit 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Tiger X Medical, Inc. (the "Company") for the quarterly period ended June 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Andrew A. Brooks, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Andrew A. Brooks

Andrew A. Brooks
Chief Executive Officer

Date:  August 10, 2012

 EX-32.2 5 exh32-2.htm CFO 906 CERTIFICATE Q2 2012 Exhibit 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Tiger X Medical, Inc. (the "Company") for the quarterly period ended June 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Andrew A. Brooks, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Andrew A. Brooks

Andrew A. Brooks
Interim Chief Financial Officer

Date:  August 10, 2012







 EX-31.1 6 exhibit31-1.pdf CEO 302 CERTIFICATE begin 644 exhibit31-1.pdf M)5!$1BTQ+C8-)>+CS],-"C$V,"`P(&]B:@T\/"]&:7)S="`R,#,O3&5N9W1H M(#0S."]&:6QT97(O1FQA=&5$96-O9&4O3B`R-2]4>7!E+T]B:E-T;3X^4 MY*!U#[4.\0?)WP]%1T0+&M`!:N*?!7*&T8'1':,'XSUC`$O(V($-LH[@B/FH MP7GF(8)'RTC@?60T$,23]X(7GH-.R[Z'SK$>`T3-.=A!=!R/$6)D']*2S4() M0V'D%,=2LO(Z\$->6WFP$0798:6A`#C:-BKW7A._^;AG!)PZ.>=A_0V M]^D"5NVG4_HUO@#7(Y3A\I+483[_?\J\_33-ZOXTOKYF3B>)4[ M5=!7#!6[BK$@=ZH@5J2*IF+UP^J'U0^K']4U9?VCVD%1J(,ZI*!9I.,UC+;(.O!-;%] M$SML8IOU`;H&60^QB8VZC8Y-!T9J'\C_LKJS31?T=Q",F4K9=KO\VKC MNQV]UB9?WFGR]6?$A!OF3SD*`\Y(5_1$3_1$3_0"O3!Z_1%@`!*B(VT-"F5N M9'-T%LQ-"`S(#(W(#$@ M,3`T(#$Y(#$R-"`S(#$R."`Q(#$V,"`S72]$96-O9&5087)M7!E+UA2968^/G-T-IB8F)8P,#$P,#`""08_\-8_QEA+#H1_QD*7C`Q,$F`W+*=`2#``)T< M!A\-"F5N9'-T7!E M+U!A9V5S+TMI9'-;,3,Q(#`@4ET^/@UE;F1O8FH-,3(@,"!O8FH-/#PO4W5B M='EP92]834PO3&5N9W1H(#,Y-#4O5'EP92]-971A9&%T83X^G)E4WI.5&-Z M:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X M.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C`M8S,R,2`T-"XS.3@Q,38L(%1U M92!!=6<@,#0@,C`P.2`Q-#HR-#HS.2(^"B`@(#QR9&8Z4D1&('AM;&YS.G)D M9CTB:'1T<#HO+W=W=RYW,RYO&%P+S$N,"\B/@H@("`@("`@("`\>&%P.D-R96%T;W)4;V]L/D%C M&%P.DUE=&%D871A1&%T93XR,#$Q+3`X+3`Y5#$W.C`R M.C`Q+3`W.C`P/"]X87`Z365T861A=&%$871E/@H@("`@("`\+W)D9CI$97-C M&UL;G,Z>&%P34T](FAT='`Z+R]N&%P+S$N,"]M;2\B/@H@("`@("`@("`\>&%P34TZ1&]C=6UE;G1)1#YU=6ED M.F9F.&-E,6%D+35B.6$M-&(U,BUB-30Q+6(X861C,S1B8V%A93PO>&%P34TZ M1&]C=6UE;G1)1#X*("`@("`@("`@/'AA<$U-.DEN&UL;G,Z9&,](FAT M='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL.FQA;F<](G@M9&5F875L="(O/@H@("`@("`@("`@("`\+W)D9CI! M;'0^"B`@("`@("`@(#PO9&,Z=&ET;&4^"B`@("`@(#PO#IX;7!M971A/@H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"CP_>'!A8VME="!E;F0](G'1!;&EG;B]3=&%R="]/+TQA>6]U="]7'1!;&EG;B]#96YT97(O3R],87EO=70O5W)I=&EN9TUO9&4O3')4 M8B]3<&%C94)E9F]R92`U+C`O5&5X=$EN9&5N="`P+C`O16YD26YD96YT(#`N M,"]3=&%R=$EN9&5N="`P+C`^/@UE;F1O8FH-,C$@,"!O8FH-/#PO4W!A8V5! M9G1E'1);F1E;G0@,"XP+T5N9$EN9&5N M="`P+C`O4W1A'1!;&EG;B]3=&%R="]/+TQA>6]U="]7'1);F1E;G0@,"XP M+T5N9$EN9&5N="`P+C`O4W1A'1!;&EG;B]3=&%R="]/ M+TQA>6]U="]7'1);F1E;G0@,"XP+T5N9$EN9&5N="`P+C`O4W1A7!E+T9O M;G0^/@UE;F1O8FH-,3,S(#`@;V)J#3P\+U-U8G1Y<&4O5')U951Y<&4O1F]N M=$1E%LM-34X("TS,#<@,C`P,"`Q,#(V72]!7!E+T9O;G1$97-C7!E+T5X=$=3=&%T92]302!F86QS92]332`P M+C`R/CX-96YD;V)J#3$S-R`P(&]B:@T\/"],96YG=&@@-S,W+T9I;'1EK21>&V>3E67Y]R/EV$FW'2Q3$OG(]TAH7@33#W!U-7U8+&]! MPO7U_'8!P?3-9PGK+I@6A00%Q2J00DJIH:@@)#/.H#B`0E-CE#Q9<9R*&#*= M"(S9!E_9W>]-\ZUQ$"G!$Z9X&#'@C\7;X.Z!LIPSJR&SSZ,HCZ0,H9H)F4.H M11(G4-2(N;C[5"SOESQE"QZS&_P*KMGR_;LS\%T1Z!2+B"'-,Y&D,%,BPT)% MGH(UP2J8OZ"M1]IGNE3!W_0BI#=+$3,7*?%#+L7W?ZA$%VBJ1_.2Z6A43VO/ M3>7!3UY)8\3-B$AS&#&S+;VM+/'("'*;L1,/?[G>?JL53BQ4(K(M!, M2$4U>[0=`3W1TJ%,$ZB,=R6*YPM)?$V_$BQY+?R?D7#E61K8^GX"RT/ M/I-F-552E91O@FBP'+`K\9IR_5>=Y(4ZV=A4Z9LJ1WEN41Z-#4.@$G-U1*VF MHL\,MEB^)_K4GGAZN9Z'\O!@[?6;H'C(X4(]S7JA>X%(`:\.PM?#B>EHV^[\ M186^/C'M2L)HH3Q/D1RGR+/06LSRV3!&[1'V&(>=V1N2J7.E,UO3.MBMH$06 M"MOG#$VH;5!-0I4#'LT/OA214.DXE[`J*^>EL'[U"/A,N%V/C:`7I<4C5-Y/ M82IDBB^#4*YA6U.9KBOMD>#ZVJBR)X-C?U$^7?B26WJ57'=RK5'K MIH7GIF=!^:,Q_Z!-GL<#E?6F)[+RZ!D*W=@*_WN$PZ93`LES^"/!'@`$`VO-720T*96YD)L$Q*X=VTF*%3VTW:$# M"NR06]N#:LN),=<.)'7!_GY\E.-T*'I)1%(D'ZGW3-N?%TF69EE>T+8FG)8; MVAXI62[3JZN2DCS-RY*VS<63>C.-3DIE=9*K!0TCC$!O.L]4IW/E>YU4RL9+ MW;##'^F5.G9A?SH[ZP]2HPX4I``%O582M[APF#NXC@-RI=%+1?7X)X8J+M+0 M*XR_"'!2K-]Y/=PSVMZ.;F]IY],O8& M8\L&L@)S9SQY6I45;>]YXB*E6UTJHPOEK;Y2#;J-#&$`0AY]S1@J1;\'_H7_ M"'^O@;-@W)7:P6$7/"5O:2\&:K0=WQD,EQSJ;NJ`-/(!%GXL+[90=L#9\T`+ M,N@2(<"YMXZ/]&4I\7-&"V!.JID`YSAPC.'($#7NOC=QNK.;I`-.G?3?*%XN MWSE(,007,H=!V*&&+$(V'@E5G0AUVBLS:5JK/)*3Y_1VB#3J!C)]CYIO)EC7 MF9X^D,53F#C2@A:28X!.3K7@-))="V6&2,+016LQ<>^]#_X#Q.7,^34P+LNT M7*T9JK"=)+7522$<&R,4QRL/+HR8CP&F3`-F.#MS:?%(0JV=S4D^"!^3'.;AY MW3;VXJ6'?=3-^*5@UO\)9G463/Y9,&4*"-N]G0BS43OA#PCC#)M"YV]\`*5I MYC&CJZW0"M=;MD$G8?!.M@^7,)VO/2LVD/^L$%%"'(K*XIHQ]X-C/DA>([588:RJ M43"\R^>+:GF<*F[#R;=C^F[(6O0+T3\!!@`;D&#L#0IE;F1S=')E86T-96YD M;V)J#3$S.2`P(&]B:@T\/"],96YG=&@@-CPG4\'SW-C,M+`J$A.YO+A^*]FWLU'"&[*O=O!^ M*8\<`^N!QQZK>S:EDL"9$0QX+8&EB:-:?F(D=>.4G=A?%OL!TQEUQYM$AO?G3T=YYQD)X\I'Y:7VZ(ML4W! MJ#7P<20Q5PZ]`WT=,CT*G9FIL+%)RJV3 M#@V8&B^])(TT-J<*3D./4JA5Q>VE[S19HFM5I0"AL12@DL=?)`9TWA&^BKD7?AI1"GD_O]U<+N7F7@`T*!D3ZQ_;@19K+M;PA( M`A"YTVT>B?X(,``04F<8#0IE;F1S=')E86T-96YD;V)J#3$T,"`P(&]B:@T\ M/"],96YG=&@@-C@W+T9I;'1EHT2['U=YL2B*LJ9=0["J->U>J2H7&[8*VK57OTV(E-V:5Y^.6;XT MOL<_I>S.B#]$1ZY//GD7KVE$R&9Y:4+RS02ORTIC0_=&K;C!]X>/%1S*2Z*3 M1,\+`]PVJPQE?V:4U7)&66^`,C_!S,M%N5*H`+4-5`6C'.Q6C+`+0-\,L]/&7IL7?0'0:NU*4[X,&0]0W)!OK:C9M`( M<`^P.AI>)#/0'F3IQFRE1@,2/>>=SPO0'V4NJI/,RW)SECEEK"[_>OX=KADC M#6P%E*/&9FLS1<;*RD7N.8&SY@A7<]A%`<>:!852,7BL-RC3)ZD%.!@)#@\O MCFL&D+&7$FC1-S`M%Y$]%_&55IV#NUE]H(?ZR^7I"&X4@GCV9C7S6Y-TGMB; MU>8#M6?SDPXB0\]<7W8$*3/(BMIQ&G65`R\Z85Y5NL[R^G/;TSQ51F7S6IGU ML5&3K`#KG.39&*=@54IL.LSJ!LD3P0_:X3@7ZKR6\)U/;[Q65MIZ?[Y!0EQY MYK"X/P1/V\6%Y MGV0@9(.=GJ2W.0VN3PSG_HI93 MY9C_%&D_!'),U3_Q^3+Q+*X9W11&?K$B#^U:]Y)M>%LSA-;J5:I!^^G!NW#W M#D4]CU^Q>?_V'%R/AL%V_-;9IG%CG+FI7)/$E,2AM+D)*/M'FCA&;I/,]R MVJPG/]16V:TFO5`OE^*D3:+ZHM.9V=AK?AW$34K M:Q%:O50M-6S8ZYE1!+?CX$(>YP%A+0Q>YZK@##4N4S:UFD-*L=L3GPTB\60/ M0:+)XO%Z"!=2WPJ8+E04D/;CY4X M]!DKZ+Q83YRWEI@`H;B:$&EEB&+L0WS[@8J[C.X:'RTL#49!3K@HP`F&R0UR MD8MGYRN@WI0\8,P[5Q?GPQA9L7O'&8EEXEP&G2$W MO$R^J^H#+D(0=NRN)/@7KUDL+#(!Q376]MZ/(RQ[+WT?^+6_N_4"4S?%OX_L M*//MES9I_`?IR%_3FB&MR9#6Y'.SS`8XG'5UQVVUEAOYW1?\H&%$4#ZPXH*F']&U2=EV4+!:RW%S]%[P\A[J&W M8Z<'D`OQ>M`AF@#60=P;3$"G1]D(`[X'^4B@Y2JO"P69RE5=)QCM0&.MDUDE MW"$A!?/B0]Q(Q-&1$GL&@F>IE-#8P^IA>$N0S+.>>*K5B6A=J8DHZ+XW733; M*_#(;DP=$'$AO*/>3\,;#/:7P4OTB2FCJAFU/J$6RWI"12ZET#)KQ,RGFEI= M090KL:>13.JVLV,,6K;"Q4O\'^&=O&JG-A5O.2N7>:,:7E*3>EEWZL-7W%'G M4T8J$3Q%`_@C77']?:K6N#`..IDI8=\72[D0K=M1\!D10+LMQ8G3U^]W<''] M`VYNKK_?/=R#*N'V]LL])GDGY;R3BLE6>;.JD'/>U">R34Z=UNB`5D"@_[^& M]^B/`)T)9Q)6!,QAGDY-'` M%OV(T>!'$OQ)C^9LU3-[M#'U:/-R44U-MN`=H*G)9H7`/=5BC#A!9UP$<_P' MU^3J$XP>Y%(<=+2$UC,WZT@[DF#REDIO5EIAFS?M![U1WD@<@A]D+6B='M4\ MDI"X-[SM+1T[[3J+!5J68BI$A;&4R@.51TQ3B:.;'6;)FC6?<[!GS/0@TMY1 M[4@'03NZ7&)R9(\"U]'+R+6]U.0NS8'L6\Z?FG@0F:-3S;(A-"N#%X`L; M1I]>&H4>39F>F@0T1(6\LU*X'3=$3<^WA[=4_8IG!^IQU"0'I7@"+B`DVHSK M)DV\&W&TC?S$)8\`?P08`-';95T-"F5N9'-T7!E,"]$ M97-C96YD86YT1F]N='-;,34S(#`@4ETO0F%S949O;G0O04M-34E$*T-A;&EB M7!E M+T9O;G0^/@UE;F1O8FH-,30U(#`@;V)J#5LO24-#0F%S960@,34P(#`@4ET- M96YD;V)J#3$T-B`P(&]B:@T\/"]3=&5M5B`W,2XW-#(O1F]N=$YA;64O5&EM M97-.97=2;VUA;E!3+4ET86QI8TU4+T9O;G13=')E=&-H+TYO5%"[;L,P#-SU%1Q;=)#B%LAB&"C2Q4,?J)WLBD0[`FI*H.7!?U])>;@CY:']:,E%D#_L38<1!D>6^W[^H9Y#?;)$=C0EYJXZGA'1+"'\X(450T#1@<1#R M\*G#EYX09"'>P7X-"%7I=YNVMS@';9`UC0BU4NJUN18D^SB_LLZ#N6@6]^UW MU8BTO>&9EV^Z^3`+<[)8#B]&L@5'>/M-\"&KY1#_`@P`W?MJ>PH-"F5N9'-T MPNWM]WM*)EF:95D.ZP8XRN>P/D"9UJL2DB*MJQK6FZM']:3,DP8] M5]^Z#GK[XFQK&[U0Q@VP00KH:-'1A^(>C-N`_D.-(WQY@E\R?%ZE65U!%J'? M=)XK,V"PIH,#FE>'?8_4J@?KN.6P1>Y!">K+"1_.V+E@2U@6(WB]6DW@X'YJ-B;40VNE82-#K)%5,,*"-YFB`,L>A%!B-FARU'MI$'F("<#&CZ M.)!YEF&.T-E7H=61VD<8?"S?["5)'4/_42&."E&_H&LMRTD@)#33MM@,P#H' ME%DL,>^'8$XR?.DOR9\EKT5R"JMB0HQ#VLX.1Q%ST$FMXH0!&Q\V,Q`!@BYC MNJ'[GD7XR8(C/'%&+N%45F_3O;T2=K%,J$ZRNU%]DTQ%U:J*7:N=9 MA8%^@);(9,H9,J?F^UBJCM-\<'PGK9;QZ*HC'/^)?_3N*]>=K/QIAZIIAR9G M3U.+);+3_MS+_CQ3FW&%W)'GI*@-1J_4.YTV/,`L6@`''GB+@4X@/#COO+"A MB)D;$H_/2$_A;YC4##BW92RA<2:YGTARV9X#I,X];T%D33C.O%`5ZJ2,PC*V M$Q@?1[F_Z%'.42E<[,ZO=U19CB-<^M!`:J&ZAE++93=W2&&RGZ<>O M_D1VG#J^2(,T_-[3\$0US.>+90^B0(W(%;@!4LG@GJ"H-;8,!6MK#+@[<2N7 MJJCE=U6PW(\?0!6-O'H,1_=QW>V!,!3O@>-.I+ZZ3P(#&`.2V.\8-FI8DP4B MUMR`^RTD*/=3K*Z]G?(&9K/RNO^X]&W9XRN+C8T\7SXC8U6AU9UY0;V5I?+& M%,<].7[PU=UV5)U\@BNM6@D+?[+=^&7S:P?1O28^^C\G"?3&9'+;0><<8^%.(M`>(N"YI7,$ M!&Y*@:!C()H+@;"=9HN4$O$<`-7(,0<@Y&*AC`R'FQ"$G`,OQTDNBD2Y*%P' M-??.X_H?ZW&"U=]Q>-RO_P0J?)ZF]3!N,R$;/O,-#')(2]OJ]M(OL'D$9<_? M,.$HC2X]U5J'-,-(9>I,N,(#T+B`=!%$89@88R@###$ULB*A`1!$1`460H(`! MHZ%(K(AB(2BH8`]($%!B,(JHJ&1&UDI\>7GOY>7WQ[W?VF?O<_?9>Y^U+@`D M3Q\N+P66`B"9)^`'>CC35X5'T+']``9X@`&F`#!9Z:F^0>[!0"0O-Q=ZNL@) M_(O>#`%(_+YEZ.E/IX/_3]*L5+X``,A?Q.9L3CI+Q/DB3LH4I(KM,R*FQB2* M&4:)F2]*4,1R8HY;Y*6??1;94!&;B)C$#PYT$?%R`'"DN"\X MY@L6<+($XD.YI*1F\[EQ\0*Z+DN/;FIMS:![[M(KT*^-PSB-;WA^VO M_%+J`&#,BFJSZP];S'X`.K8"('?_#YOF(0`D17UKO_'%>6CB>8D7"%)MC(TS M,S.-N!R6D;B@O^M_.OP-??$](_%VOY>'[LJ)90J3!'1QW5@I22E"/CT]E?^IB?\P[$]: MG&N1*/6?`#7*"$C=H`+DYSZ`HA`!$GE0W/7?^^:##P7BFQ>F.K$X]Y\%_?NN M<(GXD,X`9P\QBL5AYK`'6#NN'96(%V`+L M?NPQ[#GL('8<^Q9'Q*GBS'#NN`@<#Y>'*\$AX1202U8G6Q``BE[B) M6$$\3KQ"'"6^(\F0]$DNI$B2D+23=(1TGG2/](I,)FN3'DDN58R1[)<\J3D#LHERC@50]6A>E$3J$74;ZC]U!E9&=EELJ&R6;)5LF=D1V@( M39OF14NBE=!.T(9H[YGR M;O*)\KOE.^0?*:`4]!4"%#(5#BI<4IA6I"K:*K(4"Q5/*-Y7@I7TE0*5UBD= M5NI3FE564?903E7>KWQ1>5J%IN*HDJ!2IG)694J5HFJORE4M4SVG^HPN2W>B M)]$KZ#WT&34E-4\UH5JM6K_:O+J.>HAZGGJK^B,-@@9#(U:C3*-;8T935=-7 M,U>S6?.^%EZ+H16OM4^K5VM.6T<[3'N;=H?VI(ZYM/8P>0R]1[X#>37U8WT(_7K]*_X8!;&!IP#4X8#"P%+W4>BEO:=W284.2 MH9-AAF&SX:@1SJ/U:>MW-I8V`IL3-K_8&MHFVC;93B[7 M6/MC]D/^*@YL!TJ'-XXJCAR'9L<)QPTG-*<#KF M],+9Q)GOW.8\YV+CLM[EO"OBZN%:Z-KO)N,6XE;I]MA=W3W.O=E]QL/"8YW' M>4^TI[?G;L]A+V4OEE>CU\P*JQ7K5_1XD[R#O"N]G_CH^_!]NGQAWQ6^>WP? MKM1:R5O9X0?\O/SV^#WRU_%/\_\^`!/@'U`5\#30-#`WL#>($A05U!3T)M@Y MN"3X08ANB#"D.U0R-#*T,70NS#6L-&QDE?&J]:NNARN$<\,[([`1H1$-$;.K MW5;O73T>:1%9$#FT1F=-UIJK:Q76)JT]$R49Q8PZ&8V.#HMNBO[`]&/6,6=C MO&*J8V98+JQ]K.=L1W89>XICQRGE3,3:Q9;&3L;9Q>V)FXIWB"^/G^:Z<"NY M+Q,\$VH2YA+]$H\D+B2%);4FXY*CDT_Q9'B)O)X4E92LE(%4@]2"U)$TF[2] M:3-\;WY#.I2^)KU30!7]3/4)=85;A:,9]AE5&6\S0S-/9DEG\;+ZLO6S=V1/ MY+CG?+T.M8ZUKCM7+7=S[NAZI_6U&Z`-,1NZ-VILS-\XOLECT]'-A,V)FW_( M,\DKS7N])6Q+5[YR_J;\L:T>6YL+)`KX! MWSWM9?2RPK+7>Z/V7BU?5EZSC[!/N&^DPJ>B<[_F_EW[/U3&5]ZI5'\8- M#0H-10T?C_".C!P-/-K3:-78V*345-(,-PN;IXY%'KOYC>LWG2V&+;6MM-:B MX^"X\/BS;Z._'3KA?:+[).-DRW=:WU6W4=H*VZ'V[/:9COB.D<[PSH%3*TYU M=]EVM7UO]/V1TVJGJ\[(GBDY2SB;?W;A7,ZYV?.IYZ\+UVY['[Y8J]3[[DK=E=.7[6Y>NH:XUK'=N;70/+!\X..@Q>N.5ZZ_)MK]O7[ZR\,S`4,G1W.')XY"[[[N2] MI'LO[V?$CJ4?ECY4>U_VH]V/KB.7(F5'7T;XG04\>C+'&GO^4 M_M.'\?RGY*?E$ZH3C9-FDZ>GW*=N/EO];/QYZO/YZ8*?I7^N?J'[XKM?''_I MFUDU,_Z2_W+AU^)7\J^.O%[VNGO6?_;QF^0W\W.%;^7?'GW'>-?[/NS]Q'SF M!^R'BH]Z'[L^>7]ZN)"\L/";``,`]X3S^PH-"F5N9'-T[)L'>%35UO?7/F=*2$B#)`0"S(0A M%$.O$1!"&H08("0#"363'KHI@$@PB@A$4%0LJ#0[AC(9"T%10;'W?N_UJF"[ M%K!CA7[_O?N_S?._S,,EO_O^]=CEMG[U7?)`4$850/>DT8%)N M_T'S*ZJ:$3D`"HN7U#CW7KOO)R+5F<@:7+:X?,'WWV>W);+U(FK3J7S^A65Y M5>63B=)^1)N4BE)/R?L9>S\BFGDW^@^K0"!T3\@HHO`TE+M7+*A9UK?TR""3G>MT$@*_6&S40NJP?:O6PTFTS:C3]UG#C*/CCI!]*U'+M73F M9S+-I6K>D0/4-OT?_#3\N%U@745M]' M-FI/Y/_9?[SE3M",,_TUDT@V;2+"HD#ZZ_A"JH M$G=F'LVG!;30+"U$73F^RU":@U;%:&7X7ULMHL6@BFJHEI;@9S%\=:!DU%U@ MEFMI*7Z6T86TG"ZB%507^%YJ1E:@9KE97@96TL5X,I?0I:83Y<@JNHQ6XZFM MH;6T[D]+ZTZ[!KJ"UN,Y7TE7_5N_X3>EC?BYFJ[!?-A$U]'U="/FQG67<=(MM,9]0>H"?I?MI#>^D!\UX6XZ[Q'9'[4F;>P\6X!RMP MA:O..&.^?TM/WZV5N';CVAH"5[H,\4O/Z+$DOIRUX`W?@V[BKAKL5 MGMTVTY\9WWJZ[7:S?!O=3G?@6=QE.E&.W`E_%]V-=_L>:J1=^/G5G^E8]]!N M\\EYJ8E\="_=AR?Y`.VC9C/^9W5_%+\W$/>=CNRG!^DAS)!'Z"!6FL?P(Y&' M$7LT$#ULQKC\&#V.LM&*2T_24UBAGJ7GZ'EZB9Y`Z47S^VF47J97Z35Z2X7" MO4*?XOL4H.1Q)7-FSYHY8WI!OCLO=TK.Y$D3L\_/FI`Y?EQ&>EIJRMCD,:// M&S5RQ+E)PX<-[=^O;Y]>/1*ZN[HY8J,B(\)#0X+;!-EM5JS$BOJDNS(*G=X> MA5Y+#]?X\7V-LLN#@.>,0*'7B5#&;]MXG85F,^=O6R:C95FKELG<,OET2Q7A M'$6C^O9QIKN6Y'F M]*I"9[HW8TE%0WIA&L9K"@E.=:66!O?M0TW!(;`A<-Y>KL5-JM=H91JM5_J( M)NQ#H<9AO7I"NJ?$.SDG/STM+CZ^P(Q1JCF6UY;JM9MC.2N-<&XX0UQ? M?+QQ+EF'@=TE%K+>^R-FW#^Z^^9N`7]0[O7J/PJ+B"D,]I0VNM#2^;WGYWN0TF&1/ MX%K3FP;T1WM/(2ZBTK@-.?G>_J[%WBA7"C=`P&D\@\KY`+>OP)5?6F`\)5>$M_<1'"[>/*+9"]?6JK4T-J[< MGA#DS-?B]`+C:2'@S,"7*V44*B+PN,RB\4131CGS51Q),QPET,)POQD'!3TA M=;Q1I1M=4\?'Q1?$\^=/3BDN<$[6!&_0&6-%('#ZG/@X__;4N+5Q0KV=Z:5I M9YS@;P:U!DXP,-H?GZ=FW(O`@=$CR'B\%(]J*6BIF(,9 MB7'R6,WR.+-\NCB^576F5#L;@EQ9N0W&X*[`@.3$&X2+MO7(]%R1U&X(7LT, MK&ZN#(_+&>',:/`T^^N+&IJ2DQL6IQ=6C##&<&66-+AR\T?%F>Y/-J&9$C:!1/V)Q/5F[46,V"6BYL5F;$@B2DJ;M8X%B$Q M#3$+QY+-F/'!0XJMP"W&SXJ"BH;"`N/EHA@\2OPJKW*-)J_F&MVD M-%M;;["K-,4;XDHQXF.,^!B.VXRX'1-#Q2C<'&--:BAT89W"A,JG.,5343>& M=#;[_7GY\2_$'2^(QU2;":;G>]LD8NVW)DQ`NW$&A0B/\]87>XSS('>^T=>> MD%E<@&DK`Z))IK<-1F@3&`$M,LP^QG1$IV(\&SQ`LW\]"M[Z`F]!HG'0_,H" M&F\:P0>.X]I[6$UN<>;$+5<6%3MQM"Q7G8JKS6AHB`NX.J3.-<\+L&IVHT M/60,D]-,4US+L+(8)VV.9$>U-S0ATX/%G_N'(.)*DLY!QAH1$ACC,$?MQI6W MQ7W7$_*:_7>Y+HP_X].WC\O8'(R)27'[,;&IH*%UP#LCL6^?H-;14#/S7DGH)D1WD M^JO8XOS/&UBFTRY+&GG^D&.H.T8W6/P49Z!_0KM`>D`S`A2#.>"20'R7OIMV M6=O2C-983F(\8,5?R9J%=FD6_P1H+^BY8""8#":!BQ#O"GI:KD&[#637-OAW M6GJA/]!GF5RB%P7\8NILF4V[;&]A['/^`#LXGXK_6R8QMB^IV-(-QP+6(OA\ M>";74%S?N`#1(/9T^6,*/Q-K-[KGKV)IH&[VKG1>:RP]:0#&ZOH['J61`3J9 M^AU%_%6L,_WO&U@LM$-_CA;\$992V@'F6I;2(`.]'FWK<2ZLS@!]0&^0$HCO MT">CWZ4T_W-`3N,$4<`'BD2#6$D<[M-%$ MVFC_>OT9C`VT(R9KM(\#_BN?9C-89OHR<`^5_;<\R&"<,OT) M'`M8FN"/PS/IIDZB3,9_`GQ_NEQ`G?4"?PLKYN,&V@9N">@-H#;@?X=^BN)M MHVEX:_3G:9B^"L^L-964%B#(U#=H9BNZ_D',Q-:?L0RAS7A_I@>8"*9)V;Z( MIMO>`8I!VT++>C`7#"&/_@O-^BMH%U""[29*"'J#$BR-\#<'_*A63&I%(&Y; MTHIUK0C$?].^#8Z1>L;8JWZMLQQGK.TIP=Z+$O3#-+0UYK7^GLV6(?[=EE3_ M3^I-6JW>]"^$AD.G`R>H`OF@'/%(L%D_2*LM76FM^LS_1H!B_3;$`QAMP#E: M9U.SU"_463M%FVTEQK%^PT13;_5O,34)S^.W3/I=;!1C>]Y\=C).H?8L;6;\ M/T$7ZO&4PV#>QOM/2=FZA\%8F]77:+^'XK7#P-`#U,/R,<5;:O\:N-?Q]BS, M[[__-7">F\"5`;T<9(-U`;_I3/0MU,W:3$-;HR_%FK2-NOV.WE00P&YJ$E7I M'BK1EV&N[J(T[2.:KTTT=;S63./4(>JNW8!G]"G-5\7D40O\?T-YOIJ-]6PJ MVGYLDF[V0Q_U/70`I:@/R&7TT5:30_^2^F@KL<==3@YM.*5H>5C/:L$F8]<^ M%41T\A-MZN]C.#_2YP`S=G(;*&\5VP(JE1_EF\"MX&XS7@H*]>X8[P1B&:#< MC&\'*_6>*&>"N:?'J-/;HAP.(LW8+K!3NQK];P3;S=BGX'T-.8;V&+@?;0^! MH\@YS.SCY!0P4+V(/.1-\"*#:\DVP+5=!EVN76SJ$O4#7:8-E'S%O\[(0?1< M[*^7T0C.(5J>,O8TSA=:MAI[,^<++?@SP3_%S`.NH^ZRW^,>Y_(>[H\Q^V#? MUAN1F_`^C/VR9:&AMO8X)O93&]%&ZV2:;9W<\A/OB?Y:8R_4?C'W&!?O92VO M&&LK[ULMKUONHS+>MUH>QAZ59^Y'1RE2]AU]#4@W%Q7[L/UE4%OP%S7*%O7\>[(FC"?>EG:T1+T M+\#SGZEW)-WBIHT!ZD",=1BYK2/)C>MN9]U)FZS74(F!MLY\EL&X5\:S'J99 MZ8;3=,>\]]-"`_-Y9M-N\WDN#K`$SZ@GZ6?DCAY;!8[Q+&59C?PJ0"`?G&SD M>J?SK0](M_T,WN*\T:[_FL=9?N+G;.2IDGOA.IEFK`N;^%E;.Z/-"5!%-;9O M,$97^,\IW!8+309%-,OBH2)[$/P%R._\Z/\->-[U M%'9&/M3'N@Q[<#U-LZQ#W3JZ'EP7R''<1OZ":]UA@&>KS/FR+)"3[`1S`W/% MR+LDC]B".;L%.7=_7$A3B78_TP*;"_E..LISJ(-U%6*?@`]IGOX5 M\I=!\'[L[W/(82D&>`.QARLSCOW?DHK[8LRM-["N'PX`CSF1B3RO@[%/G+F' M8_S1R`FR++F8>[G(J7*QI_$>6&7L:_H#Z`LLT11CTZB]M9+F6,9A'^L5V*L& M@G-^W<_,',/89SI2L+'7!=;F6/U5ZF9I01QK-^;B9LM@8H^!*S"W-^#H>!=K,*UFZF1PWT M^VDUF&WR+N9V(1T'37H)+<=>,`?S^!QC3H.'C/EMO9RN1VR]$1?%,UH+$D4# ML43M`:H!!T4M'9'S=<3[$%"]`RGM/>P)>U6#?E+M03D$Y;Y:-?80H)]$/@GL MH^FZ,T'L)_TD'3K]SBV@U6"Y5H-KJJ'IVF4T%=1JR5A7DQ&?0%Y0_N_:8:RM M8"E8!I98O#3/S&/PG`_3N)]"#-SIWSX_6`"RKG0!;@7B?!#]&^Q M5V_#^_L(_G[<;1C6@V&8VV$T'NP!5:`<.$$IF`>*P1235-R;#=11OP3K8#76 MPUW40Z_`>>S#/"%ZBGM8[2X=.QMQOYW/B@ MB30>L9GV9_"\3F)?/TGG@T*0"&8'?`'`.X1GQ?5N,-68S]9/J8_%2D-MKU$E MGKU'.X[\[R0%&?F&D0<8>Z:M%&MQ'LVPQ-`$O',W@>O!,R9AM-<>ID:(!D^D MFVQ)^-NMC'KYVNC.9NVR^]K$J@DPJ\1<*N82,?5B+A:S4DR=F!5B+A*S7,R% M8I:)62IFB9A:,35BJL5<(&:QF$5B%HI9(&:^F'EBYHJI%%,AIEQ,F9A2,25B MBL44B?&(*10S1\QL,;/$S!0S0\QT,05B\L5,$S-5C%M,GIA<,5/$Y(B9+&:2 MF(EBLL6<+R9+S`0QF6+&BQDG)D-,NI@T,:EB4L2,%9,L9HR8T6+.$S-*S$@Q M(\2<*R9)S'`QP\0,%3-$S&`Q@\0,%#-`3'\Q_<3T%=-'3**8<\3T%M-+3$\Q M/<0DB.DNQB6FFYAX,4XQ#C%=Q701TUE,G)A.8CJ*B17304R,F&@Q46+:BVDG M)E),A)AP,6%B0L6T%1,B)EA,&S%!8NQB;&*L8BQB=#&:&"6&`D;YQ;2(.27F MI)A?Q/PLYB^+.2KFB)CWQ+PKYATQ_Q3SMIA_B/F[F+^)>4O, MFV+>$/.ZF-?$O"KF%3$OBWE)S(MB7A#SO)CGQ#PKYADQ3XMY2LR38IX0$W-(S$$QCXIY1,S#8@Z(>4C,@V+VBVD6LT_,`V+N%W.?F'O%^,0TB?&* MV2MFCYC=8G:):11SCYB=8NX68.\7<(>9V,;>)N57,#C';Q6P3LU7,%C&W MB+E9S$UB-HNY4)6F/DK1'2=JC).U1DO8H27N4I#U*TAXE:8^2M$=)VJ,D M[5&2]BA)>Y2D/4K2'B5ICZH2(_F/DOQ'2?ZC)/]1DO\HR7^4Y#]*\A\E^8^2 M_$=)_J,D_U&2_RC)?Y3D/TKR'R7YCY+\1TG^HR3_49+_*,E_E.0_2O(?)?F/ MDOQ'2?ZC)/]1DO\HR7^4Y#]*\A\E:8^2M$=)VJ,DVU&2[2C)=I1D.TJR'279 MCI)L1TFVHR3;4:GW&@99LZ_K:`=R9E_7:,BE7+K$UW4$I)Y+%[.L]'5M"ZGC MT@J6BUB6LUSHZS(6LLS7)16RE&4)2RW7U7"IFJ6*@Q?XNJ1`%K,L8EG(31:P MS&>9Y^N<#IG+4LE2P5+.4N;KG`8IY5()2S%+$8N'I9!E#LML[C>+2S-99K!, M9RE@R6>9QC*5QS9+%,\,5E0C)9QOOB)D#& ML63XXK(@Z;ZX\R%I+*DL*5PWEOLELXSA?J-9SF,9Q2U'LHS@[N>R)+$,9QG& M,I0'&\(RF$<9Q#*090`/UI^E'_?KR]*')9'E');>++U8>O+0/5@2>,SN+"Z6 M;CQT/(N3^SE8NK)T8>G,$L?2R==I(J0C2ZROTR1(!Y88#D:S1'&P/4L[EDBN MBV`)YV`82RA+6ZX+80EF:<-U02QV%INOXV2(U=6G[GN)R[]R/(#R_9#O?+&YD&^Y]`W+URQ?<=V77/J" MY3C+,:[[G.4S#G[*\@G+OU@^YB8?<>E#+GW`I?=9CK(97E%9:7N M8WF6FSS#\C0'GV)YDN4)EL,LCW/+Q[ATB.4@RZ-<]PC+PQP\P/(0RX,L^UF: MN>4^+CW`JUV\BAW ML]S%=7>RW,%R.\MM++>R[ SK*-!]O*HVQAN87K;F:YB64SRXWR&I?=!'D M,I95ON@RR*4LE_BBW9!Z7S068W6Q+WH89"5+'7=?P?TN8EGNBRZ!7,C=E[$L M95G"4LM2PU+-0U=Q]PM8%ONBBR&+>+"%W'(!RWR6>2QS62JY7P5+.9]9&7ED*6.2RS^:)G\9G-9)G!%SV=AR[@`^6S3./3G2RY M+%-8H3"Z-9QG' MP0Q?U$I(NB]J#23-%W4Q)-4750])\;7+@(QE2689PS+:UP[[NSJ/2Z-\D060 MD2PC?)'&U#B7)9#QGFBYP.&S/TL_[MZ7C]"')9$'.X>E-P_6BZ4G2P^6!%^D<9>ZL[AXS&X\9CP/YN11 M'"Q=N5\7ELXL<2R=6#KZ(F9!8GT1LR$=?!%S(#$LT2Q1+.U9VG&'2.X0P<%P MEC"64):VW#*$6P9SL`U+$(N=Q<8MK=S2PD&=16-1+)3L#R]R&+2$%SM.A9A M;X3.=[P>VL/Q&G@5_I701,?+X"7P(NI?0.SYT`6.Y^"?A7\&_NG0N8ZG0BL= M3X96.)X(+7<<1M_',=YCX!!(]A_$]Z/@$?!PVPL`N M<">X(Z2OXW;H;>!6]-D!W1XRS[$-?BO\%G`+_,T8ZR:,M1ECW8C8#>!Z[Z]PK&^O<(74JI"ZN+JONHKK&NK?KDK-MP2OZE[6 MN-2]I+'6;:F-JJVIU;^K58VU*JU6#:A5&M5&U#IK];8U[BIW=6.5FZHF5]57 M>:LL([U51ZHTJE+!S?Z#]U;%=.SR+BV4E9[O,;L]P3DL:[,QO'N\89S`Q,XX$XI3*0/BDN..Q'T59Z$X;]S!.+U=>"=')ZUW>$>5.JFC M6M3QXHY7==3#8U^*U9)C>_?)"._P4H?W.GS9P=(^N4/O?AD4$Q'CC-&CC6N+ MR<[+,'5,&NO`H>:U9L>X>F2$1ZOP:$>TENZ(5A1Y)/*K2#WZT8B7(K3P M[@_7DL/1/#S,$:897_XP/3ELX/",\%!'J&9\^4/UF.101(P1>[:=G)<1'N(( MT=QC0B:%:,DA8U(SDD/Z#L@@73F5(A4!T8/0]CX5[ M+*_>L(&ZI&1YN^3F^_3MV[ND%&1YZPV?G&QZO^$)30H29U?75B"2T`]N!BL!'5@!;@(+`<7@F5@*5@":D$-J`87@,5@ M$5@(%H#Y8!Z8"RI!!2@'9:`4E(!B4`0\YC^J*-'F@-E@%I@)9H#IH`#D@VE@ M*G"#/)`+IH`<,!E,`A-!-C@?9($)(!.,!^-`!D@':2`5I("Q(!F,`:/!>6`4 M&`E&@'-!$A@.AH&A8`@8#`:!@6``Z`_Z@;Z@#T@$YX#>H!?H"7J`!-`=N$`W M$`^]`.1((($`["0"AH"T)`,&@#@H`= MV(`56,;Z\:T##2A`5*(04RW@%#@)?@$_@Y_`C^`'\#TX`;X#WX)OP-?@*_`E M^`(`Z\%U8!.X%EP#K@8;P57@2K`! MK`=7@`:P#JP%:\#E8#65C*U7>/\5WG^%]U_A_5=X_Q7>?X7W7^']5WC_%=Y_ MA?=?X?U7>/\5WG^%]U_A_5=X_Q7>?U4%L`8HK`$*:X#"&J"P!BBL`0IK@,(: MH+`&**P!"FN`PAJ@L`8HK`$*:X#"&J"P!BBL`0IK@,(:H+`&**P!"FN`PAJ@ ML`8HK`$*:X#"&J"P!BBL`0IK@,(:H/#^*[S_"N^_PKNO\.XKO/L*[[["NZ_P M[BN\^PKOOL*[K_#NG]T)_J-/P=E;\!]]8N?,-C),:JG67[6&D4YV.I>R:2+- M.$"AF-,Q-$+=?W]T6EI07_LCF*\:.3'C@Y"2IB:'6[30?9TZC7'M&VK;H$=F MX@_W^\;8-V`M'W/JW5,O]C_U[O%VY_8_KOJ_<_3=HQ%?OQAY;O_!1U\_.G"` MBHR/-(D*T^SV*)NK6S]M:,\>PP8/'C1:&SJDAZM;F&;&A@P;/EH?/*BKID=) M9+1FE)7^ZLGI^J13-FVE:\S4P=:NG<*C0FU6K7-LN[ZC$B)R9R2,ZM?%KMMM MNC7(WFMX2K>L^>G=_F&/[!(=TZ5=4%"[+C'172+MI]ZVAOW\C37LEU3+_%\V MZ;:1,\=TUV\,#M(L-EMSU]B.YXR,SYP:WC["$M(^(C(FR-XNLFVOM)FG+H_N M;(S1.3J:QS+^M7C@_V9+.`K\UX&WPNP+>3G7J06,42QM$ M.FO#`UZC,"TWX'7$/0%O@:\+>!O\9G@%C_/1[@]XG(_>D7:2DP;1`/P,@\NF M2BJF*EI$U:",:A!+A:NBQ>:W!Y%*N(74#S5C:3Y^G#0%L7*J0%VU62J%EJ+U M$GR7H&4J^LU'FR+$*M&BTFQ7"JU!+Z.E$RV.&X)2@N@ M530/L46G^_QQ;=G_T;489[30',LX&R>Y4:HTS\$X?BZ95&ZWX[G8,&#!CFS*XLKEI4O:BLQIFZJ&KQHBI/3>6BA?V< M8^?/=TZI+*^HJ79.*:TNK5I26M)O;%9V=F9:8JIG?F515>6?E0+BK*QVEE;6 M5)16.3W.JM+RRNJ:TJK2$F=-E:>D=(&G:IYSD5%S1K'LC\_'6;G0B6&<[H65 M->B?6^.I*:UV>A:6],<`B\P#%"^J75A355E:W0^//@LW.)LR*8T26SW@*>9C MK$7$>"!_UO+_MN[LI/T?G+3F?T;&RN&AW5@C=@&-(M"YE,@5JR[%VF+^HQ#C MO]D??]&5.B=\U`GJ&&0N4P]]ON)Y0P^E?-+FY,"6ZC8/V+>B:*Q3YCKV7P(, M`--GO4,*#0IE;F1S=')E86T-96YD;V)J#3$U,B`P(&]B:@T\/"]3=&5M5B`X M,"]&;VYT3F%M92]!2TU-240K0V%L:6)R:2]&;VYT4W1R971C:"].;W)M86PO M1F]N=$9I;&4R(#$U,2`P(%(O1F]N=%=E:6=H="`T,#`O1FQA9W,@-"]$97-C M96YT("TR-3`O1F]N=$)";WA;+30W-B`M,3DT(#$R,30@.34R72]!7!E+T-)1$9O;G14>7!E,B]&;VYT1&5S M8W)I<'1O2]#2413>7-T96U);F9O/#PO4W5P M<&QE;65N="`P+T]R9&5R:6YG*$ED96YT:71Y*2]296=I2A!9&]B92D^ M/B]$5R`Q,#`P+U1Y<&4O1F]N=#X^#65N9&]B:@TQ-38@,"!O8FH-/#PO1FEE M;&1S6UTO1$$H+TAE;'8@,"!49B`P(&<@*2]$4CP\+T9O;G0\/"](96QV(#$U M."`P(%(O6F%$8B`Q-3<@,"!2/CXO16YC;V1I;F<\/"]01$9$;V-%;F-O9&EN M9R`Q-3D@,"!2/CX^/CX^#65N9&]B:@TQ-3<@,"!O8FH-/#PO4W5B='EP92]4 M>7!E,2].86UE+UIA1&(O0F%S949O;G0O6F%P9D1I;F=B871S+U1Y<&4O1F]N M=#X^#65N9&]B:@TQ-3@@,"!O8FH-/#PO4W5B='EP92]4>7!E,2].86UE+TAE M;'8O0F%S949O;G0O2&5L=F5T:6-A+T5N8V]D:6YG(#$U.2`P(%(O5'EP92]& M;VYT/CX-96YD;V)J#3$U.2`P(&]B:@T\/"]$:69F97)E;F-E"]%9&EE"])9&EE')E9@T*,"`Q M-C,-"C`P,#`P,#`P,#$@-C4U,S4@9@T*,#`P,#`P,#`P,B`P,#`P,"!F#0HP M,#`P,#`P,#`S(#`P,#`Q(&8-"C`P,#`P,#`P,#0@,#`P,#`@9@T*,#`P,#`P M,#`P-2`P,#`P,2!F#0HP,#`P,#`P,#`V(#`P,#`P(&8-"C`P,#`P,#`P,#<@ M,#`P,#$@9@T*,#`P,#`P,#`P."`P,#`P,"!F#0HP,#`P,#`P,#`Y(#`P,#`P M(&8-"C`P,#`P,#`P,3`@,#`P,#$@9@T*,#`P,#`P,#`R."`P,#`P,2!F#0HP M,#`P,#`Q,#4V(#`P,#`P(&X-"C`P,#`P,#$Q,3`@,#`P,#`@;@T*,#`P,#`P M-3$S,R`P,#`P,"!N#0HP,#`P,#`P,#`P(#8U-3,U(&8-"C`P,#`P,#`P,30@ M-C4U,S4@9@T*,#`P,#`P,#`Q-2`V-34S-2!F#0HP,#`P,#`U,S8T(#`P,#`P M(&X-"C`P,#`P,#4V,#$@,#`P,#`@;@T*,#`P,#`P-38X-B`P,#`P,"!N#0HP M,#`P,#`U.#(W(#`P,#`P(&X-"C`P,#`P,#4Y-C<@,#`P,#`@;@T*,#`P,#`P M-C$P-B`P,#`P,"!N#0HP,#`P,#`V,C0V(#`P,#`P(&X-"C`P,#`P,#8S.#8@ M,#`P,#`@;@T*,#`P,#`P-C4R-2`P,#`P,"!N#0HP,#`P,#`V-C8U(#`P,#`P M(&X-"C`P,#`P,#`P,38@-C4U,S4@9@T*,#`P,#`P,#`R.2`P,#`P,2!F#0HP M,#`P,#`P,#,P(#`P,#`Q(&8-"C`P,#`P,#`P,S$@,#`P,#$@9@T*,#`P,#`P M,#`S,B`P,#`P,2!F#0HP,#`P,#`P,#,S(#`P,#`Q(&8-"C`P,#`P,#`P,S0@ M,#`P,#$@9@T*,#`P,#`P,#`S-2`P,#`P,2!F#0HP,#`P,#`P,#,V(#`P,#`Q M(&8-"C`P,#`P,#`P,S<@,#`P,#$@9@T*,#`P,#`P,#`S."`P,#`P,2!F#0HP M,#`P,#`P,#,Y(#`P,#`Q(&8-"C`P,#`P,#`P-#`@,#`P,#$@9@T*,#`P,#`P M,#`T,2`P,#`P,2!F#0HP,#`P,#`P,#0R(#`P,#`Q(&8-"C`P,#`P,#`P-#,@ M,#`P,#$@9@T*,#`P,#`P,#`T-"`P,#`P,2!F#0HP,#`P,#`P,#0U(#`P,#`Q M(&8-"C`P,#`P,#`P-#8@,#`P,#$@9@T*,#`P,#`P,#`T-R`P,#`P,2!F#0HP M,#`P,#`P,#0X(#`P,#`Q(&8-"C`P,#`P,#`P-#D@,#`P,#$@9@T*,#`P,#`P M,#`U,"`P,#`P,2!F#0HP,#`P,#`P,#4Q(#`P,#`Q(&8-"C`P,#`P,#`P-3(@ M,#`P,#$@9@T*,#`P,#`P,#`U,R`P,#`P,2!F#0HP,#`P,#`P,#4T(#`P,#`Q M(&8-"C`P,#`P,#`P-34@,#`P,#$@9@T*,#`P,#`P,#`U-B`P,#`P,2!F#0HP M,#`P,#`P,#4W(#`P,#`Q(&8-"C`P,#`P,#`P-3@@,#`P,#$@9@T*,#`P,#`P M,#`U.2`P,#`P,2!F#0HP,#`P,#`P,#8P(#`P,#`Q(&8-"C`P,#`P,#`P-C$@ M,#`P,#$@9@T*,#`P,#`P,#`V,B`P,#`P,2!F#0HP,#`P,#`P,#8S(#`P,#`Q M(&8-"C`P,#`P,#`P-C0@,#`P,#$@9@T*,#`P,#`P,#`V-2`P,#`P,2!F#0HP M,#`P,#`P,#8V(#`P,#`Q(&8-"C`P,#`P,#`P-C<@,#`P,#$@9@T*,#`P,#`P M,#`V."`P,#`P,2!F#0HP,#`P,#`P,#8Y(#`P,#`Q(&8-"C`P,#`P,#`P-S`@ M,#`P,#$@9@T*,#`P,#`P,#`W,2`P,#`P,2!F#0HP,#`P,#`P,#')E M9@T*,S(W-S8-"B4E14]�HQ.#4@,"!O8FH-/#PO3&5N9W1H(#$T+U)O;W0@ M,3,P(#`@4B])1%L\-#8R0T4P-CA%,C4U1#`Y138S.#1#0T,W-3A&0S8R.30^ M/#="-$$W,S)#1C(R,40W-#,X1D4X,SA"0S(X,C)!-#=!/ETO26YF;R`Q,R`P M(%(O1FEL=&5R+T9L871E1&5C;V1E+U=;,2`R(#!=+TEN9&5X6S$X-2`Q72]$ M96-O9&5087)M7!E+UA2968^/G-T-IB8FS8"Q!@``',`4$-"F5N9'-TG)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R M92`T+C`M8S,R,2`T-"XS.3@Q,38L(%1U92!!=6<@,#0@,C`P.2`Q-#HR-#HS M.2(^"B`@(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&%P.DUE=&%D M871A1&%T93XR,#$Q+3$Q+3`X5#`Y.C$V.C`Y+3`X.C`P/"]X87`Z365T861A M=&%$871E/@H@("`@("`\+W)D9CI$97-C&UL;G,Z>&%P M34T](FAT='`Z+R]N&%P+S$N,"]M;2\B/@H@("`@("`@ M("`\>&%P34TZ1&]C=6UE;G1)1#YU=6ED.F9F.&-E,6%D+35B.6$M-&(U,BUB M-30Q+6(X861C,S1B8V%A93PO>&%P34TZ1&]C=6UE;G1)1#X*("`@("`@("`@ M/'AA<$U-.DEN&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M M96YT&UL.FQA;F<](G@M9&5F875L M="(O/@H@("`@("`@("`@("`\+W)D9CI!;'0^"B`@("`@("`@(#PO9&,Z=&ET M;&4^"B`@("`@(#PO#IX;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E M;F0](G7!E+T9O;G1$97-C M%5EYVMK9J+-^543;([T4.JXCS0%"0Q(Y-:D+1'?Y_NTP!( M27;5YL$6``*-OIX^^+2^>?^;^OGG]U\_WW]1L?KEET]?/JN;]W_]9ZQVW7Y/,K5(BTB.O-T\^_@[L>^ M?JQ[E2516`1).,L"%?YG_;>;NZ]\RWASXF[&/0G?$_,-LV09Q2LU2Z,B+]1Z M0S(_WWU;W_]Z'\Z#SV$>?*2_=9@&]__X^RCX;GV3SDF)7,U7BZB8JV42+4C1 M:#571M]L;SZ=F9UZLT=S68-+\S(R;SDGF:MHSO:1+>O_7IF23:0E(@TN2S/O MO32%;>DJ*I8+&)=E8MQ]."N"VW"6!^HC#YN-X1_]HL+9//@8J4^8M[`5LI(" MSJ)1QD(749RPSI#6LJ#O_*\C-]VJ2IN^WIY4O^>ULO_I]6#DTV!8^5`XB_+D M/!A)I"@0]_QO7X;+X%F3@_FWI@MY\!+.DD!O*/JJIZ4]3_E;%R8!G_J#O@R\ M6)K>'C$'&ISXA-''D(TM`L-;>(/B6<,S/OUKN&`CD\`\A0GE5A+3U]GO?);W M;;%O78=)'.RTX>5_\;^ON"D--JQ)5?)]MR1-W3O95?2![WK5.\69=Q8^J#&" M&GOW?"'WI!0P$E3271V;MF&E1PN>2'T8^KVQ=L)=!Z<>+>S@OUMR'MDP\5X: MB*/%0>P!>(?$;]R*[GC:M/A0T5Y/\(:3(HF3N\U)MRZJ' M*PS^0P+!1-^*;!(Z42WWHE:2A?,HGA,R1(E-PB+V$97NNM*F MHM^!Q%'0^8(^S(*R(:7(BQO>8]3+ON9->]71V8$5J&C@BFRJFQT`AU1Y MJ04:>&QT=X2,B@.#U9YUQAIO./H;3"UUF%/R46)6[;-\HKK5&_7(DQ-_H$,B MO^Y0VS1J:=WT'UXOM?E9J2W'4@/4K?]"AF:NPC*NL-7_56'9&Q4&Z[:HD9)$ M-E5M;^!C'";&3I8`T-$H*:[(6U7R+:("T(XPAQ+N35%89YP"Q$%:V?-BVRB` MEH`1[QTV8MVX?(FG2R#"*CA"6`_`9SM0[".FOMDY8E=2#%R(C4$4.]U(]E!9 ME(<#R_0%-\F1SG85S>8N`IPI63N,*NA9XG2%3&DD]_I:9K93/%QY&<'0KK()<+JH8I)SLQX0V M&H6``NE-*69SGRH[0KI;+W&"37.O7R*E*`I.P&G;&LZMY57A4-$L7=&@0U-P MCL:[6\M=Y/1^+^72OEDGB[,ZF8]UDERWI!P=>[W7-F&6P0[YPPECN(4CG=_1 M`$W&YS%IQ_0AS)%N6YIS.B&#=X*`G,AHJ-H\!#3A\P\A?V/'%=)>56FLKSMT M+TH+7ZT=GWY$;2)82&2EI>!H]R/-#U8!%KZ7VR%5"D]*B#Y)95G.<+;@!S@' M!M!1A5%5H6EV`U#KO%\:UU(/KO?:'N<@EQUKC3R"K=#^"JQG@(M1G0]!B8Z\ MX17!!.$$#@;XX]V/2G*%>A&O[>"*CY7K[M\8"Z8DH5,);,`K!0\> M0*@H"`@LKT!'^5YPXB5T`LP\P0H%C@$0A_RQPNMH'0J6UH`W24$W`$_3NA7V MW#,D&8NEC%JE@[]4X&_B1)NU^$5WPH>MYSHF*^$L9:?E5P61 M9S!X$7I7-QS]'G/.9H+:=?=K62$G1,>TYE!Z#!?\*;)[A],XB42N-D9YZ5B6*N&ZP7>"'F9)K[^`:#MHR6X`9 MDRZJI0F/H*VO$0EDW,'2#E]4.\G*]IQ)L*K"(G:.5$B6-L(G+DF)PQ!?IVP( M3QPEFO3*U.=HMKSB&\P)R+<=?@[UAG]*]$`22`E`/X_\K^/@U0`!FM6EJ3F_ MZDY8"18UXDM\C\;M"W[(0,[`F4#LX`7Q#&)/G$#8P#OW(N9-PITFT2KUKR/3 M39ESW9PSY;;3%-F>>`XK>O2LR/1U-?",\CPHS>&D-I@:Q\;_)->>^->_DS)Y M)UDU)URD%F^\P,":GAR]C#I)DB-<%K)RUJ6/WJ%02_R';09?,*2.#L>_04Y6 M#JAF(XN'EMDU.7D('D>4VD';LQP@E<4&XI_X)49)J"2!([TE?12_/PKN/8Z* MTD8IW6)DHMY>CP07($K^RPD=7)C'?D1`<"O%?HEI@)\+/+/%F=K"30%-6)#B MK2XP+9?FV#ZCRTZ?(LO@M08ZNW@<"5.>6>VGCT+FD(A=[Z.)Y^G"UH:+-AFT M\<.+."`,39@$XPX#,2V^R+@;CO*5%IXEPVJ)TJV0];-K;3ZE@81-BE]3?,I. M#I50[*!QKNRZ`=R<0LF;=BZZ1B"!`[Z3&_9.T*$6$?6A[D_T+4GEZFTX[01, MX5TGF%\A%`6A&!]QA7W$%1>/+E:@8`6P$;R!%T=P!3W$"4`[/5;L&9!-2Z3E MS9A(B^"++JXDZC`^0?P3*5G8K(U]TA*$LIU/+$M+Y,C_]%:C5XG2Y*H?F&N0 M.6)#Q\$<";$Z50L9H5B5%6VK6K,II90R=KL%O-%W$RTREW[Q:HH].]WPA8:> MD"<26NDCP3L/.`\&0D@X+!.J=S0RY=OJXT%W;V!+$I^Q(*]$_"JV5((M=\\E MR,50NHK<>(J64KZ`GF]UY0K^&7>H_>VT>O$&'*Z-_<,EISM[EV5G#65A7-I MGEZ3(^/;`P/+7.8]DGC`7,"9F".C&I8$".A7<4FZC;VR?7?._M]*;;+LJJ^? ML8I#NB/';Z6CV\T;_JG9E^CPC#U>$RWPBJ.]P=<#W=O@C.UDO#61DQ6"B(^# MG*>.75[=J,?S]DLH6,,?QV:R&,$DO0*3HS:@4BVX?H7GDC821@;B4UA,6)FC M8I)<#FKDI?58"I.&.G@!=8-_0?*B?D:;D62O+=EL/ER_.%XOL&1:8/'*%]C\ MM0+CQ++]FT/2=NYQMG*IMJ^1H,Z0G*F&>T.<$*X]DI>>O9-3-+JJL"D&CH4O MS2^-SSIW"4[&!.%=IX2@"7_(/7_(/7_@]KL(0"%RH1"RD8S"H/+<@5V9NF:: M2X+0QGZ"BA?^FEG%)K#85M5@C`_A9A#D(WJ^/[?6OA3?,?J@1BG?"-=3BR"] M,N.UB0=CO&B2(DH6N7.'KHB/DEE=18;\,3"L&W('W_X0P-7^E8I;%^[6"2S$ MA78&\@470);J@;6#5GOM2%W)K;K16:KJ*A=7X&CG-)`W$G-I%)E.W/()3E$M[@J14N4Q5@F'6IQ)E^? M?MT`"%)+YF";%JE&`WQ;D_\=I1(23'<@B!VV)>O,E@LI-C@RNZZ&O7A]NDP< M+DRC21S:1E7),E^M9XKLT*9@J@@J8>UGLJI=_5K1GT.KKI]OHH/"G2^_E-*$ M5.DGMDO-+);CZ?\?>IGL"![7-]/B%?V_Q)D_D%(1'NH(JT0MGW;PJ(&&NHRRVBZQ5 MVR@"-6`6R.P%O@F1JM.-7@75-HPA8I$.UZBVX=[J1K*7YQO"+#G"7*?YX'W3 MZV6W[MJ=T7^V#DZ7=E2@VTTY'A1DO).4R:&AGV;HGQ?Z=,9^TPZ,QV!TF&C* M898ICYQF[)<[9A&`,RS$`Q+RL'U8P:5:W'RC5X\?OL,9A87!Q!))\#=;>):4 MA#C-B5N<.?6BO3<>9?%YCN&F.DE\9A-/D=6[?2NDH7'(?(*0WG8$B)CZ M)@%N7N[-&#@]@$HXF<8%SK:!VS_=?78SWAGW M8LN]3R-!8I\YY][3M!1COM_M%$:ZFOA"9TXGJ=:@(OU;5X2:BGG(#!K!VIZC MZ%WJZYW37O51E:\-Q32H/+Q6LE&%-3(>)?GE>/0.>\J(RI$LM^_BO4P5ME;F MG$QKS)J1A7-Z.[-Q4CZ0HE_*F98HE-F&1R_G]:GQ>JN0([_'M7@^!B&V_7K% M?U395=9&I"'$7&J&C82WA7@!/Y''UY(S&'3C4V$]XA./Z%7&3H_@1^(G\%-J MCGLAYD\AIW[8\2KVQYP:%85&66GB)NM=??AF,/PI%:&#S-'P-U-\`!U9&7^\ MHG<\\_B5]6DW%.V*G'990]\?A>E$F;(#SO^ME!&*<;`=RU@A,N8$:V,9+PSL MLZT)MA:^9[Q)!O-BKPJ7!T8(BZ%-PY$<"DN&M1`I0P,S@4`E:D7&E0&M4`YD ME];&=.R\I,.3$2R>\OY9#&:]2O(V^DV>["9W,H2&+!Q[L$!V376:$KI3(5#P M9Z@MTM)**WY?F`;XJ7>>/+&CJMJK#_H+G6TE4)VPBBI))?!54@I,NGR]*HUJ M7?7-P9!C:(@DGPN?3$3V()N?079,;H2%B]QV^=Q6+_M\[J*BX:J^`H=T(*-1 MKT61)*Y4!WD$4!06Q#]+A"+%/U2?I>I\N8P4H7XS`:G`J4#)U2+5>5)D-$5% M.BR(#LNWR?17DJ6W9^H\3.Z6?^';H7P[U4E26$;.:(C!4F$H)'.I(#0+T))Y MJN."ED'Y*./B"B7/MIGYJ/=VF156"ORNXZ#0B\2K^L=T3O``\.;6Y.XQ:JX[ M0.5#W6N\I`>@'M!O7_?><7]=3N:/OP=JM2><9)@2O-]JOVHF=KV`@EVAHCC4 M$":=%P23R6:")Q?JI7\LU"GN1XG\XH>&-U&#R-W?#G1!F?%EDB:!QLE=K&$7 MNOF0MU#D;L975[GPS&@WO.FS3J30E9.QC[EU+M5X6`X@D#L(4-T>IXJ$^HJGZ32&\KV(8O$"$)(J`ESW5^BP6%/8+Y8_1GX!B+HY.MTE4: MZ$1E(2ZIT(\PAI]L+4+R?P,`XF9]"0T*96YDF4@,3@V+U!R978@,S(W-S8O4F]O="`Q,S`@,"!2+TEN9F\@,3,@,"!2 M+TE$6SPT-C)#13`V.$4R-35$,#E%-C,X-$-#0SF4@,3@V+U!R978@-#,S-S8O6%)E9E-T;2`S,CDU-R]2 M;V]T(#$S,"`P(%(O26YF;R`Q,R`P(%(O241;/#0V,D-%,#8X13(U-40P.44V M,S@T0T-#-S4X1D,V,CDT/CPW0C1!-S,R0T8R,C%$-S0S.$9%.#,X0D,R.#(R M030W03Y=/CX-"G-T87)T>')E9@T*-#,V.#(-"B4E14]�HQ.3`@,"!O8FH- M/#PO3&5N9W1H(#$T+U)O;W0@,3,P(#`@4B])1%L\-#8R0T4P-CA%,C4U1#`Y M138S.#1#0T,W-3A&0S8R.30^/$4S1#`X148W,S`R1$0X-$8X-#(T0C9$0T(Q M-#=&1C,X/ETO26YF;R`Q,R`P(%(O1FEL=&5R+T9L871E1&5C;V1E+U=;,2`R M(#!=+TEN9&5X6S$Y,"`Q72]$96-O9&5087)M7!E+UA2968^/G-T-IB8EP= M"1!@``&^`0@-"F5N9'-TG)E4WI.5&-Z:V,Y M9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM M<'1K/2)!9&]B92!835`@0V]R92`T+C`M8S,R,2`T-"XS.3@Q,38L(%1U92!! M=6<@,#0@,C`P.2`Q-#HR-#HS.2(^"B`@(#QR9&8Z4D1&('AM;&YS.G)D9CTB M:'1T<#HO+W=W=RYW,RYO&%P+S$N,"\B/@H@("`@("`@("`\>&%P.D-R96%T;W)4;V]L/D%C&%P.DUE=&%D871A1&%T93XR,#$Q+3$Q+3$T5#(Q.C$V.C(T M+3`X.C`P/"]X87`Z365T861A=&%$871E/@H@("`@("`\+W)D9CI$97-C&UL;G,Z>&%P34T](FAT='`Z+R]N&%P M+S$N,"]M;2\B/@H@("`@("`@("`\>&%P34TZ1&]C=6UE;G1)1#YU=6ED.F9F M.&-E,6%D+35B.6$M-&(U,BUB-30Q+6(X861C,S1B8V%A93PO>&%P34TZ1&]C M=6UE;G1)1#X*("`@("`@("`@/'AA<$U-.DEN&UL;G,Z9&,](FAT='`Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL.FQA;F<](G@M9&5F875L="(O/@H@("`@("`@("`@("`\+W)D9CI!;'0^ M"B`@("`@("`@(#PO9&,Z=&ET;&4^"B`@("`@(#PO#IX;7!M971A/@H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"CP_>'!A8VME="!E;F0](G7!E+T9O;G1$97-C%5EYVM MK9J+-^543;([T4.JXCS0%"0Q(Y-:D+1'?Y_NTP!(27;5YL$6``*-OIX^^+2^ M>?^;^OGG]U\_WW]1L?KEET]?/JN;]W_]9ZQVW7Y/,K5(BTB.O-T\^_@[L>^?JQ[E2516`1).,L"%?YG M_;>;NZ]\RWASXF[&/0G?$_,-LV09Q2LU2Z,B+]1Z0S(_WWU;W_]Z'\Z#SV$> M?*2_=9@&]__X^RCX;GV3SDF)7,U7BZB8JV42+4C1:#571M]L;SZ=F9UZLT=S M68-+\S(R;SDGF:MHSO:1+>O_7IF23:0E(@TN2S/OO32%;>DJ*I8+&)=E8MQ] M."N"VW"6!^HC#YN-X1_]HL+9//@8J4^8M[`5LI("SJ)1QD(749RPSI#6LJ#O M_*\C-]VJ2IN^WIY4O^>ULO_I]6#DTV!8^5`XB_+D/!A)I"@0]_QO7X;+X%F3 M@_FWI@MY\!+.DD!O*/JJIZ4]3_E;%R8!G_J#O@R\6)K>'C$'&ISXA-''D(TM M`L-;>(/B6<,S/OUKN&`CD\`\A0GE5A+3U]GO?);W;;%O78=)'.RTX>5_\;^O MN"D--JQ)5?)]MR1-W3O95?2![WK5.\69=Q8^J#&"&GOW?"'WI!0P$E3271V; MMF&E1PN>2'T8^KVQ=L)=!Z<>+>S@OUMR'MDP\5X:B*/%0>P!>(?$;]R*[GC: MM/A0T5Y/\(:3(HF3N\U)MRZJ'*PS^0P+!1-^*;!(Z42WW MHE:2A?,HGA,R1(E-PB+V$97NNM*FHM^!Q%'0^8(^S(*R(:7( MBQO>8]3+ON9->]71V8$5J&C@BFRJFQT`AU1YJ04:>&QT=X2,B@.#U9YU MQAIO./H;3"UUF%/R46)6[;-\HKK5&_7(DQ-_H$,BO^Y0VS1J:=WT'UXOM?E9 MJ2W'4@/4K?]"AF:NPC*NL-7_56'9&Q4&Z[:HD9)$-E5M;^!C'";&3I8`T-$H M*:[(6U7R+:("T(XPAQ+N35%89YP"Q$%:V?-BVRB`EH`1[QTV8MVX?(FG2R#" M*CA"6`_`9SM0[".FOMDY8E=2#%R(C4$4.]U(]E!9E(<#R_0%-\F1SG85S>8N M`IPI63N,*NA9XG2%3&DD]_I:9K93/%QY&<'0KK()< M+JH8I)SLQX0V&H6``NE-*69SGRH[0KI; M+W&"37.O7R*E*`I.P&G;&LZMY57A4-$L7=&@0U-PCL:[6\M=Y/1^+^72OEDG MB[,ZF8]UDERWI!P=>[W7-F&6P0[YPPECN(4CG=_1`$W&YS%IQ_0AS)%N6YIS M.B&#=X*`G,AHJ-H\!#3A\P\A?V/'%=)>56FLKSMT+TH+7ZT=GWY$;2)82&2E MI>!H]R/-#U8!%KZ7VR%5"D]*B#Y)95G.<+;@!S@'!M!1A5%5H6EV`U#KO%\: MUU(/KO?:'N<@EQUKC3R"K=#^"JQG@(M1G0]!B8Z\X17!!.$$#@;XX]V/2G*% M>A&O[>"*CY7K[M\8"Z8DH5,);,`K!0\>0*@H"`@LKT!'^5YPXB5T M`LP\P0H%C@$0A_RQPNMH'0J6UH`W24$W`$_3NA7VW#,D&8NEC%JE@[]4X&_B M1)NU^$5WPH>MYSHF*^$L9:?E5P619S!X$7I7-QS M]'G/.9H+:=?=K62$G1,>TYE!Z#!?\*;)[A M],XB42N-D9YZ5B6*N&ZP7>"'F9)K[^`:#MHR6X`9DRZJI0F/H*VO$0EDW,'2 M#E]4.\G*]IQ)L*K"(G:.5$B6-L(G+DF)PQ!?IVP(3QPEFO3*U.=HMKSB&\P) MR+<=?@[UAG]*]$`22`E`/X_\K^/@U0`!FM6EJ3F_ZDY8"18UXDM\C\;M"W[( M0,[`F4#LX`7Q#&)/G$#8P#OW(N9-PITFT2KUKR/339ESW9PSY;;3%-F>>`XK M>O2LR/1U-?",\CPHS>&D-I@:Q\;_)->>^->_DS)Y)UDU)URD%F^\P,":GAR] MC#I)DB-<%K)RUJ6/WJ%02_R';09?,*2.#L>_04Y6#JAF(XN'EMDU.7D('D>4 MVD';LQP@E<4&XI_X)49)J"2!([TE?12_/PKN/8Z*TD8IW6)DHMY>CP07($K^ MRPD=7)C'?D1`<"O%?HEI@)\+/+/%F=K"30%-6)#BK2XP+9?FV#ZCRTZ?(LO@ MM08ZNW@<"5.>6>VGCT+FD(A=[Z.)Y^G"UH:+-AFT\<.+."`,39@$XPX#,2V^ MR+@;CO*5%IXEPVJ)TJV0];-K;3ZE@81-BE]3?,I.#I50[*!QKNRZ`=R<0LF; M=BZZ1B"!`[Z3&_9.T*$6$?6A[D_T+4GEZFTX[01,X5TGF%\A%`6A&!]QA7W$ M%1>/+E:@8`6P$;R!%T=P!3W$"4`[/5;L&9!-2Z3ES9A(B^"++JXDZC`^0?P3 M*5G8K(U]TA*$LIU/+$M+Y,C_]%:C5XG2Y*H?F&N0.6)#Q\$<";$Z50L9H5B5 M%6VK6K,II90R=KL%O-%W$RTREW[Q:HH].]WPA8:>D"<26NDCP3L/.`\&0D@X M+!.J=S0RY=OJXT%W;V!+$I^Q(*]$_"JV5((M=\\ER,50NHK<>(J64KZ`GF]U MY0K^&7>H_>VT>O$&'*Z-_<,EISM[EV5G#65A7-IGEZ3(^/;`P/+7.8]DGC` M7,"9F".C&I8$".A7<4FZC;VR?7?._M]*;;+LJJ^?L8I#NB/';Z6CV\T;_JG9 ME^CPC#U>$RWPBJ.]P=<#W=O@C.UDO#61DQ6"B(^#G*>.75[=J,?S]DLH6,,? MQV:R&,$DO0*3HS:@4BVX?H7GDC821@;B4UA,6)FC8I)<#FKDI?58"I.&.G@! M=8-_0?*B?D:;D62O+=EL/ER_.%XOL&1:8/'*%]C\M0+CQ++]FT/2=NYQMG*I MMJ^1H,Z0G*F&>T.<$*X]DI>>O9-3-+JJL"D&CH4OS2^-SSIW"4[&!.%=IX2@ M"7_(/7_(/7_@]KL(0"%RH1"RD8S"H/+<@5V9NF::2X+0QGZ"BA?^FEG%)K#8 M5M5@C`_A9A#D(WJ^/[?6OA3?,?J@1BG?"-=3BR"],N.UB0=CO&B2(DH6N7.' MKHB/DEE=18;\,3"L&W('W_X0P-7^E8I;%^[6"2S$A7 M8&\@470);J@;6#5GOM2%W)K;K16:KJ*A=7X&C MG-)`7,1%,ZE4V)!`?3'JG%CKN">6;'@10+'(E=6T%>O#R=)PZ7)M%%'-I$5<$T7VYF MBN30NF"*""AA[V>2JGWU6M*?8Z.NUW>A@]S5ER^E,"95\HGM5C/;R_'T_XL< M.NZ-(^F>7"?4-R-#_]UF^(H3-H7M6<,O(C9B^BY30]2CAJ$!B'6RC!T_(-E$ M8Z?5KC0,D$U'AV^H/T@TRM:[PM@1J4A0&.BEN\)CM?U&&5,C;2OZVM/T0,U! M:3,\?N'?.]SDF92"^I&>P$ITX!$CE M^4:NTM76C,%B$0]7B+;EW*I:O)>G&X(L*6&FDZQWWW2]K-9MLS?\S]+![M*. M"O2Z+H:#@HQWXC+9-'33#/WS0I_.6&^:GO"8'NT[FJ+O98H3NQG[Y991A,;I M!^(!"7[8+E90J08OW^CJ\<-OV*,P,1A;(@[^9@K/XI)@I]EQBS(GGK7WQJ,T M'OL83JH5QV<.\20/ZAU>O3TT`AH:A\PG,.E-2PT14]Y$P/7+G9NGNNK!$]#J MO^G=B:TD:S$^JD7`:0$BH3*U,YQ-#;5_NOOL9KP1]F*+O4\#0F*=&6/O:5J( M,-_O]PHC745XH9I3)=4&4*1_JY*ZIF0<,H(&;6WK*'R7^'SGN%=]E,5K338- M+`^M%6]48H^41TF^'`_>80<983FBY>9=M)>APM+*F)-IC5$SD'!V;R,9)^8# M*+JMG&@)0YEC>/!R6I\8K;<,.=![/(OF8Q!BV:_6_$<5;6EE1!*"S:5D6$CX M6+`7T!-9OA&?P4TWK`KS$5<\HJN,'1]!CT1/H*>4'.="R)^"3GVSXT7LRIP8 M%@5'66KB)*M]=?QF>OA3(D0'FJ/A;Z:X`"U)&7^\ICN>>?A*.[<;"G=%CKNL MH!].@G2"3-&BS_\ME2&*H;$=TE@N-.8(:VL1+PCLO*TQMK9]1[A9].;%CA4N M#XP@%@.;FBTY&)8$:RE4A@1FT@*EL!4)5XIN!7/`NS36IN/D!15/1K!XRN=G M,IAU+,G'Z`YYMH?\\ M>>)$97E0'_07/-N(H3IC%U402^"KQ!28=/EY71C6NJJ;O2''P!!./A,\&8OL MM6PV:MDAN&$6+F+;^7,;O>C\N;.*!JOZ2CLD/1J-.BZ*Q'$E.L@B-$5NF_AG ML5#$^,?RLT2=KU:1HJ[?3B)R]P:ETU^)?=Z>*<'P;O47UL2R!L`#[@(E3^$B MT7&0A#1J13K,"3.KM\DT,5\*Y4N!3@('UAG--\@B#`5_SC"$)BX%S2AHCN@4 M-$HYI$+(4052'Q!>`=+KGPHOXQG5/GH"?G5O_N,85N6G31A[K7 MN+\'``*H:%X/WDU\74WFC[\':GV@%DHQ0'B_U6%=3^Q^`7F^7$5QJ,%9.LNI M@R8H2QHMU4NW+-0)WD<+^<6+^B\1@W#?O0YT3G;R99(L`HW*78QA-[JYR-LH M`L`@B=$N6Z>P6"G);@OEC]&?@@(K2R5'I*0GT0J4A M'BG0C]",GVPLZN3_!@`RI8*;#0IE;F1S=')E86T-96YD;V)J#7AR968-"C$R M(#(-"C`P,#`P-#0Q,C<@,#`P,#`@;@T*,#`P,#`T.#$U,"`P,#`P,"!N#0HQ M,S$@,0T*,#`P,#`T.#,X,2`P,#`P,"!N#0HQ.#8@,@T*,#`P,#`T.#8X,"`P M,#`P,"!N#0HP,#`P,#0Y.#8P(#`P,#`P(&X-"C$X.2`R#0HP,#`P,#4P,3`P M(#`P,#`P(&X-"C`P,#`P,#`P,#`@-C4U,S4@9@T*=')A:6QE<@T*/#PO4VEZ M92`Q.3$O4')E=B`T,S8X,B]2;V]T(#$S,"`P(%(O26YF;R`Q,R`P(%(O241; M/#0V,D-%,#8X13(U-40P.44V,S@T0T-#-S4X1D,V,CDT/CQ%,T0P.$5&-S,P M,D1$.#1&.#0R-$(V1$-",30W1D8S.#Y=/CX-"GAR968-"C`@,`T*=')A:6QE M<@T*/#PO4VEZ92`Q.3$O4')E=B`U-#,P-R]84F5F4W1M(#0S.#8U+U)O;W0@ M,3,P(#`@4B]);F9O(#$S(#`@4B])1%L\-#8R0T4P-CA%,C4U1#`Y138S.#1# M0T,W-3A&0S8R.30^/$4S1#`X148W,S`R1$0X-$8X-#(T0C9$0T(Q-#=&1C,X M/ET^/@T*F4@,C`W+U1Y<&4O6%)E9CX^7!E+UA- M3"],96YG=&@@,SDT-2]4>7!E+TUE=&%D871A/CYS=')E86T-"CP_>'!A8VME M="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK8SED(C\^ M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L] M(D%D;V)E(%A-4"!#;W)E(#0N,"UC,S(Q(#0T+C,Y.#$Q-BP@5'5E($%U9R`P M-"`R,#`Y(#$T.C(T.C,Y(CX*("`@/')D9CI21$8@>&UL;G,Z&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*("`@ M("`@("`@/'!D9CI0#I3;W5R8V5-;V1I9FEE9#X*("`@("`@/"]R9&8Z1&5S M8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@&%P.D-R96%T941A=&4^,C`Q M,2TP."TP.50Q-CHU.#HS,BTP-SHP,#PO>&%P.D-R96%T941A=&4^"B`@("`@ M("`@(#QX87`Z365T861A=&%$871E/C(P,3(M,#4M,3)4,34Z,S,Z-34M,#&%P34TZ26YS=&%N8V5)1#YU=6ED.C$Q9#,T964V M+60T-C$M-&8P82UB834X+6-B,F4P-3AE,F%C-#PO>&%P34TZ26YS=&%N8V5) M1#X*("`@("`@("`@/'AA<$U-.G-U8FIE8W0^"B`@("`@("`@("`@(#QR9&8Z M4V5Q/@H@("`@("`@("`@("`@("`\"UD969A=6QT(B\^"B`@("`@("`@("`@(#PO%LP(#`@-C$R(#%LP(#`@-C$R(#'1' M4W1A=&4\/"]'4S`@,3,V(#`@4CX^/CXO5'EP92]086=E/CX-96YD;V)J#3$Y M,2`P(&]B:@T\/"]3=6)T>7!E+U1R=654>7!E+T9O;G1$97-C?W7S_??U&Q^N673U\^JYOW?_UGK';=S?OU.E:)6F]O MXBB.XU2M*S7C8;Y0ZQ>5T#"E4[$=Y?D\RM4B+2(Z\W3S[^#NQ[Y^K'N5)5%8 M!$DXRP(5_F?]MYN[KWS+>'/B;L8]"=\3\PVS9!G%*S5+HR(OU'I#,C_??5O? M_WH?SH//81Y\I+]UF`;W__C[*/AN?9/.28E+J)BK91(M2-%H-5=&WVQO M/IV9G7JS1W-9@TOS,C)O.2>9JVC.]I$MZ_]>F9)-I"4B#2Y+,^^]-(5MZ2HJ ME@L8EV5BW'TX*X+;<)8'ZB,/FXWA'_VBPMD\^!BI3YBWL!6RD@+.HE'&0A=1 MG+#.D-:RH._\KR,WW:I*F[[>GE2_Y[6R_^GU8.338%CY4#B+\N0\&$FD*!#W M_&]?ALO@69.#^;>F"WGP$LZ20&\H^JJGI3U/^5L7)@&?^H.^#+Q8FMX>,0<: MG/B$T<>0C2T"PUMX@^)9PS,^_6NX8".3P#R%">56$M/7V>]\EO=ML6]=ATD< M[+3AY7_QOZ^X*0TVK$E5\GVW)$W=.]E5]('O>M4[Q9EW%CZH,8(:>_=\(?>D M%#`25-)='9NV8:5'"YY(?1CZO;%VPET'IQXM[."_6W(>V3#Q7AJ(H\5![`%X MA\1OW(KN>-JT^%#17ES,LY)E-*HM5M5DA4)A:_7G*&F)F^RU-C)X_PAI,BB9.[S4FW+JHB5I*%\RB>$S)$B4W")SK"%XO81E>ZZTIS8G&B&VOV75/:3]3G M#U"Y853J.[MU0[ZN&W6HQ0J^/_/W.]^L5KDS9;<70[:0OB!'UZ:BWX'$4=#Y M@C[,@K(AI`T>;A3+]I`[J3BO4+I M4G!$-&*/Y+ESR89+7',>W*H&0-"SB3'E3Q)T!Z"*;*J;'0"'5'FI!1IX;'1W MA(R*`X/5GG7&&F\X^AM,+7684_)18E;MLWRBNM4;]%0T2Q=T:!#4W".QKM;RUWD M]'XOY=*^62>+LSJ9CW627+>D'!U[O=YR"7'6N-/(*MT/X*K&>`BU&=#T&)CKSA%<$$X00. M!OCCW8]*ONWQ@+IB2A4PEMRW"`3LYXP"L%#QY`J"@(""RO M0$?Y7G#B)70"S#S!"@6.`1"'_+'"ZV@="I;6@#=)03<`3].Z%?;<,R09BZ6, M6J6#OU3@;^)$FYR.\#D^XSR##//^HP6V_%47WOV@_]6>_I7-#CEN??>-53CW M''\=G2=^\([C;#[S`-V2!U.QY MG,'@1>E<\YF@MIU]VM9(2=$Q[3F4'H,%_PIS60DLS/2C(-O"H69W(N MP3R8JF)+<"$M$Z>4IW=,*AU9DFOOX!H.VC);@!F3+JJE"8^@ MK:\1"63'+V,.DF2(UP6LG+6I8_>H5!+_(=M!E\PI(X.Q[]!3E8.J&8CBX>6 MV34Y>0@>1Y3:0=NS'""5Q0;BG_@E1DFH)($CO25]%+\_"NX]CHK21BG=8F2B MWEZ/!!<@2O[+"1U!P)4YY9[:>/0N:0B%WOHXGGZ<+6AHLV&;3QPXLX(`Q- MF`3C#@,Q+;[(N!N.\I46GB7#:HG2K9#ULVMM/J6!A$V*7U-\RDX.E5#LH'&N M[+H!W)Q"R9MV+KI&(($#OI,;]D[0H181]:'N3_0M2>7J;3CM!$SA72>87R$4 M!:$8'W&%?<05%X\N5J!@!;`1O($71W`%/<0)0#L]5NP9D$U+I.7-F$B+X(LN MKB3J,#Y!_!,I6=BLC7W2$H2RG4\L2TODR/_T5J-7B=+DJA^8:Y`Y8D/'P1P) ML3I5"QFA6)45;:M:LRFEE#)VNP6\T7<3+3*7?O%JBCT[W?"%AIZ0)Q):Z2/! M.P\X#P9"2#@L$ZIW-#+EV^KC07=O8$L2G[$@KT3\*K94@BUWSR7(Q5"ZBMQX MBI92OH">;W7E"OX9R^(0&G!Y=ZC][;1YRI:K%Q7"EDX?57I,CX]L# M`\M,!>2-A)&!N)36$Q8F:-BDEP.:N2E M]5@*DX8Z>`%U@W]!\J)^1IN19*\MV6P^7+\X7B^P9%I@\KX_M]:^%-\Q^J!&*=\(UU.+(+TRX[6)!V.\ M:)(B2A:YNB(^265U%AOPQ,*P;<@??_A#`U?Z5BEL7[M8)+,2%=S@NR*.4 M/&\OV+:#H=Y@;R!1=`ENJ!M8-6>^U(7!X%U?@2.=TD)\B`]M4JFRG3WDD,HANL55*:Y,68RUI$,]'.?K,ST#@"`I M*3E(HDAP,`!ZNGM(_TX2"0ZF.Q+$CKN2>6;'@10+'(E=5T->O#R=)XY6)M%E M$ME$5WFZ(94E6YCK-!^<-QTOJW77 M[@W_LW2PN[2M`CUNRG&C(.V=N$PV#7TW0W]>Z.Z<]:8="(_!Z-#1E$,O4Y[8 MS=B7.ZXB`&<8B!LD^&$[6$&E6CS\1D>/#S]AC\+$8&R)./B;*7P5EP0[S8Y; ME#GUK+W7'F7)U,=P4ITX/K.()[E0;_#JW:&5HJ%VR-R!26\[`D1">1,!-R]W MKI_J=P^>@$;_1<].;"59BW&K$0&G`8B$G6F:,]I)]4S2I'^UA6AIN(ZY`H:P=KNH_!=ZO.= MXU[U7I6O#=DTL#RT5KQ1A3DR;B7Y<+SRCOJ2$98C6F[?1'NY5%A:N>:D6^.J M&4DXN[>)C!/SH2CZJ9QH"4.997CEY;0^-5IO&7*D][@6S4%FP%]`3&?XL/H-!-]X5YB/>\9B.,G%\!#T2/8&>4G*<"U5^ M`#KUS8X7L=_FU+`H.,I2$R=9[^OCA\'PIU2(#C1'S=]<\09T)&5\>T-G//?J M*^O=;B3<%3ONLH)^.$FE4\F4'7#^3Z4,48R-[9C&"J$Q1UA;6_%2@;VW-<;6 MPG=2-\M!O]BSPN6&$<1BRJ9A2PZ&)<%:"94A@;E`H!*V(N'*@%8P![Q+:VTZ M5E[2YDD+E@2\?B:#><^2O(Q^D6>[R+TTH1$3QP%5(*NF.$T)WJE@*/@>8@NU MM)**GQ>Z`1[UQITG5E15!_5.O^#95@S5&;.HDE@"KQ)3H-/EZTUI6.NJ;@Z: M'%.&,?J\\2=;%>QXI0OYVAJ%!3H9*K5:JS@IQA%,4Z*J@< MUM]FP2_EQ]WZ3[R5R%N!BLR-I;F1FO^1_$\H"^2"C..!V%UR8;D_EUXNU+5ECR\->9A(5>+;VHOP<+`A2@NK"R M>(_F]+D#N-[5O<:Q/J!.4"SMZ\$[H"_KV>+QMU!M#H2L#'V%]ZT.FV9FYPO) M"A8J3B(-*M-Y0<":T=)IY$J]],-HU7@>+^6+!PT?(@;10?\XU`6YS)=9N@PU M=NYB##O1S4'>1+%[F%R=Y<*8T6IXT9-,)-"5G;'#W#R78CRL!Q#('00HKH,"@@!$&`"`A"P`@(L'6"^8`@#!XH"F2V6Z7KQX8M:N]7<4 M[G%75UOUY>]J:[S6U50V"U8/,9_A*[&L76R M5+I*0[U4681+"O0#I.1'&XN0_.\`R+6',`T*96YDF4@,C`W+U!R978@-30V,3,O4F]O="`Q,S`@,"!2+TEN9F\@,3,@ M,"!2+TE$6SPT-C)#13`V.$4R-35$,#E%-C,X-$-#0SF4@,C`W+U!R978@-C4R-#DO6%)E9E-T;2`U-#')E9@T*-C4U-34-"B4E14]�HR,C`@,"!O M8FH-/#PO3&5N9W1H(#$U+U)O;W0@,3,P(#`@4B])1%L\-#8R0T4P-CA%,C4U M1#`Y138S.#1#0T,W-3A&0S8R.30^/$4V.30Q.#8R,4,T,$%&-#,X,30X030Q M-D4R144P-T,T/ETO26YF;R`Q,R`P(%(O1FEL=&5R+T9L871E1&5C;V1E+U=; M,2`S(#!=+TEN9&5X6S(R,"`Q72]$96-O9&5087)M7!E+UA2968^/G-T-IB M8F1D.`408```X`#/#0IE;F1S=')E86T-96YD;V)J#3$R(#`@;V)J#3P\+U-U M8G1Y<&4O6$U,+TQE;F=T:"`S.30U+U1Y<&4O365T861A=&$^/G-TFMC.60B/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O&UL;G,Z<&1F>#TB:'1T<#HO+VYS+F%D;V)E+F-O M;2]P9&9X+S$N,R\B/@H@("`@("`@("`\<&1F>#I3;W5R8V5-;V1I9FEE9#Y$ M.C(P,3$P.#`Y,C,U.#`T/"]P9&9X.E-O=7)C94UO9&EF:65D/@H@("`@("`\ M+W)D9CI$97-C&UL;G,Z>&%P/2)H='1P.B\O;G,N861O M8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AA<#I#&%P.D-R96%T;W)4;V]L M/@H@("`@("`@("`\>&%P.DUO9&EF>41A=&4^,C`Q,BTP-RTQ,E0Q,3HR,SHU M,RTP-SHP,#PO>&%P.DUO9&EF>41A=&4^"B`@("`@("`@(#QX87`Z0W)E871E M1&%T93XR,#$Q+3`X+3`Y5#$V.C4X.C,R+3`W.C`P/"]X87`Z0W)E871E1&%T M93X*("`@("`@("`@/'AA<#I-971A9&%T841A=&4^,C`Q,BTP-RTQ,E0Q,3HR M,SHU,RTP-SHP,#PO>&%P.DUE=&%D871A1&%T93X*("`@("`@/"]R9&8Z1&5S M8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@&%P34TZ&%P34TZ&UP;65T83X*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H\/WAP86-K970@96YD/2)W(C\^#0IE;F1S=')E86T-96YD M;V)J#3$S(#`@;V)J#3P\+T-R96%T:6]N1&%T92A$.C(P,3$P.#`Y,38U.#,R M+3`W)S`P)RDO075T:&]R*$)I;&PI+T-R96%T;W(H06-R;V)A="!01$9-86ME M'1=+T5X=$=3=&%T93P\+T=3,"`Q,S8@,"!2/CX^/B]4>7!E+U!A9V4^/@UE M;F1O8FH-,C`W(#`@;V)J#3P\+U-U8G1Y<&4O5')U951Y<&4O1F]N=$1E2A4:6UE=K:V:BS?E5$VR.]%#JN(\T!0D,2.36I"T1W^?[M,` M2$EVU>;!%@`"C;Z>/OBTOGG_F_KYY_=?/]]_4;'ZY9=/7SZKF_=__6>L=MW- M^_4Z5HE:;V_B*([C5*TK->-AOE#K%Y70,*53L1WE^3S*U2(M(CKS=//OX.[' MOGZL>Y4E45@$23C+`A7^9_VWF[NO?,MX<^)NQCT)WQ/S#;-D&<4K-4NC(B_4 M>D,R/]]]6]__>A_.@\]A'GRDOW68!O?_^/LH^&Y]D\Y)B5S-5XNHF*ME$BU( MT6@U5T;?;&\^G9F=>K-'$?_:+"V3SX&*E/F+>P%;*2 M`LZB4<9"%U&5+_GM;+_Z?5@Y--@6/E0.(OR MY#P82:0H$/?\;U^&R^!9DX/YMZ8+>?`2SI)`;RCZJJ>E/4_Y6Q]ZU3O%F7<6/J@Q M@AI[]WPA]Z04,!)4TET=F[9AI4<+GDA]&/J]L7;"70>G'BWLX+]; M&HBCQ4'L`7B'Q&_7,RSDF4TJARS*/99!"O2-%JNEBZ-FI,: MZ!Q%9M#LIJXO>_VDFUZU6U62%0F%K]>5/$G0'H(ILJIL=`(=4 M>:D%&GAL='>$C(H#@]6>=<8:;SCZ&TPM=9A3\E%B5NVS?**ZU1OUR),3?Z!# M(K_N4-LT:FG=]!]>+[7Y6:DMQU(#U*W_0H9FKL(RKK#5_U5AV1L5!NNVJ)&2 M1#95;6_@8QPFQDZ6`-#1*"FNR%M5\BVB`M".,(<2[DU16&><`L1!6MGS8MLH M@):`$>\=-F+=N'R)ITL@PBHX0E@/P&<[4.PCIK[9.6)74@Q)TA4QI)/?Z6F:W-N6&0]]-5$Q] MJH-PI'F4SQ<>1G!T*ZR"7"ZJ&')AVW04"]R@JK+S.;T]M"^$BLO`GJ2<[,>$ M-AJ%@`+I32EF55X5#1+%W1H$-3 M<([&NUO+7>3T?B_ETKY9)XNS.IF/=9)"@)S(:*C:/`0TX?,/(7]CQQ727E5IK*\[ M="]*"U^M'9]^1&TB6$ADI:7@:/<.(E=`+,/,$*!8X!$(?\L<+K:!T*EM:`-TE!-P!/T[H5 M]MPS)!F+I8Q:I8._5.!OXD2;G([P.3[C/(,,\_ZC!;;\51?>_:#_U9[^EU;RG!,+?LJA896=$G9PGM?A%=\*'K>!%Z5S<<_1YSSF:"VG7W:UDA)T3'M.90>@P7_"G-9"2S,]* M,@V\*A9GN>,YAQA@U'WFR>X?3.(E$KC9&>>E8EBKANL%W@AYF2:^_@&@[:,EN` M&9,NJJ4)CZ"MKQ$)9-S!T@Y?5#O)RO:<2;"JPB)VCE1(EC;")RY)B<,07Z=L M"$\<)9KTRM3G:+:\XAO,")+?(_&[0M^R$#.P)E`[.`%\0QB3YQ`V,`[]R+F3<*=)M$J]:\C MTTV9<]V<,^6VTQ39GG@.*WKTK,CT=37PC/(\*,WAI#:8&L?&_R37GOC7OY,R M>2=9-2=7H\$%R!*_LL)'5R8QWY$0'`KQ7Z):8"?"SRSQ9G:PDT!35B0 MXJTN,"V7YM@^H\M.GR++X+4&.KMX'`E3GEGMIX]"YI"(7>^CB>?IPM:&BS89 MM/'#BS@@#$V8!.,.`S$MOLBX&X[RE1:>)<-JB=*MD/6S:VT^I8&$38I?4WS* M3@Z54.R@<:[LN@'Y/]"U)Y>IM..T$ M3.%=)YA?(10%H1@?<85]Q!47CRY6H&`%L!&\@1='<`4]Q`E`.SU6[!F034ND MY)TN2J'YAK MD#EB0\?!'`FQ.E4+&:%8E15MJUJS*:64,G:[!;S1=Q,M,I=^\6J*/3O=\(6& MGI`G$EKI(\$[#S@/!D)(."P3JG4*_AG+XA`:<'EWJ/WMM'G*EJL7%<*63A]5R83B M6#;B$0.GKQ!ARG+*D6TY]"&:`RX%I@.:,]G$#TJGNC?W#):<[>Y=E9PUE85S M:9Y>DR/CVP,#RUSF/9)XP%S`F9@CHQJ6!`CH5W%)NHV]LGUWSO[?2FVR[*JO MG[&*0[HCQV^EH]O-&_ZIV9?H\(P]7A,M\(JCO<'7`]W;X(SM9+PUD9,5@HB/ M@YRGCEU>W:C'\_9+*%C#'\=FLAC!)+T"DZ,VH%(MN'Z%YY(V$D8&XE-83%B9 MHV*27`YJY*7U6`J3ACIX`76#?T'RHGY&FY%DKRW9;#Y+[!D6F#QRA?8 M_+4"X\2R_9M#TG;N<;9RJ;:OD:#.D)RIAGM#G!"N/9*7GKV34S2ZJK`I!HZ% M+\TOC<\Z=PE.Q@3A7:>$H`E_R#U_R#U_X/:["$`ALI6R M4=;I_V.\:IH4MX'HG5^AHS?%"G_@#S:I5,U,]I!3#N&V4Y7R,@:<8>V)^9AL M?GWZ=4NR;`/)`3"VW&I)K]][3?IWEDAP,-V)(';:E\PS>PZD6.!([+H:\N+E MZ3QQM#*)+I/()JI*IOGJ9:Y(#JT+IH@H)W]7>JP.>Y-8T%/HE'`S,?3_VPS?<,)F8P?6\$<1&S%] MUZDA'E##V``D.ETECA^0;*HQTWI?&0;(@\GB6\('B4;5>4>8."(5"8I"O7)' M>*JWWREC`M*VIM>>@R.!@]+F\OB5O_&1KL!*=.#,FS<)),IUG"5V MDA?5-HI`#9B%TGNAWJ20JLN=7`75UHS!8A$/UXBVY=SJ1KR7IQM26;*%N4[S MP7G3\;):=^W!\#]+![M+VRK0XZ8<-PK2WHG+9-/0=S/T9T=WYZPW[4!X#$:' MCJ8<>IGRS&[&OMQQ%0$XPT#<(,$/V\$**M7BX3GSX"7L4)@9C2\3!WTWA MJ[@DV&EVW*+,J6?MO?8H2Z8^AI/JQ/&913S+A7J#5^^.K10-M4/F#DQZVQ$@ M$LJ;"+C9?7#]5+][\`0T^B]Z=F8KR5J,6XT(.`U`).Q,XPQGVT#MGS]\ MI/826WL?1X3$.C.MO>>@%&%^.!P46KJ:ZH7VG'92O:`4Z6]=$6HJKD.NH!&L M[3X*WZ4^WSGN5>]5^=J030/+0VO%&U68(^-6D@_'*^^H+QEA.:+E]DVTETN% MI95K3KHUKIJ1A+-[F\@X,1^*HI_*B98PE%F&5UY.ZU.C]98A1WJ/:]%\-$(L M^_6&?U39559&)"'87$J&A827!7L!/9'A+^(S&'3C76$^XAV/Z2@3QT?0(]$3 MZ"DEQ[E0Y0>@4]_L>!'[;4X-BX*C+#5QDO6A/GTW&/Z8"M&!YJCYFRO>@(ZD MC&]OZ(SG7GUEO=N-A+MBQUU6T(]GJ70JF;(#SO^IE"&*L;$=TU@A-.8(:VLK M7BJP][;&V%KX3NIF.>@7>U:XWC""6$S9-&S)P;`D6"NA,B0P%PA4PE8D7!G0 M"N:`=VFM3RXN&$6KM:V\^MG[JW,Q05:BI4K7T MHGX)%@0I@'5AA?$![>E+!WB]JP>-@WU$I:!C=T2?U[/%T^^AVAP)6QDZ M"^];'3?-S,X7DADL5)Q$&F2F\X*@-:.ET\B5VO7#(IWB>;R4+QXT?(@81`C] MXU`7Y#-WLW098O.OQ[`3W1WD312[A\G-6:Z,&:V&%SW)1`+=V!D[S,US+<;C M>@"!W$&`XGJX`B!Z/')E9@T*,3(@,@T*,#`P,#`V-C`P,2`P,#`P,"!N#0HP,#`P M,#')E9@T*,"`P#0IT EX-31.2 7 exhibit31-2.pdf CFO 302 CERTIFICATE begin 644 exhibit31-2.pdf M)5!$1BTQ+C8-)>+CS],-"C$V,"`P(&]B:@T\/"]&:7)S="`Q.#(O3&5N9W1H M(#0Q-R]&:6QT97(O1FQA=&5$96-O9&4O3B`R-2]4>7!E+T]B:E-T;3X^1#2P3,L$5R\+)DQV\C<@>/AGD@$`> M.2($01*BN.>,Z`5A1'%G@^0B9)4D$LMK<6]A,X@*.51[(;,9-H$)M% M=1-$SLF"9!&]+,2PY'!S,^Q*U0:'83]>IE_+Z3)-H/AIYV'ZO>RF*_QPF,_3 M_?@*25N0T_5U&H[+Y?VYP/P(,`,"*1YT-"F5N9'-T'^#O[)Z,\WW9,%B,9?5NAS/=7>?/]@Y6NM9`08`KDH@3@T*96YD7!E+UA2968^/G-T-IB8F)8P,#$P,#`""08_\-8_QEA M+#H1_QD*7C`Q,#&#W+*-`2#``)R'!@D-"F5N9'-T%LP(#`@-C$R(#'1' M4W1A=&4\/"]'4S`@,3,V(#`@4CX^/CXO5'EP92]086=E/CX-96YD;V)J#3(@ M,"!O8FH-/#PO3&5N9W1H(#0Q,#,O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E M86T-"DB)E%?;;N,X$GW/5_"M)2!6Z^K+]&"`OF06&:!W=WK\L,!F'Q29MK7M M2!Y*2CI_OU6G2$J^!)A]2$Q29+&NIPX_K6_>_U/]_//[KY_OOZA8_?++IR^? MU92G!?U&15ZH]8:$?K[[MK[_]3Z[_\?=1\MWZ)IV3 M%KF:KQ91,5?+)%J0LM%JKHR^V=Y\.C$]]::/)K,*YR9F^3Q:SDGF*IJS@63, M^K\7MF03:8E(@]O2S'LP3<6X550L%S`NR\2X^W!6!+?A+`_41QXV&\,_^D6% MLWGP,5*?,&]A*V0E!;Q%HXR%+J(X89TAK65!W_E?1VZZ594V?;U]5?V>U\K^ MI^O1R*?1L/*AHD&$FD*!#W_&]?ALO@69.#^;>F"WGP$LZ20&\H_*JG MI3U/^5L7)@&?^I.^#+Q8FMX>,0<:O/()HX\A&UL$AK?P!L6SAF=\^M=PP48F M@7D*$TJN)*:OL]_Y+._;8M^Z#I,XV&G#R__B?U]Q4QIL6).JY/MN29JZ=[*K MZ`/?==4[Q8EW%CZH,8(:>_=\(?>D%#`25-)='9NV8:5'"YY(?1CZO;%VPET' MIQXM[."_6W(>V3#Q7AJ(H\5![`%XA\1OW(KN>-JT^%#17ES,LY)E-*H]:K>J)"L2"E^O.4--3=YDJ;&3 MQ_E#:)%%R=SGI=J650]7&/R'!,*)OA79)'2B6NY%K20+YU$\5[,D2FP2/M$1 MOEC$-KK275>:5Q8GNK%FWS6E_41]_@"5&X:EOK-;-^3KNE&'6JS@^S-_O_/- M:I4[4W9[,60+Z0MR=&TJ^AU('`6=+^C#+"@;4HJ\N.$]1KWL:]ZT5QV='5B! MBL9]N!(_%@%.DX<[]:(-Y$XJWBN4+@5'1"/V2)X[EVRXQ#7GP:UJ``0]FQA3 M_B1!=P"JR*:ZV0%P2)676J"!QT9W1\BH.#!8[5EGK/&&H[_!U%*'.24?)6;5 M/LLGJEN]48\\>>4/=$CDUQUJFT8MK9O^P_52FY^4VG(LM>RRU#)7:AF7VNK_ M*K7LC5*#F5L42TDBFZJV-_`QCA>#*$L`^FC4%I?FK2KY%E$!L$?@0YGWIBBL M,V`!ZR"M['FQ;1302U")]PX;L6Y21E0?Y>'`,GWE39*EL^U%L[F+`&=*U@ZC"GJ6.%TA91I)PKZ6 MV:W-O>'0=Q,54Y_S8!_,"^8+CR3>'MH7 M@L=E8$]2WEKO(Z?U>ZJ9]LV`6)P4S'PLFN2R8'*U[O=W8#X.NT<1K76P^N"=MFY["7'6N-/(*VT/X* M]&>`BU&=#T&)UKSA%<$$(0<.!OCCW8]*I./+D]JWG,#(7)95*RR$\9.SI-:_*([(<;6 MON5C+"S@F/Z3%6Q);B0EHE3RO,\9I<.+O.Q#[JJ?M12 MLL"FG4,J]&(7Y0'Y(:V^=>\:S#C#AB-O-L]P>F>1J)7&2&\^JQ)%7#?8+O## ME,FU=W`-!VV9+<",V1?5TH1'T-9K1`(9=["TPQ?53K*R/642K*JPB)TC%9*E MC?")))KTR]3F:+2_X!G,"\FV'GT.]X9\2/9`$4@+0SR/_ MZSAX-4"`9G5I:LZONA-6@D6-^!+?HW'[@A\RD#-P)A`[>$$\@]A73B!LX)U[ M$?,F\TZ3:)7Z9Y+IIA2Z;DXI<]MIBFQ//(<5/7I69/JZ&GA&>1Z4YO"J-I@: M1\O_(NF>^-<_F#)Y,%DU)URD%F^\P,":WAZ]C#I)DB-<%K)RUJ6/WJ%02_R' M;09?,*2.#L>_04Y6#JAF(YV'EE?8_$/P.*+4#MJ>Y`"I+#80_\0O,4I")0D< MZ2WIH_@A4G#O<524-DKI%B,3]?9Z)#@#4?)?3NC@PCSV(P*"6RGVJ0M;&R[:9-#&#\_B@#`T81*,.PS$M/@BXVXXRE=:>)8,JR5*MT+63ZZU M^90&$C8I?DWQ*3LY5$*Q@\:YLNL&<',*)6_:N>@:@00.^$YNV#M!AUI$U(>Z M?Z5O22I7;\-I)V`*[SK!_`*A*`C%^(@K[".N.'MTL0(%*X"-X`V\.((KZ"%. M`-KIL6+/@&Q:(BUOQD1:!%]T=B51A_$)XI](R<)F;>R3EB"4[7QB65HB1_ZG MMQJ]2I0F5_W`7(/,$1LZ#N9(B-6I6L@(Q:JL:%O5FDTII92QVRW@C;Z;:)&Y M](M74^S9Z88O-/2$?"6AE3X2O/.`\V`@A(3#,J%Z1R-3OJT^'G3W!K8D\0D+ M\DK$5[&E$FRY>RY!+H;25>3&4[24\@7T?*LK5_#/6!:'T(#+NT/M;Z?-4[9< MO*@0MG3ZJ$HF%,>R$8\8.'V!"%.64XYLRZ$/T1QP*3`=T)S))GY0.M6]N2>P MY&QW[ZKDI*DLG$OS])(<&=\>&%CF,N^1Q`/F`L[$'!G5L"1`0+^*2])M[)7M MNW/V_U9JDV57??V,51S2'3E^*QW=;M[P3\V^1(=G[/&::(%7'.T-OA[HW@9G M;"?CK8F6H^E,&FH@Q=0-_@7)"_J9[092?;:DLWFP^6+ MXWJ!)=,"BU>^P.;7"HP3R_9O#DG;N<.[,K4-=-<$H0V]A-4///7S"HV@<6VJ@9C?`@W@R`?T?/]J;7VI?B. MT0P.)HDMP0]W`JCGSI2[DUMQN MK=!T%>6D]I2ME(WZ'^W5LMNX$03O^HHYRH%,<_@2M0D"V$X"["F'U2T&`JY$ MR8QETJ%D&YNO3U4W9TCJX>PE!U,T'SW-GNJJZJ[HT+]7C40'TQX`L<-C(3SS M*(&,"!S$KJTH+X,\O2>VBR[1)+8N45,(S9?KF8$<.A>,B&PEKOT54K6KGDK\ M'!ISN;Y)$.:^OK(I16=2-9_8+35S6(ZG_UUDZ[DWCA0]>9`"-R>&_KO-\`4G MW!5V9`U_5+%1TW>>&J(1-1P;@#A(%['G!R:;!EQI^5AV##"?GGQ\`WQ`-,IV ML(6Q)U*5(!L&"[^%AVKS#1D#2)L*KSU,]P`'TI;V^"S'1^[D&Y0">,0960D; M+KQYD4#L/(BRV"VR-DUM`&K"+-39B_VFC52^?9"KHMJ9,5HL\'#%:!O)K:K5 M>PUT0SM+2S@/TOEHO[&]HM9ML^OX7Z1#W*4;%7"[+HX'!1WOU&6*:>BG&?RS MQ=69Z$TS$IX.HV-'4XR]3/$J;L:]W$H7$3CC0#(@T0^[APU5JN'-9VP]_^2. M>!0AALZ6J(/_,(6OZI)HI\5QJS*G`VL_&(^R^-3'2%*M.K[N(Q[TQ+S0J[?[ M1IL&XU!WA2:]:0&(&'F#@.OME9^G^NK1$^#IOW'O5:RD:#$OU2K@>("16)G: M&\ZFIMH_7'WR,]Y)[\6N]\["]UB7"Q7EV]W.Z#B'==`OG2[20S$IHF=5E9W* ME9U32J8*>XX21T!WE16%6>21%UR2RGM9/-4P;(Q+U567A#:4"\A"MDE`V\`. M%8-F]/0:94Z^XKSO>-5K!?\U73CH]3M475YX$Q[420;/]8H^L+Q^^5A%.P92 MHF$7GI"ES$,R;58K^3%%>V:`%3$1,A9!&90S]U\[ZB(T!:P MDA`/VF9;G&II`1]@HE1@J!%:9P;)XWQ`W32BM$)K!A[?M:3H3AQX\GWS95DI[.F M%7[88R.-T`OCU07II:1OD&N,K0S2:"K#O&CZY:D7&3#Y126Z^1V_I--&?=,; M5S$%"(&O;FOFH^JQ4GHUK:O[KON:+N=T."#:S'>+/1ES#M(,'5*Y:=8A-1W: M\?_'P02LU@58I"/ZC'K9CM1IV2"9+TBBN8/N+[HPF/Y0?A+>OGWEI:T<80=L MR),99@_^6JN=X<76YO1V@^.9K^J)VZ]$&XL-Q$X$HXG1,=CLR>;"9]+E5GF_OHSU##6:VOU@-G:1@D)K,\1:"?*`$_ MNUB`^[\"#`!0D'=I#0IE;F1S=')E86T-96YD;V)J#3$Q(#`@;V)J#3P\+T-O M=6YT(#$O5'EP92]086=E7!E+UA-3"],96YG=&@@,SDT-2]4>7!E+TUE=&%D871A/CYS M=')E86T-"CP_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ MDY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#0N,"UC,S(Q(#0T+C,Y M.#$Q-BP@5'5E($%U9R`P-"`R,#`Y(#$T.C(T.C,Y(CX*("`@/')D9CI21$8@ M>&UL;G,Z&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0#I3;W5R8V5-;V1I9FEE9#X* M("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I M;VX@&%P M.D-R96%T941A=&4^,C`Q,2TP."TP.50Q-CHU.#HS,BTP-SHP,#PO>&%P.D-R M96%T941A=&4^"B`@("`@("`@(#QX87`Z365T861A=&%$871E/C(P,3$M,#@M M,#E4,3&%P34TZ26YS=&%N8V5) M1#YU=6ED.CAD9#0S.3=A+6(W-C0M-#(T.2TY,&(T+3AF,CEA-#9B,C4P83PO M>&%P34TZ26YS=&%N8V5)1#X*("`@("`@("`@/'AA<$U-.G-U8FIE8W0^"B`@ M("`@("`@("`@(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@("`\"UD969A=6QT(B\^"B`@("`@("`@("`@ M(#PO'1);F1E;G0@,"XP+T5N9$EN9&5N="`P M+C`O4W1A6]U="]7'1);F1E;G0@ M,"XP+T5N9$EN9&5N="`P+C`O4W1A'1!;&EG;B]3=&%R M="]/+TQA>6]U="]7'1);F1E;G0@,"XP+T5N9$EN9&5N="`P+C`O4W1A'1! M;&EG;B]%;F0O3R],87EO=70O5W)I=&EN9TUO9&4O3')48B]3<&%C94)E9F]R M92`U+C`O5&5X=$EN9&5N="`P+C`O16YD26YD96YT(#`N,"]3=&%R=$EN9&5N M="`P+C`^/@UE;F1O8FH-.3@@,"!O8FH-/#PO0F]R9&5R4W1Y;&4H_O\`3@!O M`&X`92DO0F]R9&5R0V]L;W);,"XP(#`N,"`P+C!=+T\O3&%Y;W5T+T)O6]U="]%;F1);F1E;G0@,3%LW,2XU-S`U(#7!E+T-A=&%L M;V7!E+U1R=654>7!E+T9O;G1$97-C2A4 M:6UE%LM-38X("TS,#<@,C`P,"`Q,#`W72]!7!E+T9O;G1$97-C7!E,"]$97-C96YD86YT1F]N='-;,34S(#`@4ETO0F%S949O;G0O04M- M34E$*T-A;&EB6^W[^H9Y#?;)$=C0EYJXZGA'1+"'\X M(450T#1@<1#R\*G#EYX09"'>P7X-"%7I=YNVMS@';9`UC0BU4NJUN18D^SB_ MLLZ#N6@6]^UWU8BTO>&9EV^Z^3`+<[)8#B]&L@5'>/M-\"&KY1#_`@P`W?MJ M>PH-"F5N9'-TJ'-,-(9>I,N,(#T+B`=!%$89@88R@## M#$ULB*A`1!$1`460H(`!HZ%(K(AB(2BH8`]($%!B,(JHJ&1&UDI\>7GOY>7W MQ[W?VF?O<_?9>Y^U+@`D3Q\N+P66`B"9)^`'>CC35X5'T+']``9X@`&F`#!9 MZ:F^0>[!0"0O-Q=ZNL@)_(O>#`%(_+YEZ.E/IX/_3]*L5+X``,A?Q.9L3CI+ MQ/DB3LH4I(KM,R*FQB2*&4:)F2]*4,1R8HY;Y*6??1;94!&; MB)C$#PYT$?%R`'"DN"\XY@L6<+($XD.YI*1F\[EQ\0*Z+DN/;FIMS:![[M(KT*^-PSB-;WA^VO_%+J`&#,BFJSZP];S'X`.K8"('?_#YOF(0`D17UK MO_'%>6CB>8D7"%)MC(TS,S.-N!R6D;B@O^M_.OP-??$](_%VOY>'[LJ)90J3 M!'1QW5@I22E"/CT]E?^IB?\P[$]:G&N1*/6?`#7*"$C=H`+DYSZ`HA`!$GE0W/7?^^:# M#P7BFQ>F.K$X]Y\%_?NN<(GXD,X`9P\QB ML5AYK`'6#NN'96(%V`+L?NPQ[#GL('8<^Q9'Q*GBS'#NN`@<#Y>'*\$AX1202U8G6Q``BE[B)6$$\3KQ"'"6^(\F0]$DNI$B2D+23=(1TGG2/](I, M)FN3'DDN58R M1[)<\J3D#LHERC@50]6A>E$3J$74;ZC]U!E9 M&=EELJ&R6;)5LF=D1V@(39OF14NBE=!.T(9H[YGR;O*)\KOE.^0?*:`4]!4"%#(5#BI<4IA6I"K:*K(4 M"Q5/*-Y7@I7TE0*5UBD=5NI3FE564?903E7>KWQ1>5J%IN*HDJ!2IG)694J5 MHFJORE4M4SVG^HPN2W>B)]$KZ#WT&34E-4\UH5JM6K_:O+J.>HAZGGJK^B,- M@@9#(U:C3*-;8T935=-7,U>S6?.^%EZ+H16OM4^K5VM.6T<[3'N;=H?VI(Z< MCI=.CDZSSD-=LJZ#;IING>YM/8P>0R]1[X#>37U8WT(_7K]*_X8!;&!IP#4X M8#"P%+W4>BEO:=W284.2H9-AAF&SX:@1SJ/U:>MW-I8V M`IL3-K_8&MHFVC;93B[76/MC]D/^*@YL!TJ'-X MXJCAR'9L<)QPTG-*<#KF],+9Q)GOW.8\YV+CLM[EO"OBZN%:Z-KO)N,6XE;I M]MA=W3W.O=E]QL/"8YW'>4^TI[?G;L]A+V4OEE>CU\P*JQ7K5_1XD[R#O"N] MG_CH^_!]NGQAWQ6^>WP?KM1:R5O9X0?\O/SV^#WRU_%/\_\^`!/@'U`5\#30 M-#`WL#>($A05U!3T)M@YN"3X08ANB#"D.U0R-#*T,70NS#6L-&QDE?&J]:NN MARN$<\,[([`1H1$-$;.KW5;O73T>:1%9$#FT1F=-UIJK:Q76)JT]$R49Q8PZ M&8V.#HMNBO[`]&/6,6=CO&*J8V98+JQ]K.=L1W89>XICQRGE3,3:Q9;&3L;9 MQ>V)FXIWB"^/G^:Z<"NY+Q,\$VH2YA+]$H\D+B2%);4FXY*CDT_Q9'B)O)X4 ME92LE(%4@]2"U)$TF[2]:3-\;WY#.I2^)KU30!7]3/4)=85;A:,9]AE5&6\S M0S-/9DEG\;+ZLO6S=V1/Y+CG?+T.M8ZUKCM7+7=S[NAZI_6U&Z`-,1NZ-VIL MS-\XOLECT]'-A,V)FW_(,\DKS7N])6Q+5[YR_J;\L:T>6YL+)`KX!WSWM9?2RPK+7>Z/V7BU?5EZSC[!/N&^DPJ>B<[_F M_EW[/U3&5]ZI5 M'\8-#0H-10T?C_".C!P-/-K3:-78V*345-(,-PN;IXY% M'KOYC>LWG2V&+;6MM-:BX^"X\/BS;Z._'3KA?:+[).-DRW=:WU6W4=H*VZ'V M[/:9COB.D<[PSH%3*TYU=]EVM7UO]/V1TVJGJ\[(GBDY2SB;?W;A7,ZYV?.I MYZ\+UVY['[Y8J]3[[DK=E=.7[6Y>NH:XUK' M=N;70/+!\X..@Q>N.5ZZ_)MK]O7[ZR\ M,S`4,G1W.')XY"[[[N2]I'LO[V?$CJ4?ECY4>U_VH]V/KB.7( MF5'7T;XG04\>C+'&GO^4_M.'\?RGY*?E$ZH3C9-FDZ>GW*=N/EO];/QYZO/Y MZ8*?I7^N?J'[XKM?''_IFUDU,_Z2_W+AU^)7\J^.O%[VNGO6?_;QF^0W\W.% M;^7?'GW'>-?[/NS]Q'SF!^R'BH]Z'[L^>7]ZN)"\L/";``,`]X3S^PH-"F5N M9'-T[)L'>%35 MUO?7/F=*2$B#)`0"S(0A%$.O$1!"&H08("0#"363'KHI@$@PB@A$4%0LJ#0[ MAC(9"T%10;'W?N_UJF"[%K!CA7[_O?N_S?._S,,EO_O^]=CEM MG[U7?)`4$850/>DT8%)N_T'S*ZJ:$3D`"HN7U#CW7KOO)R+5F<@:7+:X?,'W MWV>W);+U(FK3J7S^A65Y5>63B=)^1)N4BE)/R?L9>S\BFGDW^@^K0"!T3\@H MHO`TE+M7+*A9UK?TR""3G>MT$@*_6&S40NJP?:O6PTFTS:C3 M]UG#C*/CCI!]*U'+M73F9S+-I6K>D0 M/4-OT?_#3\N%U@745M]'-FI/Y/_9?[SE3M",,_TUDT@V;2+"HD#ZZ_A"JH$G=F'LVG!;30+"U$73F^RU":@U;%:&7X7ULMHL6@ MBFJHEI;@9S%\=:!DU%U@EFMI*7Z6T86TG"ZB%507^%YJ1E:@9KE97@96TL5X M,I?0I:83Y<@JNHQ6XZFMH;6T[D]+ZTZ[!KJ"UN,Y7TE7_5N_X3>EC?BYFJ[! M?-A$U]'U="/FQG67<=(MM,9]0>H"?I?MI#>^D!\UX6 MXZ[Q'9'[4F;>P\6X!RMPA:O..&.^?TM/WZV5N';CVAH"5[H,\4O/Z+$DOIRUX`W?@V[BKAKL5GMTVTY\9WWJZ[7:S?!O=3G?@6=QE.E&.W`E_%]V- M=_L>:J1=^/G5G^E8]]!N\\EYJ8E\="_=AR?Y`.VC9C/^9W5_%+\W$/>=CNRG M!^DAS)!'Z"!6FL?P(Y&'$7LT$#ULQKC\&#V.LM&*2T_24UBAGJ7GZ'EZB9Y` MZ47S^VF47J97Z35Z2X7"O4*?XOL4H.1Q)7-FSYHY8WI!OCLO=TK.Y$D3L\_/ MFI`Y?EQ&>EIJRMCD,://&S5RQ+E)PX<-[=^O;Y]>/1*ZN[HY8J,B(\)#0X+; M!-EM5JS$BOJDNS(*G=X>A5Y+#]?X\7V-LLN#@.>,0*'7B5#&;]MXG85F,^=O M6R:C95FKELG<,OET2Q7A'$6C^O9QIKN6Y'F]*I"9[HW8TE%0WIA&L9K"@E.=:66!O?M0TW!(;`A M<-Y>KL5-JM=H91JM5_J()NQ#H<9AO7I"NJ?$.SDG/STM+CZ^P(Q1JCF6UY;J MM9MC.2N-<&XX0UQ??+QQ+EF'@=TE%K+>^R-FW#^Z^^9N`7]0[O7J/PJ+B"D,] MI0VNM#2^;WGYWN0TF&1/X%K3FP;T1WM/(2ZBTK@-.?G>_J[%WBA7"C=`P&D\ M@\KY`+>OP)5?6F`\)5>$M_<1 M'"[>/*+9"]?6JK4T-J[\%(]J*6BIF(,9B7'R6,WR.+-\NCB^576F5#L;@EQ9N0W&X*[`@.3$ M&X2+MO7(]%R1U&X(7LT,K&ZN#(_+&>',:/`T^^N+&IJ2DQL6IQ=6C##&<&66 M-+AR\T?%F>Y/-J&9$C:!1/V)Q/5F[46,V"6 MBYL5F;$@B2DJ;M8X%B$Q#3$+QY+-F/'!0XJMP"W&SXJ"BH;"`N/E MHA@\2OPJKW*-)J_F&MVD-%M;;["K-,4;XDHQXF.,^!B.VXRX'1-#Q2C<'&-- M:BAT89W"A,JG.,5343>&=#;[_7GY\2_$'2^(QU2;":;G>]LD8NVW)DQ`NW$& MA0B/\]87>XSS('>^T=>>D%E<@&DK`Z))IK<-1F@3&`$M,LP^QG1$IV(\&SQ` MLW\]"M[Z`F]!HG'0_,H"&F\:P0>.X]I[6$UN<>;$+5<6%3MQM"Q7G8JKS6AHB`NX.J3.-<\+L&IVHT/60,D]-,4US+L+(8)VV.9$>U-S0ATX/%G_N'(.)* MDLY!QAH1$ACC,$?MQI6WQ7W7$_*:_7>Y+HP_X].WC\O8'(R)27'[,;&IH*%U MP#LCL6^?H-;14#/S7DGH)D1WD^JO8XOS/&UBFTRY+&GG^D&.H.T8W6/P49Z!_0KM` M>D`S`A2#.>"20'R7OIMV6=O2C-983F(\8,5?R9J%=FD6_P1H+^BY8""8#":! MBQ#O"GI:KD&[#637-OAW6GJA/]!GF5RB%P7\8NILF4V[;&]A['/^`#LXGXK_ M6R8QMB^IV-(-QP+6(OA\>";74%S?N`#1(/9T^6,*/Q-K-[KGKV)IH&[VKG1> M:RP]:0#&ZOH['J61`3J9^AU%_%6L,_WO&U@LM$-_CA;\$992V@'F6I;2(`.] M'FWK<2ZLS@!]0&^0$HCOT">CWZ4T_W-`3 MN,$4<`'BD2#6$D<[M-%$VFC_>OT9C`VT(R9KM(\#_BN?9C-8 M9OHR<`^5_;<\R&"<,OT)'`M8FN"/PS/IIDZB3,9_`GQ_NEQ`G?4"?PLKYN,& MV@9N">@-H#;@?X=^BN)MHVEX:_3G:9B^"L^L-964%B#(U#=H9BNZ_D',Q-:? ML0RAS7A_I@>8"*9)V;Z(IMO>`8I!VT++>C`7#"&/_@O-^BMH%U""[29*"'J# M$BR-\#<'_*A63&I%(&Y;THIUK0C$?].^#8Z1>L;8JWZMLQQGK.TIP=Z+$O3# M-+0UYK7^GLV6(?[=EE3_3^I-6JW>]"^$AD.G`R>H`OF@'/%(L%D_2*LM76FM M^LS_1H!B_3;$`QAMP#E:9U.SU"_463M%FVTEQK%^PT13;_5O,34)S^.W3/I= M;!1C>]Y\=C).H?8L;6;\/T$7ZO&4PV#>QOM/2=FZA\%8F]77:+^'XK7#P-`# MU,/R,<5;:O\:N-?Q]BS,[[__-7">F\"5`;T<9(-U`;_I3/0MU,W:3$-;HR_% MFK2-NOV.WE00P&YJ$E7I'BK1EV&N[J(T[2.:KTTT=;S63./4(>JNW8!G]"G- M5\7D40O\?T-YOIJ-]6PJVGYLDF[V0Q_U/70`I:@/R&7TT5:30_^2^F@KL<== M3@YM.*5H>5C/:L$F8]<^%41T\A-MZN]C.#_2YP`S=G(;*&\5VP(JE1_EF\"M MX&XS7@H*]>X8[P1B&:#*&>"N:?'J-/;HAP.(LW8+K!3NQK];P3; MS=BGX'T-.8;V&+@?;0^!H\@YS.SCY!0P4+V(/.1-\"*#:\DVP+5=!EVN76SJ M$O4#7:8-E'S%O\[(0?1<[*^7T0C.(5J>,O8TSA=:MAI[,^<++?@SP3_%S`.N MH^ZRW^,>Y_(>[H\Q^V#?UAN1F_`^C/VR9:&AMO8X)O93&]%&ZV2:;9W<\A/O MB?Y:8R_4?C'W&!?O92VO&&LK[ULMKUONHS+>MUH>QAZ59^Y'1RE2]AU]#4@W%Q7[L/UE4%OP%S7 M*%O7\>[(FC"?>EG:T1+T+\#SGZEW)-WBIHT!ZD",=1BYK2/)C>MN9]U)FZS7 M4(F!MLY\EL&X5\:S'J99Z8;3=,>\]]-"`_-Y9M-N\WDN#K`$SZ@GZ6?DCAY; M!8[Q+&59C?PJ0"`?G&SD>J?SK0](M_T,WN*\T:[_FL=9?N+G;.2IDGOA.IEF MK`N;^%E;.Z/-"5!%-;9O,$97^,\IW!8+309%-,OBH2)[$/P%R._\Z/\->-[U%'9&/M3'N@Q[<#U-LZQ#W3JZ'EP7R''<1OZ":]UA M@&>KS/FR+)"3[`1S`W/%R+LDC]B".;L%.7=_7$A3B78_TP*;"_E. M.LISJ(-U%6*?@`]IGOX5\I=!\'[L[W/(82D&>`.QARLSCOW?DHK[8LRM-["N M'PX`CSF1B3RO@[%/G+F'8_S1R`FR++F8>[G(J7*QI_$>6&7L:_H#Z`LLT11C MTZB]M9+F6,9A'^L5V*L&@G-^W<_,',/89SI2L+'7!=;F6/U5ZF9I01QK-^;B M9LM@8H^!*S"W-^#H>!=K,*UFZF1PWT^VDUF&WR+N9V(1T'37H)+<=>,`?S^!QC3H.'C/EM MO9RN1VR]$1?%,UH+$D4#L43M`:H!!T4M'9'S=<3[$%"]`RGM/>P)>U6#?E+M M03D$Y;Y:-?80H)]$/@GLH^FZ,T'L)_TD'3K]SBV@U6"Y5H-KJJ'IVF4T%=1J MR5A7DQ&?0%Y0_N_:8:RM8"E8!I98O#3/S&/PG`_3N)]"#-SIWSX M_6`"RKG0!;@7B?!#]&^Q5V_#^_L(_G[<;1C6@V&8VV$T'NP!5:`<.$$IF`>* MP1235-R;#=11OP3K8#76PUW40Z_`>>S#/" M%ZBGM8[2X=.QMQOYW/B@B30>L9GV9_"\3F)?/TGG@T*0"&8'?`'`.X1GQ?5N M,-68S]9/J8_%2D-MKU$EGKU'.X[\[R0%&?F&D0<8>Z:M%&MQ'LVPQ-`$O',W M@>O!,R9AM-<>ID:(!D^DFVQ)^-NMC'KYVNC.9NVR^]K$J@DPJ\1<*N82,?5B M+A:S4DR=F!5B+A*S7,R%8I:)62IFB9A:,35BJL5<(&:QF$5B%HI9(&:^F'EB MYHJI%%,AIEQ,F9A2,25BBL44B?&(*10S1\QL,;/$S!0S0\QT,05B\L5,$S-5 MC%M,GIA<,5/$Y(B9+&:2F(EBLL6<+R9+S`0QF6+&BQDG)D-,NI@T,:EB4L2, M%9,L9HR8T6+.$S-*S$@Q(\2<*R9)S'`QP\0,%3-$S&`Q@\0,%#-`3'\Q_<3T M%=-'3**8<\3T%M-+3$\Q/<0DB.DNQB6FFYAX,4XQ#C%=Q701TUE,G)A.8CJ* MB17304R,F&@Q46+:BVDG)E),A)AP,6%B0L6T%1,B)EA,&S%!8NQB;&*L8BQB M=#&:&"6&`D;YQ;2(.27FI)A?Q/PLYB^+.2KFB)CWQ+PKYATQ M_Q3SMIA_B/F[F+^)>4O,FV+>$/.ZF-?$O"KF%3$OBWE)S(MB7A#SO)CGQ#PK MYADQ3XMY2LR38IX0$W-(S$$QCXIY1,S#8@Z(>4C,@V+VBVD6LT_, M`V+N%W.?F'O%^,0TB?&*V2MFCYC=8G:):11SCYB=8NX68.\7<(>9V,;>) MN57,#C';Q6P3LU7,%C&WB+E9S$UB-HNY4)6F/DK1'2=JC).U1DO8H27N4 MI#U*TAXE:8^2M$=)VJ,D[5&2]BA)>Y2D/4K2'B5ICZH2(_F/DOQ'2?ZC)/]1 MDO\HR7^4Y#]*\A\E^8^2_$=)_J,D_U&2_RC)?Y3D/TKR'R7YCY+\1TG^HR3_ M49+_*,E_E.0_2O(?)?F/DOQ'2?ZC)/]1DO\HR7^4Y#]*\A\E:8^2M$=)VJ,D MVU&2[2C)=I1D.TJR'279CI)L1TFVHR3;4:GW&@99LZ_K:`=R9E_7:,BE7+K$ MUW4$I)Y+%[.L]'5M"ZGCT@J6BUB6LUSHZS(6LLS7)16RE&4)2RW7U7"IFJ6* M@Q?XNJ1`%K,L8EG(31:PS&>9Y^N<#IG+4LE2P5+.4N;KG`8IY5()2S%+$8N' MI9!E#LML[C>+2S-99K!,9RE@R6>9QC*5QS M9+%,\,5E0C)9QOOB)D#&L63XXK(@Z;ZX\R%I+*DL*5PWEOLELXSA?J-9SF,9 MQ2U'LHS@[N>R)+$,9QG&,I0'&\(RF$<9Q#*090`/UI^E'_?KR]*')9'E');> M++U8>O+0/5@2>,SN+"Z6;CQT/(N3^SE8NK)T8>G,$L?2R==I(J0C2ZROTR1( M!Y88#D:S1'&P/4L[EDBNBV`)YV`82RA+6ZX+80EF:<-U02QV%INOXV2(U=6G[GN)R[]R/(#R_9#O?+&Y MD&^Y]`W+URQ?<=V77/J"Y3C+,:[[G.4S#G[*\@G+OU@^YB8?<>E#+GW`I?=9 MCK(97E M%9:7N8WF6FSS#\C0'GV)YDN4)EL,LCW/+Q[ATB.4@RZ-< M]PC+PQP\P/(0RX,L^UF:N>4^+CW`JUV\BAWL]S%=7>RW,%R.\MM++>R[ SK*-!]O*HVQAN87K M;F:YB64SRXWR&I?=!'D,I95ON@RR*4LE_BBW9!Z7S068W6Q+WH89"5+'7=? MP?TN8EGNBRZ!7,C=E[$L95G"4LM2PU+-0U=Q]PM8%ONBBR&+>+"%W'(!RWR6 M>2QS62JY7P5+.9]9&7ED*6.2RS^:)G\9G-9)G!%SV=AR[@ M`^6S3./3G2RY+%-8H3"Z-9QG'P0Q?U$I(NB]J#23-%W4Q)-4750])\;7+@(QE2689 MPS+:UP[[NSJ/2Z-\D060D2PC?)'&U#B7)9#QGFBYP.&S/TL_[MZ7C]"')9$'.X>E-P_6BZ4G2P^6!%^D M<9>ZL[AXS&X\9CP/YN11'"Q=N5\7ELXL<2R=6#KZ(F9!8GT1LR$=?!%S(#$L MT2Q1+.U9VG&'2.X0P<%PEC"64):VW#*$6P9SL`U+$(N=Q<8MK=S2PD&=16-1 M+)3L#R]R&+2$%SM.A9A;X3.=[P>VL/Q&G@5_I701,?+X"7P(NI?0.SYT`6. MY^"?A7\&_NG0N8ZG0BL=3X96.)X(+7<<1M_',=YCX!!(]A_$]Z/@$?!PVPL< M!]I6.1YJ6^UXL&V-8S]H!OL0?P#`N<">X(Z2OXW;H;>!6]-D!W1XRS[$-?BO\%G`+_,T8 MZR:,M1ECW8C8#>!Z[Z]PK&^O<(74JI"ZN+JONHKK&NK?KDK-M MP2OZE[6N-2]I+'6;:F-JJVIU;^K58VU*JU6#:A5&M5&U#IK M];8U[BIW=6.5FZHF5]57>:LL([U51ZHTJE+!S?Z#]U;%=.SR+BV4E9[O,;L]P3 MDL:[,QO'N\89S`Q,XX$XI3*0/BDN..Q'T59Z$X;]S! M.+U=>"=')ZUW>$>5.JFC6M3QXHY7==3#8U^*U9)C>_?)"._P4H?W.GS9P=(^ MN4/O?AD4$Q'CC-&CC6N+R<[+,'5,&NO`H>:U9L>X>F2$1ZOP:$>TENZ(5A1Y M)/*K2#WZT8B7(K3P[@_7DL/1/#S,$:897_XP/3ELX/",\%!'J&9\^4/U MF.101(P1>[:=G)<1'N((T=QC0B:%:,DA8U(SDD/Z#L@@73F5(A4!T8/0]CX5 M[+*_>L(&ZI&1YN^3F^_3MV[ND%&1YZPV?G&QZO^$) M30H29U?75B"2T`]N!BL!'5@!;@(+`<7 M@F5@*5@":D$-J`87@,5@$5@(%H#Y8!Z8"RI!!2@'9:`4E(!B4`0\YC^J*-'F M@-E@%I@)9H#IH`#D@VE@*G"#/)`+IH`<,!E,`A-!-C@?9($)(!.,!^-`!D@' M:2`5I("Q(!F,`:/!>6`4&`E&@'-!$A@.AH&A8`@8#`:!@6``Z`_Z@;Z@#T@$ MYX#>H!?H"7J`!-`=N$`W$`^]`.1((( M$`["0"AH"T)`,&@#@H`=V(`56,;Z\:T##2A`5*(04RW@%#@)?@$_@Y_`C^`' M\#TX`;X#WX)OP-?@*_`E^`(`Z\%U M8!.X%EP#K@8;P57@2K`!K`=7@`:P#JP%:\#E8#65C*U7>/\5WG^%]U_A_5=X M_Q7>?X7W7^']5WC_%=Y_A?=?X?U7>/\5WG^%]U_A_5=X_Q7>?U4%L`8HK`$* M:X#"&J"P!BBL`0IK@,(:H+`&**P!"FN`PAJ@L`8HK`$*:X#"&J"P!BBL`0IK M@,(:H+`&**P!"FN`PAJ@L`8HK`$*:X#"&J"P!BBL`0IK@,(:H/#^*[S_"N^_ MPKNO\.XKO/L*[[["NZ_P[BN\^PKOOL*[K_#NG]T)_J-/P=E;\!]]8N?,-C), M:JG67[6&D4YV.I>R:2+-.$"AF-,Q-$+=?W]T6EI07_LCF*\:.3'C@Y"2IB:' M6[30?9TZC7'M&VK;H$=FX@_W^\;8-V`M'W/JW5,O]C_U[O%VY_8_KOJ_<_3= MHQ%?OQAY;O_!1U\_.G"`BHR/-(D*T^SV*)NK6S]M:,\>PP8/'C1:&SJDAZM; MF&;&A@P;/EH?/*BKID=)9+1FE)7^ZLGI^J13-FVE:\S4P=:NG<*C0FU6K7-L MN[ZC$B)R9R2,ZM?%KMMMNC7(WFMX2K>L^>G=_F&/[!(=TZ5=4%"[+C'172+M MI]ZVAOW\C37LEU3+_%\VZ;:1,\=TUV\,#M(L-EMSU]B.YXR,SYP:WC["$M(^ M(C(FR-XNLFVOM)FG+H_N;(S1.3J:QS+^M7C@_V9+.`K\U MX&WPNP+>3G7J06,42QM$.FO#`UZC,"TWX'7$/0%O@:\+>!O\9G@%C_/1[@]X MG(_>D7:2DP;1`/P,@\NF2BJF*EI$U:",:A!+A:NBQ>:W!Y%*N(74#S5C:3Y^ MG#0%L7*J0%VU62J%EJ+U$GR7H&4J^LU'FR+$*M&BTFQ7"JU!+Z.E$RV.&X)2@N@530/L46G^_QQ;=G_T;489[30',LX&R>Y4:HTS\$X M?BZ95&ZWX[G8,&#!CFS*XLKEI4O:BL MQIFZJ&KQHBI/3>6BA?V<8^?/=TZI+*^HJ79.*:TNK5I26M)O;%9V=F9:8JIG M?F515>6?E0+BK*QVEE;65)16.3W.JM+RRNJ:TJK2$F=-E:>D=(&G:IYSD5%S M1K'LC\_'6;G0B6&<[H65->B?6^.I*:UV>A:6],<`B\P#%"^J75A355E:W0^/ M/@LW.)LR*8T26SW@*>9CK$7$>"!_UO+_MN[LI/T?G+3F?T;&RN&AW5@C=@&- M(M"YE,@5JR[%VF+^HQ#CO]D??]&5.B=\U`GJ&&0N4P]]ON)Y0P^E?-+FY,"6 MZC8/V+>B:*Q3YCKV7P(,`--GO4,*#0IE;F1S=')E86T-96YD;V)J#3$U,B`P M(&]B:@T\/"]3=&5M5B`X,"]&;VYT3F%M92]!2TU-240K0V%L:6)R:2]&;VYT M4W1R971C:"].;W)M86PO1F]N=$9I;&4R(#$U,2`P(%(O1F]N=%=E:6=H="`T M,#`O1FQA9W,@-"]$97-C96YT("TR-3`O1F]N=$)";WA;+30W-B`M,3DT(#$R M,30@.34R72]!7!E+T-)1$9O M;G14>7!E,B]&;VYT1&5S8W)I<'1O2]#2413 M>7-T96U);F9O/#PO4W5P<&QE;65N="`P+T]R9&5R:6YG*$ED96YT:71Y*2]2 M96=I2A!9&]B92D^/B]$5R`Q,#`P+U1Y<&4O1F]N=#X^#65N9&]B:@TQ M-38@,"!O8FH-/#PO1FEE;&1S6UTO1$$H+TAE;'8@,"!49B`P(&<@*2]$4CP\ M+T9O;G0\/"](96QV(#$U."`P(%(O6F%$8B`Q-3<@,"!2/CXO16YC;V1I;F<\ M/"]01$9$;V-%;F-O9&EN9R`Q-3D@,"!2/CX^/CX^#65N9&]B:@TQ-3<@,"!O M8FH-/#PO4W5B='EP92]4>7!E,2].86UE+UIA1&(O0F%S949O;G0O6F%P9D1I M;F=B871S+U1Y<&4O1F]N=#X^#65N9&]B:@TQ-3@@,"!O8FH-/#PO4W5B='EP M92]4>7!E,2].86UE+TAE;'8O0F%S949O;G0O2&5L=F5T:6-A+T5N8V]D:6YG M(#$U.2`P(%(O5'EP92]&;VYT/CX-96YD;V)J#3$U.2`P(&]B:@T\/"]$:69F M97)E;F-E"])9&EE')E9@T*,"`Q-C,-"C`P,#`P,#`P,#,@-C4U,S4@9@T*,#`P,#`P M,3`S,B`P,#`P,"!N#0HP,#`P,#`Q,S`S(#`P,#`P(&X-"C`P,#`P,#`P,#0@ M,#`P,#`@9@T*,#`P,#`P,#`P-2`P,#`P,2!F#0HP,#`P,#`P,#`V(#`P,#`P M(&8-"C`P,#`P,#`P,#<@,#`P,#$@9@T*,#`P,#`P,#`P."`P,#`P,"!F#0HP M,#`P,#`P,#`Y(#`P,#`P(&8-"C`P,#`P,#`P,3`@,#`P,#$@9@T*,#`P,#`P M,#`R-R`P,#`P,2!F#0HP,#`P,#`U-#')E9@T*,S$P,S8-"B4E14]�HQ.#4@,"!O8FH-/#PO M3&5N9W1H(#$T+U)O;W0@,3,P(#`@4B])1%L\-#8R0T4P-CA%,C4U1#`Y138S M.#1#0T,W-3A&0S8R.30^/#%%0S%",D-!-S(R,$0T-#(Y,#$W-D5"044Y-3,Q M.37!E+UA2968^/G-T-IB8JS\"!!@ M``'R`6X-"F5N9'-T'1=+T5X=$=3=&%T M93P\+T=3,"`Q,S8@,"!2/CX^/B]4>7!E+U!A9V4^/@UE;F1O8FH-,3(@,"!O M8FH-/#PO4W5B='EP92]834PO3&5N9W1H(#,Y-#4O5'EP92]-971A9&%T83X^ MG)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C`M8S,R,2`T-"XS M.3@Q,38L(%1U92!!=6<@,#0@,C`P.2`Q-#HR-#HS.2(^"B`@(#QR9&8Z4D1& M('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&%P+S$N,"\B/@H@("`@("`@("`\>&%P.D-R96%T M;W)4;V]L/D%C&%P.DUE=&%D871A1&%T93XR,#$Q+3$Q M+3`X5#`Y.C$V.C4Q+3`X.C`P/"]X87`Z365T861A=&%$871E/@H@("`@("`\ M+W)D9CI$97-C&UL;G,Z>&%P34T](FAT='`Z+R]N&%P+S$N,"]M;2\B/@H@("`@("`@("`\>&%P34TZ1&]C=6UE M;G1)1#YU=6ED.F9F.&-E,6%D+35B.6$M-&(U,BUB-30Q+6(X861C,S1B8V%A M93PO>&%P34TZ1&]C=6UE;G1)1#X*("`@("`@("`@/'AA<$U-.DEN&UL M;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL.FQA;F<](G@M9&5F875L="(O/@H@("`@("`@("`@ M("`\+W)D9CI!;'0^"B`@("`@("`@(#PO9&,Z=&ET;&4^"B`@("`@(#PO#IX;7!M971A/@H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0](G2A4:6UE=K:V:BS?E5$VR.]%#JN(\T!0D M,2.36I"T1W^?[M,`2$EVU>;!%@`"C;Z>/OBTOGG_F_KYY_=?/]]_4;'ZY9=/ M7SZKF_=__6>L=MW-^_4Z5HE:;V_B*([C5*TK->-AOE#K%Y70,*53L1T5\2I: M+E8KM4B+B(X]W?P[N/NQKQ_K7F5)%!9!&LZR0(7_6?_MYNXK7S1>GKC+<57" M5\5\R2S-HSPMZ#FI-WTTF56X-#'+Y]%R3C)7T9P- M)&/6_[VR)9M(2T0:W)9FWH-I*L:MHF*Y@'%9)L;=A[,BN`UG>:`^\K#9&/[1 M+RJ0M;(2LIX"T:92QT$<4)ZPQI+0OZSO\Z M*_N?7H]&/HV&E0^%LRA/5F?!2")%@;CG?_LR7`;/FAS,OS5=R(.7<)8$>D/A M5STM[7G*W[HP"?C4'_1EX,72]/:(.=#@Q">,/H9L;!$8WL(;%,\:GO'I7\,% M&YD$YBE,*+F2F+[.?N>SO&^+?>LZ3.)@IPTO_XO_?<5-:;!A3:J2[[LE:>K> MR:ZB#WS7J]XISKRS\$&-$=38N^<+N2>E@)&@DN[JV+0-*SU:\$3JP]#OC;43 M[CHX]6AA!__=DO/(AHGWTD`<+0YB#\`[)'[C5G3'TZ;%AXKVXF*>E2RC4>68 M1;'/(EB1IM%RM71IU)S40.LGW?2JW:J2K$@H?+WF##4U>9.E MQDX>YP^A118EUDBR<1_%F[/9BR!;2%^3HVE3T.Y`X"CI?T(=94#:D%'EQPWN,>MG7O&FO.CH[ ML`(5C?MP)7XL`IPF#W?J11O(G52\5RA="HZ(1NR1/'Z.D%%Q8+#:L\Y8XPU'?X.II0YS2CY* MS*I]ED]4MWJC'GERX@]T2.37'6J;1BVMF_[#ZZ4V/RNUY5AJ@+KU7\C0S%58 MQA6V^K\J+'NCPF#=%C52DLBFJNT-?(S#Q-C)$@`Z&B7%%7FK2KY%5`#:$>90 MPKTI"NN,4X`X2"M[7FP;!=`2,.*]PT:L&Y*HOR<&"9ON`F.=+9KJ+9W$6`,R5KAU$%/4N1>7\OLUJ;<<.B[B8JI3W60#J8#\X6'$1S="JT@EXLJAES8-AW%`C>HJNQ\ M3F\/[0NAXC*P)RDG^S&AC48AH$!Z4XK9W*?*CI#NUDN<8-/55X5#1+%W1H$-3<([&NUO+7>3T?B_ETKY9)XNS.IF/=9)"@)S(:*C:/`0T MX?,/(7]CQQ727E5IK*\[="]*"U^M'9]^1&TB6$ADI:7@:/<.(E=**@`S3@%0H<`R`.^6.% MU]$Z%"RM`6^2@FX`GJ9U*^RY9T@R%DL9M4H'?ZG`W\2)-CD=X7-\QGD&&>;] M1PML^:LNO/M!_ZL]_2N;'7+<^NX;JW#N.?XZ.D_\X!W'V7SF`;HY$:<55UYV M7/,A9!^&CI[:#+[H+`0SKU3<18@LF_[I31JZ/*MY3PF$OV51L%4LSN1<@GDP5<66X$):)DXI3^^85#JXS,<^ MZ*KZ44O)`IMV#JG0BUV4!^2'M/K6/6P34.$HTZ96IS]%L><4WF!.0;SO\'.H-_Y3H@220 M$H!^'OE?Q\&K`0(TJTM3C=L7_)"!G($S@=C!"^(9Q)XX M@;"!=^Y%S)N$.TVB5>I?1Z:;,N>Z.6?*;:MJX!GE>5": MPTEM,#6.C?])KCWQKW\G9?).LFI.N$@MWGB!@34].7H9=9(D1[@L9.6L2Q^] M0Z&6^`_;#+Y@2!T=CG^#G*P<4,U&%@\MLVMR\A`\CBBU@[9G.4`JBPW$/_%+ MC))020)'>DOZ*'Y_%-Q['!6EC5*ZQ"2Y`E/R7$SJX,(_]B(#@5HK] M$M,`/Q=X9HLSM86;`IJP(,5;76!:+LVQ?4:7G3Y%EL%K#71V\3@2ICRSVD\? MA1Q//TX6M#1=M,FCCAQ=Q0!B:,`G&'09B6GR1<3<-`,O MCN`*>H@3@'9ZK-@S()N62,N;,9$6P1==7$G487R"^"=2LK!9&_ND)0AE.Y]8 MEI;(D?_IK4:O$J7)53\PUR!SQ(:.@SD28G6J%C)"L2HKVE:U9E-**67L=@MX MH^\F6F0N_>+5%'MVNN$+#3TA3R2TTD>"=QYP'@R$D'!8)E3O:&3*M]7'@^[> MP)8D/F-!7HGX56RI!%ONGDN0BZ%T%;GQ%"VE?`$]W^K*%?PSEL4A-.#R[E#[ MVVGSE"U7+RJ$+9T^JI()Q;%LQ",&3E\API3EE"/;RB1^4 M3G5O[ADL.=O=NRHY:RH+Y](\O29'QK<'!I:YS'LD\8"Y@#,Q1T8U+`D0T*_B MDG0;>V7[[IS]OY7:9-E57S]C%8=T1X[?2D>WFS?\4[,OT>$9>[PF6N`51WN# MKP>ZM\$9V\EX:R(G*P01'PX2G(P)PKM."4$3_I![_I![_L#M=Q&` M0N1"(60C&85!Y;D#NS)US327!*&-_005+_PULXI-8+&MJL$8'\+-(,A']'Q_ M;JU]*;YC]$&-4KX1KJ<607IEQFL3#\9XT21%E"QRYPY=$1\EL[J*#/EC8%@W MY`Z^_2&`J_TK%;=Y>L&T'0[W!WD"BZ!+<4#>P:LY\ MJ0NY-;=;*S1=13FI/64K_Z.]:IH;-8+H7;]BCG)*QL``0IM4JFPGJ=I+B!5"HK"8.&O<%]MOB!B%-*FPFMWTQV*`V%+>WR6ST?>Y!N8 M`O6()Z(2+EQP\RR`1/,@SJQSLC9-;5#4++-09R_VFS92^?9!K%K53HQ18@&' M*UK;2&Q5K=IKP!O:69K">9#.1_>-ZQ6V;IMMA_]"':(NW:B`Y;HX'!1TO%.5 M*:*AGV;PSP-^G0G?-"/BZ6ITK&B*L98I7D7-N)=;Z2(6SMB0#$C4PVZS(4LU M7'S&U?-/5D2C"#!TLD05_(M.B("SB!@#7#Q=^GNJS1TV`W?]B[56DI'`Q?ZJ5 MP+&!EIB9V@O.IB;;WUU\\C/>4>]9UWLGR_>0EPLEY>OMUN@X!S_HEXX7J:$8 M%*MG594=RY6=4DJF6O8<)0X*W656&&:1QYYP"2KO9?%40[#1+EE751+:4'Y` M%')-4K0-Y%`Q:$8/KW'FZ,OF?<ZMDK9%I<3#+CP"2YF'9-JL5O)EBO;$`"MD(F`LA#)(9^Y/;%TZDYZEUHAZ MQW>41"@+F$F0A]SD!>G?BYR8(@<.SZ?3!GGBK5?;:B_!,*5H`0QZ,_.B*5OA M^F:&@CJ92@T\$U/:ZK_2J+=UWV&:M:KZS-]DHSFPQX%=$!<_B#M0?SH.J3^ MXL)J:5<0BZYG>L6E@A+X"2)&`8(2I7%JG##&`^BD9=$)S!A[?M:#H2AQX\'W MS:5DJ[-F)/BPPT4:@1?:JPO"2TG=(+_1MB)(HZ$,XZ+HEUTO,F#R1"6Z^1W? MA--&==,;O9@"@,!7'VK&H^RQ4G@UKE^XLZ!M+ORT]J]6JY MC`T.O9E`DH1$O]#HTR(-LARU'T5Q$.6@\.7S9/H[P.?Y'J>(DHOE/WP[TK?3 M($D\O,TPO-!5%&EK>340=0[@_[IE[;R;ZX!*[H9MP%YHGG:#=/^ZG%S=_AF: MU0[5D7$Z&'R:W:J>.'\A!%UN8L`L1%,(T$"]3#83[ER8AWY;%*1')E9@T*,"`P#0IT%LQ.3`@,5TO1&5C M;V1E4&%R;7,\/"]#;VQU;6YS(#,O4')E9&EC=&]R(#$R/CXO4VEZ92`Q.3$O M5'EP92]84F5F/CYS=')E86T-"GC:8F)<,AT@P``![@$_#0IE;F1S=')E86T- M96YD;V)J#3$@,"!O8FH-/#PO0W)O<$)O>%LP(#`@-C$R(#%LP(#`@-C$R(#'1'4W1A=&4\/"]' M4S`@,3,V(#`@4CX^/CXO5'EP92]086=E/CX-96YD;V)J#3$R(#`@;V)J#3P\ M+U-U8G1Y<&4O6$U,+TQE;F=T:"`S.30U+U1Y<&4O365T861A=&$^/G-TFMC.60B/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O&UL;G,Z<&1F>#TB:'1T<#HO+VYS+F%D;V)E M+F-O;2]P9&9X+S$N,R\B/@H@("`@("`@("`\<&1F>#I3;W5R8V5-;V1I9FEE M9#Y$.C(P,3$P.#`Y,C,U.#`T/"]P9&9X.E-O=7)C94UO9&EF:65D/@H@("`@ M("`\+W)D9CI$97-C&UL;G,Z>&%P/2)H='1P.B\O;G,N M861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AA<#I#&%P.D-R96%T;W)4 M;V]L/@H@("`@("`@("`\>&%P.DUO9&EF>41A=&4^,C`Q,2TQ,2TQ-%0R,3HQ M-CHP,2TP.#HP,#PO>&%P.DUO9&EF>41A=&4^"B`@("`@("`@(#QX87`Z0W)E M871E1&%T93XR,#$Q+3`X+3`Y5#$V.C4X.C,R+3`W.C`P/"]X87`Z0W)E871E M1&%T93X*("`@("`@("`@/'AA<#I-971A9&%T841A=&4^,C`Q,2TQ,2TQ-%0R M,3HQ-CHP,2TP.#HP,#PO>&%P.DUE=&%D871A1&%T93X*("`@("`@/"]R9&8Z M1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@&%P34TZ&%P34TZ M&UP;65T83X*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2)W(C\^#0IE;F1S=')E86T- M96YD;V)J#3$S(#`@;V)J#3P\+T-R96%T:6]N1&%T92A$.C(P,3$P.#`Y,38U M.#,R+3`W)S`P)RDO075T:&]R*$)I;&PI+T-R96%T;W(H06-R;V)A="!01$9- M86ME7!E+U1R=654>7!E+T9O M;G1$97-C?W7S_??U&Q^N673U\^JYOW M?_UGK';=S?OU.E:)6F]OXBB.XU2M*S7C8;Y0ZQ>5T#"E4[$=%?$J6BY6*[5( MBXB./=W\.[C[L:\?ZUYE210601K.LD"%_UG_[>;N*U\T7IZXRW%5PE?%?,DL MS:,\+>@W*O)"K3S(K@-9WF@/O*PV1C^T2\JG,V# MCY'ZA'D+6R$K*>`M&F4L=!'%">L,:2T+^L[_.G+3K:JTZ>OM2?5[7BO[GUZ/ M1CZ-AI4/A;,H3U9GP4@B18&XYW_[,EP&SYHUY MRM^Z,`GXU!_T9>#%TO3VB#G0X,0GC#Z&;&P1&-["&Q3/&I[QZ5_#!1N9!.8I M3"BYDIB^SG[GL[QOBWWK.DSB8*<-+_^+_WW%36FP84VJDN^[)6GJWLFNH@]\ MUZO>**]N)BGI4LHU'EF$6QSR)8 MD:;1W;LC7=:,.M5C!]V?^?N>;U2IW MINSV8L@6TA?DZ-I4]#N0.`HZ7]"'65`VI!1Y<<-[C'K9U[QIKSHZ.[`"%8W[ M<"5^+`*<)@]WZD4;R)U4O%58:H"Z]5_(T,Q56,85MOJ_ M*BQ[H\)@W18U4I+(IJKM#7R,P\38R1(`.AHEQ15YJTJ^150`VA'F4,*]*0KK MC%.`.$@K>UYL&P70$C#BO<-&K!N7+_%T"418!4<(ZP'X;`>*?<34-SM'[$J* M@0NQ,8ABIQO)'BJ+\G!@F;[@)CG2V:ZBV=Q%@#,E:X=1!3U+G*Z0*8WD7E_+ M[-:FW'#HNXF*J4]UD`ZF`_.%AQ$+*H9(RL"E.*V=RGRHZ0[M9+GW.N7>+Y""D[`:=L:SJWE M5>%0T2Q=T:!#4W".QKM;RUWD]'XOY=*^62>+LSJ9CW627+>D'!U[O=YR"7'6N-/(*MT/X* MK&>`BU&=#T&)CKSA%<$$X00.!OCCW8]*ONWQ@+IB2A4PEM MRW"`3LYXP"L%#QY`J"@(""RO0$?Y7G#B)72BH`,TX!4*'`,@#OECA=?1.A0L MK0%ODH)N`)ZF=2OLN6=(,A9+&;5*!W^IP-_$B38Y'>%S?,9Y!AGF_4<+;/FK M+KS[0?^K/?TKFQURW/KN&ZMP[CG^.CI/_.`=Q]E\Y@&Z.1&G%5=>=ESS(60? MAHZ>V@R^Z"P$,Z]4W$6(+)O^Z4T:NCRK>4\)A+]E4;'*SH@Z.4]J\8ONA`]; MSW5,5L)9RD[+KPHBY8+(`ZG9\SB#P8O2N;CGZ/.>05M?(Q+(N(.E';ZH=I*5[3F38%6%1>P.(&P@7?N M1FFS+GNCEGRFVG*;(]\1Q6].A9D>GK:N`9Y7E0FL-);3`U MCHW_2:X]\:]_)V7R3K)J3KA(+=YX@8$U/3EZ&762)$>X+&3EK$L?O4.AEO@/ MVPR^8$@='8Y_@YRL'%#-1A8/+;-KQP5I8U2NL7(1+V]'@DN0)3\EQ,ZN#"/_8B`X%:*_1+3`#\7 M>&:+,[6%FP*:L"#%6UU@6B[-L7U&EYT^19;!:PUT=O$X$J8\L]I/'X7,(1&[ MWD<3S].%K0T7;3)HXX<7<4`8FC`)QAT&8EI\D7$W'.4K+3Q+AM42I5LAZV?7 MVGQ*`PF;%+^F^)2='"JAV$'C7-EU`[@YA9(W[5QTC4`"!WPG-^R=H$,M(NI# MW9_H6Y+*U=MPV@F8PKM.,+]"*`I",3[B"ON(*RX>7:Q`P0I@(W@#+X[@"GJ( M$X!V>JS8,R";EDC+FS&1%L$775Q)U&%\@O@G4K*P61O[I"4(93N?6):6R)'_ MZ:U&KQ*ER54_,-<@<\2&CH,Y$F)UJA8R0K$J*]I6M6932BEE['8+>*/O)EID M+OWBU11[=KKA"PT](4\DM-)'@G<>.WTI'MYLW_%.S+]'A&7N\)EK@%4=[@Z\'NK?! M&=O)>&LB)RL$$1\'.4\=N[RZ48_G[9=0L(8_CLUD,8))>@4F1VU`I5IP_0K/ M)6TDC`S$I["8L#)'Q22Y'-3(2^NQ%"8-=?`"Z@;_@N1%_8PV(\E>6[+9?+A^ M<;Q>8,FTP.*5+[#Y:P7&B67[-X>D[=SC;.52;5\C09TA.5,-]X8X(5Q[)"\] M>R>G:'1585,,'`M?FE\:GW7N$IR,"<*[3@E!$_Z0>_Z0>_[`[7<1@$+D0B%D M(QF%0>6Y`[LR=-$D190L7K!M!T.]P=Y`HN@2W%`WL&K.?*D+N36W M6RLT744YJ3UE*_^CO6J:&S6"Z%V_8HYR2L;``$*;5*IL)ZG:2W*(;G%5"DO( M)I;!0;)=FU^?][J9`?3AW5M9JH*>GY_5[KXO:=$6'_KUJ)#J8=@^([1\+ MX9E'"61$X"!V;45Y&>3I/7&TZ!)-;.02-870?+F>&0JFWU M5.+/OC'GZYL$8>[K*Y=2="95\[%NJYG#LIU^OB^<;VBUFVS[?A?I$/B-\U(>#J,CAU-,?8RQ:NX&?=R*UU$X(P#R8!$/^P>-E2IAHO/N'K^ MDQ7Q*$(,G2U1!_]A"O?JDFBGQ7&K,J<#:S\8CS)[[&,DJ58=7W>(._UB7NC5 MVUVC38-QJ/N%)KUI`0B+O$'`]<.%GZ?ZZM$3X.E_L?8J5E*TF#_5*N!X@)%8 MF=H;SJ:FVM]=?/(SWE'O6==[)^%[J,N%BO+U=FMTG,,^Z)=.%^FAF!31LZK* M3N7*SBDE4X4]1XD#H+O*BL(L\M@++DGEO2R>:A@VQJ7JJDM"&\H/R$*N24#; MP`X5@V;T]!IG3KYLWG>\ZK6"_Y(N'/3Z#:HN+[P)#^HD@^=Z11]87K^]5=&V M0$H\[,(CLI1Y2*;-:B5_3-&>&&!%3(2,15`&YY,3T^1@P_/EM$&>^.C5MMI+,BPI6@"#WLR\:,E6N+Z9H:%. MIH*!9W)*6_U7&MUMW7>85NURZ'46P1RJ.)1TQT%HCG9_H77;<+*%VBX.A]S* MM=Q&;QKO(`D:+"QPL8&+9:GYZOI,GR2C^;!G`1T0ES](>Y`_N@ZIO[BT6L85 MQN+6,[WB4DD)^@03HP1!B](X-TX:XP%TTK+H!%:,/3_KR5"R+QR8G=-.*Q;8NG=7`=T=C=L"_9&\[0;E/_7Y>3J]L_0 MK'9`2\9I8?!I=JMZXO8+8?!R$X-V8:)"D`CP,V%9LGAA'OK'HB#E>ISHASPT M7F0,-'V_'`8YO./#)$U"<@8B(#@#D'`<`XN*&AHK\02`X M'&"[1+>[[*VN?.W9^+,3\NI9`MT^BL:5&_.;:CP]K^FUE?K0>^I6&0F"SB5P3ZB:KRLXL%N/\_ M`,H[A]<-"F5N9'-T')E9@T*,2`Q#0HP,#`P,#0R,SDW M(#`P,#`P(&X-"C$R(#(-"C`P,#`P-#(V.30@,#`P,#`@;@T*,#`P,#`T-CF4@,C`W M+U1Y<&4O6%)E9CX^7!E+UA-3"],96YG=&@@,SDT-2]4>7!E+TUE M=&%D871A/CYS=')E86T-"CP_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5- M,$UP0V5H:4AZDY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB M861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#0N,"UC M,S(Q(#0T+C,Y.#$Q-BP@5'5E($%U9R`P-"`R,#`Y(#$T.C(T.C,Y(CX*("`@ M/')D9CI21$8@>&UL;G,Z&UL;G,Z<&1F/2)H='1P.B\O;G,N M861O8F4N8V]M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0#I3;W5R8V5- M;V1I9FEE9#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z M1&5S8W)I<'1I;VX@&%P.D-R96%T941A=&4^,C`Q,2TP."TP.50Q-CHU.#HS,BTP-SHP M,#PO>&%P.D-R96%T941A=&4^"B`@("`@("`@(#QX87`Z365T861A=&%$871E M/C(P,3(M,#4M,3)4,34Z,S,Z,3$M,#&%P34TZ M26YS=&%N8V5)1#YU=6ED.C(W,38R9C0U+60W.34M-#DR-"UA-68S+6%F83AD M,64X-F9D93PO>&%P34TZ26YS=&%N8V5)1#X*("`@("`@("`@/'AA<$U-.G-U M8FIE8W0^"B`@("`@("`@("`@(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@("`\ M"UD969A=6QT(B\^"B`@ M("`@("`@("`@(#PO7!E+T9O;G1$97-C%5EYVMK9J+-^543;([ MT4.JXCS0%"0Q(Y-:D+1'?Y_NTP!(27;5YL$6``*-OIX^^+2^>?^;^OGG]U\_ MWW]1L?KEET]?/JN;]W_]9ZQVW94D4%D$:SK)`A?]9_^WF[BM? M-%Z>N,MQ5<)7Q7S)+,VC/"WH-RKR0JTW)/3SW;?U_:_WX3SX'.;!1_I;AVEP M_X^_CY+OUC?IG+3(U7RUB(JY6B;1@I2-5G-E],WVYM.9Z:DW?3295;@T,@VDJQJVB8KF`<5DFQMV'LR*X#6=Y MH#[RL-D8_M$O*IS-@X^1^H1Y"ULA*RG@+1IE+'01Q0GK#&DM"_K._SIRTZVJ MM.GK[4GU>UXK^Y]>CT8^C8:5#X6S*$]69\%((D6!N.=_^S)PAL4 MSQJ>\>E?PP4;F03F*4PHN9*8OLY^Y[.\;XM]ZSI,XF"G#2__B_]]Q4UIL&%- MJI+ONR5IZM[)KJ(/?->KWBG.O+/P08T1U-B[YPNY)Z6`D:"2[NK8M`TK/5KP M1.K#T.^-M1/N.CCU:&$'_]V2\\B&B??20!PM#F(/P#LD?N-6=,?3IL6'BO;B M8IZ5+*-1Y9A%L<\B6)&FT7*U=&G4G-1`YR@R@V8W=7W9ZR?=]*K=JI*L2"A\ MO>8,-35YDZ7&3A[G#Z%%%B5SGY=J6U8]7&'P'Q(()_I69)/0B6JY%[62+)Q' M\5S-DBBQ2?A$1_AB$=OH2G==:4XL3G1CS;YK2ON)^OP!*C<,2WUGMV[(UW6C M#K58P?=G_G[GF]4J=Z;L]F+(%M(7Y.C:5/0[D#@*.E_0AUE0-J04>7'#>XQZ MV=>\::\Z.CNP`A6-^W`E?BP"G"8/=^I%&\B=5+Q7*%T*CHA&[)$\=R[9<(EK MSH-;U0`(>C8QIOQ)@NX`5)%-=;,#X)`J+[5``X^-[HZ047%@L-JSSECC#4=_ M@ZFE#G-*/DK,JGV63U2W>J,>>7+B#W1(Y-<=:IM&+:V;_L/KI38_*[7E6&J` MNO5?R-#,55C&%;;ZORHL>Z/"8-T6-5*2R*:J[0U\C,/$V,D2`#H:)<45>:M* MOD54`-H1YE#"O2D*ZXQ3@#A(*WM>;!L%T!(PXKW#1JP;ER_Q=`E$6`5'".L! M^&P'BGW$U#<[1^Q*BH$+L3&(8J<;R1XJB_)P8)F^X"8YTMFNHMG<18`S)6N' M404]2YRND"F-Y%Y?R^S6IMQPZ+N)BJE/=9`.I@/SA8<1'-T*K2"7BRJ&7-@V M'<4"-ZBJ['Q.;P_M"Z'B,K`G*2?[,:&-1B&@0'I3BMG[W7-F&6P0[YPPECN(4CG=_1`$W&YS%IQ_0AS)%N6YIS.B&#=X*` MG,AHJ-H\!#3A\P\A?V/'%=)>56FLKSMT+TH+7ZT=GWY$;2)82&2EI>!H]R/- M#U8!%KZ7VR%5"D]*B#Y)95G.<+;@!S@'!M!1A5%5H6EV`U#KO%\:UU(/KO?: M'N<@EQUKC3R"K=#^"JQG@(M1G0]!B8Z\X17!!.$$#@;XX]V/2G*%>A&O[>"* MCY7K[M\8"Z8DH5,);,`K!0\>0*@H"`@LKT!'^5YPXB5THJ`#-.`5 M"AP#(`[Y8X77T3H4+*T!;Y*";@">IG4K[+EG2#(62QFU2@=_J<#?Q(DV.1WA M089YOU'"VSYJRZ\^T'_JSW]*YL=3!5Q9;@0EHF3BE/ M[YA4.KC,QS[HJOI12\D"FW8.J="+790'Y(>T^M8]9S#C#!N.O-D\P^F=1:)6 M&B,]]:Q*%''=8+O`#S,EU][!-1RT9;8`,R9=5$L3'D%;7R,2R+B#I1V^J':2 ME>TYDV!5A47L'*F0+&V$3UR2$H8$Y!O._P< MZ@W_E.B!))`2@'X>^5_'P:L!`C2K2U-S?M6=L!(L:L27^!Z-VQ?\D(&<@3.! MV,$+XAG$GCB!L(%W[D7,FX0[3:)5ZE]'IILRY[HY9\IMIRFR/?$<5O3H69'I MZVK@&>5Y4)K#26TP-8Z-_TFN/?&O?R=E\DZR:DZX2"W>>(&!-3TY>AEUDB1' MN"QDY:Q+'[U#H9;X#]L,OF!('1V.?X.=/D66P6L-=';Q M.!*F/+/:3Q^%S"$1N]Y'$\_3A:T-%VTR:..'%W%`&)HP"<8=!F):?)%Q-QSE M*RT\2X;5$J5;(>MGU]I\2@,)FQ2_IOB4G1PJH=A!XUS9=0.X.862-^U<=(U` M`@=\)S?LG:!#+2+J0]V?Z%N2RM7;<-H)F,*[3C"_0B@*0C$^X@K[B"LN'EVL M0,$*8"-X`R^.X`IZB!.`=GJLV#,@FY9(RYLQD1;!%UU<2=1A?(+X)U*RL%D; M^Z0E"&4[GUB6ELB1_^FM1J\2IQV"WBC[R9:9"[]XM44>W:ZX0L-/2%/)+321X)W'G`>#(20<%@F5.]H M9,JWU<>#[M[`EB0^8T%>B?A5;*D$6^Z>2Y"+H705N?$4+:5\`3W?ZLH5_#.6 MQ2$TX/+N4/O;:?.4+5R3Q@+F`,S%' M1C4L"1#0K^*2=!M[9?ONG/V_E=IDV55?/V,5AW1'CM]*1[>;-_Q3LR_1X1E[ MO"9:X!5'>X.O![JWP1G;R7AK(BPF+`R1\4DN1S4R$OKL10F#77P`NH&_X+D M1?V,-B/)7ENRV7RX?G&\7F#)M,#BE2^P^6L%QHEE^S>'I.W&."%<>R0O/7LGIVAT56%3#!P+7YI?&I]U[A*F7&:Q,/QGC1)$64+'+G#ET1'R6S MNHH,^6-@6#?D#K[](8"K_2L5MR[0*+H M$MQ0-[!JSGRI"[DUMULK-%U%.:D]92O_H[U:=ALW@N#=7S%'.=#2?)/:!`%L M)P'V$.00W6(@X$J4S5@F'4JVX7Q]JKIGAJ0>SEYRL"R1\^CIJ:ZJKEICDP[] M>]&5Z&#Z/2"V?ZB$9QYD(2,"!['K&\K+*$[OB:.%#31-(A>HJ83FZ_7<0`Z= M"\:*+"7N_152M6T>:_S;=^9\?M,@+'U^Y5(J:U(UGL1M-7=83F;_G>3(<'!IL%W&GY M4%L&*&9'A^^`#XA&W8^N,/%$JA(4A<'"7^&^V;PC8@!ITV#:W6P'<"!L*8\O M\OG`FWR%4@"/^$96PH4+;YXED*@(XCQQFZQ-UQJ`FC`+M?=BO6DAU:\?Q*JH M=F:,%@L\W'"UC<36M.J]1KJAE:4I+(*LF-PWKE?4NN^VEO]%.L1=NE8!K]OJ ML%'0]DY=IIB&H9O!CWL\G8O>=!/AL1B=.IIJZF6J%W$S;G(O543@3!>2!HE^ MV`TV5*F.+Y]P]?R3-^)1A!BL+5$'_V$(7]4ET4Z+XU9ESD;6?M0>YG5\]A!W^L4\TZOWNTZ+!NV0?4*3WO4`1(*X0<#M_:7OIX;LT1-@]-]X]R)6 M4K28CUH5<`S@2LQ,ZPUGUU+M[RX_^Q[OJ/825WLGX7NHRY6*\O5V:[2=PSZH M%ZN+]%`,BNA9-;55N=HZI72FL&\$EJ;S5U6,+P\9UJ;KJ MDE"&\@!1R#4):#O8H6I4C)Y>X]S)5U(.%:]ZK>#_1!<.>OT&59<)K\*#VLE@ MW*#H(\OKMT]4M!,@)1Y7X1%92C\DW6:SDG^FZD\TL"(F0L8B**-TEO[$B4MG M.JC4&E'O.$=%A+:`F81XR$U>4OZ]R8EIQUUD$!51Q+.F.@U`<_?Y2 M\[9A9PNU71PVN8TKN8W>-.8@"!HLO.#+#BZ6J>;4]9DZ22?]X<`"VB`NOY/R M('_8"FG?75@]UQ7&XM9SO>):20GZ!!.C!$&+TCDW3AKC`;332E`)S!AK?CZ0 MH3AQX\GWU:5DJ[UF)/RPPT4:H1>NUU:DEYJ^09YQ;6603D,9QT73+Z.>I<'D MB6I4\QO^DTX[]4VOW,54(`1.O6\9CZK'2NG5]"[O6WL:&W,V;A"CW%=+=-3F M[*48+%)Y:9%#:C:VX_^/@PF8K3.PR";T&0^R':O3BH*T6)!$2P?=GW1C,/V^ M_JRK7BV7L<&A-Q>P)"'9+S3Z;9$%>0GL1U$<1"4D?/ET,?NU>K]<_L59B$U`;/NB;8W-N=$$_+R^N;G\/S6H'/.7L)T:?9K=J+]Q^(2Q@:6(0,VQ6")H!PBYP M=(Q7V1I2-8_O8;;Z,-!HXUB_S(Y MN\N),0>GD4,?1:(+G4BPQ`(#@?8+M/M/@UF6+X.?/W%27WS)`O=/H@*UAOSB[H` MNEX5=J4'5?_?M$-PVWQ0+6F2!D5NBH*?YTNE='FZNHW_##T1,+^:#WS+PB`U M><2O6.@'ZLZ/;BW`_=\!`#D%CI8-"F5N9'-T')E9@T* M,2`Q#0HP,#`P,#4S,S,S(#`P,#`P(&X-"C$R(#(-"C`P,#`P-3,V-#(@,#`P M,#`@;@T*,#`P,#`U-S8V-2`P,#`P,"!N#0HQ.3$@,@T*,#`P,#`U-S@Y-B`P M,#`P,"!N#0HP,#`P,#4Y,#F4@,C(U+U1Y<&4O6%)E9CX^7!E+UA-3"],96YG=&@@,SDT-2]4>7!E+TUE=&%D871A/CYS=')E86T-"CP_ M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK M8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#0N,"UC,S(Q(#0T+C,Y.#$Q-BP@5'5E M($%U9R`P-"`R,#`Y(#$T.C(T.C,Y(CX*("`@/')D9CI21$8@>&UL;G,Z&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O M(CX*("`@("`@("`@/'!D9CI0#I3;W5R8V5-;V1I9FEE9#X*("`@("`@/"]R M9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@&%P.D-R96%T941A M=&4^,C`Q,2TP."TP.50Q-CHU.#HS,BTP-SHP,#PO>&%P.D-R96%T941A=&4^ M"B`@("`@("`@(#QX87`Z365T861A=&%$871E/C(P,3(M,#&%P34TZ26YS=&%N8V5)1#YU=6ED.C

&%P34TZ26YS M=&%N8V5)1#X*("`@("`@("`@/'AA<$U-.G-U8FIE8W0^"B`@("`@("`@("`@ M(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@("`\"UD969A=6QT(B\^"B`@("`@("`@("`@(#PO7!E+T9O;G1$ M97-C=K:V: MBS?E5$VR.]%#JN(\T!0D,2.36I"T1W^?[M,`2$EVU>;!%@`"C;Z>/OBTOGG_ MF_KYY_=?/]]_4;'ZY9=/7SZKF_=__6>L=MW-^_4Z5HE:;V_B*([C5*TK->-A MOE#K%Y70,*53L1T5\2I:+E8KM4B+B(X]W?P[N/NQKQ_K7F5)%!9!&LZR0(7_ M6?_MYNXK7S1>GKC+<57"5\5\R2S-HSPMZ#FI-WTT MF56X-#'+Y]%R3C)7T9P-)&/6_[VR)9M(2T0:W)9FWH-I*L:MHF*Y@'%9)L;= MA[,BN`UG>:`^\K#9&/[1+RJ0M;(2LIX"T:92QT$<4)ZPQI+0OZ MSO\Z*_N?7H]&/HV&E0^%LRA/5F?!2")%@;CG?_LR7`;/ MFAS,OS5=R(.7<)8$>D/A5STM[7G*W[HP"?C4'_1EX,72]/:(.=#@Q">,/H9L M;!$8WL(;%,\:GO'I7\,%&YD$YBE,*+F2F+[.?N>SO&^+?>LZ3.)@IPTO_XO_ M?<5-:;!A3:J2[[LE:>K>R:ZB#WS7J]XISKRS\$&-$=38N^<+N2>E@)&@DN[J MV+0-*SU:\$3JP]#OC;43[CHX]6AA!__=DO/(AHGWTD`<+0YB#\`[)'[C5G3' MTZ;%AXKVXF*>E2RC4>681;'/(EB1IM%RM71IU)S40.LGW?2J MW:J2K$@H?+WF##4U>9.EQDX>YP^A118EUDBR<1_%F[/9BR!;2%^3HVE3T.Y`X"CI?T(=94#:D M%'EQPWN,>MG7O&FO.CH[L`(5C?MP)7XL`IPF#W?J11O(G52\5RA="HZ(1NR1 M/'Z.D%%Q8+#: ML\Y8XPU'?X.II0YS2CY*S*I]ED]4MWJC'GERX@]T2.37'6J;1BVMF_[#ZZ4V M/RNUY5AJ@+KU7\C0S%58QA6V^K\J+'NCPF#=%C52DLBFJNT-?(S#Q-C)$@`Z M&B7%%7FK2KY%5`#:$>90PKTI"NN,4X`X2"M[7FP;!=`2,.*]PT:L&Y*HOR<&"9ON`F.=+9KJ+9 MW$6`,R5KAU$%/4N1>7\OLUJ;<<.B[B8JI3W60#J8#\X6'$1S="JT@ MEXLJAES8-AW%`C>HJNQ\3F\/[0NAXC*P)RDG^S&AC48AH$!Z4XK9W*?*CI#N MUDN<8-/55X5#1+%W1H$-3<([&NUO+7>3T?B_ETKY9 M)XNS.IF/=9)"@)S(:*C:/`0TX?,/(7]CQQ727E5IK*\[="]*"U^M'9]^1&TB6$AD MI:7@:/<.(E M=**@`S3@%0H<`R`.^6.%U]$Z%"RM`6^2@FX`GJ9U*^RY9T@R%DL9M4H'?ZG` MW\2)-CD=X7-\QGD&&>;]1PML^:LNO/M!_ZL]_2N;'7+<^NX;JW#N.?XZ.D_\ MX!W'V7SF`;HY$:<55UYV7/,A9!^&CI[:#+[H+`0SKU3<18@LF_[I31JZ/*MY M3PF$OV51L%4LSN1<@GDP5<66 MX$):)DXI3^^85#JXS,<^Z*KZ44O)`IMV#JG0BUV4!^2'M/K6/6P34.$HTZ96IS]%L><4W MF!.0;SO\'.H-_Y3H@220$H!^'OE?Q\&K`0(TJTM3C=L7 M_)"!G($S@=C!"^(9Q)XX@;"!=^Y%S)N$.TVB5>I?1Z:;,N>Z.6?*;:MJX!GE>5":PTEM,#6.C?])KCWQKW\G9?).LFI.N$@MWGB!@34] M.7H9=9(D1[@L9.6L2Q^]0Z&6^`_;#+Y@2!T=CG^#G*P<4,U&%@\MLVMR\A`\ MCBBU@[9G.4`JBPW$/_%+C))020)'>DOZ*'Y_%-Q['!6EC5*ZQ"2Y` ME/R7$SJX,(_]B(#@5HK]$M,`/Q=X9HLSM86;`IJP(,5;76!:+LVQ?4:7G3Y% MEL%K#71V\3@2ICRSVD\?A1Q//TX6M#1=M,FCCAQ=Q0!B:,`G&'09B M6GR1<3<-`,OCN`*>H@3@'9ZK-@S()N62,N;,9$6P1==7$G487R" M^"=2LK!9&_ND)0AE.Y]8EI;(D?_IK4:O$J7)53\PUR!SQ(:.@SD28G6J%C)" ML2HKVE:U9E-**67L=@MXH^\F6F0N_>+5%'MVNN$+#3TA3R2TTD>"=QYP'@R$ MD'!8)E3O:&3*M]7'@^[>P)8D/F-!7HGX56RI!%ONGDN0BZ%T%;GQ%"VE?`$] MW^K*%?PSEL4A-.#R[E#[VVGSE"U7+RJ$+9T^JI()Q;%LQ",&3E\API3EE"/; MRB1^43G5O[ADL.=O=NRHY:RH+Y](\O29'QK<'!I:YS'LD M\8"Y@#,Q1T8U+`D0T*_BDG0;>V7[[IS]OY7:9-E57S]C%8=T1X[?2D>WFS?\ M4[,OT>$9>[PF6N`51WN#KP>ZM\$9V\EX:R(G*P01'PX2G(P)PKM. M"4$3_I![_I![_L#M=Q&`0N1"(60C&85!Y;D#NS)US327!*&-_005+_PULXI- M8+&MJL$8'\+-(,A']'Q_;JU]*;YC]$&-4KX1KJ<607IEQFL3#\9XT21%E"QR MYPY=$1\EL[J*#/EC8%@WY`Z^_2&`J_TK%;=Y>L&T' M0[W!WD"BZ!+<4#>P:LY\J0NY-;=;*S1=13FI/64K_Z.]6G8;-X+@75\Q1SF0 M:;Y%;8(`MI,`>\IA=8N!@"M1,F.9="C9QN;K4]4],R3U!G%Z3QPM;*!I$KE`32DT M7ZUG!G+H7#!69"EQ[Z^0JEW]5.'?H367\YL&8>'S*Y=26I.J\21NJYG#ZLTW1`P@;6I,>YCN M`0Z$+>7Q63X?>9-O4`K@$4]D)5RX\.9%`HGF09PG;I.U:1L#4!-FH?9>K#=PH:'NG+E-,0]_-X,L6O\Y$;]J1\%B,CAU-.?8RY:NX&3>YDRHB M<,8+28-$/^P&&ZI4RY?/N'K^R1OQ*$(,UI:H@_\PA*_JDFBGQ7&K,F<#:S]H MC_+DU,=(4)TZ/GN(!WTP+_3JW;[5HD$[9'^A26\[`")!W"#@9GOE^ZD^>_0$ M&/TWWKV*E10MYD^-"C@&<"5FIO&&LVVH]@]7GWR/=U)[B:N]L_`]UN521?EV MMS/:SF$?U(O517HH!D7TK.K*JEQEG5(Z5=BSE3@"NLNL*,RBB+W@DE3>J_*I M@6'CNE1==4DH0_D!4<@U"6A;V*%R4(R>7N/JW@OZ8+![U^AZK+ MA#?A0>UD,*Y7]('E]=LG*MH)D!(/J_"$+*4?DFZS7LD_4W9G&E@1$R%C$91! M.@M_XL2E,^U5:HVH]YRC(D);P$Q"/.0FKRC_WN3$-#G8\'(ZDZ!(_>KUKCY( M,$PI2@"-WLR\:,I6N+Z9H:%.IX*!9W)*5_]3&=UMW5>89NUZZ'46P1RJ.)1T MQT$HCNYPI7G;L+.%VBZ.F]S:E=Q&;QIS$`0-%E[P90L7RU1SZOI"G:2C_K!G M`6T0ES](>9`_;(4TWUQ8'=<5QN+6,[WB2DD)^@03HP1!B](Z-TX:XP&TTTI0 M"/)]\VE9*>]9B3\L,=%&J$7KM>4I)>*OD%^X]K*(*V&,HR+ MIE]&O4B#R1-5J.9W_">=MNJ;WKB+*4$(G+IM&(^JQTKIU70N[SM[&AMS-FP0 MH]Q72W32YARD&"Q2>6F10VHVM./_CX,)F*T+L,A&]!GWLAVKTXJ"=+X@B18. MNK_HQF#Z0_5)5[U9+F.#0V\FL"0AV2\T^K3(@KP`]J,H#J("$KY\GDQO7[>O ML`U7R[\X,]&9T\A^3^WWT'Z/]'M*ZK&E.D-?PR@BMWMFY\3C.:%W$)$-"F'F M<0`/7$A(Y`$$)*&S6U`]W?'TF']M$_[P17]NISA"%S+CAOE]SJUQMQQ!8.XA@'4'N!K3?)Y_ M`(AB$<0%^R0BP@*`O.0`0%S>L3\[L:^?9:'[ M1]'!:F-^4Q]`WZO2K@2A^O^[]@ANFP^J)4W28)Z;^9R?ETNE<'FZN8__##T5 M,+^:#SQE89":/.(C%OJ)RO.S6PMP_W<`(,6/LPT*96YDF4@,C(U+U!R978@-C,X,S@O4F]O="`Q,S`@,"!2+TEN9F\@ M,3,@,"!2+TE$6SPT-C)#13`V.$4R-35$,#E%-C,X-$-#0SF4@,C(U+U!R978@-S4Y,3')E9@T*-S8R-C@-"B4E14]�H_ ` end EX-32.1 8 exhibit32-1.pdf CEO 906 CERTIFICATE begin 644 exhibit32-1.pdf M)5!$1BTQ+C8-)>+CS],-"C$V,"`P(&]B:@T\/"]&:7)S="`R,3DO3&5N9W1H M(#0U-2]&:6QT97(O1FQA=&5$96-O9&4O3B`S,"]4>7!E+T]B:E-T;3X^P!K]C&0HA>WV+K2$Q'>A%]ZNZ$VZ+JD7-F_? M(X_<_;E8+#`<1O[FS$B*)^S)$`=B8\GW9*.E8,BQ4&!R8BA@W7@*CKQ/%#PH M(`$+0/`D()'$`DDD`J2GR):0&LL+I@1KL90\(D<)Z>*I=X@"]0F1E.H((Q3U MX<',B'LH$B,:M";"%8IV@+#M$7MBYQEEH%$(#WL#1;Y'OS+CD3MO;WRF/^->_RE7QWF,[Y87PC%"_(<'W+W7&^_'Q>N,,TS=W7\_C^ MOC"I,+>WI@G-PBK&)5W")1-(HJ247S1/-$\T3S1//$JP05=1%U$741 M=8GJ$A>7IVZ/4UBV<>R.^7E>.OU"5G>_(U.`4(''Z?(ZGKO]"[G/78$UE>4- M+%?6;F!M95T#ZQMZ"&!C^C_K*RN%M=O8N(%=>T@;^@V5[1M8-BTPM\"V!78M ML&^!0PLL+7!L@5LND%MNT&ZYP?4SM=P";[C!Z!0^!9TH0=9Q$==Q,=S7L:;? M4/W)+\CJ/=3)MR;MZWPKK^ZF[UBM_,]7U MSYX^!!@`402$#PT*96YD-HDS#$.@"`01-&K[`UD$09)"$>PL"4%LQ-"`S(#(Y(#$@-#D@,C0@-S0@,R`W."`Q(#$V,"`S72]$ M96-O9&5087)M7!E+UA2968^/G-T-IB8F)8P,#$P,#`""08_\-8_QEAK($F M_C,4/&9B8-($.7(W`T"``0#HFP8^#0IE;F1S=')E86T-96YD;V)J#3,@,"!O M8FH-/#PO0W)O<$)O>%LP(#`@-C$R(#?Q)LWAQ^F)\?"$V_?'AU/Q>CP][DG M+IO1899Y0HEL-?*DYWE:9`LQQC"(178K%`TUG?+:4>BE,HG35,0ZE'3L>O35 MF?V\*K^5.^%KZ8:.^(]R_L_>CV0<(ZH4K*YQ%)9VHT(>HL4ZD4@%]91B$ M(EL2Z^GL+#MY=^+&SM0-G`D]F>L[)Z>8B%!8*1,W''HS"V+R3&FIY^R&0^@"GW.YN?0(GL._CB2 M7IP,\<]GTPSF(+8I^'ND2L2"3M^)[(\9-N:3LZ/)Q]E\?/KES]E?8C+-L*D] MIM<&U3YWZ2Y6LDSU,:+BSG$(%RA,'O-3=ISO&UPG&PH%L:CHO>%GK)QBL2-7 ME?14F#(%P;O%"G:NL"JZ4>$FCOA,1#>8Y32K,O,KF-^S\7!,=B\V2T8-_N]O`)1%^5;U`YH(;6?*Y"NQ M!Y(&:;""V'5KT>5+7#0O8!YV$F$F#:V7P:$1^8:YS'Z"ZLJZ92W]T'3+W(8!9E=%#6[&DW`':,D?)C`29XMS[`(;0*\HQR]< M-@:\>2`F;:`N:YC_EM-4MD;O2V+8VQNI#8,?U57UO2'R`RY`4Z,DZ5&L2&S<[,K_"G&Z6I4+BJYJQ80[2UATYRI,K[=]^FO5B=8!5^-$:O*_9W(LWZ!N MW!G!Q!J9O"M7^-#B]@:[O-B0QCS+C3U#9V,.=\66U93K%DWBV8ID41[$$!>2E&7L1S\B8^ M3'&%8='G@&^JH1]0W$?WRF%>?V,1S+]HQJ?X_L1K7=P)KL,+=ZQ)M.4?.:B$ M(5="1()KY>4[T4*[IEOECJX!\1W3375K^"TO6G+ M,/7O774*S*2Y/*D8M2J?%5O&4.^PNF+[K==WJ*PTND:DLZ'79=&(V](@%]9@ M=?Y24'^/8D!?&](U@#BND4$-A^K2+M2^]+N9V)1_;L%^4?^'D5.&J6C#Z MD&QTX;#':1449.2><="9(`7?1)+#+=\.,E43$ROE#BK-V'<+XY"-,3C\QPFZ MV'$V$1`.'#]H/6C#Q.LD*F4"1IF+J@\8BM>XK7$8II0"YP]J27;;HQ[N\I'.;5E=EBKDYWIGI05SD94U! ML>TROFBLFP^&[438P6X=B_NZ]4!)E6K#S4"^7@L.E9S+95&7^9I"J=DRYP5X M[HCXBJ5%3U::%D'0/+F#]+\+K!:$U1.$#W($7&+;Z!M_J0 M->7%U+Q\A^N"IJASG-=!;ZCI@T1IBZ;<[^6PZU`9BVWG8FYN$M/.D5>S?T>J M[8JUB*D*45^L98RVCSIB0_"0=31L?G7?0\5Z7Y_M>PD*ZY#M5^?0A8X^?SF] M)AOBT*`/X9'4;=;%"(U?I%-QV9-ADS*:7TPQV,%IE0SV/)FDBDZ'@2?)8GM. M6_Y/4PP`QG;/?X+]/I('^%G-1R`,GR=L87.Y1 M]$P(4/#).#(!,&E;E`@MBO$WPN"(XAZ+%7J<[VU.D31MI)GLZOXDPD=-X_3* M=BMH5<#==BN6D\7=944?_@%"-!%!E,`&3X9_,@Q_U?_[F5+T^#=3DN9^*J/$ M:'[<-GR^\QI)SOT:VMM+O!K;\RO/;:]P[7%K:]O;O=O\W4_V/]TA#3Z:) MA40C`XE^=5*&]`;0W^Y15'F]SZEH^/A=.GZ&7%GR[+=GJ/2+J/P7404OH@I_ M38WHU\CC%V%(7D25OH1*>R^B4H__>?M0#R,E(W(P-43)TY&N]7U3:%AB0$JU M^'\!!@#4S^[I#0IE;F1S=')E86T-96YD;V)J#3$Q(#`@;V)J#3P\+T-O=6YT M(#$O5'EP92]086=E7!E+UA-3"],96YG=&@@,SDT-2]4>7!E+TUE=&%D871A/CYS=')E M86T-"CP_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T M82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#0N,"UC,S(Q(#0T+C,Y.#$Q M-BP@5'5E($%U9R`P-"`R,#`Y(#$T.C(T.C,Y(CX*("`@/')D9CI21$8@>&UL M;G,Z&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D M9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0#I3;W5R8V5-;V1I9FEE9#X*("`@ M("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@ M&%P.D-R M96%T941A=&4^,C`Q,2TP."TP.50Q-CHU.#HS,BTP-SHP,#PO>&%P.D-R96%T M941A=&4^"B`@("`@("`@(#QX87`Z365T861A=&%$871E/C(P,3$M,#@M,#E4 M,3&%P34TZ26YS=&%N8V5)1#YU M=6ED.C1A,C5A,S5C+64Q,F8M-&)D-"UA.64V+30W-C)C93)D8F(V-#PO>&%P M34TZ26YS=&%N8V5)1#X*("`@("`@("`@/'AA<$U-.G-U8FIE8W0^"B`@("`@ M("`@("`@(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@("`\"UD969A=6QT(B\^"B`@("`@("`@("`@(#PO M'1);F1E;G0@,"XP+T5N9$EN9&5N="`P+C`O M4W1A6]U="]7'1);F1E;G0@,"XP M+T5N9$EN9&5N="`P+C`O4W1A'1!;&EG;B]3=&%R="]/ M+TQA>6]U="]7'1);F1E;G0@,"XP+T5N9$EN9&5N="`P+C`O4W1A'1!;&EG M;B]%;F0O3R],87EO=70O5W)I=&EN9TUO9&4O3')48B]3<&%C94)E9F]R92`U M+C`O5&5X=$EN9&5N="`P+C`O16YD26YD96YT(#`N,"]3=&%R=$EN9&5N="`P M+C`^/@UE;F1O8FH--S,@,"!O8FH-/#PO0F]R9&5R4W1Y;&4H_O\`3@!O`&X` M92DO0F]R9&5R0V]L;W);,"XP(#`N,"`P+C!=+T\O3&%Y;W5T+T)O7!E+T-A=&%L;V7!E+U1R=654>7!E+T9O;G1$97-C2A4:6UE%LM-38X("TS,#<@,C`P,"`Q,#`W72]!7!E+T9O;G1$97-C7!E M,"]$97-C96YD86YT1F]N='-;,34S(#`@4ETO0F%S949O;G0O04M-34E$*T-A M;&EB7!E+T9O;G0^/@UE;F1O8FH-,30U(#`@;V)J#5LO24-#0F%S960@,34P(#`@ M4ET-96YD;V)J#3$T-B`P(&]B:@T\/"]3=&5M5B`W,2XW-#(O1F]N=$YA;64O M5&EM97-.97=2;VUA;E!3+4ET86QI8TU4+T9O;G13=')E=&-H+TYO5%"[;L,P#-SU%1Q;=)#B%LAB&"C2Q4,?J)WLBD0[`FI*H.7!?U]) M>;@CY:']:,E%D#_L38<1!D>6^W[^H9Y#?;)$=C0EYJXZGA'1+"'\X(450T#1@ M<1#R\*G#EYX09"'>P7X-"%7I=YNVMS@';9`UC0BU4NJUN18D^SB_LLZ#N6@6 M]^UWU8BTO>&9EV^Z^3`+<[)8#B]&L@5'>/M-\"&KY1#_`@P`W?MJ>PH-"F5N M9'-TJ'-,-(9>I,N,(#T+B`=!%$89@88R@###$ULB*A` M1!$1`460H(`!HZ%(K(AB(2BH8`]($%!B,(JHJ&1&UDI\>7GOY>7WQ[W?VF?O M<_?9>Y^U+@`D3Q\N+P66`B"9)^`'>CC35X5'T+']``9X@`&F`#!9Z:F^0>[! M0"0O-Q=ZNL@)_(O>#`%(_+YEZ.E/IX/_3]*L5+X``,A?Q.9L3CI+Q/DB3LH4 MI(KM,R*FQB2*&4:)F2]*4,1R8HY;Y*6??1;94!&;B)C$#PYT M$?%R`'"DN"\XY@L6<+($XD.YI*1F\[EQ\0*Z+DN/;FIMS:![[M(KT* M^-PSB-;WA^VO_%+J`&#,BFJSZP];S'X`.K8"('?_#YOF(0`D17UKO_'%>6CB M>8D7"%)MC(TS,S.-N!R6D;B@O^M_.OP-??$](_%VOY>'[LJ)90J3!'1QW5@I M22E"/CT]E?^IB?\P[$]:G&N1*/6?`#7*"$C=H`+DYSZ`HA`!$GE0W/7?^^:##P7BFQ>F M.K$X]Y\%_?NN<(GXD,X`9P\QBL5AYK`'6 M#NN'96(%V`+L?NPQ[#GL('8<^Q9'Q*GBS'#NN`@<#Y>'*\$AX1202 MU8G6Q``BE[B)6$$\3KQ"'"6^(\F0]$DNI$B2D+23=(1TGG2/](I,)FN3'DDN58R1[)<\J3D M#LHERC@50]6A>E$3J$74;ZC]U!E9&=EELJ&R M6;)5LF=D1V@(39OF14NBE=!.T(9H[YGR;O*)\KOE.^0?*:`4]!4"%#(5#BI<4IA6I"K:*K(4"Q5/*-Y7 M@I7TE0*5UBD=5NI3FE564?903E7>KWQ1>5J%IN*HDJ!2IG)694J5HFJORE4M M4SVG^HPN2W>B)]$KZ#WT&34E-4\UH5JM6K_:O+J.>HAZGGJK^B,-@@9#(U:C M3*-;8T935=-7,U>S6?.^%EZ+H16OM4^K5VM.6T<[3'N;=H?VI(ZYM/8P>0R]1[X#>37U8WT(_7K]*_X8!;&!IP#4X8#"P%+W4 M>BEO:=W284.2H9-AAF&SX:@1SJ/U:>MW-I8V`IL3-K_8 M&MHFVC;93B[76/MC]D/^*@YL!TJ'-XXJCAR'9L M<)QPTG-*<#KF],+9Q)GOW.8\YV+CLM[EO"OBZN%:Z-KO)N,6XE;I]MA=W3W. MO=E]QL/"8YW'>4^TI[?G;L]A+V4OEE>CU\P*JQ7K5_1XD[R#O"N]G_CH^_!] MNGQAWQ6^>WP?KM1:R5O9X0?\O/SV^#WRU_%/\_\^`!/@'U`5\#30-#`WL#>( M$A05U!3T)M@YN"3X08ANB#"D.U0R-#*T,70NS#6L-&QDE?&J]:NNARN$<\,[ M([`1H1$-$;.KW5;O73T>:1%9$#FT1F=-UIJK:Q76)JT]$R49Q8PZ&8V.#HMN MBO[`]&/6,6=CO&*J8V98+JQ]K.=L1W89>XICQRGE3,3:Q9;&3L;9Q>V)FXIW MB"^/G^:Z<"NY+Q,\$VH2YA+]$H\D+B2%);4FXY*CDT_Q9'B)O)X4E92LE(%4 M@]2"U)$TF[2]:3-\;WY#.I2^)KU30!7]3/4)=85;A:,9]AE5&6\S0S-/9DEG M\;+ZLO6S=V1/Y+CG?+T.M8ZUKCM7+7=S[NAZI_6U&Z`-,1NZ-VILS-\XOLEC MT]'-A,V)FW_(,\DKS7N])6Q+5[YR_J;\L:T>6YL+)`KX!WSWM9?2RPK+7>Z/V7BU?5EZSC[!/N&^DPJ>B<[_F_EW[/U3& M5]ZI5'\8-#0H-10T?C_".C!P-/-K3:-78V*345-(,-PN;IXY%'KOYC>LW MG2V&+;6MM-:BX^"X\/BS;Z._'3KA?:+[).-DRW=:WU6W4=H*VZ'V[/:9COB. MD<[PSH%3*TYU=]EVM7UO]/V1TVJGJ\[(GBDY2SB;?W;A7,ZYV?.IYZ\+UVY['[Y8J]3[[DK=E=.7[6Y>NH:XUK'=N;70/+!\X..@Q>N.5ZZ_)MK]O7[ZR\,S`4,G1W M.')XY"[[[N2]I'LO[V?$CJ4?ECY4>U_VH]V/KB.7(F5'7T;XG M04\>C+'&GO^4_M.'\?RGY*?E$ZH3C9-FDZ>GW*=N/EO];/QYZO/YZ8*?I7^N M?J'[XKM?''_IFUDU,_Z2_W+AU^)7\J^.O%[VNGO6?_;QF^0W\W.%;^7?'GW' M>-?[/NS]Q'SF!^R'BH]Z'[L^>7]ZN)"\L/";``,`]X3S^PH-"F5N9'-T[)L'>%35UO?7/F=* M2$B#)`0"S(0A%$.O$1!"&H08("0#"363'KHI@$@PB@A$4%0LJ#0[AC(9"T%1 M0;'W?N_UJF"[%K!CA7[_O?N_S?._S,,EO_O^]=CEMG[U7?)`4 M$850/>DT8%)N_T'S*ZJ:$3D`"HN7U#CW7KOO)R+5F<@:7+:X?,'WWV>W);+U M(FK3J7S^A65Y5>63B=)^1)N4BE)/R?L9>S\BFGDW^@^K0"!T3\@HHO`TE+M7 M+*A9UK?TR""3G>MT$@*_6&S40NJP?:O6PTFTS:C3]UG#C*/C MCI!]*U'+M73F9S+-I6K>D0/4-OT?_# M3\N%U@745M]'-FI/Y/_9?[SE3M",,_TUDT@V;2 M+"HD#ZZ_A"JH$G=F'LVG!;30+"U$73F^RU":@U;%:&7X7ULMHL6@BFJHEI;@ M9S%\=:!DU%U@EFMI*7Z6T86TG"ZB%507^%YJ1E:@9KE97@96TL5X,I?0I:83 MY<@JNHQ6XZFMH;6T[D]+ZTZ[!KJ"UN,Y7TE7_5N_X3>EC?BYFJ[!?-A$U]'U M="/FQG67<=(MM,9]0>H"?I?MI#>^D!\UX6XZ[Q'9'[ M4F;>P\6X!RMPA:O..&.^?TM/WZV5N';CVAH"5[H,\4O/Z+$DOIRUX M`W?@V[BKAKL5GMTVTY\9WWJZ[7:S?!O=3G?@6=QE.E&.W`E_%]V-=_L>:J1= M^/G5G^E8]]!N\\EYJ8E\="_=AR?Y`.VC9C/^9W5_%+\W$/>=CNRG!^DAS)!' MZ"!6FL?P(Y&'$7LT$#ULQKC\&#V.LM&*2T_24UBAGJ7GZ'EZB9Y`Z47S^VF4 M7J97Z35Z2X7"O4*?XOL4H.1Q)7-FSYHY8WI!OCLO=TK.Y$D3L\_/FI`Y?EQ& M>EIJRMCD,://&S5RQ+E)PX<-[=^O;Y]>/1*ZN[HY8J,B(\)#0X+;!-EM5JS$ MBOJDNS(*G=X>A5Y+#]?X\7V-LLN#@.>,0*'7B5#&;]MXG85F,^=O6R:C95FK MELG<,OET2Q7A'$6C^O9QIKN6Y'F]*I"9[HW8TE%0WIA&L9K"@E.=:66!O?M0TW!(;`A<-Y>KL5- MJM=H91JM5_J()NQ#H<9AO7I"NJ?$.SDG/STM+CZ^P(Q1JCF6UY;JM9MC.2N- M<&XX0UQ??+QQ+EF'@=TE%K+>^R-FW#^Z^^9N`7]0[O7J/PJ+B"D,]I0VNM#2^ M;WGYWN0TF&1/X%K3FP;T1WM/(2ZBTK@-.?G>_J[%WBA7"C=`P&D\@\KY`+>OP)5?6F`\)5>$M_<1'"[>/*+9 M"]?6JK4T-J[\ M%(]J*6BIF(,9B7'R6,WR.+-\NCB^576F5#L;@EQ9N0W&X*[`@.3$&X2+MO7( M]%R1U&X(7LT,K&ZN#(_+&>',:/`T^^N+&IJ2DQL6IQ=6C##&<&66-+AR\T?% MF>Y/-J&9$C:!1/V)Q/5F[46,V"6BYL5F;$@ MB2DJ;M8X%B$Q#3$+QY+-F/'!0XJMP"W&SXJ"BH;"`N/EHA@\2OPJ MKW*-)J_F&MVD-%M;;["K-,4;XDHQXF.,^!B.VXRX'1-#Q2C<'&--:BAT89W" MA,JG.,5343>&=#;[_7GY\2_$'2^(QU2;":;G>]LD8NVW)DQ`NW$&A0B/\]87 M>XSS('>^T=>>D%E<@&DK`Z))IK<-1F@3&`$M,LP^QG1$IV(\&SQ`LW\]"M[Z M`F]!HG'0_,H"&F\:P0>.X]I[6$UN<>;$+5<6%3MQM"Q7G8JKS6AHB`NX.J M3.-<\+L&IVHT/60,D]-,4US+L+(8)VV.9$>U-S0ATX/%G_N'(.)*DLY!QAH1 M$ACC,$?MQI6WQ7W7$_*:_7>Y+HP_X].WC\O8'(R)27'[,;&IH*%UP#LCL6^? MH-;14#/S7DGH)D1WD^JO8XOS/&UBFTRY+&GG^D&.H.T8W6/P49Z!_0KM`>D`S`A2# M.>"20'R7OIMV6=O2C-983F(\8,5?R9J%=FD6_P1H+^BY8""8#":!BQ#O"GI: MKD&[#637-OAW6GJA/]!GF5RB%P7\8NILF4V[;&]A['/^`#LXGXK_6R8QMB^I MV-(-QP+6(OA\>";74%S?N`#1(/9T^6,*/Q-K-[KGKV)IH&[VKG1>:RP]:0#& MZOH['J61`3J9^AU%_%6L,_WO&U@LM$-_CA;\$992V@'F6I;2(`.]'FWK<2ZL MS@!]0&^0$HCOT">CWZ4T_W-`3N,$4<`'B MD2#6$D<[M-%$VFC_>OT9C`VT(R9KM(\#_BN?9C-89OHR<`^5 M_;<\R&"<,OT)'`M8FN"/PS/IIDZB3,9_`GQ_NEQ`G?4"?PLKYN,&V@9N">@- MH#;@?X=^BN)MHVEX:_3G:9B^"L^L-964%B#(U#=H9BNZ_D',Q-:?L0RAS7A_ MI@>8"*9)V;Z(IMO>`8I!VT++>C`7#"&/_@O-^BMH%U""[29*"'J#$BR-\#<' M_*A63&I%(&Y;THIUK0C$?].^#8Z1>L;8JWZMLQQGK.TIP=Z+$O3#-+0UYK7^ MGLV6(?[=EE3_3^I-6JW>]"^$AD.G`R>H`OF@'/%(L%D_2*LM76FM^LS_1H!B M_3;$`QAMP#E:9U.SU"_463M%FVTEQK%^PT13;_5O,34)S^.W3/I=;!1C>]Y\ M=C).H?8L;6;\/T$7ZO&4PV#>QOM/2=FZA\%8F]77:+^'XK7#P-`#U,/R,<5; M:O\:N-?Q]BS,[[__-7">F\"5`;T<9(-U`;_I3/0MU,W:3$-;HR_%FK2-NOV. MWE00P&YJ$E7I'BK1EV&N[J(T[2.:KTTT=;S63./4(>JNW8!G]"G-5\7D40O\ M?T-YOIJ-]6PJVGYLDF[V0Q_U/70`I:@/R&7TT5:30_^2^F@KL<==3@YM.*5H M>5C/:L$F8]<^%41T\A-MZN]C.#_2YP`S=G(;*&\5VP(JE1_EF\"MX&XS7@H* M]>X8[P1B&:#*&>"N:?'J-/;HAP.(LW8+K!3NQK];P3;S=BGX'T- M.8;V&+@?;0^!H\@YS.SCY!0P4+V(/.1-\"*#:\DVP+5=!EVN76SJ$O4#7:8- ME'S%O\[(0?1<[*^7T0C.(5J>,O8TSA=:MAI[,^<++?@SP3_%S`.NH^ZRW^,> MY_(>[H\Q^V#?UAN1F_`^C/VR9:&AMO8X)O93&]%&ZV2:;9W<\A/OB?Y:8R_4 M?C'W&!?O92VO&&LK[ULMKUONHS+>MUH>QAZ59^Y'1RE2]AU]#4@W%Q7[L/UE4%OP%S7*%O7\>[( MFC"?>EG:T1+T+\#SGZEW)-WBIHT!ZD",=1BYK2/)C>MN9]U)FZS74(F!MLY\ MEL&X5\:S'J99Z8;3=,>\]]-"`_-Y9M-N\WDN#K`$SZ@GZ6?DCAY;!8[Q+&59 MC?PJ0"`?G&SD>J?SK0](M_T,WN*\T:[_FL=9?N+G;.2IDGOA.IEFK`N;^%E; M.Z/-"5!%-;9O,$97^,\IW!8+309%-,OBH2)[$/P%R._\Z/\->-[U%'9&/M3'N@Q[<#U-LZQ#W3JZ'EP7R''<1OZ":]UA@&>KS/FR M+)"3[`1S`W/%R+LDC]B".;L%.7=_7$A3B78_TP*;"_E..LISJ(-U M%6*?@`]IGOX5\I=!\'[L[W/(82D&>`.QARLSCOW?DHK[8LRM-["N'PX`CSF1 MB3RO@[%/G+F'8_S1R`FR++F8>[G(J7*QI_$>6&7L:_H#Z`LLT11CTZB]M9+F M6,9A'^L5V*L&@G-^W<_,',/89SI2L+'7!=;F6/U5ZF9I01QK-^;B9LM@8H^!*S"W-^#H>! M=K,*UFZF1PWT^VDUF&WR+N9V(1T'37H)+<=>,`?S^!QC3H.'C/EMO9RN1VR] M$1?%,UH+$D4#L43M`:H!!T4M'9'S=<3[$%"]`RGM/>P)>U6#?E+M03D$Y;Y: M-?80H)]$/@GLH^FZ,T'L)_TD'3K]SBV@U6"Y5H-KJJ'IVF4T%=1JR5A7DQ&? M0%Y0_N_:8:RM8"E8!I98O#3/S&/PG`_3N)]"#-SIWSX_6`"RKG0 M!;@7B?!#]&^Q5V_#^_L(_G[<;1C6@V&8VV$T'NP!5:`<.$$IF`>*P1235-R; M#=11OP3K8#76PUW40Z_`>>S#/"%ZBGM8[2 MX=.QMQOYW/B@B30>L9GV9_"\3F)?/TGG@T*0"&8'?`'`.X1GQ?5N,-68S]9/ MJ8_%2D-MKU$EGKU'.X[\[R0%&?F&D0<8>Z:M%&MQ'LVPQ-`$O',W@>O!,R9A MM-<>ID:(!D^DFVQ)^-NMC'KYVNC.9NVR^]K$J@DPJ\1<*N82,?5B+A:S4DR= MF!5B+A*S7,R%8I:)62IFB9A:,35BJL5<(&:QF$5B%HI9(&:^F'EBYHJI%%,A MIEQ,F9A2,25BBL44B?&(*10S1\QL,;/$S!0S0\QT,05B\L5,$S-5C%M,GIA< M,5/$Y(B9+&:2F(EBLL6<+R9+S`0QF6+&BQDG)D-,NI@T,:EB4L2,%9,L9HR8 MT6+.$S-*S$@Q(\2<*R9)S'`QP\0,%3-$S&`Q@\0,%#-`3'\Q_<3T%=-'3**8 M<\3T%M-+3$\Q/<0DB.DNQB6FFYAX,4XQ#C%=Q701TUE,G)A.8CJ*B17304R, MF&@Q46+:BVDG)E),A)AP,6%B0L6T%1,B)EA,&S%!8NQB;&*L8BQB=#&:&"6& M`D;YQ;2(.27FI)A?Q/PLYB^+.2KFB)CWQ+PKYATQ_Q3SMIA_ MB/F[F+^)>4O,FV+>$/.ZF-?$O"KF%3$OBWE)S(MB7A#SO)CGQ#PKYADQ3XMY M2LR38IX0$W-(S$$QCXIY1,S#8@Z(>4C,@V+VBVD6LT_,`V+N%W.? MF'O%^,0TB?&*V2MFCYC=8G:):11SCYB=8NX68.\7<(>9V,;>)N57,#C'; MQ6P3LU7,%C&WB+E9S$UB-HNY4)6F/DK1'2=JC).U1DO8H27N4I#U*TAXE M:8^2M$=)VJ,D[5&2]BA)>Y2D/4K2'B5ICZH2(_F/DOQ'2?ZC)/]1DO\HR7^4 MY#]*\A\E^8^2_$=)_J,D_U&2_RC)?Y3D/TKR'R7YCY+\1TG^HR3_49+_*,E_ ME.0_2O(?)?F/DOQ'2?ZC)/]1DO\HR7^4Y#]*\A\E:8^2M$=)VJ,DVU&2[2C) M=I1D.TJR'279CI)L1TFVHR3;4:GW&@99LZ_K:`=R9E_7:,BE7+K$UW4$I)Y+ M%[.L]'5M"ZGCT@J6BUB6LUSHZS(6LLS7)16RE&4)2RW7U7"IFJ6*@Q?XNJ1` M%K,L8EG(31:PS&>9Y^N<#IG+4LE2P5+.4N;KG`8IY5()2S%+$8N'I9!E#LML M[C>+2S-99K!,9RE@R6>9QC*5QS9+%,\,5E M0C)9QOOB)D#&L63XXK(@Z;ZX\R%I+*DL*5PWEOLELXSA?J-9SF,9Q2U'LHS@ M[N>R)+$,9QG&,I0'&\(RF$<9Q#*090`/UI^E'_?KR]*')9'E');>++U8>O+0 M/5@2>,SN+"Z6;CQT/(N3^SE8NK)T8>G,$L?2R==I(J0C2ZROTR1(!Y88#D:S M1'&P/4L[EDBNBV`)YV`82RA+6ZX+80EF:<-U02QV%INOXV2(U=6G[GN)R[]R/(#R_9#O?+&YD&^Y]`W+ MURQ?<=V77/J"Y3C+,:[[G.4S#G[*\@G+OU@^YB8?<>E#+GW`I?=9CK(97E%9:7N8WF6FSS#\C0'GV)YDN4)EL,LCW/+Q[ATB.4@RZ-<]PC+PQP\ MP/(0RX,L^UF:N>4^+CW`JUV\BAWL]S%=7>RW,%R.\MM++>R[ SK*-!]O*HVQAN87K;F:YB64S MRXWR&I?=!'D,I95ON@RR*4LE_BBW9!Z7S068W6Q+WH89"5+'7=?P?TN8EGN MBRZ!7,C=E[$L95G"4LM2PU+-0U=Q]PM8%ONBBR&+>+"%W'(!RWR6>2QS62JY M7P5+.9]9&7ED*6.2RS^:)G\9G-9)G!%SV=AR[@`^6S3./3 MG2RY+%-8H3"Z-9QG'P0Q?U$I(NB]J#23-%W4Q)-4750])\;7+@(QE2689PS+:UP[[ MNSJ/2Z-\D060D2PC?)'&U#B7)9#QGFBYP.&S/TL_[MZ7C]"')9$'.X>E-P_6BZ4G2P^6!%^D<9>ZL[AX MS&X\9CP/YN11'"Q=N5\7ELXL<2R=6#KZ(F9!8GT1LR$=?!%S(#$LT2Q1+.U9 MVG&'2.X0P<%PEC"64):VW#*$6P9SL`U+$(N=Q<8MK=S2PD&=16-1+)3L#R]R M&+2$%SM.A9A;X3.=[P>VL/Q&G@5_I701,?+X"7P(NI?0.SYT`6.Y^"?A7\& M_NG0N8ZG0BL=3X96.)X(+7<<1M_',=YCX!!(]A_$]Z/@$?!PVPL`N<">X(Z2OXW;H;>!6]-D!W1XRS[$-?BO\%G`+_,T8ZR:,M1EC MW8C8#>!Z[Z]PK&^O<(74JI"ZN+JONHKK&NK?KDK-MP2OZE[6N-2]I+'6;:F-JJVIU;^K58VU*JU6#:A5&M5&U#IK];8U[BIW M=6.5FZHF5]57>:LL([U51ZHTJE+!S?Z#]U;%=.SR+BV4E9[O,;L]P3DL:[,QO' MN\89S`Q,XX$XI3*0/BDN..Q'T59Z$X;]S!.+U=>"=' M)ZUW>$>5.JFC6M3QXHY7==3#8U^*U9)C>_?)"._P4H?W.GS9P=(^N4/O?AD4 M$Q'CC-&CC6N+R<[+,'5,&NO`H>:U9L>X>F2$1ZOP:$>TENZ(5A1Y)/*K2#WZ MT8B7(K3P[@_7DL/1/#S,$:897_XP/3ELX/",\%!'J&9\^4/UF.101(P1 M>[:=G)<1'N((T=QC0B:%:,DA8U(SDD/Z#L@@73F5(A4!T8/0]CX5[+*_>L(&ZI&1YN^3F^_3MV[ND%&1YZPV?G&QZO^$)30H29U?7 M5B"2T`]N!BL!'5@!;@(+`<7@F5@*5@" M:D$-J`87@,5@$5@(%H#Y8!Z8"RI!!2@'9:`4E(!B4`0\YC^J*-'F@-E@%I@) M9H#IH`#D@VE@*G"#/)`+IH`<,!E,`A-!-C@?9($)(!.,!^-`!D@':2`5I("Q M(!F,`:/!>6`4&`E&@'-!$A@.AH&A8`@8#`:!@6``Z`_Z@;Z@#T@$YX#>H!?H M"7J`!-`=N$`W$`^]`.1((($`["0"AH M"T)`,&@#@H`=V(`56,;Z\:T##2A`5*(04RW@%#@)?@$_@Y_`C^`'\#TX`;X# MWX)OP-?@*_`E^`(`Z\%U8!.X%EP# MK@8;P57@2K`!K`=7@`:P#JP%:\#E8#65C*U7>/\5WG^%]U_A_5=X_Q7>?X7W M7^']5WC_%=Y_A?=?X?U7>/\5WG^%]U_A_5=X_Q7>?U4%L`8HK`$*:X#"&J"P M!BBL`0IK@,(:H+`&**P!"FN`PAJ@L`8HK`$*:X#"&J"P!BBL`0IK@,(:H+`& M**P!"FN`PAJ@L`8HK`$*:X#"&J"P!BBL`0IK@,(:H/#^*[S_"N^_PKNO\.XK MO/L*[[["NZ_P[BN\^PKOOL*[K_#NG]T)_J-/P=E;\!]]8N?,-C),:JG67[6& MD4YV.I>R:2+-.$"AF-,Q-$+=?W]T6EI07_LCF*\:.3'C@Y"2IB:'6[30?9TZ MC7'M&VK;H$=FX@_W^\;8-V`M'W/JW5,O]C_U[O%VY_8_KOJ_<_3=HQ%?OQAY M;O_!1U\_.G"`BHR/-(D*T^SV*)NK6S]M:,\>PP8/'C1:&SJDAZM;F&;&A@P; M/EH?/*BKID=)9+1FE)7^ZLGI^J13-FVE:\S4P=:NG<*C0FU6K7-LN[ZC$B)R M9R2,ZM?%KMMMNC7(WFMX2K>L^>G=_F&/[!(=TZ5=4%"[+C'172+MI]ZVAOW\ MC37LEU3+_%\VZ;:1,\=TUV\,#M(L-EMSU]B.YXR,SYP:WC["$M(^(C(FR-XN MLFVOM)FG+H_N;(S1.3J:QS+^M7C@_V9+.`K\UX&WPNP+> M3G7J06,42QM$.FO#`UZC,"TWX'7$/0%O@:\+>!O\9G@%C_/1[@]XG(_>D7:2 MDP;1`/P,@\NF2BJF*EI$U:",:A!+A:NBQ>:W!Y%*N(74#S5C:3Y^G#0%L7*J M0%VU62J%EJ+U$GR7H&4J^LU'FR+$*M&BTFQ7"JU!+Z.E$RV.&X)2@N@530/L46G^_QQ;=G_T;489[30',LX&R>Y4:HTS\$X?BZ95&ZWX[G8,&#!CFS*XLKEI4O:BLQIFZJ&KQ MHBI/3>6BA?V<8^?/=TZI+*^HJ79.*:TNK5I26M)O;%9V=F9:8JIG?F515>6? ME0+BK*QVEE;65)16.3W.JM+RRNJ:TJK2$F=-E:>D=(&G:IYSD5%S1K'LC\_' M6;G0B6&<[H65->B?6^.I*:UV>A:6],<`B\P#%"^J75A355E:W0^//@LW.)LR M*8T26SW@*>9CK$7$>"!_UO+_MN[LI/T?G+3F?T;&RN&AW5@C=@&-(M"YE,@5 MJR[%VF+^HQ#CO]D??]&5.B=\U`GJ&&0N4P]]ON)Y0P^E?-+FY,"6ZC8/V+>B M:*Q3YCKV7P(,`--GO4,*#0IE;F1S=')E86T-96YD;V)J#3$U,B`P(&]B:@T\ M/"]3=&5M5B`X,"]&;VYT3F%M92]!2TU-240K0V%L:6)R:2]&;VYT4W1R971C M:"].;W)M86PO1F]N=$9I;&4R(#$U,2`P(%(O1F]N=%=E:6=H="`T,#`O1FQA M9W,@-"]$97-C96YT("TR-3`O1F]N=$)";WA;+30W-B`M,3DT(#$R,30@.34R M72]!7!E+T-)1$9O;G14>7!E M,B]&;VYT1&5S8W)I<'1O2]#2413>7-T96U) M;F9O/#PO4W5P<&QE;65N="`P+T]R9&5R:6YG*$ED96YT:71Y*2]296=I2A!9&]B92D^/B]$5R`Q,#`P+U1Y<&4O1F]N=#X^#65N9&]B:@TQ-38@,"!O M8FH-/#PO1FEE;&1S6UTO1$$H+TAE;'8@,"!49B`P(&<@*2]$4CP\+T9O;G0\ M/"](96QV(#$U."`P(%(O6F%$8B`Q-3<@,"!2/CXO16YC;V1I;F<\/"]01$9$ M;V-%;F-O9&EN9R`Q-3D@,"!2/CX^/CX^#65N9&]B:@TQ-3<@,"!O8FH-/#PO M4W5B='EP92]4>7!E,2].86UE+UIA1&(O0F%S949O;G0O6F%P9D1I;F=B871S M+U1Y<&4O1F]N=#X^#65N9&]B:@TQ-3@@,"!O8FH-/#PO4W5B='EP92]4>7!E M,2].86UE+TAE;'8O0F%S949O;G0O2&5L=F5T:6-A+T5N8V]D:6YG(#$U.2`P M(%(O5'EP92]&;VYT/CX-96YD;V)J#3$U.2`P(&]B:@T\/"]$:69F97)E;F-E M"])9&EE')E9@T*,"`Q-C,-"C`P,#`P,#`P,#$@-C4U,S4@9@T*,#`P,#`P,#`P,B`P M,#`P,"!F#0HP,#`P,#`P,#`U(#`P,#`Q(&8-"C`P,#`P,#$P-S4@,#`P,#`@ M;@T*,#`P,#`P,3,T-B`P,#`P,"!N#0HP,#`P,#`P,#`V(#`P,#`P(&8-"C`P M,#`P,#`P,#<@,#`P,#$@9@T*,#`P,#`P,#`P."`P,#`P,"!F#0HP,#`P,#`P M,#`Y(#`P,#`P(&8-"C`P,#`P,#`P,3`@,#`P,#$@9@T*,#`P,#`P,#`R-R`P M,#`P,2!F#0HP,#`P,#`S,3,S(#`P,#`P(&X-"C`P,#`P,#,Q.#4@,#`P,#`@ M;@T*,#`P,#`P-S(P."`P,#`P,"!N#0HP,#`P,#`P,#`P(#8U-3,U(&8-"C`P M,#`P,#`P,30@-C4U,S4@9@T*,#`P,#`P,#`Q-2`V-34S-2!F#0HP,#`P,#`W M-#,Y(#`P,#`P(&X-"C`P,#`P,#')E9@T*,C@V.3`-"B4E14]�HR,#8@,"!O8FH-/#PO3&5N9W1H M(#$T+U)O;W0@,3,P(#`@4B])1%L\-#8R0T4P-CA%,C4U1#`Y138S.#1#0T,W M-3A&0S8R.30^/#="0D(W-30X-C(U-C%!-#)"13DR,#$V-D%"-S,P044T/ETO M26YF;R`Q,R`P(%(O1FEL=&5R+T9L871E1&5C;V1E+U=;,2`R(#!=+TEN9&5X M6S(P-B`Q72]$96-O9&5087)M7!E+UA2968^/G-T-IB8BPX#A!@``&V`3L- M"F5N9'-T'1=+T5X=$=3=&%T93P\+T=3 M,"`Q,S8@,"!2/CX^/B]4>7!E+U!A9V4^/@UE;F1O8FH-,3(@,"!O8FH-/#PO M4W5B='EP92]834PO3&5N9W1H(#,Y-#4O5'EP92]-971A9&%T83X^G)E4WI. M5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O M(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C`M8S,R,2`T-"XS.3@Q,38L M(%1U92!!=6<@,#0@,C`P.2`Q-#HR-#HS.2(^"B`@(#QR9&8Z4D1&('AM;&YS M.G)D9CTB:'1T<#HO+W=W=RYW,RYO&%P+S$N,"\B/@H@("`@("`@("`\>&%P.D-R96%T;W)4;V]L M/D%C&%P.DUE=&%D871A1&%T93XR,#$Q+3$Q+3`X5#`Y M.C$W.C4R+3`X.C`P/"]X87`Z365T861A=&%$871E/@H@("`@("`\+W)D9CI$ M97-C&UL;G,Z>&%P34T](FAT='`Z+R]N&%P+S$N,"]M;2\B/@H@("`@("`@("`\>&%P34TZ1&]C=6UE;G1)1#YU M=6ED.F9F.&-E,6%D+35B.6$M-&(U,BUB-30Q+6(X861C,S1B8V%A93PO>&%P M34TZ1&]C=6UE;G1)1#X*("`@("`@("`@/'AA<$U-.DEN&UL;G,Z9&,] M(FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL.FQA;F<](G@M9&5F875L="(O/@H@("`@("`@("`@("`\+W)D M9CI!;'0^"B`@("`@("`@(#PO9&,Z=&ET;&4^"B`@("`@(#PO#IX;7!M971A/@H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"CP_>'!A8VME="!E;F0](G2A4:6UE MO(/HD#19#4O>B*.`X[I9A3=I8`3HTPZ#*WHV9Y.3WY>"W3:3 MDR013+)D/1%<"*%8DC$'EU[(DAV3L%1P2W0K7\0\"N.8A(J.7]W;H?6W/:L&?P2V[7.+R_8AVO87"WMP,+%[")AMA/`V]BZU,*)LW11 M"*Y4A#(45Z'/',EE)P"T]:S(5A:[YDL^QQT'"6RY()D."I0H$)<,I-$%UQL7^5V9+&/0/2`NQ1V-2[P?0Y6UAM8/"*/J^YDB])J?(]L M*\/_757?VQ(PE7`@D(4#BX\D#.G6'5V">MSF-:X_L?=PBAJL\#2#10H24.24 MG1N#,HZT-UKYG+V:VU)8%0G;IB7J]NK&9LB?-`/3X+VV#2]^>R"CR*#!FFTG MN-:.\JV5UA01(O<'@_LENE^8>#@#O^?EBK36]`"^_H`N2_T:H>X!K"%<)6==X<0HF,&5V4J<^:(I&-9A1:[1@TX&S M.@;M98Z>)KS!?'"6"1CDT+"T)"Z+'TAU9Z*BO*6[;)I"!T)E M0-M'896:B,+=75XC-QT4B"S2`K0ZQB)KB_<(31.+KZ! MVN)[SB[7ZR(#`*LU$;:&,._O5;B]WPY%1LE>(^51S8^Y!WGM6!@ MC?6B+=;X@,/M`[ZEPP:<0;M4N]JW6JU#155.1O2XUB46_J#<N/ M-'('C:C"2)_'GE%(3%G:$.=T56U)3KXBWITR3:>%=T`+E!?C2@2T!Z#Q011W MN,R'3'.CPQV0NS&4XT#X7`D1ZLQ)ZR^(V:_;I>-Y'*NY(R6/,>\&'^>-:F?GNZM\2SK4+9ZN"8C-YA$; M`:SN,9L(L4V1-VQ7:,V9\7R=?Z,;!>2@$VKR7&/8,.*PQC1M(-Y?CA7E1+,CO:^R=,>02P&%\29!EP[I- M"[A7=K9*[#V!I:_W;MJ+B[2H(2BV?>G(&P/S=#S]^+W:';#^4)8**'DES2[I M9L,H5%(JR7E=I!L(I69+G#/DV0+Q'6U)?%&F=#7#"TB=5=!9X*`@&SW#F!XK MY/6`JPU$X4B[O11Q.OU&:`TAJ^N4+IYIBRT)ME@P*:^]P5'SO43IJB\_C++? M#]2DBYD^0YK%HJZ=4#.1756"SN]!(?*%XB%.J5B\B&"?=3">U=4P\H7J4%%T M1805>LSVLW5BHXTN/2F]9B7V6TCNV-JQ&0=0V"FVT@K',&AOO8D+^&:9P_=) MUH"#`Y`^_F=-5DXZ@5X,Y@80&O``?3@,QW4^P3DU4#&[' MEM'HG>!1+.&V[PD.'CMPV_!_F6*D8&C>N2^P/T2RIS^9^4P)S><%7QBRD9CG M/$Z??!V&0SS=[DW]HRD!N]:+(0#!![U"!\"L&X,"'(,TWA@&IQ#W>%CA'/6U MZ0_'#Y5=2DZ,!.`Y6[,@TA;?M8-E:[U&I/\E],XS(`*:L?`PKJHONM17'I/ MAT&?>Y%OJN"T&PC\T?Q]L%+$_;?<7/TKGKE'\#@R^L!*VP.?=3$I\P;M?GO` M2U(,`0,5Q\5/P[.?D$M#GOSV$RIU%)5[%)5W%)5_%%5P%%5X%%5T%%5\#)42 M1U'UOA]":<@*/Y`\`#AA=HI>3@JEGL*M$.T1*93M_P48`.YR'C@-"F5N9'-T M')E9@T*,R`Q#0HP,#`P,#(Y,3,S(#`P,#`P(&X-"C$R M(#(-"C`P,#`P,CDT,3@@,#`P,#`@;@T*,#`P,#`S,S0T,2`P,#`P,"!N#0HQ M-C0@,@T*,#`P,#`S,S8W,B`P,#`P,"!N#0HP,#`P,#,T.#4R(#`P,#`P(&X- M"C(P-2`R#0HP,#`P,#,U,#DR(#`P,#`P(&X-"C`P,#`P,#`P,#`@-C4U,S4@ M9@T*=')A:6QE<@T*/#PO4VEZ92`R,#F4@,C$R+U1Y<&4O6%)E9CX^ M7!E+UA- M3"],96YG=&@@,SDT-2]4>7!E+TUE=&%D871A/CYS=')E86T-"CP_>'!A8VME M="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK8SED(C\^ M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L] M(D%D;V)E(%A-4"!#;W)E(#0N,"UC,S(Q(#0T+C,Y.#$Q-BP@5'5E($%U9R`P M-"`R,#`Y(#$T.C(T.C,Y(CX*("`@/')D9CI21$8@>&UL;G,Z&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*("`@ M("`@("`@/'!D9CI0#I3;W5R8V5-;V1I9FEE9#X*("`@("`@/"]R9&8Z1&5S M8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@&%P.D-R96%T941A=&4^,C`Q M,2TP."TP.50Q-CHU.#HS,BTP-SHP,#PO>&%P.D-R96%T941A=&4^"B`@("`@ M("`@(#QX87`Z365T861A=&%$871E/C(P,3$M,3$M,314,C$Z,34Z-#`M,#@Z M,#`\+WAA<#I-971A9&%T841A=&4^"B`@("`@(#PO&%P34TZ26YS=&%N8V5)1#YU=6ED.C$U83$W.31F M+30R,6$M-#&%P34TZ26YS=&%N8V5) M1#X*("`@("`@("`@/'AA<$U-.G-U8FIE8W0^"B`@("`@("`@("`@(#QR9&8Z M4V5Q/@H@("`@("`@("`@("`@("`\"UD969A=6QT(B\^"B`@("`@("`@("`@(#PO7!E+T9O;G1$97-CC9GDY-?EX+=-9.3)!%,LF0]$5P( MH5B2,0>77LB2'9.P5'!+="M?Q#P*XYB%RN=P[6%R8RU^W!=?BI:YBMN^)6W' MM9C]=_+[9/$1!0W"I1%.HJ)>E.^B*$=%7$H/GMSW?):L@/5\<96]8,?HGM6N>7%^S3-6RNEG9@X6)VD3#;">`TMBZU<.(L712"*Q6A#,55Z#-' M+&=7I[.+Q=*Y_/./Q5]L-D_P4`FB5UJK0^%2/5:21`X8 MD6$?.(0+&@P1=(*\]:"%4!OPJW1`'J[?`-GMSC M6]:OL1="KL:%WB>@Y7U!A9/R..J>[-%:36>(]O*\/]0U0^VA)A* M>"&0A0.+SR0,Z=8=78)ZW.4UKO]D'^$M:K#"MQDL4I"`(J?LW!B4<:2]U-@J>L`J(T6-IA>:S1GTT5J M=4SHESFZG8(/O@#/&?0@AX:E)7%9_$"J>P.1\H[NS@W('B"-*2!XL6D*C8K* M1'`_)*O4P`MW]WF-W#1",,Q("W'6@(NL+=ZCT!I@OH':<6N3,Q`E4S;K$F!5 M8UAW^V$10[G5M2/D0>B.:H-8"8>Y#47:S3$DO5DQ8, MK+%XM,4:'_!R^XBG]+(!9]`NU:[VK5;K4%')DQ$]KG6]A3^HO9S=*B_$]]+U M1QJY@T94;J3/XP%\4Y8VQ#E=55N2DZ^(=Z=,TVGA'=`"Y<6X$@'M(=#X((I[ M7.9#VKFZ`+L^=T/O605.ZR\DHB3:_V^8CN=R$2$/R6/,)^22-\XE:WNB-SWAXN M]*XI]+KIQ*;IN(0`P2/UK"E+Y,5UFX>RV7GJ*M^2"G6+;]?D]LWF"7L`K!XP M=R@^FR)OV*[0BC/CYSK_1C<*R#@GU.2YCEC#B,,:D[(!=+^.#`6.#0PRVH*N ME11.Z=Y:*=3BJF:DO0\NNK4(*/`6*<#'`V.O]T",?",..#%\>Y6A/FF(%2V: MM*#093H>I?8WAH\Z?M92$H(BA#?7ZP)HT"5ZB5)JG$G=4@><`LV+>!>V=DJ ML>T$EK[>NVD/%VE1`RBV?:'(&Q/FZ7CP\7NUN\#Z0Q$JH,"5-+:DFPTCJ*14 M@/.Z2#<`I69+G#/DV0+Q/6U)?%&F=#7#"TB=5=!'X$5!-GJ&,3U6R.L15QM` MX4B[O0QQ.OU&T1H@JZN2+I5IBPT(ME@>*:V]P5'SO43I:BT_'&6_GZ5)%S-X MAC2&15WSH-8ANW($K=R#"N0+Q4,<4*$4:8)]UL%X3%?#M!>J0U\$KHBP'H_9 MWE@G-MKHTI/2:U9B=X7DCJT=FW$("CO%QEGA!`;-K#=Q`9\K<_@TR1IP<`#2 MQ_^LR.S`;9P^^S`, M!SS=[0W\HYD`V]6K$`#P\3#0`)AU0T^`0X^.-\+@%'"/+RN#N_-T,.3CC(W0PYAI,<#5:4%0/\/81HQ+P@0A^\"O]H#'\Y?*7J M4O2ROW.PW(UY$&G+S[H1TK7>8I*_&,0OJN]Z#I?=7.?I@WW&4L%H+D>LH6D] M&P1!<-QWNVDW'?BCV?M@W8C[C[JY^D>\<);@<624@)6V#K[O8E+A'7KA_0&? M23'`!^J/B]^(9S\AEX8\^>4G5.HH*O%LR-#D@,5TO1&5C;V1E4&%R;7,\/"]# M;VQU;6YS(#,O4')E9&EC=&]R(#$R/CXO4VEZ92`R-3`O5'EP92]84F5F/CYS M=')E86T-"GC:8F+%LP(#`@-C$R(#%LP(#`@-C$R(#'1'4W1A=&4\/"]'4S`@,3,V(#`@4CX^/CXO5'EP92]086=E/CX-96YD;V)J M#3$R(#`@;V)J#3P\+U-U8G1Y<&4O6$U,+TQE;F=T:"`S.30U+U1Y<&4O365T M861A=&$^/G-TFMC.60B/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O&UL;G,Z<&1F>#TB:'1T M<#HO+VYS+F%D;V)E+F-O;2]P9&9X+S$N,R\B/@H@("`@("`@("`\<&1F>#I3 M;W5R8V5-;V1I9FEE9#Y$.C(P,3$P.#`Y,C,U.#`T/"]P9&9X.E-O=7)C94UO M9&EF:65D/@H@("`@("`\+W)D9CI$97-C&UL;G,Z>&%P M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AA M<#I#&%P.D-R96%T;W)4;V]L/@H@("`@("`@("`\>&%P.DUO9&EF>41A=&4^,C`Q M,BTP-2TQ,E0Q-3HS,CHS-2TP-SHP,#PO>&%P.DUO9&EF>41A=&4^"B`@("`@ M("`@(#QX87`Z0W)E871E1&%T93XR,#$Q+3`X+3`Y5#$V.C4X.C,R+3`W.C`P M/"]X87`Z0W)E871E1&%T93X*("`@("`@("`@/'AA<#I-971A9&%T841A=&4^ M,C`Q,BTP-2TQ,E0Q-3HS,CHS-2TP-SHP,#PO>&%P.DUE=&%D871A1&%T93X* M("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I M;VX@&%P34TZ&%P34TZ&UP;65T M83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2)W(C\^ M#0IE;F1S=')E86T-96YD;V)J#3$S(#`@;V)J#3P\+T-R96%T:6]N1&%T92A$ M.C(P,3$P.#`Y,38U.#,R+3`W)S`P)RDO075T:&]R*$)I;&PI+T-R96%T;W(H M06-R;V)A="!01$9-86ME7!E M+U1R=654>7!E+T9O;G1$97-C7!E+T9O;G1$97-C M/(,@@"PKK8LZ3BP&2!$7!2M1%AM95$BYCO]]9V9W24J6 M4O5!XAZSQ&G*8A5R./8P^.)-OB_+O\HMTXK[ MH2?]H?:8_T?VZV!RC8(ZX=())U%)*RK4*&JH$BYE`%\>!B'+YL!Z/+G-KMY= M^;$W]@-O!+_,U][5S7OVX1-,;J=^Y.%@]#YC_C""W=2[,<*)L]0H!$W%Z/UD.KSY_-OD=S8:9[BI!-$KH]6A<*D6 M*UDF.XS(N`TC7TIO(J$;?(UZO;JSF?(GS0#TV#?V(8'OSV246109\W&"JZ-HT)O M;C3%")'[H\[]$MTO'!XNP>_%>DY:&WH(G#*!V[_'<<230$0LPDN71!'>9.\Z M][._\9`VA\#A9FZ9>+/E'@&S(&W(38.G\BA8?F: MN$R^(]72@7!]3V?'#L8/D"@HY'BP:4J#N\IA9#_H\]P!&&?+HD9N!H,()*0% M)!E()]X&SQ%X'/1?07:Z\\EAB,,S-K)7;%XC<)[:P-L0B2ZAAX<3.M+13F#JUJPIY'N M-*+$*$.>MA@79RQOB',^KS8DIY@3;ZM,8[4(#FB!\E(_T4BB'_1#&_HS'^7^&$@.096\A1#C;R^(XM5\H%`_0V5E7W&ZKIX,O_D]J?;Z<$'2KB"9 MXIBZXJ@#6W=%M-L^2.3&34,""=YZZK;8D!+U%E<7Y/;5ZAFK%8P>\`Y2?%9E MT;"GTJC.G)_KXAN=*.'F#F-#7IB(-8PX+/!R-X#NX\A0&G1UR-B6=&Q-X93Z MSLNA:E0U(^U#<-*=1T"!5:0`+W>,@]8'*?)-.."D38U.99`.)PO*62S;KS-2SBWMK9*+)"1 M9XZW;MK#15[6`(I-FRB*QH7YK-^BA:W:-K#8`]D(E)#@UM1@Y:L5(ZCDE,B+ MNLQ7`*5F0YQGR',+Q$N:DOARG=/1&1Y`ZED%]0@62K(Q<(SI,T=>CSA:`0I[ MVNW?$:M?+UH=9$U6,JDRWV(A@RFF1[K80>>H\=Y%L;F6'XYRV';]I(MKD6-J M&!-3*DPC(6T:@OH20.8)A>(QMM)8DHA@GW74?U"HKB^-U:%2IT6"^;C/]HMW M[J.-FKYTO49KK-)PN5/OB8TX!(5=8`&NL%>$8M::.(&'U1@>4;,&'!R!]/X_ M:V;K@148I&!N!-#``@G[4&WK8H#-=*12=M^1X2;<:/HCBMX.GI9);T_P))5P M.@P$!X\=..WX'Z?H*1B[/7V$_2&2/?W)S!=*&#Y'?.'(>F)>\KC8><+&'9[N M]YXFO9X`"]51"`#X>!P9`(QL\Q1A\V3BC3"X`-SC8H7=U]>F;:M"(\W@T:WHH-_@!!-6!`EZ(.C\$_Z\`=PM.\"?:33 M`\MURJ/$6'YI6U'MO<9+SO;:[A<]7PP1@MS1L8`'PS-S?7UDF_5PMW.$0IX/P__3XAVU/V\?I6/TI7KA2\#1QNL/(V`[OU)04?X,^>GN`JQ0=N"`[ M:7SK7OZ`7#KR[*F4@,C4P+U!R978@-#4X-34O4F]O="`Q,S`@,"!2+TEN M9F\@,3,@,"!2+TE$6SPT-C)#13`V.$4R-35$,#E%-C,X-$-#0SF4@,C4P+U!R978@-34V,C4O6%)E9E-T M;2`T-C`S."]2;V]T(#$S,"`P(%(O26YF;R`Q,R`P(%(O241;/#0V,D-%,#8X M13(U-40P.44V,S@T0T-#-S4X1D,V,CDT/CPY1#')E9@T*-34Y-S8-"B4E14]�HR M.#`@,"!O8FH-/#PO3&5N9W1H(#$T+U)O;W0@,3,P(#`@4B])1%L\-#8R0T4P M-CA%,C4U1#`Y138S.#1#0T,W-3A&0S8R.30^/#0T,#0U13E%0C(V-C@U-$1! M-#DS-S%&-#DY,C7!E+UA2968^/G-T-IB8KP=#Q!@``(D`3X-"F5N9'-T'1=+T5X=$=3 M=&%T93P\+T=3,"`Q,S8@,"!2/CX^/B]4>7!E+U!A9V4^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO4W5B='EP92]834PO3&5N9W1H(#,Y-#4O5'EP92]-971A9&%T M83X^G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E M.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C`M8S,R,2`T M-"XS.3@Q,38L(%1U92!!=6<@,#0@,C`P.2`Q-#HR-#HS.2(^"B`@(#QR9&8Z M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&%P.DUE=&%D871A1&%T93XR,#$R M+3`W+3$R5#$Q.C(R.C(S+3`W.C`P/"]X87`Z365T861A=&%$871E/@H@("`@ M("`\+W)D9CI$97-C&UL;G,Z>&%P34T](FAT='`Z+R]N M&%P+S$N,"]M;2\B/@H@("`@("`@("`\>&%P34TZ1&]C M=6UE;G1)1#YU=6ED.F9F.&-E,6%D+35B.6$M-&(U,BUB-30Q+6(X861C,S1B M8V%A93PO>&%P34TZ1&]C=6UE;G1)1#X*("`@("`@("`@/'AA<$U-.DEN&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL.FQA;F<](G@M9&5F875L="(O/@H@("`@("`@ M("`@("`\+W)D9CI!;'0^"B`@("`@("`@(#PO9&,Z=&ET;&4^"B`@("`@(#PO M#IX;7!M971A/@H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0](G2A4:6UE7!E+U1R=654>7!E+T9O;G1$97-CQA\=:9/]_FW?,.TXJ[O2'>D M'>;^F;P?3#^@H$ZXM,))5-2*\C6*&JF(2^G!D_N>SY(%L)Y,KY/+=Y=NZ$Q< MSQG#+W&U$[G*83=\QB>XXR"!S:8DDE8%:/R)W3T@2 MXGE&RM@=^<[,LAA?X/;J4S*E!9H"C^O9#5J1_$S]4L>2WZ9X,!M?GX\_3F>CJR^_3_]@XTF"ATH0O3):'0J7:K&2)++# MB`S;P"%9&#OL,1%OH@8+?#N'10H24.2075J#YAQI;XWR M&7LU<:5P2A*V3@O4[=6MRY`_:0:FP;FQ#2_^V))19%!GS;H17!E'^<[":(H1 M(O<'G?LENE]8/%R`W[-B05H;>@B<,H';S^,PX)$G`A9@TD5!@)GLO-\6F9O\ MC=>TN09RS;Z)O^(B\H`)Q-C1S9'7D(I=4HD)84B_.D,PERGK?VF5\YNK:E^* M#Z8U5QDZJ<8,7:)'5DVP%Z>@9Y9AY`@_X$YPO@4@,]0H?% M]BLH/[F\">5V7YO<;S4U`#U2[8K79#*L43XU-P6[8$%T,D0F>[R?_)V-5RF<\A MS\HE$6XL8=;>*W'[L.X*H9*ME2*K&,Z'%CV@#\04O@[%9Y(;Z7VN]II#N-5*-1W.)= M#%E:$^=T4:Y)3K8@WHTR=:.%=T`+E!?C2@2T!_#@@RCN<9EUU4";OJ#!':&W MTQC2ZAN)(/Y9/;K"^T]T\;^;^L@3/(A#8"AYC'%&EJOLF5$GF[LC!2I;O0(' M>XE/O00!ZUH]TPUK3'J`OOP,C91]QVU1/N)CE2WN2+G7A_N/MOW'],+8]D+M M-6W6#\*=:4$B-V[F#ZCGC:^NLS4I46WP[9(\R- MZLQZNLI^T(T<\G@4&O+,Q*QFQ&&)J5X#OH]C0VD.6=-@8Y/3M8("*O6MDT*3 M*"M&VOO@I%N'H`)OD0*\W#'V6A_$R#?B@)2V4%J5H>H9D.4;-&GZ1#$S$2F, MQS&`-(K,-Y2&H`@A3GM-""V^1"M12H,T:7I]AS0`>@IN4=1[%D.LJH?CZ>W$ M4[6F^$T7,U,$M3%U,)(Y^7V)_3R&W(%P6%]2R.;=>I/F<*]H;)78#P/'7&_= MM(>+-*\`%.NV5&2U#?.P/Y'YK=I-8''D:2*00XDK:)Y*5RM&4$FIK&=5GJX` M2O6:.,^1YP:([VE+XO,BI:MSO(#4\Q*Z$[S(R4;/,J;'`GEM<;4"%/:TV\^1 M1K]>M#K(FKIDBF6ZP;8&6RR0E-A>YZC)7J(TU98?CK+?#OFDBYV(0YH/(],C MS%@AFQH$?<6#LN,+Q4.E)ZC0OLV9#_F3F"R4,GR.^L&0],2]YG.]\L88=GN[VOD1Z M4P'VJ*,0`/#Q,#``&#>C5("CE(DWPN`<<(\O2YS%OM?MD!48:2:[VH\Q_\7< M/;FW8P[..,C=CCF6D^R-:Y05'?P]A&C$O"!"'QR%?]2'/X"C_0S01^8^L%S' M/(B,Y1?-8*J=UYCDK8G>D2^$$"($M:-CX8RW=]MZ`^>[LR,DK]=VH6$S#_C_ M9\H_;&_4G5.HD*GT2E7<2E7\257`257@2570257P*E1(G4;6^[WVHM%GC!Y)# M>@J8K:+C2:/4;K@51KM'"F7]7P$&`"N_0\$-"F5N9'-T')E9@T*,R`Q#0HP,#`P,#4V-#(Q(#`P,#`P(&X-"C$R(#(-"C`P,#`P-38W M-#(@,#`P,#`@;@T*,#`P,#`V,#')E9@T*,"`P M#0IT EX-32.2 9 exhibit32-2.pdf CFO 906 CERTIFICATE begin 644 exhibit32-2.pdf M)5!$1BTQ+C8-)>+CS],-"C(Q-B`P(&]B:@T\/"]&:7)S="`Q,C0O3&5N9W1H M(#,T,B]&:6QT97(O1FQA=&5$96-O9&4O3B`Q."]4>7!E+T]B:E-T;3X^ M;DL6Q5D86:,CZT"1>0V`U]>.I.X(H1:2^G(/;3^/F2N-TP3.*A[\[GQ/C(K->Q MRX%'8R>.EHS)AK))"J*VY-79D]FDO*-HH!(L]F(?7J94]0XZ*]U`1L`68#N, M[UTOFC?8'P7,RL*J!:PJK%[`ZL*:&UBZ08-EEOS_+!76158O8ZL%[*S!+]!K M"UO?P*H%/XY,A@^FR@OBYY6@>27:Q[)F^3N5L1(RUV[+)LY)3=FW&+H?7B^Y MV8%RC]SS&/%R/7Y5MMUS'ZZTQ7M9JO[5]"W``+BIY$X-"F5N9'-T7!E+UA2968^/G-T-IB8F*XP<#$P,#`""08_\-8_QEA+&H0_QDL MWC,Q,.X`6L2XG`$@P`!0K0:A#0IE;F1S=')E86T-96YD;V)J#34@,"!O8FH- M/#PO0W)O<$)O>%LP(#`@-C$R(#,^F1+\<0SOE=5)4+(+E5;VN!*736KE0LF\98`M8G2_/L] MWQF/[20TV@=@KM]W[G,XRT>GG\2;-ZC*] MS&<7,S=Q)F[HC.F3NX$SFW\4G[[0Y'+AQ@X&XX^Y<+V8=C-G;L@9604@P4BG MX-!2)Y'PE%0M@7*]T$E=[8@OZ"'OF*2,#0L8]>+G(6%&)]C.O^43WD`5>CG_%TD_2H?R+Z22' M.0@V`[Y/JL1,-+\0^9]3;"S&EV?CC].%-__Z?OJ7&$]R;&J?SVLCU3%WZ2Y6 M\ESU,:*2SG$(%RA,'@LR=EP0&+EF6PH%L=S1]Y8_GG+*Y8%<5=%GARF?(/'N ML8*=&ZR*;E2ZJ2,^TZ$[S`J:U1A@OR0MZPT-'H!QV:[LP59C'[`[BW^QJV]= M13Y5M.`#PJ/!9R;#N75[+H<[E=L52`__='01EJL"J?D(3H>T,%E$,#TD:I,$:M)O6 MHJO_XZ)%"?.PDTAFTM!Z&0B-*+:,,OV%4S?6E=MKOCNQP7!+Z<:&P\6FJ8SW M=M;23TVW*FP88'93UD`SGH0[<);\80(C=?:XQRZP`?2*,Q'@/ M+$%[]5`Q$JWM[WBAN>M/'L2!`;C`I7;$94GB+%5&*:YTF"@L4?7#SXDHR+LK M#'=[H^'*7MTSN.$A4Q@JX\S';`#%./-CNS10L"^$66?^\%G,6R,L"B;\WNM5 M-AY6Y@3V"_,-U?+R@9SM(:<1"X\)M<^:Z1-A,`L2E0+32'N+L'H@!,$NWN[N M`;,I5]=,]?IX$0UL$0UDE`6/'C?5VCB5[2AG.UC.^@JBN:"K@/IQV1C MEO)0\;4MOZ\JN'(*JFF[6K#T$9GCRF&WTRI.4!+VP&'GM0RXJ0R3S.)V(E/] M,-%2':#2E#VU-/;?&MNZG@GW\?(@=FN.THPC,32!V!5'OV-47!N]0)FGJ7\Q M$;1D%LVEAR!^J@G35:O\?QD2.ZDLR6[;-F/ M#T5%][:MKLJ4;W.],].3N"BJFH)BWZ59V5@WGPSS)NK$;AV+%[KU0$6AO>6R M4FPV)KRY!%&E0@VJRV;/R$M@(@]N>,KTU;;8=EF$T\L=U7F4*M8QM,#\LP+6 M'6<+1>%`NJ23SC02K7P#;_4A:VJ,*6;%`0]$6V]KN#+(O3 M8ZUUX">2'I0A[#?GU(WX73[EEYCR:VQ>J9)"ZEZ,)7E%G.%EP_.V^]$,=)Q2 MXS^A)G_9D(ECG3SZ%LUR.VH9PTS++*;@"&5(`DGJ,.MRA&8/5KCNCY%W:)NR MFK_XS*,](*ATL.O+-%.$$(6PZ'$$R_+2F0&+MGO!;RF>'WFB!ZO[3`R#\QN; MV&,=S3&,LT=_M9(^L*Z?M-!:];$0OQ`+8:JDCDTDM(ZGY"NMXQ$/9Y0!6-PA M`*S_B4T;MD$5\+HR\.CUG'&*(N=O&7#"64ZMB6E+0FY\A[G.>2SFZS5W)2V= M5:[+H3Y9PB"`$F&3%=$F'Z:+ZOX=&Z.?_1"49**1,3(V!SMN>,'!>HRIP M2X<.^!I?C?U;H'SN]VBD?>Y^;0=\M#ADSXO#L/(;/4XG^A_?Z$^B9:D5DD9& M2%\CITC(-U#F[1'5E=\3$7R`RGC^Y#CE\W\"#`!KDHUL#0IE;F1S=')E86T- M96YD;V)J#3$Q(#`@;V)J#3P\+T-O=6YT(#$O5'EP92]086=E7!E+UA-3"],96YG=&@@ M,SDT-2]4>7!E+TUE=&%D871A/CYS=')E86T-"CP_>'!A8VME="!B96=I;CTB M[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK8SED(C\^"CQX.GAM<&UE M=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A- M4"!#;W)E(#0N,"UC,S(Q(#0T+C,Y.#$Q-BP@5'5E($%U9R`P-"`R,#`Y(#$T M.C(T.C,Y(CX*("`@/')D9CI21$8@>&UL;G,Z&UL;G,Z<&1F M/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D M9CI0#I3;W5R8V5-;V1I9FEE9#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^ M"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@&%P.D-R96%T941A=&4^,C`Q,2TP."TP.50Q M-CHU.#HS,BTP-SHP,#PO>&%P.D-R96%T941A=&4^"B`@("`@("`@(#QX87`Z M365T861A=&%$871E/C(P,3$M,#@M,#E4,3&%P34TZ26YS=&%N8V5)1#YU=6ED.F,S-35A9#4X+6,R96,M-#EE M-BTX.&0R+3(W86%D9#(T-3(S9CPO>&%P34TZ26YS=&%N8V5)1#X*("`@("`@ M("`@/'AA<$U-.G-U8FIE8W0^"B`@("`@("`@("`@(#QR9&8Z4V5Q/@H@("`@ M("`@("`@("`@("`\"UD M969A=6QT(B\^"B`@("`@("`@("`@(#PO'1";W@O1&EV+TYO'1) M;F1E;G0@,"XP+T5N9$EN9&5N="`P+C`O4W1A6]U="]7'1);F1E;G0@,"XP+T5N9$EN9&5N="`P+C`O4W1A'1!;&EG;B]3=&%R="]/+TQA>6]U="]7'1);F1E;G0@,"XP+T5N9$EN M9&5N="`P+C`O4W1A'1!;&EG;B]%;F0O3R],87EO=70O5W)I=&EN M9TUO9&4O3')48B]3<&%C94)E9F]R92`U+C`O5&5X=$EN9&5N="`P+C`O16YD M26YD96YT(#`N,"]3=&%R=$EN9&5N="`P+C`^/@UE;F1O8FH--#,@,"!O8FH- M/#PO0F]R9&5R4W1Y;&4H_O\`3@!O`&X`92DO0F]R9&5R0V]L;W);,"XP(#`N M,"`P+C!=+T\O3&%Y;W5T+T)O7!E+T-A=&%L;V7!E+U1R=654>7!E M+T9O;G1$97-C%LM-38X("TS M,#<@,C`P,"`Q,#`W72]!7!E+T9O;G1$ M97-C5%"[;L,P#-SU%1Q;=)#B M%LAB&"C2Q4,?J)WLBD0[`FI*H.7!?U])>;@CY:']:,E%D#_L38<1 M!D>6^W[^H M9Y#?;)$=C0EYJXZGA'1+"'\X(450T#1@<1#R\*G#EYX09"'>P7X-"%7I=YNV MMS@';9`UC0BU4NJUN18D^SB_LLZ#N6@6]^UWU8BTO>&9EV^Z^3`+<[)8#B]& ML@5'>/M-\"&KY1#_`@P`W?MJ>PH-"F5N9'-TJ'-,-(9 M>I,N,(#T+B`=!%$89@88R@###$ULB*A`1!$1`460H(`!HZ%(K(AB(2BH8`]( M$%!B,(JHJ&1&UDI\>7GOY>7WQ[W?VF?O<_?9>Y^U+@`D3Q\N+P66`B"9)^`' M>CC35X5'T+']``9X@`&F`#!9Z:F^0>[!0"0O-Q=ZNL@)_(O>#`%(_+YEZ.E/ MIX/_3]*L5+X``,A?Q.9L3CI+Q/DB3LH4I(KM,R*FQB2*&4:)F2]*4,1R8HY; MY*6??1;94!&;B)C$#PYT$?%R`'"DN"\XY@L6<+($XD.YI*1F M\[EQ\0*Z+DN/;FIMS:![[M(KT*^-PSB-;WA^VO_%+J`&#,BFJSZP]; MS'X`.K8"('?_#YOF(0`D17UKO_'%>6CB>8D7"%)MC(TS,S.-N!R6D;B@O^M_ M.OP-??$](_%VOY>'[LJ)90J3!'1QW5@I22E"/CT]E?^IB?\P[$]:G&N1*/6?`#7*"$C= MH`+DYSZ`HA`!$GE0W/7?^^:##P7BFQ>F.K$X]Y\%_?NN<(GXD,X`9P\QBL5AYK`'6#NN'96(%V`+L?NPQ[#GL('8<^Q9' MQ*GBS'#NN`@<#Y>'*\$AX1202U8G6Q``BE[B)6$$\3KQ"'"6^(\F0 M]$DNI$B2D+23=(1TGG2/](I,)FN3'DDN58R1[)<\J3D#LHE MRC@50]6A>E$3J$74;ZC]U!E9&=EELJ&R6;)5LF=D1V@(39OF14NBE=!.T(9H M[YGR;O*)\KOE.^0?*:`4 M]!4"%#(5#BI<4IA6I"K:*K(4"Q5/*-Y7@I7TE0*5UBD=5NI3FE564?903E7> MKWQ1>5J%IN*HDJ!2IG)694J5HFJORE4M4SVG^HPN2W>B)]$KZ#WT&34E-4\U MH5JM6K_:O+J.>HAZGGJK^B,-@@9#(U:C3*-;8T935=-7,U>S6?.^%EZ+H16O MM4^K5VM.6T<[3'N;=H?VI(ZYM/8P>0R]1[X#> M37U8WT(_7K]*_X8!;&!IP#4X8#"P%+W4>BEO:=W284.2H9-AAF&SX:@1SJ/U:>MW-I8V`IL3-K_8&MHFVC;93B[76/MC]D/^*@YL!TJ'-XXJCAR'9L<)QPTG-*<#KF],+9Q)GOW.8\YV+C MLM[EO"OBZN%:Z-KO)N,6XE;I]MA=W3W.O=E]QL/"8YW'>4^TI[?G;L]A+V4O MEE>CU\P*JQ7K5_1XD[R#O"N]G_CH^_!]NGQAWQ6^>WP?KM1:R5O9X0?\O/SV M^#WRU_%/\_\^`!/@'U`5\#30-#`WL#>($A05U!3T)M@YN"3X08ANB#"D.U0R M-#*T,70NS#6L-&QDE?&J]:NNARN$<\,[([`1H1$-$;.KW5;O73T>:1%9$#FT M1F=-UIJK:Q76)JT]$R49Q8PZ&8V.#HMNBO[`]&/6,6=CO&*J8V98+JQ]K.=L M1W89>XICQRGE3,3:Q9;&3L;9Q>V)FXIWB"^/G^:Z<"NY+Q,\$VH2YA+]$H\D M+B2%);4FXY*CDT_Q9'B)O)X4E92LE(%4@]2"U)$TF[2]:3-\;WY#.I2^)KU3 M0!7]3/4)=85;A:,9]AE5&6\S0S-/9DEG\;+ZLO6S=V1/Y+CG?+T.M8ZUKCM7 M+7=S[NAZI_6U&Z`-,1NZ-VILS-\XOLECT]'-A,V)FW_(,\DKS7N])6Q+5[YR M_J;\L:T>6YL+)`KX!WSWM9?2RPK+7>Z/V M7BU?5EZSC[!/N&^DPJ>B<[_F_EW[/U3&5]ZI5'\8-#0H-10T?C_".C!P- M/-K3:-78V*345-(,-PN;IXY%'KOYC>LWG2V&+;6MM-:BX^"X\/BS;Z._'3KA M?:+[).-DRW=:WU6W4=H*VZ'V[/:9COB.D<[PSH%3*TYU=]EVM7UO]/V1TVJG MJ\[(GBDY2SB;?W;A7,ZYV?.IYZ\+UVY['[Y M8J]3[[DK=E=.7[6Y>NH:XUK'=N;70/+ M!\X..@Q>N.5ZZ_)MK]O7[ZR\,S`4,G1W.')XY"[[[N2]I'LO[V?$CJ4?ECY4>U_VH]V/KB.7(F5'7T;XG04\>C+'&GO^4_M.'\?RGY*?E$ZH3 MC9-FDZ>GW*=N/EO];/QYZO/YZ8*?I7^N?J'[XKM?''_IFUDU,_Z2_W+AU^)7 M\J^.O%[VNGO6?_;QF^0W\W.%;^7?'GW'>-?[/NS]Q'SF!^R'BH]Z'[L^>7]Z MN)"\L/";``,`]X3S^PH-"F5N9'-T%35UO?7/F=*2$B#)`0"S(0A%$.O$1!"&H08("0# M"363'KHI@$@PB@A$4%0LJ#0[AC(9"T%10;'W?N_UJF"[%K!CA M7[_O?N_S?._S,,EO_O^]=CEMG[U7?)`4$850/>DT8%)N_T'S*ZJ:$3D`"HN7 MU#CW7KOO)R+5F<@:7+:X?,'WWV>W);+U(FK3J7S^A65Y5>63B=)^1)N4BE)/ MR?L9>S\BFGDW^@^K0"!T3\@HHO`TE+M7+*A9UK?TR""3G>MT M$@*_6&S40NJP?:O6PTFTS:C3]UG#C*/CCI!]*U'+M73F9S+-I6K>D0/4-OT?_#3\N%U@745M]'-FI/Y/_9?[SE3M", M,_TUDT@V;2+"HD#ZZ_A"JH$G=F'LVG!;30+"U$ M73F^RU":@U;%:&7X7ULMHL6@BFJHEI;@9S%\=:!DU%U@EFMI*7Z6T86TG"ZB M%507^%YJ1E:@9KE97@96TL5X,I?0I:83Y<@JNHQ6XZFMH;6T[D]+ZTZ[!KJ" MUN,Y7TE7_5N_X3>EC?BYFJ[!?-A$U]'U="/FQG67<= M(MM,9]0>H"?I?MI#>^D!\UX6XZ[Q'9'[4F;>P\6X!RMPA:O..&.^?TM/WZV5 MN';CVAH"5[H,\4O/Z+$DOIRUX`W?@V[BKAKL5GMTVTY\9WWJZ[7:S M?!O=3G?@6=QE.E&.W`E_%]V-=_L>:J1=^/G5G^E8]]!N\\EYJ8E\="_=AR?Y M`.VC9C/^9W5_%+\W$/>=CNRG!^DAS)!'Z"!6FL?P(Y&'$7LT$#ULQKC\&#V. MLM&*2T_24UBAGJ7GZ'EZB9Y`Z47S^VF47J97Z35Z2X7"O4*?XOL4H.1Q)7-F MSYHY8WI!OCLO=TK.Y$D3L\_/FI`Y?EQ&>EIJRMCD,://&S5RQ+E)PX<-[=^O M;Y]>/1*ZN[HY8J,B(\)#0X+;!-EM5JS$BOJDNS(*G=X>A5Y+#]?X\7V-LLN# M@.>,0*'7B5#&;]MXG85F,^=O6R:C95FKELG<,OET2Q7A'$6C^O9QIKN6Y'F]*I"9[HW8TE%0WIA M&L9K"@E.=:66!O?M0TW!(;`A<-Y>KL5-JM=H91JM5_J()NQ#H<9AO7I"NJ?$ M.SDG/STM+CZ^P(Q1JCF6UY;JM9MC.2N-<&XX0UQ??+QQ+EF'@=TE%K+>^R-FW M#^Z^^9N`7]0[O7J/PJ+B"D,]I0VNM#2^;WGYWN0TF&1/X%K3FP;T1WM/(2ZB MTK@-.?G>_J[%WBA7"C=`P&D\@\KY`+>OP)5?6F`\)5>$M_<1'"[>/*+9"]?6JK4T-J[\%(]J*6BIF(,9B7'R6,WR.+-\NCB^ M576F5#L;@EQ9N0W&X*[`@.3$&X2+MO7(]%R1U&X(7LT,K&ZN#(_+&>',:/`T M^^N+&IJ2DQL6IQ=6C##&<&66-+AR\T?%F>Y/-J&9$C:!1/V)Q/5F[46,V"6BYL5F;$@B2DJ;M8X%B$Q#3$+QY+-F/'!0XJM MP"W&SXJ"BH;"`N/EHA@\2OPJKW*-)J_F&MVD-%M;;["K-,4;XDHQ MXF.,^!B.VXRX'1-#Q2C<'&--:BAT89W"A,JG.,5343>&=#;[_7GY\2_$'2^( MQU2;":;G>]LD8NVW)DQ`NW$&A0B/\]87>XSS('>^T=>>D%E<@&DK`Z))IK<- M1F@3&`$M,LP^QG1$IV(\&SQ`LW\]"M[Z`F]!HG'0_,H"&F\:P0>.X]I M[6$UN<>;$+5<6%3MQM M"Q7G8JKS6AHB`NX.J3.-<\+L&IVHT/60,D]-,4US+L+(8 M)VV.9$>U-S0ATX/%G_N'(.)*DLY!QAH1$ACC,$?MQI6WQ7W7$_*:_7>Y+HP_ MX].WC\O8'(R)27'[,;&IH*%UP#LCL6^?H-;14#/S7DGH)D1WD^JO8XOS/&UBFTRY+ M&GG^D&.H.T8W6/P49Z!_0KM`>D`S`A2#.>"20'R7OIMV6=O2C-983F(\8,5? MR9J%=FD6_P1H+^BY8""8#":!BQ#O"GI:KD&[#637-OAW6GJA/]!GF5RB%P7\ M8NILF4V[;&]A['/^`#LXGXK_6R8QMB^IV-(-QP+6(OA\>";74%S?N`#1(/9T M^6,*/Q-K-[KGKV)IH&[VKG1>:RP]:0#&ZOH['J61`3J9^AU%_%6L,_WO&U@L MM$-_CA;\$992V@'F6I;2(`.]'FWK<2ZLS@!]0&^0$HCOT">CWZ4T_W-`3N,$4<`'BD2#6$D<[M-%$VFC_>OT9C`VT(R9K MM(\#_BN?9C-89OHR<`^5_;<\R&"<,OT)'`M8FN"/PS/IIDZB M3,9_`GQ_NEQ`G?4"?PLKYN,&V@9N">@-H#;@?X=^BN)MHVEX:_3G:9B^"L^L M-964%B#(U#=H9BNZ_D',Q-:?L0RAS7A_I@>8"*9)V;Z(IMO>`8I!VT++>C`7 M#"&/_@O-^BMH%U""[29*"'J#$BR-\#<'_*A63&I%(&Y;THIUK0C$?].^#8Z1 M>L;8JWZMLQQGK.TIP=Z+$O3#-+0UYK7^GLV6(?[=EE3_3^I-6JW>]"^$AD.G M`R>H`OF@'/%(L%D_2*LM76FM^LS_1H!B_3;$`QAMP#E:9U.SU"_463M%FVTE MQK%^PT13;_5O,34)S^.W3/I=;!1C>]Y\=C).H?8L;6;\/T$7ZO&4PV#>QOM/ M2=FZA\%8F]77:+^'XK7#P-`#U,/R,<5;:O\:N-?Q]BS,[[__-7">F\"5`;T< M9(-U`;_I3/0MU,W:3$-;HR_%FK2-NOV.WE00P&YJ$E7I'BK1EV&N[J(T[2.: MKTTT=;S63./4(>JNW8!G]"G-5\7D40O\?T-YOIJ-]6PJVGYLDF[V0Q_U/70` MI:@/R&7TT5:30_^2^F@KL<==3@YM.*5H>5C/:L$F8]<^%41T\A-MZN]C.#_2 MYP`S=G(;*&\5VP(JE1_EF\"MX&XS7@H*]>X8[P1B&:#*&>"N:?' MJ-/;HAP.(LW8+K!3NQK];P3;S=BGX'T-.8;V&+@?;0^!H\@YS.SCY!0P4+V( M/.1-\"*#:\DVP+5=!EVN76SJ$O4#7:8-E'S%O\[(0?1<[*^7T0C.(5J>,O8T MSA=:MAI[,^<++?@SP3_%S`.NH^ZRW^,>Y_(>[H\Q^V#?UAN1F_`^C/VR9:&A MMO8X)O93&]%&ZV2:;9W<\A/OB?Y:8R_4?C'W&!?O92VO&&LK[ULMKUONHS+> MMUH>QAZ59^Y'1RE2]AU]#4@W%Q7[L/UE4%OP%S7*%O7\>[(FC"?>EG:T1+T+\#SGZEW)-WBIHT! MZD",=1BYK2/)C>MN9]U)FZS74(F!MLY\EL&X5\:S'J99Z8;3=,>\]]-"`_-Y M9M-N\WDN#K`$SZ@GZ6?DCAY;!8[Q+&59C?PJ0"`?G&SD>J?SK0](M_T,WN*\ MT:[_FL=9?N+G;.2IDGOA.IEFK`N;^%E;.Z/-"5!%-;9O,$97^,\IW!8+309% M-,OBH2)[$/P%R._\Z/\->-[U%'9&/M3'N@Q[<#U- MLZQ#W3JZ'EP7R''<1OZ":]UA@&>KS/FR+)"3[`1S`W/%R+LDC]B".;L%.7=_ M7$A3B78_TP*;"_E..LISJ(-U%6*?@`]IGOX5\I=!\'[L[W/(82D& M>`.QARLSCOW?DHK[8LRM-["N'PX`CSF1B3RO@[%/G+F'8_S1R`FR++F8>[G( MJ7*QI_$>6&7L:_H#Z`LLT11CTZB]M9+F6,9A'^L5V*L&@G-^W<_,',/89SI2 ML+'7!=;F6/U5ZF9I01QK-^;B9LM@8H^!*S"W-^#< MGH1_CI(LN?Z?C+T9SSM67XAK"X"Y>H>!=K,*UFZF1PWT^VDUF&WR+N9V(1T' M37H)+<=>,`?S^!QC3H.'C/EMO9RN1VR]$1?%,UH+$D4#L43M`:H!!T4M'9'S M=<3[$%"]`RGM/>P)>U6#?E+M03D$Y;Y:-?80H)]$/@GLH^FZ,T'L)_TD'3K] MSBV@U6"Y5H-KJJ'IVF4T%=1JR5A7DQ&?0%Y0_N_:8:RM8"E8!I98O#3/S&/PG`_3N)]"#-SIWSX_6`"RKG0!;@7B?!#]&^Q5V_#^_L(_G[<;1C6 M@V&8VV$T'NP!5:`<.$$IF`>*P1235-R;#=11OP3K8#76PUW40Z_`>>S#/"%ZBGM8[2X=.QMQOYW/B@B30>L9GV9_"\3F)? M/TGG@T*0"&8'?`'`.X1GQ?5N,-68S]9/J8_%2D-MKU$EGKU'.X[\[R0%&?F& MD0<8>Z:M%&MQ'LVPQ-`$O',W@>O!,R9AM-<>ID:(!D^DFVQ)^-NMC'KYVNC. M9NVR^]K$J@DPJ\1<*N82,?5B+A:S4DR=F!5B+A*S7,R%8I:)62IFB9A:,35B MJL5<(&:QF$5B%HI9(&:^F'EBYHJI%%,AIEQ,F9A2,25BBL44B?&(*10S1\QL M,;/$S!0S0\QT,05B\L5,$S-5C%M,GIA<,5/$Y(B9+&:2F(EBLL6<+R9+S`0Q MF6+&BQDG)D-,NI@T,:EB4L2,%9,L9HR8T6+.$S-*S$@Q(\2<*R9)S'`QP\0, M%3-$S&`Q@\0,%#-`3'\Q_<3T%=-'3**8<\3T%M-+3$\Q/<0DB.DNQB6FFYAX M,4XQ#C%=Q701TUE,G)A.8CJ*B17304R,F&@Q46+:BVDG)E),A)AP,6%B0L6T M%1,B)EA,&S%!8NQB;&*L8BQB=#&:&"6&`D;YQ;2(.27FI)A?Q/PLYB^+.2KFB)CWQ+PKYATQ_Q3SMIA_B/F[F+^)>4O,FV+>$/.ZF-?$O"KF M%3$OBWE)S(MB7A#SO)CGQ#PKYADQ3XMY2LR38IX0$W-(S$$QCXIY M1,S#8@Z(>4C,@V+VBVD6LT_,`V+N%W.?F'O%^,0TB?&*V2MFCYC=8G:):11S MCYB=8NX68.\7<(>9V,;>)N57,#C';Q6P3LU7,%C&WB+E9S$UB-HNY4 M)6F/DK1'2=JC).U1DO8H27N4I#U*TAXE:8^2M$=)VJ,D[5&2]BA)>Y2D/4K2 M'B5ICZH2(_F/DOQ'2?ZC)/]1DO\HR7^4Y#]*\A\E^8^2_$=)_J,D_U&2_RC) M?Y3D/TKR'R7YCY+\1TG^HR3_49+_*,E_E.0_2O(?)?F/DOQ'2?ZC)/]1DO\H MR7^4Y#]*\A\E:8^2M$=)VJ,DVU&2[2C)=I1D.TJR'279CI)L1TFVHR3;4:GW M&@99LZ_K:`=R9E_7:,BE7+K$UW4$I)Y+%[.L]'5M"ZGCT@J6BUB6LUSHZS(6 MLLS7)16RE&4)2RW7U7"IFJ6*@Q?XNJ1`%K,L8EG(31:PS&>9Y^N<#IG+4LE2 MP5+.4N;KG`8IY5()2S%+$8N'I9!E#LML[C>+2S-99K!,9RE@R6>9QC*5QS9+%,\,5E0C)9QOOB)D#&L63XXK(@Z;ZX\R%I M+*DL*5PWEOLELXSA?J-9SF,9Q2U'LHS@[N>R)+$,9QG&,I0'&\(RF$<9Q#*0 M90`/UI^E'_?KR]*')9'E');>++U8>O+0/5@2>,SN+"Z6;CQT/(N3^SE8NK)T M8>G,$L?2R==I(J0C2ZROTR1(!Y88#D:S1'&P/4L[EDBNBV`)YV`82RA+6ZX+ M80EF:<-U02QV%INOXV2(U=6G[GN M)R[]R/(#R_9#O?+&YD&^Y]`W+URQ?<=V77/J"Y3C+,:[[G.4S#G[* M\@G+OU@^YB8?<>E#+GW`I?=9CK(97E%9:7N8WF6FSS#\C0'GV)Y MDN4)EL,LCW/+Q[ATB.4@RZ-<]PC+PQP\P/(0RX,L^UF:N>4^+CW`JUV\BAWL]S%=7>RW,%R.\MM M++>R[ SK*-!]O*HVQAN87K;F:YB64SRXWR&I?=!'D,I95ON@RR*4LE_BB MW9!Z7S068W6Q+WH89"5+'7=?P?TN8EGNBRZ!7,C=E[$L95G"4LM2PU+-0U=Q M]PM8%ONBBR&+>+"%W'(!RWR6>2QS62JY7P5+.9]9&7ED*6 M.2RS^:)G\9G-9)G!%SV=AR[@`^6S3./3G2RY+%-8H3"Z-9QG'P0Q?U$I(NB]J#23- M%W4Q)-4750])\;7+@(QE2689PS+:UP[[NSJ/2Z-\D060D2PC?)'&U#B7)9#QGFBYP.&S/TL_[MZ7C]"' M)9$'.X>E-P_6BZ4G2P^6!%^D<9>ZL[AXS&X\9CP/YN11'"Q=N5\7ELXL<2R= M6#KZ(F9!8GT1LR$=?!%S(#$LT2Q1+.U9VG&'2.X0P<%PEC"64):VW#*$6P9S ML`U+$(N=Q<8MK=S2PD&=16-1+)3L#R]R&+2$%SM.A9A;X3.=[P>VL/Q&G@5 M_I701,?+X"7P(NI?0.SYT`6.Y^"?A7\&_NG0N8ZG0BL=3X96.)X(+7<<1M_' M,=YCX!!(]A_$]Z/@$?!PVPL`N<">X(Z2OXW;H;>!6 M]-D!W1XRS[$-?BO\%G`+_,T8ZR:,M1ECW8C8#>!Z[Z]PK&^O< M(74JI"ZN+JONHKK&NK?KDK-MP2OZE[6N-2]I+'6;:F-JJVI MU;^K58VU*JU6#:A5&M5&U#IK];8U[BIW=6.5FZHF5]57>:LL([U51ZHTJE+! MS?Z#]U;%=.SR+BV4E9[O,;L]P3DL:[,QO'N\89S`Q,XX M$XI3*0/BDN..Q'T59Z$X;]S!.+U=>"=')ZUW>$>5.JFC6M3QXHY7==3#8U^* MU9)C>_?)"._P4H?W.GS9P=(^N4/O?AD4$Q'CC-&CC6N+R<[+,'5,&NO`H>:U M9L>X>F2$1ZOP:$>TENZ(5A1Y)/*K2#WZT8B7(K3P[@_7DL/1/#S,$:89 M7_XP/3ELX/",\%!'J&9\^4/UF.101(P1>[:=G)<1'N((T=QC0B:%:,DA8U(S MDD/Z#L@@73F5(A4!T8/0]CX5[+*_>L(&ZI&1YN^3F M^_3MV[ND%&1YZPV?G&QZO^$)30H29U?75B"2T`]N!BL!'5@!;@(+`<7@F5@*5@":D$-J`87@,5@$5@(%H#Y8!Z8"RI! M!2@'9:`4E(!B4`0\YC^J*-'F@-E@%I@)9H#IH`#D@VE@*G"#/)`+IH`<,!E, M`A-!-C@?9($)(!.,!^-`!D@':2`5I("Q(!F,`:/!>6`4&`E&@'-!$A@.AH&A M8`@8#`:!@6``Z`_Z@;Z@#T@$YX#>H!?H"7J`!-`=N$`W$`^]`.1((($`["0"AH"T)`,&@#@H`=V(`56,;Z\:T##2A` M5*(04RW@%#@)?@$_@Y_`C^`'\#TX`;X#WX)OP-?@*_`E^`(`Z\%U8!.X%EP#K@8;P57@2K`!K`=7@`:P#JP%:\#E M8#65C*U7>/\5WG^%]U_A_5=X_Q7>?X7W7^']5WC_%=Y_A?=?X?U7>/\5WG^% M]U_A_5=X_Q7>?U4%L`8HK`$*:X#"&J"P!BBL`0IK@,(:H+`&**P!"FN`PAJ@ ML`8HK`$*:X#"&J"P!BBL`0IK@,(:H+`&**P!"FN`PAJ@L`8HK`$*:X#"&J"P M!BBL`0IK@,(:H/#^*[S_"N^_PKNO\.XKO/L*[[["NZ_P[BN\^PKOOL*[K_#N MG]T)_J-/P=E;\!]]8N?,-C),:JG67[6&D4YV.I>R:2+-.$"AF-,Q-$+=?W]T M6EI07_LCF*\:.3'C@Y"2IB:'6[30?9TZC7'M&VK;H$=FX@_W^\;8-V`M'W/J MW5,O]C_U[O%VY_8_KOJ_<_3=HQ%?OQAY;O_!1U\_.G"`BHR/-(D*T^SV*)NK M6S]M:,\>PP8/'C1:&SJDAZM;F&;&A@P;/EH?/*BKID=)9+1FE)7^ZLGI^J13 M-FVE:\S4P=:NG<*C0FU6K7-LN[ZC$B)R9R2,ZM?%KMMMNC7(WFMX2K>L^>G= M_F&/[!(=TZ5=4%"[+C'172+MI]ZVAOW\C37LEU3+_%\VZ;:1,\=TUV\,#M(L M-EMSU]B.YXR,SYP:WC["$M(^(C(FR-XNLFVOM)FG+H_N;(S1.3J:QS+^M7C@ M_V9+.`K\UX&WPNP+>3G7J06,42QM$.FO#`UZC,"TWX'7$ M/0%O@:\+>!O\9G@%C_/1[@]XG(_>D7:2DP;1`/P,@\NF2BJF*EI$U:",:A!+ MA:NBQ>:W!Y%*N(74#S5C:3Y^G#0%L7*J0%VU62J%EJ+U$GR7H&4J^LU'FR+$ M*M&BTFQ7"JU!+Z.E$RV.&X)2@N@530/L46G^_QQ;=G_ MT;489[30',LX&R>Y4:HTS\$X?BZ95& MZWX[G8,&#!CFS*XLKEI4O:BLQIFZJ&KQHBI/3>6BA?V<8^?/=TZI+*^HJ79. M*:TNK5I26M)O;%9V=F9:8JIG?F515>6?E0+BK*QVEE;65)16.3W.JM+RRNJ: MTJK2$F=-E:>D=(&G:IYSD5%S1K'LC\_'6;G0B6&<[H65->B?6^.I*:UV>A:6 M],<`B\P#%"^J75A355E:W0^//@LW.)LR*8T26SW@*>9CK$7$>"!_UO+_MN[L MI/T?G+3F?T;&RN&AW5@C=@&-(M"YE,@5JR[%VF+^HQ#CO]D??]&5.B=\U`GJ M&&0N4P]]ON)Y0P^E?-+FY,"6ZC8/V+>B:*Q3YCKV7P(,`--GO4,*#0IE;F1S M=')E86T-96YD;V)J#3$U,B`P(&]B:@T\/"]3=&5M5B`X,"]&;VYT3F%M92]! M2TU-240K0V%L:6)R:2]&;VYT4W1R971C:"].;W)M86PO1F]N=$9I;&4R(#$U M,2`P(%(O1F]N=%=E:6=H="`T,#`O1FQA9W,@-"]$97-C96YT("TR-3`O1F]N M=$)";WA;+30W-B`M,3DT(#$R,30@.34R72]!7!E+T-)1$9O;G14>7!E,B]&;VYT1&5S8W)I<'1O2]#2413>7-T96U);F9O/#PO4W5P<&QE;65N="`P+T]R M9&5R:6YG*$ED96YT:71Y*2]296=I2A!9&]B92D^/B]$5R`Q,#`P+U1Y M<&4O1F]N=#X^#65N9&]B:@TR,3(@,"!O8FH-/#PO1FEE;&1S6UTO1$$H+TAE M;'8@,"!49B`P(&<@*2]$4CP\+T9O;G0\/"](96QV(#(Q-"`P(%(O6F%$8B`R M,3,@,"!2/CXO16YC;V1I;F<\/"]01$9$;V-%;F-O9&EN9R`R,34@,"!2/CX^ M/CX^#65N9&]B:@TR,3,@,"!O8FH-/#PO4W5B='EP92]4>7!E,2].86UE+UIA M1&(O0F%S949O;G0O6F%P9D1I;F=B871S+U1Y<&4O1F]N=#X^#65N9&]B:@TR M,30@,"!O8FH-/#PO4W5B='EP92]4>7!E,2].86UE+TAE;'8O0F%S949O;G0O M2&5L=F5T:6-A+T5N8V]D:6YG(#(Q-2`P(%(O5'EP92]&;VYT/CX-96YD;V)J M#3(Q-2`P(&]B:@T\/"]$:69F97)E;F-E"])9&EE')E9@T*,"`R,3D-"C`P,#`P,#`P M,#$@-C4U,S4@9@T*,#`P,#`P,#`P,B`P,#`P,"!F#0HP,#`P,#`P,#`S(#`P M,#`Q(&8-"C`P,#`P,#`P,#0@,#`P,#`@9@T*,#`P,#`P,#$U-B`P,#`P,2!F M#0HP,#`P,#`P.3,W(#`P,#`P(&X-"C`P,#`P,#$R,#@@,#`P,#`@;@T*,#`P M,#`P,#`P."`P,#`P,"!F#0HP,#`P,#`P,34T(#`P,#`P(&8-"C`P,#`P,#`P M,3`@,#`P,#$@9@T*,#`P,#`P,#`R-R`P,#`P,2!F#0HP,#`P,#`R.3,R(#`P M,#`P(&X-"C`P,#`P,#(Y.#0@,#`P,#`@;@T*,#`P,#`P-S`P-R`P,#`P,"!N M#0HP,#`P,#`P,#`P(#8U-3,U(&8-"C`P,#`P,#`P,30@-C4U,S4@9@T*,#`P M,#`P,#`Q-2`V-34S-2!F#0HP,#`P,#`W,C,X(#`P,#`P(&X-"C`P,#`P,#F4@,C$Y+U)O;W0@,3,P(#`@4CX^#0IX MF4@,C$Y+U!R978@,C4Q-SDO6%)E M9E-T;2`V,C,O4F]O="`Q,S`@,"!2+TEN9F\@,3,@,"!2+TE$6SPT-C)#13`V M.$4R-35$,#E%-C,X-$-#0S%LR-C$@,5TO1&5C;V1E4&%R;7,\/"]#;VQU M;6YS(#,O4')E9&EC=&]R(#$R/CXO4VEZ92`R-C(O5'EP92]84F5F/CYS=')E M86T-"GC:8F(LB0,(,``!50#6#0IE;F1S=')E86T-96YD;V)J#34@,"!O8FH- M/#PO0W)O<$)O>%LP(#`@-C$R(#%LP M(#`@-C$R(#'1'4W1A=&4\/"]'4S`@,3,V(#`@4CX^/CXO5'EP92]086=E/CX- M96YD;V)J#3$R(#`@;V)J#3P\+U-U8G1Y<&4O6$U,+TQE;F=T:"`S.30U+U1Y M<&4O365T861A=&$^/G-TFMC.60B/SX*/'@Z>&UP;65T82!X;6QN M#IX;7!T:STB061O8F4@6$U0($-O&UL;G,Z<&1F M>#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&9X+S$N,R\B/@H@("`@("`@("`\ M<&1F>#I3;W5R8V5-;V1I9FEE9#Y$.C(P,3$P.#`Y,C,U.#`T/"]P9&9X.E-O M=7)C94UO9&EF:65D/@H@("`@("`\+W)D9CI$97-C&UL M;G,Z>&%P/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@ M("`@/'AA<#I#&%P.D-R96%T;W)4;V]L/@H@("`@("`@("`\>&%P.DUO9&EF>41A M=&4^,C`Q,2TQ,2TP.%0P.3HQ.3HP,2TP.#HP,#PO>&%P.DUO9&EF>41A=&4^ M"B`@("`@("`@(#QX87`Z0W)E871E1&%T93XR,#$Q+3`X+3`Y5#$V.C4X.C,R M+3`W.C`P/"]X87`Z0W)E871E1&%T93X*("`@("`@("`@/'AA<#I-971A9&%T M841A=&4^,C`Q,2TQ,2TP.%0P.3HQ.3HP,2TP.#HP,#PO>&%P.DUE=&%D871A M1&%T93X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S M8W)I<'1I;VX@&%P M34TZ&%P34TZ&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD M/2)W(C\^#0IE;F1S=')E86T-96YD;V)J#3$S(#`@;V)J#3P\+T-R96%T:6]N M1&%T92A$.C(P,3$P.#`Y,38U.#,R+3`W)S`P)RDO075T:&]R*$)I;&PI+T-R M96%T;W(H06-R;V)A="!01$9-86ME7!E+U1R=654>7!E+T9O;G1$97-CYO((@@"S+ MK8K&3BP&2!$7A2)1-AM94DBYCO]]YYOE)5EQ^B!IC]DYOSETE@U.WXLW;T[? MC2;GPA=OWYZ=C\3@]->I+VZKP6F6^4*);#GPI>_[6F1SX6%I8I$]"D5+3:_\ M>A7ZJ4SB-!6Q#B4]NQ]\=L;?[XHOQ4X$6KJAHUTO<(3[5_;[8/P.@CKAJA'. MHI)65!A`E*<3J92A7QF:4&0+8CT:7V>3BXD;.R/7.$/Z9&[@3*XNQ?N/M+F> MNI&#Q?`R$ZX7T6WJ7%GAS%D%$(*53B!#2QV'PE-2U0*4ZQDG<;4C/LJI'&$G M28*8CEFF!X$*`K$4)(T?!*'?$]+*@-:/X&Y\Q4*,L5*&KA?[RA4!7TVV#(%J?>($]S]=13%5=."#A4>+#RP,=,N:+H,>MWF) M]2?QCDZAP0*G),F=E^S<>Z_Y.4^R6=V7M#X M]H0V0C<[N%RQ_C"U0IXM8=>J#MGB_V!@FL/_C`)R"KFP@1$X5&*V9B[C[Z"Z M:["RON6WHP9M]Y3/'!D\K*K"PF/3A/(P-HM9@S/L[O(2W"Q4$&_04L`M\A)G MBW<)7&&A+@# M[Y^5R.#-!C7D*[XJ!BE)GN!BC:-=SD3%/95',;K#49$O.?,O"J:8<4;.B]E* M7&'/E_Q5S.UCSA5[99VR8SZY&/$I6&^9$_-[8@WJI[N".='9]H$/JH>.CHM(V*@91R7X9$!2>!:+QQW3&LK]T)N:5AY,K$O`=^Q6U ME/R)(.&AM``Q^\[5/ANI3X3E.2.M";Y6\7N`[XDX"([V>O,(-JM\<UOZX MSK>L>J]43F@/CALSA$*Z*O!*/A359--XL\V_\HJ`,]&)+GMM05J)S M644UHFV;.FA+I.8.I:DSA3%9PAKN"GZWYHE!!3?.C*KTIA0,L)`\>^,PF.@4 M%)3U'6?30B$%XT2:.&WXMCI3P;(8+':P:M%J\.LK5RV M1,YVZ$AU]29$L*S#"MMD2EUBI3@>YK`=LUF9>B:--$]H43\/3,<<9;3 MP&.''<.C?#_7.8_%U7+)LTXMKC&NS:$N64P0P`@3I3)^,5V2?KJH[@^O5?IY M@Y7D($.9F%@'G==#:."\1E7XZ4P?2Z6IV'0LG,O-OSE&=J',_K@22I.$3=GD M68W^#X:]>?UH94F?5Y;C1JA8ZB#5G6=.1_IOOU6;QHSZ!:WL"U\C2XG^#=SS M]H@SE=])IT(6H-:>'Y!3A?A/@`$`\27,70T*96YD')E9@T*,"`P#0IT M%LR-C8@,5TO1&5C;V1E4&%R;7,\/"]#;VQU;6YS(#,O4')E M9&EC=&]R(#$R/CXO4VEZ92`R-C%LP(#`@-C$R(#%LP(#`@-C$R(#'1'4W1A=&4\/"]'4S`@,3,V(#`@4CX^/CXO5'EP92]086=E M/CX-96YD;V)J#3$R(#`@;V)J#3P\+U-U8G1Y<&4O6$U,+TQE;F=T:"`S.30U M+U1Y<&4O365T861A=&$^/G-TFMC.60B/SX*/'@Z>&UP;65T82!X M;6QN#IX;7!T:STB061O8F4@6$U0($-O M&UL;G,Z M<&1F>#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&9X+S$N,R\B/@H@("`@("`@ M("`\<&1F>#I3;W5R8V5-;V1I9FEE9#Y$.C(P,3$P.#`Y,C,U.#`T/"]P9&9X M.E-O=7)C94UO9&EF:65D/@H@("`@("`\+W)D9CI$97-C&UL;G,Z>&%P/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@ M("`@("`@/'AA<#I#&%P.D-R96%T;W)4;V]L/@H@("`@("`@("`\>&%P.DUO9&EF M>41A=&4^,C`Q,2TQ,2TQ-%0R,3HQ-3HP,2TP.#HP,#PO>&%P.DUO9&EF>41A M=&4^"B`@("`@("`@(#QX87`Z0W)E871E1&%T93XR,#$Q+3`X+3`Y5#$V.C4X M.C,R+3`W.C`P/"]X87`Z0W)E871E1&%T93X*("`@("`@("`@/'AA<#I-971A M9&%T841A=&4^,C`Q,2TQ,2TQ-%0R,3HQ-3HP,2TP.#HP,#PO>&%P.DUE=&%D M871A1&%T93X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z M1&5S8W)I<'1I;VX@&%P34TZ&%P34TZ&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@ M96YD/2)W(C\^#0IE;F1S=')E86T-96YD;V)J#3$S(#`@;V)J#3P\+T-R96%T M:6]N1&%T92A$.C(P,3$P.#`Y,38U.#,R+3`W)S`P)RDO075T:&]R*$)I;&PI M+T-R96%T;W(H06-R;V)A="!01$9-86ME7!E+U1R=654>7!E+T9O;G1$97-C@R"` M+"NMBL9*+`9($1<%(U$V&YE22+F._[YS9KDD)2MN'R3M97;N%)VZ;T7F6>4**;#WR7,_SE,B6PL$RB$7V*"0M M%;WRVE7HI6X2IZF(5>C2L_O1%VOZXZ[\6NZ%KUP[M)3M^):P_\Q^&TW?0U`O M7!KA+"KI1(4^1#DJ<:4,Z-<-@U!D*V(]F5YGLW+3[`B>TE])W*].!GJOYA.,KB#V*;@[Y$I$0N:OQ/9KU-< M+,;7%^.KZ<*9?_Y]^H<83S)<*H_IE=;J5+A4ERM9)OLU7K.*4D$LM_1=\<>15K'<4ZA*^FRQ90I2[Q$GN+G#J>A6A9U8XB,1/6"7 MTZ[&`O<%65EO:/$$'M?MR0[2:MR#[=;P?[>M[VU),95TX(&%0XN/+`QTZY8N M@QZW18WU9_&>3J'!"J=+6N0D`2+/Q,P8M'1!>Z.5+\2KB2T]:\O"=GD%W5[= MV`+\63,RC>ZU;7CX_8&-8H-Z:W:MX%H[*K166E-$B-T?]>Z7<+]G\N&2_%Y4 M*]9:TU/@E`ZSO[>Q!+DJ+WAN3^:U$?DGQAQ_C&;V>T$,9?I#U#=F3RH;OGMQ&32/=4J M>QT/FZ;4H=^:,!W[?96;',+NKJC!3:)&(@)1) M%`%^@3;J$&TN:M3T=@M4^8:OAM.6])WAHL+1OF"B\IX`4TSN<%06:\:"=R53 MY%RCRS+?B#GV?,E?Y5(_YNK15]J5>^93B`F?@O6..3&_)]:@?;HOF1.=[1[X MH'GH*?=BSPP8;A.S8I!T04LX[8H;%<021X3%^#D3.:7+"LOM3ENX,D]WS%S+ M(5=H43H[#J6!*=:I%^DC99V,I4R[6`8MY"LZZW"9LDD<5Y)QSB)G1;[V]A:- M@Y,Y2?N!_88Z3O%$6>4`>9!TAYY6'ENLSH3FF9,)5`':BGOD[Q-Q$!SZ:OL( M-IMB=M]`O>^&J7_0@J7V.U[]]S#@!-(-D8T!_4C-@+&U-?ZZV+&: M-9NTYDAL-D]H%)PQI#L';U,6C7@LM7W"N*XNOO.+DBK6B35YH8/8B-X_#6%* MUT*5W\&EXFZEE.M3#7E:N7W)[RJ>'J1_8^6$V-M:L-4AN?'&XC2B4U`02O2< M@RX)4C!.W"!.#=].9P(XG7WE'C9-.<)+';=*Q\1V=/F,EWN!Q"%%4L[L0"=V M!_U>)U$R\CN^U(VWGP=0!.07Q8U@=08`/1WQP$1N>DH,?*RIJS8=65;-";. M9\/Q*.S4YLCZ/'^T$2BI)"J&J7RST67!D$;(!TRKBV;'G)?@B?JYXRV++ZN\ MZJH/U,LM-2)`']L8&,;\LP*O!ZXR2L.!=G&GG1Z36OT&T>IS5F.6!L=\CP[6 MXC9E!,LZQE93*2VXNN)TF,-NY&9E6K"*%$]K4:K1BK%*MI5-;89NJ+8#5V&. MI:K6!,>LH^$T/RBS*#GUQ\'W8I<:U)#M%^O<#GEP..=1@>IKK-MH02GU*,8N M145GG&)HN;OF>&$JYQ&'3WF M!#S6#VN=ZUC,UVN>9TR;)V%5^JGH_G4_47UZG:YJ8%[32+SR%FB7Z M-W#6VQ.NE5XOG6#-!_)>'I$37OPKP`!!X](3#0IE;F1S=')E86T-96YD;V)J M#7AR968-"C4@,0T*,#`P,#`S.#4Y,R`P,#`P,"!N#0HQ,B`R#0HP,#`P,#,X M.#DP(#`P,#`P(&X-"C`P,#`P-#(Y,3,@,#`P,#`@;@T*,C8R(#(-"C`P,#`P M-#,Q-#0@,#`P,#`@;@T*,#`P,#`T-#,R-"`P,#`P,"!N#0HR-C4@,@T*,#`P M,#`T-#4V-"`P,#`P,"!N#0HP,#`P,#`P,#`P(#8U-3,U(&8-"G1R86EL97(- M"CP\+U-I>F4@,C8W+U!R978@,S@Q-#@O4F]O="`Q,S`@,"!2+TEN9F\@,3,@ M,"!2+TE$6SPT-C)#13`V.$4R-35$,#E%-C,X-$-#0SF4@,C8W+U!R978@-#8S.38O6%)E9E-T;2`S.#,S M,2]2;V]T(#$S,"`P(%(O26YF;R`Q,R`P(%(O241;/#0V,D-%,#8X13(U-40P M.44V,S@T0T-#-S4X1D,V,CDT/CQ!,C')E9@T*-#8W,#`-"B4E14]�HS,#`@,"!O M8FH-/#PO3&5N9W1H(#$T+U)O;W0@,3,P(#`@4B])1%L\-#8R0T4P-CA%,C4U M1#`Y138S.#1#0T,W-3A&0S8R.30^/#1&039%-$5"0CA!0D%$-#7!E+UA2968^/G-T-IB M8MRN#!!@``&@`-X-"F5N9'-T'1=+T5X=$=3=&%T93P\ M+T=3,"`Q,S8@,"!2/CX^/B]4>7!E+U!A9V4^/@UE;F1O8FH-,3(@,"!O8FH- M/#PO4W5B='EP92]834PO3&5N9W1H(#,Y-#4O5'EP92]-971A9&%T83X^G)E M4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE M=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C`M8S,R,2`T-"XS.3@Q M,38L(%1U92!!=6<@,#0@,C`P.2`Q-#HR-#HS.2(^"B`@(#QR9&8Z4D1&('AM M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&%P+S$N,"\B/@H@("`@("`@("`\>&%P.D-R96%T;W)4 M;V]L/D%C&%P.DUE=&%D871A1&%T93XR,#$R+3`U+3$R M5#$U.C,Q.C0R+3`W.C`P/"]X87`Z365T861A=&%$871E/@H@("`@("`\+W)D M9CI$97-C&UL;G,Z>&%P34T](FAT='`Z+R]N&%P+S$N,"]M;2\B/@H@("`@("`@("`\>&%P34TZ1&]C=6UE;G1) M1#YU=6ED.F9F.&-E,6%D+35B.6$M-&(U,BUB-30Q+6(X861C,S1B8V%A93PO M>&%P34TZ1&]C=6UE;G1)1#X*("`@("`@("`@/'AA<$U-.DEN&UL;G,Z M9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL.FQA;F<](G@M9&5F875L="(O/@H@("`@("`@("`@("`\ M+W)D9CI!;'0^"B`@("`@("`@(#PO9&,Z=&ET;&4^"B`@("`@(#PO#IX;7!M971A/@H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0](G2A4 M:6UE7!E+U1R=654>7!E+T9O;G1$97-C1DATGZSY8YLOQ7I^[ M(R^RT?E']N[=^?5D=LE\]O[]Q>6$CCT$]Y$JH'#W#^S MWT;3:Q34"Q=&.(E*K*@P0%&>3+@0"OYYJ$*6+8'U9'J3S:YF;NQ,7.6,X9>Y M@3.;?V`?/\/D9N%&#@[&'S+F>A'LILY<"R?.(D`A.)()RI!=`.%Z MRDE5YD=E6[B ML$]`](BS'&8-#G"_!"N;-0R>D,=-M[)%:0WN(]N-X7^U:1Y<`3$5L.`C"P\& MGT@8TJTZN@SUN"L;'']AU["*&BQQM8!!#A)0Y!F;&8,*CK2W6OF2O9FXPGSO_%0H`^!P_5< M=?/BOEOHX/"5'!<!(E()F`<08'F#21$,='Y>%10!08V1UEZ*X6 M(YP8E#^!@K1K4L. M0\B=L7&732(/NZ*XB3K"V?:2% M]K&GW+$=,:!2GY@1%6B.M-`C.+N5*A:X!'T`_\Y8#A!:XG"SU18NS=$M,==R MP!5:E$;,H31DBN/4C_22=$[&5Z0VODJW32YAS?8$0!@[SE+CG$5.BGSK[2U; M#U?F(.T'SM?0[.AIZ9/%\HQIGCF8`%FAK7A`3#\!!T:AKS=[ M9+,NEW.H0C6$4**!T] M8V51D"+?A*LXM872QKLL-/RJ'9HTI1`7.G"U#HKKZ?P9%SN&R`%%4H*VTLBV M?<>W$@6U'2\0NNOWEQ',`G"+I"ZT/,.J>CKDRH1,''WZ[R@F@:E#XM:4[9;XEP@3TR@>YJ2^*K. M:YM^2%ULH#MA[2,;E6%,?TOD]4AI!B@<:!=;[?0=K=-O$*T>LKIHZ>J8[["M M=84;$$&RCHNK292NNG)V.LRAO>^3,MWE.))T58Q27:ZH6(DNJZ'#P`[DM>(2 M+]'8FXC@F'4T?$H,LBQ*3O6\P(\Y]*8AVZ_.N1O2;>*<[@^07V/=6TN`U)Z- M.42%76`_QJ:\^:<=V#B%-]4$WD]%"RZ.H)D.OZPMZE$G4:62IQ&`0T&/A'VX MO#?E"._1Z(6[G@RB`]N0U?0AFH,]Y""2P:[/DU0`AU"A1T]S,%)>HQE(D68O M>%'$6'='KQ.XB5@L1*]@0278*#02 MNL!#\I4F\(B'"\@`7-P@`$S\05HX[,:A%1<\NXS/*$4QYQ^(X82R'.XZ^IZC MZ$TQS'7*8S9?K>B:TXDSQMDN%Q$7,AH=CT+.!I\73TMF#FE1!U"^'QJ\%/^E<# M5D9XL8;_Y\5PVA7I\Z)TVGX1F4@,S(W+U1Y<&4O6%)E9CX^7!E+UA-3"],96YG=&@@,SDT-2]4>7!E+TUE=&%D871A/CYS=')E M86T-"CP_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T M82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#0N,"UC,S(Q(#0T+C,Y.#$Q M-BP@5'5E($%U9R`P-"`R,#`Y(#$T.C(T.C,Y(CX*("`@/')D9CI21$8@>&UL M;G,Z&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D M9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0#I3;W5R8V5-;V1I9FEE9#X*("`@ M("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@ M&%P.D-R M96%T941A=&4^,C`Q,2TP."TP.50Q-CHU.#HS,BTP-SHP,#PO>&%P.D-R96%T M941A=&4^"B`@("`@("`@(#QX87`Z365T861A=&%$871E/C(P,3(M,#&%P34TZ26YS=&%N8V5)1#YU M=6ED.F-A,#0X,C,W+3(R8F,M-#4T,2UA-#`S+3%F8CEF-F$U,&)D-SPO>&%P M34TZ26YS=&%N8V5)1#X*("`@("`@("`@/'AA<$U-.G-U8FIE8W0^"B`@("`@ M("`@("`@(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@("`\"UD969A=6QT(B\^"B`@("`@("`@("`@(#PO M7!E M+T9O;G1$97-CO6.2)!,SU M7KR"((`L*ZV#)DHL!D@1%P4C439;F5)("8[_?6=FN20ERT;Z8'FY.SOG-\=> M9*/S3^S-F_,/DZM+)MC;MQ>7$S8Z_VTNV&TS.L\RP23+5B/!A1"*90L6X-+$ M+'M@$I8*;HEV%8J4)W&:LEB%'*[=C[YYTY]WY?=RQ[3B?N@I/]`>\__*WH^F M'U!0+UPZX20JZ42%&D4%*N%2&OC/0Q.R;`FL)]/K[.K=E1][$]]X8_C+?.U= MS3ZR3U_@XWKN1QXNQA\SY@<1G*;>S`HGSE*C$%RI!&4HKN*0!9++5H#T`^,E MOO+8%S[G$_SB(('-IR0S0($2!>*2@32ZH$,Q$-+)0*T?D+L1DH088Z6,_2#T MYH[%^!(_9Y^R*2W0%/AW/?^"5F0OJ1]$7,3)4/_Y=)*A.X!MBOP%F!*1H-D[ MEOT^Q8/Y^/IB_'$Z#V9?_YC^R<:3#`^5('IEM3H5+M5A)W?@,^9-F8!J<6]OPXH\]&44&]=9L6\&U=53H+:VF&"%R?]2[7Z+[ MA&!&Q"),NB2+,9._]OBK\[)]!O+^19_01 M,_#B`97F(DF!-47^#"XPY5PMW57=7E6'5P$R8$5[E:$_&DS&%1J_;N.Z_!6@ MS`L,$D$%/`=^=EA##@W+*^(R_8E4=PY0U2W=G3A(WD/24_CP8M.4%D,;%^_C M`"YS!T;\NBMJY&;QA*!`6D"%A6?B;?$>`<'!^!54FAN?'(:8.F/C-EV6-8+@ M@751--9;%'6E7%'0SY1HKA,5LTA&/%9(`Z$=`U2/(GM18]G9;$C&K^!#\#`Y M*&O_(H.&<@)LN,)*4N'6KJAQ7=Y#-6:3.]PJBQ45FG14`!9EOF8S_*9# M^BD7]C*EICVR[MT1GX)-:!=9;XD3\7LD#=JKNY(XP=YV3QO-OJ? MN!558(ZTT`0XNU$FEK@%A1[_G;$<(+0D?VVMA4MW=4O,K1QPA15E$7,H#9GB M.A61W5+>R?C*M(NOH?*J.82\J_D`L">A=+Z9YZ3']][X3T(W!@%/EJ\X!LUL7RED2]/MU& MM&LCFH>I/FCOLG6[M@7X[B04GXX<@1'@#&`E#0^EM+P*=EUL2<^:;%I1)-;K M1^Q"A!A0GH*W+HN&/9360.9\5Q<_Z$8)61S$EKRP06Q8[Z`&ZDS7GY7N:K&B M5J@$3TWBZMFNI'L5C292WW@YM(--SRD M[>K]L(%)`'Y1U&669UA43X?PKVJM55BYXL\>[USTQ$P\K(&5&R[M"T:%^>SX>P5=FI39#4- M-VT$2LB)BLI4OE[;O*"2!I4/:UI=-%OBO$">F$!W]$GBRRJONO1#ZL4&FA.6 M/K+1.,;T;XF\]I1F`,.!=G&GG9W!6OT&T>HQ:VN6+8[Y#KM:6[GPQQV\SPITPZ_D:)1,$IMN:)B)=N$AL8")Y#2ABL_K%E4HU:B215/(P"'X084XC"!)*H%#:-"CISDX*2_1#*0H=Z:?%?&4Y,@.,O>) M&I;/,SYQ9)V84SPN#EZI<0^LVZ/7AY(]%J(7L&`2R55DD=`&'I*O<(%'/%Q` M!N#F!@'@X@_2PF$S#CMQ^LFP?44IBCE_3PPGE.4PZM@QQ]";89CKE,=LMEK1 ME-.*<\9U.=0GB]$:C3!1RN,7TR49I@O@J'LAZ&Z^Q M*G2>B)YY/,1<*B@V/0MOO+_=-SLWF+3C#/1W^QV=?C<`Y$W_;L#B"(_2\/^\ M&4Y[(WU:ETZ[0,9$PAP'^C?HW+')E9@T*-2`Q M#0HP,#`P,#4W,C(T(#`P,#`P(&X-"C$R(#(-"C`P,#`P-3')E9@T*,"`P#0IT73X^#0IS=&%R='AR968-"C8V.#4R#0HE)45/1@T* ` end EX-101.INS 10 cdom-20120630.xml XBRL INSTANCE DOCUMENT 0000925741 2010-12-31 0000925741 2011-12-31 0000925741 2012-06-30 0000925741 2012-04-01 2012-06-30 0000925741 2011-04-01 2011-06-30 0000925741 2012-01-01 2012-06-30 0000925741 2011-01-01 2011-06-30 0000925741 2011-06-30 0000925741 2012-08-10 0000925741 CDOM:ReconstructiveDivisionMember 2011-04-01 2011-06-30 0000925741 CDOM:ReconstructiveDivisionMember 2011-01-01 2011-06-30 0000925741 CDOM:ReconstructiveDivisionMember 2012-06-30 0000925741 CDOM:SpineDivisionMember 2011-04-01 2011-06-30 0000925741 CDOM:SpineDivisionMember 2011-01-01 2011-06-30 0000925741 CDOM:SpineDivisionMember 2012-06-30 0000925741 CDOM:ReconstructiveDivisionMember 2011-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares CDOM:Years xbrli:pure Tiger X Medical, Inc. 0000925741 10-Q 2012-06-30 false --12-31 No No Yes Smaller Reporting Company Q2 2012 230293141 127000 12678000 12884000 12692000 67000 24000 89000 32000 13734000 12940000 756000 142000 756000 142000 230000 230000 25810000 25814000 50000 50000 -13012000 -13196000 12978000 12798000 13734000 12940000 278000 250000 0.001 0.001 750000000 750000000 230293141 230293141 230293141 230293141 <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 1 &#151; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Tiger X Medical, Inc. (&#34;Tiger X&#34; or the &#34;Company&#34;), formerly known as Cardo Medical, Inc., previously operated as an orthopedic medical device company specializing in designing, developing and marketing high performance reconstructive joint devices and spinal surgical devices.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As discussed below in the discontinued operations section, we sold our Reconstructive and Spine Divisions during the quarter ended June 30, 2011. Our continuing operations include the collection and management of our royalty income earned in connection with the Asset Purchase Agreement with Arthrex, as well as continuing to promote our former products sold to Arthrex and seek a joint venture partner or buyer for the remaining intellectual property owned by the Company. The Company will also be evaluating future investment opportunities and uses for its cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The accompanying condensed consolidated balance sheet as of December 31, 2011, which has been derived from the Company's audited financial statements as of that date, and the unaudited condensed consolidated financial information of the Company as of June 30, 2012 and for the three and six months ended June 30, 2012 and 2011, has been prepared in accordance with accounting principles generally accepted in the United States of America (&#34;U.S. GAAP&#34;) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. In the opinion of management, such financial information includes all adjustments considered necessary for a fair presentation of the Company's financial position at such date and the operating results and cash flows for such periods. Operating results for the interim period ended June 30, 2012 are not necessarily indicative of the results that may be expected for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Certain information and footnote disclosure normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the United States Securities and Exchange Commission (&#34;SEC&#34;). These unaudited financial statements should be read in conjunction with our audited financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 filed on March 29, 2012.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Principles of Consolidation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The condensed consolidated financial statements include the accounts of Tiger X Medical, Inc., Accelerated Innovation, Inc. (&#34;Accelerated&#34;), Uni-Knee LLC (&#34;Uni&#34;) and Cervical Xpand LLC (&#34;Cervical&#34;). All significant intercompany transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Discontinued Operations</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On October 7, 2010, the Company's management and Board of Directors decided to put substantially all of its assets up for sale. The assets determined to be held for sale were inventories, intellectual properties, and property and equipment of its reconstructive products line (the &#34;Reconstructive Division&#34;) and spine products line (the &#34;Spine Division&#34;). The Company decided to put the assets of its Reconstructive and Spine Divisions up for sale primarily because it did not have sufficient working capital, and was not able to procure such financial resources through equity or debt financing, in order to fully execute a profitable sales strategy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On January 24, 2011, the Company entered into an Asset Purchase Agreement with Arthrex, Inc. (&#34;Arthrex&#34;) (the agreement being the &#34;Arthrex Asset Purchase Agreement&#34;), pursuant to which the Company agreed to sell the assets of the Reconstructive Division to Arthrex. The Arthrex Asset Purchase Agreement also provides for the Company to receive royalty payments equal to 5% of net sales of the Company's products made by Arthrex on a quarterly basis for a term up to and including the 20th anniversary of the closing date. During the three and six months ended June 30, 2012, the Company received total royalty payments of $17,000 and $28,000 from Arthrex and reflected this payment as revenue on the accompanying condensed consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company completed the sale of the Reconstructive Division on June 10, 2011. The total cash consideration received by the Company from Arthrex amounted to $14,586,000, which was comprised of $9,960,000 plus inventory with a value of $2,908,000 and property and equipment with a value of $1,718,000. From this amount, $1,159,000 was deposited with an escrow agent to be held for twelve months for any potential adjustments to the purchase price relating to future adjustments to the value of the inventory and property and equipment and other unasserted claims. The total gain on the sale of the Reconstructive Division assets as of June 30, 2011 amounted to $10,527,000, which represents the excess of the cash consideration over the carrying amount of the assets sold of $4,059,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On April 4, 2011, the Company entered into and closed an Asset Purchase Agreement with Altus Partners, LLC, a Delaware limited liability company (&#34;Altus&#34;), pursuant to which the Company sold substantially all of the assets of the Spine Division in exchange for cash consideration of $3,000,000 (the &#34;Altus Asset Purchase Agreement&#34;). Pursuant to the terms of the Altus Asset Purchase Agreement, $2,700,000 of the purchase price was paid at the closing and $300,000 was deposited into escrow with an escrow agent for a period of 90 days from the closing date (assuming there are no disputes) to be used for any adjustments to the closing value of the Company's inventory and property and equipment. The total gain on the sale of the Spine Division assets as of June 30, 2011 amounted to $2,286,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The total gain associated with the above sales of the assets of the Reconstructive and Spine divisions amounted to $12,253,000, which is presented net of the income tax expense effect of $560,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Pursuant to the sale transaction with Arthrex, the total aggregate amount remaining in escrow accounts as of December 31, 2011 was $900,000, which is reflected as restricted cash on the accompanying condensed consolidated balance sheets. As of June 30, 2012, there were no amounts remaining in the escrow accounts relating to the sales transaction with Arthrex or Altus.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $214,000, respectively. Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $761,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $1,170,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $1,366,000, respectively. The continuing operations reflected are expenses associated with business insurance, legal and accounting fees that the Company will continue to incur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Financial statements prepared in accordance with U.S. GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Among other things, management makes estimates relating to allowances for doubtful accounts, share-based payments and deferred income tax assets. Given the short operating history of Tiger X, actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Revenue Recognition</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company's revenue consists of royalty revenue from the Arthrex Asset Purchase Agreement, which is recognized as the amount becomes known and collectability is reasonably assured.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Net Income (Loss) Per Share</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Basic net income (loss) per share is computed by using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental common shares issuable upon exercise of stock options or warrants. No dilutive potential common shares are included in the computation of any diluted per share amount when a loss from continuing operations is reported by the Company because they are anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Income Taxes</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The likelihood of realizing the tax benefits related to a potential deferred tax asset is evaluated, and a valuation allowance is recognized to reduce that deferred tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are calculated at the beginning and end of the year; the change in the sum of the deferred tax asset, valuation allowance and deferred tax liability during the year generally is recognized as a deferred tax expense or benefit. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company evaluates the accounting for uncertainty in income tax recognized in its financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its financial statements. For those tax positions where it is &#34;not more likely than not&#34; that a tax benefit will be sustained, no tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has not accrued for any such uncertain tax positions as of June 30, 2012 (unaudited) or December 31, 2011.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Reclassifications</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Certain amounts from prior periods have been reclassified to conform to the current period presentation due to the treatment of discontinued operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Concentration of Credit Risk</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The cash and cash equivalents held in the Company's business money market and escrow bank accounts are with local and national banking institutions and subjected to current FDIC insurance limits of $250,000 per banking institution. As of June 30, 2012, the Company bank balances in these bank accounts exceeded the insured amount by $12,582,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Recent Accounting Pronouncements</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 3 &#151; STOCKHOLDERS' EQUITY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our authorized capital consists of 750,000,000 shares of common stock and 50,000,000 shares of preferred stock. Our preferred stock may be designated into series pursuant to authority granted by our Certificate of Incorporation, and on approval from our Board of Directors. As of June 30, 2012 and December 31, 2011, we did not have any preferred stock issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> 0 25000 553000 0 230293141 230293141 230293141 230293141 900000 0 <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 2 &#151; SHARE BASED PAYMENT</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On August 29, 2008, the Company issued options to certain employees and Board members to purchase membership units in the Company. The options give the grantees the right to purchase up to 2,398,400 shares of the Company's common stock at an exercise price of $0.23 per share. The options vest 20% each year over a five-year period and expire after ten years. The weighted average grant date fair value of options granted was $0.13 per option. Stock option compensation recognized for the three months ended June 30, 2012 and 2011 in the accompanying condensed consolidated statements of operations amounted to $2,000 and $11,000, respectively. Stock option compensation recognized for the six months ended June 30, 2012 and 2011 in the accompanying condensed consolidated statements of operations amounted to $4,000 and $22,000, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As a result of the sale of substantially all of the Company's assets in the second quarter of 2011, other than the CEO, the Company no longer has any employees. As a result, the only options expected to vest are those held by the Company's Board of Directors and CEO. As a result, the estimated forfeiture rate has been adjusted to 75.6%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A summary of stock option activity as of June 30, 2012, and changes during the period then ended is presented below.</p> <table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 52%; padding: 0.75pt">&#160;</td> <td style="width: 8%; padding: 0.75pt">&#160;</td> <td style="width: 1%; padding: 0.75pt">&#160;</td> <td style="width: 1%; padding: 0.75pt">&#160;</td> <td style="width: 11%; padding: 0.75pt">&#160;</td> <td style="width: 1%; padding: 0.75pt">&#160;</td> <td style="width: 13%; padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Weighted-</td> <td style="width: 1%; padding: 0.75pt">&#160;</td> <td style="width: 1%; padding: 0.75pt">&#160;</td> <td style="width: 11%; padding: 0.75pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Weighted-</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Average</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Average</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Remaining</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Aggregate</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Exercise</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Contractual</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Intrinsic</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding: 0.75pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Options</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Price</td> <td style="padding: 0.75pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Life (Years)</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; font-size: 10pt; font-weight: bold; text-align: center">Value</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">Outstanding at December 31, 2011</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">385,000</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">$</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">0.23</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">6.67</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">$</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">Granted</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">Exercised</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td></tr> <tr style="vertical-align: top"> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">Forfeited</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; font-size: 10pt; text-align: right">-</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td></tr> <tr style="vertical-align: top"> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">Outstanding at June 30, 2012 (unaudited)</td> <td style="border-bottom: black 2.25pt double; padding: 0.75pt; font-size: 10pt; text-align: right">385,000</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">$</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">0.23</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">6.17</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">$</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">Vested and expected to vest</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">at June 30, 2012 (unaudited)</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">385,000</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">$</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">0.23</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">6.17</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">$</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white">&#160;</td> <td style="padding: 0.75pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">Exercisable at June 30, 2012 (unaudited)</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">231,000</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">$</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">0.23</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">6.17</td> <td style="padding: 0.75pt">&#160;</td> <td style="padding: 0.75pt; background-color: white; font-size: 10pt">$</td> <td style="padding: 0.75pt; font-size: 10pt; text-align: right">-</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company had 575,613 warrants outstanding as of June 30, 2012 which entitle the holders to immediately purchase one share of the Company's common stock at an exercise price of $0.44 per share. The warrants expire on November 13, 2014.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> 17000 0 28000 0 0 0 0 0 17000 0 28000 0 149000 249000 218000 350000 -132000 -249000 -190000 -350000 3000 2000 6000 -22000 -129000 -247000 -184000 -372000 0 0 0 0 -129000 -247000 -184000 -372000 0 -1170000 0 -1366000 -129000 10836000 -184000 10515000 0.00 0.00 0.00 0.00 0.00 0.05 0.00 0.05 0.00 0.05 0.00 0.05 2000 11000 4000 22000 43000 -38000 0 85000 57000 64000 -614000 -826000 -694000 -2365000 0 137000 900000 15430000 0 1224000 0 1724000 0 -500000 206000 12565000 0 12253000 0 12253000 0 44000 0 12253000 0 184000 0 -193000 0 31000 -900000 1459000 0 17026000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Tiger X Medical, Inc. (&#34;Tiger X&#34; or the &#34;Company&#34;), formerly known as Cardo Medical, Inc., previously operated as an orthopedic medical device company specializing in designing, developing and marketing high performance reconstructive joint devices and spinal surgical devices.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As discussed below in the discontinued operations section, we sold our Reconstructive and Spine Divisions during the quarter ended June 30, 2011. Our continuing operations include the collection and management of our royalty income earned in connection with the Asset Purchase Agreement with Arthrex, as well as continuing to promote our former products sold to Arthrex and seek a joint venture partner or buyer for the remaining intellectual property owned by the Company. The Company will also be evaluating future investment opportunities and uses for its cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basis of Presentation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The accompanying condensed consolidated balance sheet as of December 31, 2011, which has been derived from the Company's audited financial statements as of that date, and the unaudited condensed consolidated financial information of the Company as of June 30, 2012 and for the three and six months ended June 30, 2012 and 2011, has been prepared in accordance with accounting principles generally accepted in the United States of America (&#34;U.S. GAAP&#34;) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. In the opinion of management, such financial information includes all adjustments considered necessary for a fair presentation of the Company's financial position at such date and the operating results and cash flows for such periods. Operating results for the interim period ended June 30, 2012 are not necessarily indicative of the results that may be expected for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Certain information and footnote disclosure normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the United States Securities and Exchange Commission (&#34;SEC&#34;). These unaudited financial statements should be read in conjunction with our audited financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 filed on March 29, 2012.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Principles of Consolidation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The condensed consolidated financial statements include the accounts of Tiger X Medical, Inc., Accelerated Innovation, Inc. (&#34;Accelerated&#34;), Uni-Knee LLC (&#34;Uni&#34;) and Cervical Xpand LLC (&#34;Cervical&#34;). All significant intercompany transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Discontinued Operations</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On October 7, 2010, the Company's management and Board of Directors decided to put substantially all of its assets up for sale. The assets determined to be held for sale were inventories, intellectual properties, and property and equipment of its reconstructive products line (the &#34;Reconstructive Division&#34;) and spine products line (the &#34;Spine Division&#34;). The Company decided to put the assets of its Reconstructive and Spine Divisions up for sale primarily because it did not have sufficient working capital, and was not able to procure such financial resources through equity or debt financing, in order to fully execute a profitable sales strategy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On January 24, 2011, the Company entered into an Asset Purchase Agreement with Arthrex, Inc. (&#34;Arthrex&#34;) (the agreement being the &#34;Arthrex Asset Purchase Agreement&#34;), pursuant to which the Company agreed to sell the assets of the Reconstructive Division to Arthrex. The Arthrex Asset Purchase Agreement also provides for the Company to receive royalty payments equal to 5% of net sales of the Company's products made by Arthrex on a quarterly basis for a term up to and including the 20th anniversary of the closing date. During the three and six months ended June 30, 2012, the Company received total royalty payments of $17,000 and $28,000 from Arthrex and reflected this payment as revenue on the accompanying condensed consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company completed the sale of the Reconstructive Division on June 10, 2011. The total cash consideration received by the Company from Arthrex amounted to $14,586,000, which was comprised of $9,960,000 plus inventory with a value of $2,908,000 and property and equipment with a value of $1,718,000. From this amount, $1,159,000 was deposited with an escrow agent to be held for twelve months for any potential adjustments to the purchase price relating to future adjustments to the value of the inventory and property and equipment and other unasserted claims. The total gain on the sale of the Reconstructive Division assets as of June 30, 2011 amounted to $10,527,000, which represents the excess of the cash consideration over the carrying amount of the assets sold of $4,059,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On April 4, 2011, the Company entered into and closed an Asset Purchase Agreement with Altus Partners, LLC, a Delaware limited liability company (&#34;Altus&#34;), pursuant to which the Company sold substantially all of the assets of the Spine Division in exchange for cash consideration of $3,000,000 (the &#34;Altus Asset Purchase Agreement&#34;). Pursuant to the terms of the Altus Asset Purchase Agreement, $2,700,000 of the purchase price was paid at the closing and $300,000 was deposited into escrow with an escrow agent for a period of 90 days from the closing date (assuming there are no disputes) to be used for any adjustments to the closing value of the Company's inventory and property and equipment. The total gain on the sale of the Spine Division assets as of June 30, 2011 amounted to $2,286,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The total gain associated with the above sales of the assets of the Reconstructive and Spine divisions amounted to $12,253,000, which is presented net of the income tax expense effect of $560,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Pursuant to the sale transaction with Arthrex, the total aggregate amount remaining in escrow accounts as of December 31, 2011 was $900,000, which is reflected as restricted cash on the accompanying condensed consolidated balance sheets. As of June 30, 2012, there were no amounts remaining in the escrow accounts relating to the sales transaction with Arthrex or Altus.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $214,000, respectively. Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $761,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $1,170,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $1,366,000, respectively. The continuing operations reflected are expenses associated with business insurance, legal and accounting fees that the Company will continue to incur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Use of Estimates</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Financial statements prepared in accordance with U.S. GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Among other things, management makes estimates relating to allowances for doubtful accounts, share-based payments and deferred income tax assets. Given the short operating history of Tiger X, actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Revenue Recognition</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company's revenue consists of royalty revenue from the Arthrex Asset Purchase Agreement, which is recognized as the amount becomes known and collectability is reasonably assured.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net Income (Loss) Per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic net income (loss) per share is computed by using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental common shares issuable upon exercise of stock options or warrants. No dilutive potential common shares are included in the computation of any diluted per share amount when a loss from continuing operations is reported by the Company because they are anti- dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income Taxes</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The likelihood of realizing the tax benefits related to a potential deferred tax asset is evaluated, and a valuation allowance is recognized to reduce that deferred tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are calculated at the beginning and end of the year; the change in the sum of the deferred tax asset, valuation allowance and deferred tax liability during the year generally is recognized as a deferred tax expense or benefit. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company evaluates the accounting for uncertainty in income tax recognized in its financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its financial statements. For those tax positions where it is &#34;not more likely than not&#34; that a tax benefit will be sustained, no tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has not accrued for any such uncertain tax positions as of June 30, 2012 (unaudited) or December 31, 2011.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Reclassifications</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain amounts from prior periods have been reclassified to conform to the current period presentation due to the treatment of discontinued operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Concentration of Credit Risk</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The cash and cash equivalents held in the Company's business money market and escrow bank accounts are with local and national banking institutions and subjected to current FDIC insurance limits of $250,000 per banking institution. As of June 30, 2012, the Company bank balances in these bank accounts exceeded the insured amount by $12,582,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recent Accounting Pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> 50000000 50000000 0 0 250000 12582000 385000 385000 0 0 0 385000 231000 .23 .23 0 0 0 6.67 6.17 6.17 0 0 .23 .23 6.17 0 0 900000 0 214000 0 761000 0 1170000 0 1366000 17000 0 28000 0 9960000 9960000 3000000 3000000 2908000 2908000 1718000 1718000 14586000 14586000 3000000 3000000 1159000 1159000 300000 300000 2398400 P5Y 10 575613 .44 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of stock option activity as of June 30, 2012, and changes during the period then ended is presented below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="font-weight: bold; text-align: center"><b>Weighted-</b></td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center"><b>Weighted-</b></td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center"><b>Average </b></td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center"><b>Average</b></td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center"><b>Remaining </b></td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center"><b>Aggregate</b></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center"><b>Exercise</b></td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center"><b>Contractual</b></td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center"><b>Intrinsic</b></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-weight: bold">&#160;</td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"><b>Options</b></td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"><b>Price</b></td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"><b>Life (Years)</b></td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"><b>Value</b></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-weight: bold">&#160;</td> <td style="font-style: italic; text-align: center">&#160;</td> <td style="font-style: italic; text-align: center">&#160;</td> <td style="font-style: italic; text-align: center">&#160;</td> <td style="font-style: italic; text-align: center">&#160;</td> <td style="font-style: italic; text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white">Outstanding at December 31, 2011</td> <td style="text-align: right">385,000&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white">$</td> <td style="text-align: right">0.23&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">6.67&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white">$</td> <td style="text-align: right">-&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white">Granted</td> <td style="text-align: right">-&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">- &#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">- &#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">-&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white">Exercised</td> <td style="text-align: right">-&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">- &#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">- &#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">-&#160;</td></tr> <tr style="vertical-align: top"> <td style="background-color: white">Forfeited</td> <td style="border-bottom: black 1.5pt solid; text-align: right">-&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">- &#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">- &#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">-&#160;</td></tr> <tr style="vertical-align: top"> <td style="background-color: white">Outstanding at June 30, 2012 (unaudited)</td> <td style="border-bottom: black 2.25pt double; text-align: right">385,000&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white">$</td> <td style="text-align: right">0.23&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">6.17&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white">$</td> <td style="text-align: right">-&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; color: green; text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white">Vested and expected to vest</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; color: green; text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white">&#160;&#160;&#160;&#160; at June 30, 2012 (unaudited)</td> <td style="text-align: right">385,000&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white">$</td> <td style="text-align: right">0.23&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">6.17&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white">$</td> <td style="text-align: right">-&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white; text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="background-color: white">Exercisable at June 30, 2012 (unaudited)</td> <td style="text-align: right">231,000&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white">$</td> <td style="text-align: right">0.23&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">6.17&#160;</td> <td style="text-align: right">&#160;</td> <td style="background-color: white">$</td> <td style="text-align: right">-&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> 0.756 2014-11-13 0.13 0.05 2011-06-10 2011-04-04 0 12813000 0 12813000 10527000 10527000 2286000 2286000 0 560000 0 560000 4059000 4059000 EX-101.SCH 11 cdom-20120630.xsd XBRL TAXONOMY EXTENSION SCHEMA 0001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0006 - Disclosure - NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0007 - Disclosure - NOTE 2 - SHARE BASED PAYMENT link:presentationLink link:calculationLink link:definitionLink 0008 - Disclosure - NOTE 3 - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0009 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0010 - Disclosure - Share Based Payment (Tables) link:presentationLink link:calculationLink link:definitionLink 0011 - Disclosure - Discontinued Operations (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0012 - Disclosure - Concentration of Credit Risk (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0013 - Disclosure - Share-Based Payment (Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 0014 - Disclosure - Share Based Payment (Narrative) (Details 1) link:presentationLink link:calculationLink link:definitionLink 0015 - Disclosure - Share Based Payment (Narrative) (Details 2) link:presentationLink link:calculationLink link:definitionLink 0016 - Disclosure - Stockholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 cdom-20120630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 13 cdom-20120630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 14 cdom-20120630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Reconstructive Division Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Axis] Spine Division Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Restricted cash Accounts receivable, net of allowance for doubtful accounts of $250 and $278, respectively Prepaid expenses and other current assets Total assets Liabilities and Stockholders' Equity Current liabilities Accounts payable and accrued expenses Total liabilities Stockholders' equity Common stock, $0.001 parvalue, 750,000,000 shares authorized, 230,293,141 issued and outstanding as of June 30, 2012 (unaudited) and December 31, 2011 Additional paid-in capital Note receivable from stockholder Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Accounts receivable allowance for doubtful accounts Stockholders' equity: Common stock, par value per share Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of revenue Gross profit General and administrative expenses Loss from operations Interest income (expense), net Loss from continuing operations before income tax provision Provision for income taxes Loss from continuing operations Discontinued operations (Note 1) Gain from sale of discontinued Reconstructive and Spine Divisions, net of income taxes Loss from operations of discontinued Reconstructive and Spine Divisions, net of income taxes Net income (loss) Net income (loss) per share: Basic and diluted Continuing operations Discontinued operations Total Weighted average shares outstanding: Basic and diluted Statement of Cash Flows [Abstract] Cash flows from operating activities Net incomre (loss) Adjustments to reconcile net loss to net cash used in operating activities: Loss on abandonment of property and equipment Gain on sale of Reconstructive and Spine Divisions Allowance for doubtful accounts Stock option compensation Changes in operating assets and liabilities: Accounts receivable Inventories Due from Arthrex Prepaid expenses and other current assets Other assets Accounts payable and accrued expenses Net cash used in operating activities Cash flows from investing activities Purchases of property and equipment Decrease (increase) in restricted cash Proceeds from sale of Reconstructive and Spine Divisions Net cash provided by investing activities Cash flows from financing activities Proceeds from notes payable Payments of notes payable Net cash used in financing activities Net change in cash Cash, beginning of period Cash, end of period Supplemental disclosure of cash flow information: Interest paid Income taxes paid Notes to Financial Statements NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NOTE 2 — SHARE BASED PAYMENT NOTE 3 — STOCKHOLDERS' EQUITY Summary of Significant Accounting Policies (Policies) Basis of Presentation Principles of Consolidation Discontinued Operations Use of Estimates Revenue Recognition Net Income (Loss) Per Share Income Taxes Reclassifications Concentration of Credit Risk Recent Accounting Pronouncements Share Based Payment Tables Summary of Stock Option Activity Statement [Table] Statement [Line Items] Date division sold Sale of product line Inventory sold Property and equipment sold Total cash consideration received by the Company Cash held in escrow at sale Cash remaining in escrow Carrying amount of assets sold Gain on sale of division before income taxes Income tax expense on sale of divisions Gain from sale of discontinued divisions, net of income taxes Sales associated with discontinued operations Pretax loss associated with discontinued operations Royalty payments received Future royalty income on net sales, percent Concentration Of Credit Risk Narrative Details FDIC current limits on bank accounts per banking institution Company bank balances in these bank accounts exceeding the insured amount Share-Based Payment Stock Option Activity Details Outstanding at December 31, 2011 Granted Exercised Forfeited Outstanding at June 30, 2012 (unaudited) Vested and expected to vest at June 30, 2012 (unaudited) Exercisable at June 30, 2012 (unaudited) Weighted-average exercise price of options outstanding, beginning balance Weighted-average exercise price of options granted during period Weighted-average exercise price of options exercised during the period Weighted-average exercise price of options forfeited, cancelled or expired during the period Weighted-average exercise price of options outstanding, ending balance Weighted-average exercise price of options vested and expected to vest Weighted-average exercise price of options exercisable Weighted-average remaining contractual term (in years) of options outstanding Weighted-average remaining contractual term (in years) of options vested and expected to vest Weighted-average remaining contractual term (in years) of options exercisable Aggregate intrinsic value of options outstanding Aggregate intrinsic value of options vested and expected to vest Aggregate intrinsic value of options exercisable Share Based Payment Narrative Details 1 Shares made available under option grants Option grant exercise price Weighted-average grant date fair value of granted options Option vesting period, in years Option expiration period, in years Option estimated forfeiture rate, in percent Number of shares of common stock available for purchase under warrants outstanding Warrant exercise price, per share Warrant expiration date Share Based Payment Narrative Details 2 Share-based compensation expense Stockholders Equity Narrative Details Preferred Shares Authorized Preferred Shares Outstanding Common Shares Authorized Assets [Default Label] Liabilities Stockholders' Equity Note, Subscriptions Receivable Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income (Loss) from Continuing Operations Attributable to Parent Earnings Per Share, Basic and Diluted Weighted Average Number of Shares Outstanding, Diluted Other Noncash Income Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Increase (Decrease) in Restricted Cash Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) TotalCashConsiderationReceivedByCompany Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price The disclosure for the organization of the basis of presentation of financial statements. Date the product line sale agreement closed. Cost of assets net of accumulated depreciation sold EX-101.PRE 15 cdom-20120630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2012
Notes to Financial Statements  
Summary of Significant Accounting Policies (Policies)

Tiger X Medical, Inc. ("Tiger X" or the "Company"), formerly known as Cardo Medical, Inc., previously operated as an orthopedic medical device company specializing in designing, developing and marketing high performance reconstructive joint devices and spinal surgical devices.

As discussed below in the discontinued operations section, we sold our Reconstructive and Spine Divisions during the quarter ended June 30, 2011. Our continuing operations include the collection and management of our royalty income earned in connection with the Asset Purchase Agreement with Arthrex, as well as continuing to promote our former products sold to Arthrex and seek a joint venture partner or buyer for the remaining intellectual property owned by the Company. The Company will also be evaluating future investment opportunities and uses for its cash.

 
Basis of Presentation

Basis of Presentation

 

The accompanying condensed consolidated balance sheet as of December 31, 2011, which has been derived from the Company's audited financial statements as of that date, and the unaudited condensed consolidated financial information of the Company as of June 30, 2012 and for the three and six months ended June 30, 2012 and 2011, has been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. In the opinion of management, such financial information includes all adjustments considered necessary for a fair presentation of the Company's financial position at such date and the operating results and cash flows for such periods. Operating results for the interim period ended June 30, 2012 are not necessarily indicative of the results that may be expected for the entire year.

Certain information and footnote disclosure normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the United States Securities and Exchange Commission ("SEC"). These unaudited financial statements should be read in conjunction with our audited financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 filed on March 29, 2012.
Principles of Consolidation

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of Tiger X Medical, Inc., Accelerated Innovation, Inc. ("Accelerated"), Uni-Knee LLC ("Uni") and Cervical Xpand LLC ("Cervical"). All significant intercompany transactions have been eliminated in consolidation.

 

 

 
Discontinued Operations

Discontinued Operations

 

On October 7, 2010, the Company's management and Board of Directors decided to put substantially all of its assets up for sale. The assets determined to be held for sale were inventories, intellectual properties, and property and equipment of its reconstructive products line (the "Reconstructive Division") and spine products line (the "Spine Division"). The Company decided to put the assets of its Reconstructive and Spine Divisions up for sale primarily because it did not have sufficient working capital, and was not able to procure such financial resources through equity or debt financing, in order to fully execute a profitable sales strategy.

On January 24, 2011, the Company entered into an Asset Purchase Agreement with Arthrex, Inc. ("Arthrex") (the agreement being the "Arthrex Asset Purchase Agreement"), pursuant to which the Company agreed to sell the assets of the Reconstructive Division to Arthrex. The Arthrex Asset Purchase Agreement also provides for the Company to receive royalty payments equal to 5% of net sales of the Company's products made by Arthrex on a quarterly basis for a term up to and including the 20th anniversary of the closing date. During the three and six months ended June 30, 2012, the Company received total royalty payments of $17,000 and $28,000 from Arthrex and reflected this payment as revenue on the accompanying condensed consolidated statements of operations.

The Company completed the sale of the Reconstructive Division on June 10, 2011. The total cash consideration received by the Company from Arthrex amounted to $14,586,000, which was comprised of $9,960,000 plus inventory with a value of $2,908,000 and property and equipment with a value of $1,718,000. From this amount, $1,159,000 was deposited with an escrow agent to be held for twelve months for any potential adjustments to the purchase price relating to future adjustments to the value of the inventory and property and equipment and other unasserted claims. The total gain on the sale of the Reconstructive Division assets as of June 30, 2011 amounted to $10,527,000, which represents the excess of the cash consideration over the carrying amount of the assets sold of $4,059,000.

On April 4, 2011, the Company entered into and closed an Asset Purchase Agreement with Altus Partners, LLC, a Delaware limited liability company ("Altus"), pursuant to which the Company sold substantially all of the assets of the Spine Division in exchange for cash consideration of $3,000,000 (the "Altus Asset Purchase Agreement"). Pursuant to the terms of the Altus Asset Purchase Agreement, $2,700,000 of the purchase price was paid at the closing and $300,000 was deposited into escrow with an escrow agent for a period of 90 days from the closing date (assuming there are no disputes) to be used for any adjustments to the closing value of the Company's inventory and property and equipment. The total gain on the sale of the Spine Division assets as of June 30, 2011 amounted to $2,286,000.

The total gain associated with the above sales of the assets of the Reconstructive and Spine divisions amounted to $12,253,000, which is presented net of the income tax expense effect of $560,000.

Pursuant to the sale transaction with Arthrex, the total aggregate amount remaining in escrow accounts as of December 31, 2011 was $900,000, which is reflected as restricted cash on the accompanying condensed consolidated balance sheets. As of June 30, 2012, there were no amounts remaining in the escrow accounts relating to the sales transaction with Arthrex or Altus.

Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $214,000, respectively. Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $761,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $1,170,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $1,366,000, respectively. The continuing operations reflected are expenses associated with business insurance, legal and accounting fees that the Company will continue to incur.

 
Use of Estimates

Use of Estimates

 

Financial statements prepared in accordance with U.S. GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Among other things, management makes estimates relating to allowances for doubtful accounts, share-based payments and deferred income tax assets. Given the short operating history of Tiger X, actual results could differ from those estimates.

 

 
Revenue Recognition

Revenue Recognition

 

The Company's revenue consists of royalty revenue from the Arthrex Asset Purchase Agreement, which is recognized as the amount becomes known and collectability is reasonably assured.

 

 
Net Income (Loss) Per Share

Net Income (Loss) Per Share

 

Basic net income (loss) per share is computed by using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental common shares issuable upon exercise of stock options or warrants. No dilutive potential common shares are included in the computation of any diluted per share amount when a loss from continuing operations is reported by the Company because they are anti- dilutive.

 

 
Income Taxes

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The likelihood of realizing the tax benefits related to a potential deferred tax asset is evaluated, and a valuation allowance is recognized to reduce that deferred tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are calculated at the beginning and end of the year; the change in the sum of the deferred tax asset, valuation allowance and deferred tax liability during the year generally is recognized as a deferred tax expense or benefit. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.

 

The Company evaluates the accounting for uncertainty in income tax recognized in its financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its financial statements. For those tax positions where it is "not more likely than not" that a tax benefit will be sustained, no tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has not accrued for any such uncertain tax positions as of June 30, 2012 (unaudited) or December 31, 2011.
Reclassifications

Reclassifications

 

Certain amounts from prior periods have been reclassified to conform to the current period presentation due to the treatment of discontinued operations.

 

 
Concentration of Credit Risk

Concentration of Credit Risk

 

The cash and cash equivalents held in the Company's business money market and escrow bank accounts are with local and national banking institutions and subjected to current FDIC insurance limits of $250,000 per banking institution. As of June 30, 2012, the Company bank balances in these bank accounts exceeded the insured amount by $12,582,000.

 

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

 

 

EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Y,F(R8V0X8E]F.#@X7S0Q,S=?8C,W.5\X-C$S M,34X-#5D,3(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K M6UE;G1?4W1O8VM?3W!T M:6\\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I%>&-E;%=O M5].87)R871I=F5?/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV M95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^5&EG97(@6"!-961I8V%L+"!);F,N/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^2G5N(#,P+`T* M"0DR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^9F%L2!A(%=E;&PM:VYO=VX@4V5A'0^3F\\2!A(%9O;'5N=&%R M>2!&:6QE'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^4VUA;&QE3QS<&%N/CPO'0^43(\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y M,F(R8V0X8E]F.#@X7S0Q,S=?8C,W.5\X-C$S,34X-#5D,3(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3)B,F-D.&)?9C@X.%\T,3,W7V(S-SE? M.#8Q,S$U.#0U9#$R+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA3H\+W-T7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA&-E<'0@ M4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'!E;G-E2!A;F0@97%U:7!M M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!I;G9E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6%L='D@:6YC;VUE(&5A6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2=S M(&%U9&ET960@9FEN86YC:6%L('-T871E;65N=',@87,@;V8@=&AA="!D871E M+"!A;F0@=&AE#0IU;F%U9&ET960@8V]N9&5N2=S(&9I;F%N8VEA;"!P;W-I=&EO;B!A="!S=6-H(&1A=&4@ M86YD('1H92!O<&5R871I;F<@2!B92!E M>'!E8W1E9"!F;W(@=&AE(&5N=&ER92!Y96%R+CPO<#X-"@T*/'`@&-H86YG92!#;VUM M:7-S:6]N("@F(S,T.U-%0R8C,S0[*2X@5&AE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2!A M;F0@97%U:7!M96YT(&]F(&ET2!D96-I9&5D('1O('!U="!T:&4@87-S M971S(&]F(&ET2!E>&5C=71E(&$@<')O9FET86)L92!S86QE2X\+W`^#0H- M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M"P@26YC M+B`H)B,S-#M!"X@5&AE($%R=&AR97@@07-S970@4'5R8VAA2!T;R!R96-E:79E M(')O>6%L='D@<&%Y;65N=',@97%U86P@=&\@-24@;V8@;F5T('-A;&5S(&]F M('1H92!#;VUP86YY)W,@<')O9'5C=',@;6%D92!B>2!!2!B87-I2!P M87EM96YT"!A M;F0@2!T:&4@0V]M<&%N>2!F&-E6EN9R!A;6]U;G0@;V8@=&AE(&%S2!E;G1E2!C;VUP86YY("@F(S,T.T%L='5S)B,S-#LI+"!P=7)S=6%N M=`T*=&\@=VAI8V@@=&AE($-O;7!A;GD@&-H M86YG92!F;W(@8V%S:"!C;VYS:61E7,@9G)O;0T*=&AE(&-L;W-I;F<@9&%T M92`H87-S=6UI;F<@=&AE2!A;F0@97%U M:7!M96YT+B!4:&4@=&]T86P@9V%I;B!O;B!T:&4@6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2X-"E1H92!C;VYT:6YU:6YG(&]P97)A=&EO;G,@'!E;G-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6%L='D-"G)E=F5N=64@9G)O;2!T:&4@07)T:')E>"!!2!I&5S/"]I/CPO8CX\+W`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`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2=S(&-O;6UO;B!S=&]C M:R!A="!A;B!E>&5R8VES92!P65A M65A2X@4W1O8VL@;W!T:6]N(&-O;7!E;G-A=&EO;B!R96-O9VYI>F5D M(&9O"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,B!A;F0@ M,C`Q,2!I;B!T:&4@86-C;VUP86YY:6YG(&-O;F1E;G-E9"!C;VYS;VQI9&%T M960@2X\+W`^#0H-"CQP('-T>6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2=S(&%S2!N;R!L;VYG97(@:&%S M(&%N>2!E;7!L;WEE97,N($%S(&$@'!E8W1E9"!T;R!V97-T(&%R92!T:&]S92!H96QD(&)Y('1H92!#;VUP M86YY)W,@0F]A6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W=I9'1H.B`U,B4[('!A9&1I;F6QE/3-$)W=I M9'1H.B`Q)3L@<&%D9&EN9SH@,"XW-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=W:61T:#H@,24[('!A9&1I;FF4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G M/E=E:6=H=&5D+3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M<&%D9&EN9SH@,"XW-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=W:61T:#H@,24[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;FF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/E)E;6%I M;FEN9SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&-E;G1E6QE M/3-$)W9E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI M9VXZ(&-E;G1E6QE/3-$ M)W9E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$ M)W!A9&1I;F6QE M/3-$)W9EF4Z(#$P<'0G/D]U='-T86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R M,#$Q/"]T9#X-"B`@("`\=&0@F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXS.#4L,#`P/"]T M9#X-"B`@("`\=&0@F4Z(#$P<'0G/B0\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=P861D:6YG.B`P+C6QE/3-$)W!A9&1I;F6QE/3-$ M)W!A9&1I;FF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I M9VAT)SXM/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9EF4Z(#$P<'0G/D=R M86YT960\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG.B`P+C6QE/3-$)W!A9&1I;F6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A9&1I;FF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM M/"]T9#X-"B`@("`\=&0@6QE/3-$)W!A9&1I M;FF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I M9VAT)SXM/"]T9#X-"B`@("`\=&0@6QE M/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;FF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM/"]T9#X\+W1R/@T*/'1R M('-T>6QE/3-$)W9EF4Z(#$P<'0G/D9O6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)W!A9&1I;FF4Z(#$P<'0[('1E>'0M86QI M9VXZ(')I9VAT)SXM/"]T9#X-"B`@("`\=&0@6QE M/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;FF4Z M(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXP+C(S/"]T9#X-"B`@("`\=&0@ M6QE M/3-$)W!A9&1I;F6QE/3-$)W!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A M9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'!E8W1E9"!T;R!V97-T/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)W!A9&1I;FF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I M9VAT)SXP+C(S/"]T9#X-"B`@("`\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A9&1I M;FF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXP M+C(S/"]T9#X-"B`@("`\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE'!I M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,F(R8V0X M8E]F.#@X7S0Q,S=?8C,W.5\X-C$S,34X-#5D,3(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO.3)B,F-D.&)?9C@X.%\T,3,W7V(S-SE?.#8Q,S$U M.#0U9#$R+U=O'0O:'1M;#L@8VAA'0^/'`@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UEF5D(&-A<&ET86P@8V]N2!P6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@&-H86YG92!#;VUM:7-S:6]N M("@F(S,T.U-%0R8C,S0[*2X@5&AE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0^/'`@6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!T6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0^/'`@6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2!A;F0@97%U:7!M96YT(&]F(&ET2!D96-I9&5D('1O('!U="!T:&4@ M87-S971S(&]F(&ET2!E>&5C=71E(&$@<')O9FET86)L92!S86QE2X\+W`^ M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE"P@ M26YC+B`H)B,S-#M!"X@5&AE($%R=&AR97@@07-S970@4'5R8VAA2!T;R!R96-E M:79E(')O>6%L='D@<&%Y;65N=',@97%U86P@=&\@-24@;V8@;F5T('-A;&5S M(&]F('1H92!#;VUP86YY)W,@<')O9'5C=',@;6%D92!B>2!!2!B87-I2!P87EM96YT"!A;F0@2!T:&4@0V]M<&%N>2!F&-E6EN9R!A;6]U;G0@;V8@=&AE(&%S2!E;G1E M2!C;VUP86YY("@F(S,T.T%L='5S)B,S-#LI+"!P=7)S M=6%N=`T*=&\@=VAI8V@@=&AE($-O;7!A;GD@&-H86YG92!F;W(@8V%S:"!C;VYS:61E7,@9G)O;0T*=&AE(&-L;W-I;F<@ M9&%T92`H87-S=6UI;F<@=&AE2!A;F0@ M97%U:7!M96YT+B!4:&4@=&]T86P@9V%I;B!O;B!T:&4@6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2X-"E1H92!C;VYT:6YU:6YG(&]P97)A=&EO;G,@'!E;G-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'!E;G-E"!A6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0^/'`@2=S(')E=F5N=64@8V]N2!R979E;G5E M(&9R;VT@=&AE($%R=&AR97@-"D%S6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0^/'`@ M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2!U&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&]R M('=A2!B M96-A=7-E('1H97D@87)E(&%N=&DM(&1I;'5T:79E+CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE&5S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`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`@ M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE'!E M8W1E9"!T;R!H879E(&$@;6%T97)I86P@969F96-T(&]N(&ET3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,F(R8V0X8E]F.#@X7S0Q M,S=?8C,W.5\X-C$S,34X-#5D,3(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.3)B,F-D.&)?9C@X.%\T,3,W7V(S-SE?.#8Q,S$U.#0U9#$R+U=O M'0O:'1M M;#L@8VAA6UE;G0@*%1A8FQE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'`@ M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@ M=&5X="UA;&EG;CH@8V5N=&5R)SX\8CY796EG:'1E9"T\+V(^/"]T9#X-"B`@ M("`\=&0@'0M86QI9VXZ M(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$ M)V9O;G0M=V5I9VAT.B!B;VQD)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L M9#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@ M8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\8CY796EG:'1E9"T\+V(^/"]T M9#X-"B`@("`\=&0@'0M M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E M;G1E'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/CQB/E)E;6%I;FEN9R`\+V(^/"]T M9#X-"B`@("`\=&0@'0M M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I M9VAT.B!B;VQD)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT M+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA M;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F M;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X M="UA;&EG;CH@8V5N=&5R)SX\8CY%>&5R8VES93PO8CX\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N M=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H M=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\8CY#;VYT6QE/3-$)W9E6QE/3-$ M)V)O6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT M+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O'0M86QI9VXZ(&-E M;G1E6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)V)O6QE/3-$)V9O;G0M'0M86QI9VXZ M(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\+W1R M/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^ M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXP M+C(S)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXV+C8W)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)V)A8VMG6QE/3-$)V)A8VMG'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^+2`F(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG&5R8VES960\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H="<^+28C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXM("8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^+2`F(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^+28C,38P.SPO=&0^/"]T6QE M/3-$)V)O6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXM("8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^+2`F(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^+28C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B86-K M9W)O=6YD+6-O;&]R.B!W:&ET92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXP+C(S)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXV+C$W)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W M:&ET93L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W M:&ET93L@8V]L;W(Z(&=R965N.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXS.#4L,#`P)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)V)A8VMG'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B86-K9W)O=6YD M+6-O;&]R.B!W:&ET92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXP+C(S)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXV+C$W)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)V)A8VMG6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,C`Q,2TP M-BTQ,#QS<&%N/CPO'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6EN9R!A;6]U;G0@;V8@87-S971S('-O;&0\+W1D/@T*("`@("`@("`\ M=&0@8VQA"!E>'!E;G-E(&]N('-A;&4@;V8@9&EV:7-I;VYS/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!L;W-S(&%S6%L M='D@<&%Y;65N=',@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\Y,F(R8V0X8E]F.#@X7S0Q,S=?8C,W.5\X-C$S M,34X-#5D,3(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3)B,F-D M.&)?9C@X.%\T,3,W7V(S-SE?.#8Q,S$U.#0U9#$R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R&-E961I M;F<@=&AE(&EN'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!$971A:6QS/"]S M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES960\+W1D/@T*("`@("`@("`\ M=&0@8VQA'!E8W1E9"!T;R!V97-T(&%T($IU;F4@ M,S`L(#(P,3(@*'5N875D:71E9"D\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES92!P'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'!I&5R8VES92!P'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'10 M87)T7SDR8C)C9#AB7V8X.#A?-#$S-U]B,S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G0@3F%R'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A65A'!I65A'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y M,F(R8V0X8E]F.#@X7S0Q,S=?8C,W.5\X-C$S,34X-#5D,3(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3)B,F-D.&)?9C@X.%\T,3,W7V(S-SE? M.#8Q,S$U.#0U9#$R+U=O'0O:'1M;#L@8VAA'1087)T7SDR8C)C9#AB7V8X.#A?-#$S-U]B,S XML 19 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
NOTE 3 - STOCKHOLDERS' EQUITY
 6 Months Ended
Jun. 30, 2012
Notes to Financial Statements  
NOTE 3 — STOCKHOLDERS' EQUITY

NOTE 3 — STOCKHOLDERS' EQUITY

Our authorized capital consists of 750,000,000 shares of common stock and 50,000,000 shares of preferred stock. Our preferred stock may be designated into series pursuant to authority granted by our Certificate of Incorporation, and on approval from our Board of Directors. As of June 30, 2012 and December 31, 2011, we did not have any preferred stock issued.
XML 20 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Dec. 31, 2011
Current assets    
Cash and cash equivalents $ 12,884 $ 12,678
Restricted cash 0 900
Accounts receivable, net of allowance for doubtful accounts of $250 and $278, respectively 24 67
Prepaid expenses and other current assets 32 89
Total assets 12,940 13,734
Current liabilities    
Accounts payable and accrued expenses 142 756
Total liabilities 142 756
Stockholders' equity    
Common stock, $0.001 parvalue, 750,000,000 shares authorized, 230,293,141 issued and outstanding as of June 30, 2012 (unaudited) and December 31, 2011 230 230
Additional paid-in capital 25,814 25,810
Note receivable from stockholder (50) (50)
Accumulated deficit (13,196) (13,012)
Total stockholders' equity 12,798 12,978
Total liabilities and stockholders' equity $ 12,940 $ 13,734
XML 21 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 6 Months Ended
Jun. 30, 2012
Notes to Financial Statements  
NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Tiger X Medical, Inc. ("Tiger X" or the "Company"), formerly known as Cardo Medical, Inc., previously operated as an orthopedic medical device company specializing in designing, developing and marketing high performance reconstructive joint devices and spinal surgical devices.

As discussed below in the discontinued operations section, we sold our Reconstructive and Spine Divisions during the quarter ended June 30, 2011. Our continuing operations include the collection and management of our royalty income earned in connection with the Asset Purchase Agreement with Arthrex, as well as continuing to promote our former products sold to Arthrex and seek a joint venture partner or buyer for the remaining intellectual property owned by the Company. The Company will also be evaluating future investment opportunities and uses for its cash.

Basis of Presentation

The accompanying condensed consolidated balance sheet as of December 31, 2011, which has been derived from the Company's audited financial statements as of that date, and the unaudited condensed consolidated financial information of the Company as of June 30, 2012 and for the three and six months ended June 30, 2012 and 2011, has been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. In the opinion of management, such financial information includes all adjustments considered necessary for a fair presentation of the Company's financial position at such date and the operating results and cash flows for such periods. Operating results for the interim period ended June 30, 2012 are not necessarily indicative of the results that may be expected for the entire year.

Certain information and footnote disclosure normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the United States Securities and Exchange Commission ("SEC"). These unaudited financial statements should be read in conjunction with our audited financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 filed on March 29, 2012.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of Tiger X Medical, Inc., Accelerated Innovation, Inc. ("Accelerated"), Uni-Knee LLC ("Uni") and Cervical Xpand LLC ("Cervical"). All significant intercompany transactions have been eliminated in consolidation.

Discontinued Operations

On October 7, 2010, the Company's management and Board of Directors decided to put substantially all of its assets up for sale. The assets determined to be held for sale were inventories, intellectual properties, and property and equipment of its reconstructive products line (the "Reconstructive Division") and spine products line (the "Spine Division"). The Company decided to put the assets of its Reconstructive and Spine Divisions up for sale primarily because it did not have sufficient working capital, and was not able to procure such financial resources through equity or debt financing, in order to fully execute a profitable sales strategy.

On January 24, 2011, the Company entered into an Asset Purchase Agreement with Arthrex, Inc. ("Arthrex") (the agreement being the "Arthrex Asset Purchase Agreement"), pursuant to which the Company agreed to sell the assets of the Reconstructive Division to Arthrex. The Arthrex Asset Purchase Agreement also provides for the Company to receive royalty payments equal to 5% of net sales of the Company's products made by Arthrex on a quarterly basis for a term up to and including the 20th anniversary of the closing date. During the three and six months ended June 30, 2012, the Company received total royalty payments of $17,000 and $28,000 from Arthrex and reflected this payment as revenue on the accompanying condensed consolidated statements of operations.

The Company completed the sale of the Reconstructive Division on June 10, 2011. The total cash consideration received by the Company from Arthrex amounted to $14,586,000, which was comprised of $9,960,000 plus inventory with a value of $2,908,000 and property and equipment with a value of $1,718,000. From this amount, $1,159,000 was deposited with an escrow agent to be held for twelve months for any potential adjustments to the purchase price relating to future adjustments to the value of the inventory and property and equipment and other unasserted claims. The total gain on the sale of the Reconstructive Division assets as of June 30, 2011 amounted to $10,527,000, which represents the excess of the cash consideration over the carrying amount of the assets sold of $4,059,000.

On April 4, 2011, the Company entered into and closed an Asset Purchase Agreement with Altus Partners, LLC, a Delaware limited liability company ("Altus"), pursuant to which the Company sold substantially all of the assets of the Spine Division in exchange for cash consideration of $3,000,000 (the "Altus Asset Purchase Agreement"). Pursuant to the terms of the Altus Asset Purchase Agreement, $2,700,000 of the purchase price was paid at the closing and $300,000 was deposited into escrow with an escrow agent for a period of 90 days from the closing date (assuming there are no disputes) to be used for any adjustments to the closing value of the Company's inventory and property and equipment. The total gain on the sale of the Spine Division assets as of June 30, 2011 amounted to $2,286,000.

The total gain associated with the above sales of the assets of the Reconstructive and Spine divisions amounted to $12,253,000, which is presented net of the income tax expense effect of $560,000.

Pursuant to the sale transaction with Arthrex, the total aggregate amount remaining in escrow accounts as of December 31, 2011 was $900,000, which is reflected as restricted cash on the accompanying condensed consolidated balance sheets. As of June 30, 2012, there were no amounts remaining in the escrow accounts relating to the sales transaction with Arthrex or Altus.

Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $214,000, respectively. Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $761,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the three months ended June 30, 2012 and 2011, were $0 and $1,170,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the six months ended June 30, 2012 and 2011, were $0 and $1,366,000, respectively. The continuing operations reflected are expenses associated with business insurance, legal and accounting fees that the Company will continue to incur.

Use of Estimates

Financial statements prepared in accordance with U.S. GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Among other things, management makes estimates relating to allowances for doubtful accounts, share-based payments and deferred income tax assets. Given the short operating history of Tiger X, actual results could differ from those estimates.

Revenue Recognition

The Company's revenue consists of royalty revenue from the Arthrex Asset Purchase Agreement, which is recognized as the amount becomes known and collectability is reasonably assured.

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental common shares issuable upon exercise of stock options or warrants. No dilutive potential common shares are included in the computation of any diluted per share amount when a loss from continuing operations is reported by the Company because they are anti-dilutive.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The likelihood of realizing the tax benefits related to a potential deferred tax asset is evaluated, and a valuation allowance is recognized to reduce that deferred tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are calculated at the beginning and end of the year; the change in the sum of the deferred tax asset, valuation allowance and deferred tax liability during the year generally is recognized as a deferred tax expense or benefit. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.

The Company evaluates the accounting for uncertainty in income tax recognized in its financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its financial statements. For those tax positions where it is "not more likely than not" that a tax benefit will be sustained, no tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has not accrued for any such uncertain tax positions as of June 30, 2012 (unaudited) or December 31, 2011.

Reclassifications

Certain amounts from prior periods have been reclassified to conform to the current period presentation due to the treatment of discontinued operations.

Concentration of Credit Risk

The cash and cash equivalents held in the Company's business money market and escrow bank accounts are with local and national banking institutions and subjected to current FDIC insurance limits of $250,000 per banking institution. As of June 30, 2012, the Company bank balances in these bank accounts exceeded the insured amount by $12,582,000.

Recent Accounting Pronouncements

There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.
XML 22 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 23 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
NOTE 2 - SHARE BASED PAYMENT
 6 Months Ended
Jun. 30, 2012
Notes to Financial Statements  
NOTE 2 — SHARE BASED PAYMENT

NOTE 2 — SHARE BASED PAYMENT

On August 29, 2008, the Company issued options to certain employees and Board members to purchase membership units in the Company. The options give the grantees the right to purchase up to 2,398,400 shares of the Company's common stock at an exercise price of $0.23 per share. The options vest 20% each year over a five-year period and expire after ten years. The weighted average grant date fair value of options granted was $0.13 per option. Stock option compensation recognized for the three months ended June 30, 2012 and 2011 in the accompanying condensed consolidated statements of operations amounted to $2,000 and $11,000, respectively. Stock option compensation recognized for the six months ended June 30, 2012 and 2011 in the accompanying condensed consolidated statements of operations amounted to $4,000 and $22,000, respectively.

As a result of the sale of substantially all of the Company's assets in the second quarter of 2011, other than the CEO, the Company no longer has any employees. As a result, the only options expected to vest are those held by the Company's Board of Directors and CEO. As a result, the estimated forfeiture rate has been adjusted to 75.6%.

A summary of stock option activity as of June 30, 2012, and changes during the period then ended is presented below.

            Weighted-      
        Weighted-   Average      
        Average   Remaining     Aggregate
        Exercise   Contractual     Intrinsic
  Options     Price   Life (Years)     Value
                   
Outstanding at December 31, 2011 385,000   $ 0.23   6.67   $ -
Granted -     -   -     -
Exercised -     -   -     -
Forfeited -     -   -     -
Outstanding at June 30, 2012 (unaudited) 385,000   $ 0.23   6.17   $ -
                   
Vested and expected to vest                  
at June 30, 2012 (unaudited) 385,000   $ 0.23   6.17   $ -
                   
Exercisable at June 30, 2012 (unaudited) 231,000   $ 0.23   6.17   $ -

 

The Company had 575,613 warrants outstanding as of June 30, 2012 which entitle the holders to immediately purchase one share of the Company's common stock at an exercise price of $0.44 per share. The warrants expire on November 13, 2014.
XML 24 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Jun. 30, 2012
Dec. 31, 2011
Current assets    
Accounts receivable allowance for doubtful accounts $ 250 $ 278
Stockholders' equity:    
Common stock, par value per share $ 0.001 $ 0.001
Common stock, shares authorized 750,000,000 750,000,000
Common stock, shares issued 230,293,141 230,293,141
Common stock, shares outstanding 230,293,141 230,293,141
XML 25 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information
 6 Months Ended
Jun. 30, 2012
Aug. 10, 2012
Document And Entity Information    
Entity Registrant Name Tiger X Medical, Inc.  
Entity Central Index Key 0000925741  
Document Type 10-Q  
Document Period End Date Jun. 30, 2012  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   230,293,141
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2012  
XML 26 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Income Statement [Abstract]        
Revenue $ 17 $ 0 $ 28 $ 0
Cost of revenue 0 0 0 0
Gross profit 17 0 28 0
General and administrative expenses 149 249 218 350
Loss from operations (132) (249) (190) (350)
Interest income (expense), net 3 2 6 (22)
Loss from continuing operations before income tax provision (129) (247) (184) (372)
Provision for income taxes 0 0 0 0
Loss from continuing operations (129) (247) (184) (372)
Discontinued operations (Note 1)        
Gain from sale of discontinued Reconstructive and Spine Divisions, net of income taxes 0 12,253 0 12,253
Loss from operations of discontinued Reconstructive and Spine Divisions, net of income taxes 0 (1,170) 0 (1,366)
Net income (loss) $ (129) $ 10,836 $ (184) $ 10,515
Basic and diluted        
Continuing operations $ 0.00 $ 0.00 $ 0.00 $ 0.00
Discontinued operations $ 0.00 $ 0.05 $ 0.00 $ 0.05
Total $ 0.00 $ 0.05 $ 0.00 $ 0.05
Weighted average shares outstanding:        
Basic and diluted 230,293,141 230,293,141 230,293,141 230,293,141
XML 27 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Concentration of Credit Risk (Narrative) (Details) (USD $)
Jun. 30, 2012
Concentration Of Credit Risk Narrative Details  
FDIC current limits on bank accounts per banking institution $ 250,000
Company bank balances in these bank accounts exceeding the insured amount $ 12,582,000
XML 28 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Discontinued Operations (Narrative) (Details) (USD $)
 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2011
Reconstructive Division
Jun. 30, 2011
Reconstructive Division
Jun. 30, 2012
Reconstructive Division
Dec. 31, 2011
Reconstructive Division
Jun. 30, 2011
Spine Division
Jun. 30, 2011
Spine Division
Jun. 30, 2012
Spine Division
Date division sold             2011-06-10       2011-04-04
Sale of product line         $ 9,960,000 $ 9,960,000     $ 3,000,000 $ 3,000,000  
Inventory sold         2,908,000 2,908,000          
Property and equipment sold         1,718,000 1,718,000          
Total cash consideration received by the Company         14,586,000 14,586,000     3,000,000 3,000,000  
Cash held in escrow at sale         1,159,000 1,159,000     300,000 300,000  
Cash remaining in escrow             0 900,000      
Carrying amount of assets sold         4,059,000 4,059,000          
Gain on sale of division before income taxes 0 12,813,000 0 12,813,000 10,527,000 10,527,000     2,286,000 2,286,000  
Income tax expense on sale of divisions 0 560,000 0 560,000              
Gain from sale of discontinued divisions, net of income taxes 0 12,253,000 0 12,253,000              
Sales associated with discontinued operations 0 214,000 0 761,000              
Pretax loss associated with discontinued operations 0 1,170,000 0 1,366,000              
Royalty payments received $ 17,000 $ 0 $ 28,000 $ 0              
Future royalty income on net sales, percent             5.00%        
XML 29 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Share Based Payment (Narrative) (Details 2) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Share Based Payment Narrative Details 2        
Share-based compensation expense $ 2 $ 11 $ 4 $ 22
XML 30 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Share-Based Payment (Stock Option Activity) (Details) (USD $)
 6 Months Ended
Jun. 30, 2012
Years
Dec. 31, 2011
Years
Share-Based Payment Stock Option Activity Details    
Outstanding at December 31, 2011 385,000  
Granted 0  
Exercised 0  
Forfeited 0  
Outstanding at June 30, 2012 (unaudited) 385,000  
Vested and expected to vest at June 30, 2012 (unaudited) 385,000  
Exercisable at June 30, 2012 (unaudited) 231,000  
Weighted-average exercise price of options outstanding, beginning balance $ 0.23  
Weighted-average exercise price of options granted during period $ 0  
Weighted-average exercise price of options exercised during the period $ 0  
Weighted-average exercise price of options forfeited, cancelled or expired during the period $ 0  
Weighted-average exercise price of options outstanding, ending balance $ 0.23  
Weighted-average exercise price of options vested and expected to vest $ 0.23  
Weighted-average exercise price of options exercisable $ 0.23  
Weighted-average remaining contractual term (in years) of options outstanding 6.17 6.67
Weighted-average remaining contractual term (in years) of options vested and expected to vest 6.17  
Weighted-average remaining contractual term (in years) of options exercisable 6.17  
Aggregate intrinsic value of options outstanding $ 0  
Aggregate intrinsic value of options vested and expected to vest 0  
Aggregate intrinsic value of options exercisable $ 0  
XML 31 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Share Based Payment (Narrative) (Details 1) (USD $)
 6 Months Ended
Jun. 30, 2012
Years
Dec. 31, 2011
Share Based Payment Narrative Details 1    
Shares made available under option grants 2,398,400  
Option grant exercise price $ 0.23 $ 0.23
Weighted-average grant date fair value of granted options $ 0.13  
Option vesting period, in years 5 years  
Option expiration period, in years 10  
Option estimated forfeiture rate, in percent 75.60%  
Number of shares of common stock available for purchase under warrants outstanding 575,613  
Warrant exercise price, per share $ 0.44  
Warrant expiration date 2014-11-13  
XML 32 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity (Narrative) (Details)
Jun. 30, 2012
Dec. 31, 2011
Stockholders Equity Narrative Details    
Preferred Shares Authorized 50,000,000 50,000,000
Preferred Shares Outstanding 0 0
Common Shares Authorized 750,000,000 750,000,000
XML 33 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Cash flows from operating activities    
Net incomre (loss) $ (184) $ 10,515
Adjustments to reconcile net loss to net cash used in operating activities:    
Loss on abandonment of property and equipment 0 44
Gain on sale of Reconstructive and Spine Divisions 0 (12,253)
Allowance for doubtful accounts 0 184
Stock option compensation 4 22
Changes in operating assets and liabilities:    
Accounts receivable 43 (38)
Inventories 0 85
Due from Arthrex 0 (193)
Prepaid expenses and other current assets 57 64
Other assets 0 31
Accounts payable and accrued expenses (614) (826)
Net cash used in operating activities (694) (2,365)
Cash flows from investing activities    
Purchases of property and equipment 0 (137)
Decrease (increase) in restricted cash 900 (1,459)
Proceeds from sale of Reconstructive and Spine Divisions 0 17,026
Net cash provided by investing activities 900 15,430
Cash flows from financing activities    
Proceeds from notes payable 0 1,224
Payments of notes payable 0 (1,724)
Net cash used in financing activities 0 (500)
Net change in cash 206 12,565
Cash, beginning of period 12,678 127
Cash, end of period 12,884 12,692
Supplemental disclosure of cash flow information:    
Interest paid 0 25
Income taxes paid $ 553 $ 0
XML 34 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Share Based Payment (Tables)
 6 Months Ended
Jun. 30, 2012
Share Based Payment Tables  
Summary of Stock Option Activity

A summary of stock option activity as of June 30, 2012, and changes during the period then ended is presented below.

 

            Weighted-      
        Weighted-   Average      
        Average   Remaining     Aggregate
        Exercise   Contractual     Intrinsic
  Options     Price   Life (Years)     Value
                   
Outstanding at December 31, 2011 385,000    $ 0.23    6.67    $ - 
Granted -      -     -       - 
Exercised -      -     -       - 
Forfeited -      -     -       - 
Outstanding at June 30, 2012 (unaudited) 385,000    $ 0.23    6.17    $ - 
                   
Vested and expected to vest                  
     at June 30, 2012 (unaudited) 385,000    $ 0.23    6.17    $ - 
                   
Exercisable at June 30, 2012 (unaudited) 231,000    $ 0.23    6.17    $ - 

 

 
XML 35 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 16 127 1 false 2 0 false 5 false false R1.htm 0001 - Document - Document and Entity Information Sheet http://cardomedical.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://cardomedical.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://cardomedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://cardomedical.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://cardomedical.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R6.htm 0006 - Disclosure - NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://cardomedical.com/role/Note1-SummaryOfSignificantAccountingPolicies NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R7.htm 0007 - Disclosure - NOTE 2 - SHARE BASED PAYMENT Sheet http://cardomedical.com/role/Note2-ShareBasedPayment NOTE 2 - SHARE BASED PAYMENT false false R8.htm 0008 - Disclosure - NOTE 3 - STOCKHOLDERS' EQUITY Sheet http://cardomedical.com/role/Note3-StockholdersEquity NOTE 3 - STOCKHOLDERS' EQUITY false false R9.htm 0009 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://cardomedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R10.htm 0010 - Disclosure - Share Based Payment (Tables) Sheet http://cardomedical.com/role/ShareBasedPaymentTables Share Based Payment (Tables) false false R11.htm 0011 - Disclosure - Discontinued Operations (Narrative) (Details) Sheet http://cardomedical.com/role/DiscontinuedOperationsNarrativeDetails Discontinued Operations (Narrative) (Details) false false R12.htm 0012 - Disclosure - Concentration of Credit Risk (Narrative) (Details) Sheet http://cardomedical.com/role/ConcentrationOfCreditRiskNarrativeDetails Concentration of Credit Risk (Narrative) (Details) false false R13.htm 0013 - Disclosure - Share-Based Payment (Stock Option Activity) (Details) Sheet http://cardomedical.com/role/Share-BasedPaymentStockOptionActivityDetails Share-Based Payment (Stock Option Activity) (Details) false false R14.htm 0014 - Disclosure - Share Based Payment (Narrative) (Details 1) Sheet http://cardomedical.com/role/ShareBasedPaymentNarrativeDetails1 Share Based Payment (Narrative) (Details 1) false false R15.htm 0015 - Disclosure - Share Based Payment (Narrative) (Details 2) Sheet http://cardomedical.com/role/ShareBasedPaymentNarrativeDetails2 Share Based Payment (Narrative) (Details 2) false false R16.htm 0016 - Disclosure - Stockholders' Equity (Narrative) (Details) Sheet http://cardomedical.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity (Narrative) (Details) false false All Reports Book All Reports Process Flow-Through: 0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS cdom-20120630.xml cdom-20120630.xsd cdom-20120630_cal.xml cdom-20120630_def.xml cdom-20120630_lab.xml cdom-20120630_pre.xml true true ZIP 36 0001136261-12-000441-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001136261-12-000441-xbrl.zip M4$L#!!0````(`(UT"D$L:!%!Y#L``/S<`0`1`!P`8V1O;2TR,#$R,#8S,"YX M;6Q55`D``ZI4)5"J5"50=7@+``$$)0X```0Y`0``[#UI<]M&EM^W:O]#CR:3 M=:I(B8=N'U.R9+DTL26-9&>23UM-H$EV#`)(-R")^?7[WNL##1*4J".2['6J M)A&)/MY]@_/JGU>3A%T(I666OE[IKG96F$BC+);IZ/7*Y_/VWOG^T=$*^^>; M__XO!O^\^EN[S0ZE2.)==I!%[:-TF+UDQWPB=ME[D0K%BTR]9+_PI,1OLE_? MGGV`C^;\7=9?[0]8N[W$8;^(-,[4Y[,C?]BX*/+=M;7+R\O5-+O@EYGZHE>C M;+GCSK-21<*?M7]P\I']JTS%/WH'_0[\J]?I]E:OA@#Z`2]@`7Y>ZVRO=38_ M=7J[Z_W=]Z5EJ]7`MPN^ZN9 M&JWU.IWNVJ\?/YQ'8S'A;9GJ@J>16'&[$IE^:=K7W=G96:.G;NG<2KSUI;)QZ:99*MW26,RLTR):'647:_`` MUG>[[4ZWW>^ZY4H,%X*\N09/W4*IL_5>=^LZ_,P*MZ'4[1'GN=\PY'I`B^V# M!F#@B9[/?67%*A8*XJTG< MS\20D0SOCHFS$6QMNPVK5SI>L8\1WMQ MM=Y]M3:[N;INK?$^>UL.?,KB!BA(Y8HW%0+^"OMD]OS:2>Y+2X\;B=3]VHG4 M?00B]=J=S78EO5\?D2P"?PV1#E4V,7>L@TTHLJ^68$`456!(\*9"QYU4/9O; M!L%+L"FDLWORH'3N!G3N?OUT[MZ%SMU'H',/'=PW)<_=YRK/W6]+GF]/Y[]4 MGKVG_QII6_/T?Z$3JSS]=KO[%1/)(O"7>OH&#_2_9P(6ZD*542$OQ(&\D%@$ M^"@F`Z&>C)J5AHK11`1D\(]B`.8J3V0D"P,KBR6L-`42F_7M'J60PPA,]@6> M\I8GF!.?CX4H]M)X+XYE`>MY:^R,M=P1%)BG077 M`$5E6HKX),<2"FS5>U=2K[S!'&KW.D*^6FN$.<1WK1GA;]E1-SB0[^+X_T$< MGZ>?[7T7P6]7!!\YIV[RM.>Y3+^+T]W%J8%^3VW(OAZ_^EWXOCGA>]Y>]+O` M??4"]U@^L][1^!Y_?>/QUX,W?LI4&D'Z?'XP)R`3P9&,;VS'>!?6N,/-J"\\_''!BR\`I++UITYSL`OM,%]\3`P;C!PN/>8^P?XUC'O&#>@@:S,#:= M&EQZ(-)L(M.;KKV9+K/W-AWLGM>HL`1!?Q-<+>89*0HMN3/'3H6*0!EN$(L< M_ES^BEC(W7>D8&=B)$&'04-P=(59!3C#AOMU_8Y/<@06Z%?VT33S6PS,QNJK MM47GSM^[#R@IGAREL;CZ64R7OCBTI@M/"Z\[R*(2#MU.^]_F_'![ MT[&G9$;>F5!GZ?-#E[?PM/"Z/7@:XXK#A(^6OF;($RW,#;4#PI/W2Z7P:[#V M/$%)O2TN;6=OKSMM7@#^(Y+DYS2[3,]!6K-4Q$=:ER!3RUY[G(4"L."T^6M_ MR9(RA6AV>B@3H?0=KYLYI4&\#1W.1)XI<*$C,Q&V]&V_H26[Z;3Y6PF:?2#W M*%/+J]3YA">PC_GCV7XVR7DZ#4&H'=VD"(;E1H`/X;OED?UWKZX$EYDT1?C.4_*`F,*#))J]\[TBAA:7'I@'2Z+122! MV/KURM'Q(<#2[_1V^MT94W;-;0XV%^[M\4^5VH* MZVG^L`E$-P)5@8BQ30!?NP]&L+<%QO;5VJUN>S`0N\N!N+FU_81`.K&Z`120&[N].X/Y%X496`9->0&`K8,$G$L"FN^[LSES;H<7G?'?>%9BJ&] M]3O#4^*L5![6HM"WY=,VSLUL):XZH&@6XIH_=Y]H3,/ M[VXK^EO]&<;1@:43U%D,#V/(@6Y]@?)!S*!1%W<6R*V M-C8;)76).Q\8W.5(M]Y[*'"#%0]&O>#,6UYW)^RON2Z($>[G/R$"J=O\F8/O MEJU.P&D?I/L]EP9.[([ZQW9W1TN8;[@'(0?Z)^+Z7%6B/-RH",E03+[C M*H6(1X/Y*2=E`EE0?""&6-:\,V';W3Z^RA"">O-M#P/?4F0$^+H[F_>$;Y[X M]XCT=V8B_?G#[W;]DEY]:^>VUP<&'%S70])B+I*YZ:J'`.V.T<]M0=M+DNP2 MNQ:'F3K(RD$Q+)/Y"/N^D5%O1IAN=>N#@[RDI^@\',B!OSWEZD11RR@FUWLJ M%!4>EJ;MZ8+R1F>U@QWD6USY0%`VDO-1H#1W[)7%.%/R3Q$O1\,%D&UMV+=& M&Z&;O>J>4,W3['&@HCKM_>@4E-%NN.8>T"Q-GP>$YH8ZXX,2Z+HJX^WKGP]' MJFO@.I>C5$++TRA$V[ MK-O)"_9)3B"K.Q:7["R;\+1EOFBQ. M/[&]_?V3S\>?CH[?__CW;O_EZVK>`__]1BPTQ-A$JF[`LV;QC7;!_?$:[?TV*Y M$A@?V>2?#FYC)->S6< M`O?K$LA7`:)7'YE7>YK%4D>EUD"E`2!WB2@C)^)@I,,2$A,@0R(1X8<6NQ1, M0X#&LA);0C64$4D:'&)NV@.N*A52"X__H^2J`#$0:0SGXR\KL'ZGA3^CT%UE M)Z7I[<'EN+ZZ'8##B1-!4.`Q498D!AC+D92/:)R%94."2F53GD"0*FG:A0G( M1^`^P!'.3^W.2UF,"2BJOK'34D5CKN'C2`ES&*W8`_%1XJJ%TG0ID@3_&T!9 M9"!ZV00R1KK82"M^%0-%M*$3K+&G&"$0X@OC5CHNX*(2@I0<")/"SDP1EH-R M*N@T@E")">151C(+0;B7(#UP"]`(T`3%0$9.:;'5H57VJ?I`9UY*A#[1&;"< MB0L(6#B)\;`D",P+^H:*.?;YT#A+*[BEAC\0'(F%3Z['CRVRWD#B'Q+_>,NU MU,CP4W`"`#7)"D$EO?E[$D,(9.>1M2W6`<98PJ:H`01"QF2=!F;TRJ@6SE^A M9`$Z!Q"9T_16OVLT`Q1N+*,Q`^D$S@FT30IT+69#$+R0Y?\#O"ICB8WYQ9B#48(O6\19V$\@E*G;NP#>ZDB9DL4C+:(#/03VBE"Q>W2+ MDV34`F,EM+QBX,B+L3;6@("8WV@(X%'/L2F@C"XCD55,AI M`"]']',S"?@%>"[RPNQ%6#ZGA"[%[P3V'OT"!B=(*L?U>?5\E;W?VSNMO)+1 M!%!%)2<+Z(*P>PLCG85$8P;6`/*Q"<,)$EH&MD%&B6#;[4X?P3@3(ZR9H#0C M).?M7U?!R=%!Z(4LU2NCUP)_`N+1#(7-\@9G`J(#!BW-"H^:3-`9H/3 M2DSXE`SC%40").]69'',$$Z;@A-Y;*.W#]8=#/^<8`VSK$C1Y<1^2I-`27%5 M0J@2UTG4&TU!@_HT*$JS1HTY4)"T,9O(`M?EI=(E!-F&0YFA;9D([0A=5[5S M$4%(X'W+NRMPO.F(1&LB-08-0=QX_FZ_4CQR:N"C*V/5B)T>9V5B+,H`NH.9QG53CD37->K656(O3=$QFSD99A7':?O/7J10EJS8SEE[ M@"3!V"ME'SE$)*RW8T3ZZ1WN:24"P-9][QN>C]N]T7-5O"5P+".))U;6";?& M7*;%((<4BK""J4.M#\ M"\H0?LWQ8WV+>QCJQ1Z8=UVEN\9&6LEE.&6IN?4_E?J*1-*,JP^-*X8^O;2% MP^6LFBY_!I)VDK*3J,A0:;=(-\'IU,U`Y9L]0]]FD+52>`?.!'8K3;4.-`&8 M0I3H.`00]0%A]7H$?Q!^ES%UNA>#,)+D^U4DPZWM12^?KR2%! MX=+"()ARB?'U9]6SRAF7X.//&9H6%9DL]`T@->6L`;'1]4U,!#$0$8=,"`X" MSQM3@$':I,LA=K!:)$( M<;][(%PA8G;/PAL#"T[`N5`':6[2LEKZ@]M(^C26"NKBAY]FRB5.X((2@9'G M&\$B0F$N#XS&UQ&T#RX<+'"DHB:/\.60G$]-8`,R!;(&*S;^@9"E<(>1DKD@ MWZODA(.C'$P]9#:XX:ZF@^I!&;G)(=`FH1;!':@!TKTS1,?W.IBNI:G$7Q1% MR;#78BR+:]!MK[*#JFYTF[2Q+EV6!,@3',*8HP3<_$-WJX6_O(G'_]#;IK\I MM0Z+-DH,$Y,7%&-`TN['?%<)L*NE,259ZF.)F]+_(,S$HI5W<(^MGZ'U1*@3 M89`T=J-9;FN6'$-58D#75_+P3$-ORO)KUJAN03#,:,*OW076]M M;&\B7UPI!`PJP8``*XFT13[NM'8V.\2^/"DU3'@A)C82L!8->$CE1V"69" M&`L2>NOB4B2@JU:X28N`*CED'!03U))WFV/EUBX8RZ0DE:`3DSB33Z#"7L-& MCY-)IQV=KB$&?LIP`!-S+S!*BBI%"9<33?RVJ1_R?(0IJ]6$Q3)4V3YK(>=+ M1]T9,>BT-GI;H1@H8:L4VI>QQ!4F_-Z@S(M?=B&4?6:FE.TE;HN%QA2X@>GK MK8YAZ1,XSCW@:<*6]9HQV4],VV]TH`F^:G)J2LX`%:07$*A`+IKP2ZR<8%Z` M5$_L9,;4M4I"9XMGA/G-;!%@WCL231O#W'E'60_(,-01KDR`JM'$6&!6GZ0# M_F=J>'5/3TC?[.=7\:GW\>1]P)=YP*X_IH6V9XL,&L-%J*U@&'F[%@ M%CH^Z8`?G6JRJU7G)/"P[`60O)Q8'XN& M@HIF6%2"V%GHGZR%*K6MAE&$,V],W)DUHU)%$-Z\>#%M-C&AVUAD0F:D8EG+ MT6OUC/]X"N<:8`3P9A#E>X]`8C_(+FR,'I99KPT;JXPE]AE+W50"QAO]T%1B MS&)L)15\B\KX4X>LX%=4^4RM,Q'#(40[I%,;QJ<^-NEFE9#$("ADU%,!+^"& MVGP$"CFB(K0Q[F$'S:N-J_@LZ+N0`OZP8[0QH&,5"E+T!VR1^,D$)&B7;A$% MVB80HP80>-*]^?Y)RVHG)O*HG@8C74>)"M6$EM$RAUH8#C@JZH5DQ"23[-NC MZPEQS0#7I"1A6YI@6:+MK*@(:[BTH*T]TY8*\XJ&'I;MQ;EZR@\N8X#PE`0$ M1`%;!P!/@MW76Z"T3!=]$3K&:,RC-)LH78L0<\AL;78;D?&:!48$;068_!`M MVU^^&VJMF>RPMCW*%."-FJQ+ZDI;!"'082C!%]+4K1QYC/@_.,<]@2#"W^HL M0R("9(9,=^;^74EDC<$\F991BKM)4+?5W]QL(!"!8HOT#2,>@5%5PKFB>=H- M2@@U,,"7J2X5FLX62\#2)[Y78_M50R%L7R^(1JHQ"((AZZ9NTEMHWVQ'=;V(4J+T8^7 MM/'_@26NBE<(7RR&0AEV^$C.T,>HW'M0/QM(CZDIZ5OK8ZDIZZ\:7BTTJ:6I M0E-C/,(^*A@*8(=RXR9H>3T63Z\V9X999$1'J7Q&W<@J!;("91)6;87,5"() M$/?<#_3<5/ZM1:.$]Y_&IE/<:4+>@4!YT&YN$LL#9FS.Y?2T&7\+@P\2FYQI M'"6(GYZIQX"U^:4J]N(#^-"?V*E5+)KY?08,QNFSB!(IJW+N(VOP!U'$%@7U+N`8(1T8"S.00D)9BD#BR0LSL' M,BE=1C<'B!TM0X<:`C*":`".L2F>L3Z@XW`0]?-\P;$."-EE\O3+@.2*Q(M. MLYI`7;DT4B348,N,RP&)>9XK>KJ,( MWTT))*R,M1T"3Z^(5@D_\:MG$9`<>1]G.6@=I"U0E6ELB[OD`7W!J:IC3@0X M,!12YS4K=SD;3M#Y@75U8;&MJN-&E&*(<00Y;EX42@[*PC5YC=>D9W82J;@4 MUA4WA"2S]6AR$N(*E(2^6P"BB6*D"F)M@@P#!1V.+'NW'^0EJ4$?U"^6]GY` M$E0)1_"6I9#]*;'8&C>16)L\3[$R:&(E?$:VLW;(ZB+-1 M-)_FZL<8;P"),,51TY"J/E-PIP\,ORZH,([=>U$4";@SRLT2^44D\U47(*P M5)QV3+F.VQ%/(O-"KRM=#P0H:>J*UR*-W?W(R)?&K)JZO64PA/J+032%O"8" MUF)=*D%XI0Z<$$W659.,<_$1KY]A@WLDH>5]UTBL:3G*MM#CNJK@!,Q-^>>Q6<>S;V;,`7L)3 M"8NE[T,A=DTH^P4A[@X<4O`0[196C%TU:@9HPY!5]A_3_,GQ9UC1(+?"J@O- M$4*Z9WK#((R)MP4T?N*PKX]AC=W`D_DU%M<],A3!26\O+C.D:'I_X(6?]OT) M%76N3O_T41+DG@G0C&8OG\N4HIL==]$$Q:@@YT!!.V9?38+:)-0A81P4!#Z[?/;E=&NLPM<#P``+WRL%OU*X<<$%%<:G9]A^ED;T@Z#.8>Z;&.A,ZB_/ M@'>?W.B"?U%"5+^O1A,CSL;66ZV^.@IY#N03YDU%XY=-RVO`TR]!WTO9T?\D MBVP%U=A&^(`K36\)`M"BM-J9QE:%![_[J,L)QN'!T7Y5EC4S!&:^JK=AIW)` M:1O.7=SUJM(DV&5,F.F7.=<)IK2.$HY_B-@.,!$POK2'!A\;HQO;O:?H9S9: M#:1;]68R.U59FJ%I-"/JST(0J[D`1?!25$7OP-?>#JD!;F*7>NV=?,)4F()# M#*F[]5\S,3S9),ZPN*@P.JBBL'K4X%Q&R]LS:GC63[5U1;F=I, M%?;P,'XD]TX529P9[V:"UTEV=C[=$JBQ-1$2*PD[S*^_Y]'=:@D!$@@!#C55 M&0-2]SFGS[M/GV8_4A6*T#&C_`6O:^EKYK3O"T^CYTZA$__%^DXE+?#WN%5` M)]4JX'/_[3]_[7]X=WWWZ>_6];^^W'S^8W?').AT5=)1)&F#IG/@%VP8=,&6 MRGDF25#*\Z%A2IZTDJ?`"9&1&3W(1\@S7ZIS?7R@7_FT6*"-)R$LHYZ;TT72 M]Y]9]YA0Y(P='A1#?XH=/,I`8B:*MUU)"5%YI,_!!-AI]K;PM?ES'[GFC@90 MGBT!8IS^%>G3!A2+9)!DE?P=JKA5?=QRA#@K_3D4%?&D?)J/QC3EV MV7GSKK==W?^IZ-P8FU-:MS*TN]U.9O[4'&N`4)H"Q6?_76[`]'C_Y2-MO_1' M1>;)=>6K]/1IB0H6\`D[V+PP\1D.=,>$B;+>;\V3.YT?:/L]GVCVX1L MW'SX*M,EK,!<%8%75HVO`5EB>/HC#(&$'Y&O<,=;"V\#\(&(^F^PIN-6EG3L ML:?93GF:O_;NKJTWO4_7[ZS;WA^_77_\O,OSN+WI_32*Y5GYYF4Z>2##5;E; MK(XGJ/RC&$^\8";D9AJ[:V-RPR(^12IK+^1W#^Z$F$8G[U/M=M2.]#WMP\$7 M[$3*E#EAH1Q-/3`?DFLW.E>7C;.4>YM.[J1=XICJ_]66.)\JP%Q+\[3=23:K MTU`ARP)]?K"$+<^=TG8)G8BQ(;9^%"?TA4SQR>HGK."R1]BU*18^;\_QL*J& MP5(U#(0LEUY1"Q%]($"31;K45%C=/&UUF!)8]S#A3-`G8V.?MN.5V.3MQ!:N MX51KE5^1+4^2%3B;ESU5H$\-MG*K9LL@P_%/L8K+Y>@4.V:81N5,AV!9+7,[2A;429"Y(T3FP0FC%Q+OU*EM1RRR=70',GB:HRL^U$:[*_3Z M=3^M/?S`\@(?R^,>J)_<+-$8%,DI(),C"(%/3>B8S&9NB^0/$UZ\"40G_]+U M(`!U3J,`:@AQW4]/)TO^N0Z/V&@DW%AU@J%R8-TUB0_M,!`7W=/S'VI?3-SU M'-U6B^W`C_]*6PI(ZX4%>[A6ARD<90>%XT ML?$P_?_^#7P5_#RQ'8<^@W.0)D5[-2F>7"=^0*HU?_A;,BG.%ZK!'C&-,+2] M$]MS[_U7UB"(XV#\VAK8PZ_W(8BD>"AG+44'*V;ON' MUY8$&^A]>M&=Q/P:F^OS)AODV%D]UF5U0[7VC/O;M_8-DPXV`OE-'5[^SM5*GDH]"M_/W-UK(:YEW.2RHWP98\40'O+ZO MY;H!O%T_'*'<#:O%VPA``)!Z`8+5.82B+LCS5Q@W]25*_N-?\42]9;C&_ M^MR0^N".A/62KI[_\;C@:=K0=3Z'J"Z.[Q_?WUJT5X)Q%S+_G%C*8K%D,]R. MYVO\JW`83%&G;#7-W+GLTN9'_1Y-*0*]V!X%<,MP'QRZ?.C.3\\OON/%.=E; MD?V%-W-K0GVWRUX;M^]%$G1_0-NKY=@KZ5,IB*/\'3S.>PS:7BU'*?F+@\GV MA.\]%UL4$;XJPM8C/QS%<_^78W_$,Q-,+CQ-OJ;TMD_;*+[8I,T3Z\OO,?#< M]\"S=0P\=^OZ[G'V[/M&;-?O[X*P>Q7^_5M0/:]J4&I6&!\7MX?)JBVSAO=703=+-#.\&2UU63VRMC8^/8X[/J MLG<.78DR'@L'&X!ZL^0$?.`+V0*]_-ET`H//IY^=9<^G:[CE:7,8Z6/PR`5` MK0[!>_9=MS;:L)?$7+LSO)1*WIN!-RV4[FV3TRRC=9%JY9&98@T(EO>D6=ZN M8_/92S<_:E]6C__:O8]6S([\TA_=)9>2;+SZQMRIP4O/O,FJ;S;S)EV^-L9Y M[95>.O,O81!%MW01_#9DW!B^Y,R;K/+ZLVXJTQOAN_8*+YN5^]SW?*?GC%W? MC:BA\:.XEEWM*UGSLZLT$9;/60&(I9FC73N(Y3FI=5D_%B\#BJ5Y*3VNG12?(8SXT%7OHFK MK_M=O:%[/(RFH-??0*$%(<3(=CB[B<4X^ACXB$,8>!ZQKKSXHAHMUK[*Z8VZ M%8!W3)MUM.K%=T*;-;3\Y=EW0ILUK,Y%5EG43!L80JJD-_)FG8ICZ073;`#- M)I%7]=!LUEE["[39O-MT$6B6L>BNS$TUD-:A_"NCZ=95<64TW;IB7`[I.^,: MI^0=<,/ZH\]\"V;U2J_8W%7#79Y_6Y04VQ/P-]>G.R-[219O=7&!"C'(*UFM]4M#L!J#7DK0KKRN^<[ M9NO\M;CE=D'W_N9I.:V]`*:M(K>2%0\9N95L?LC(K92AG2*W7&/O6OK6@JXF MA#>1R.XA(KP5*=UGA#>1W.VN\+4=8AM/%'E5?V*^LT7Y7#%S!8!6)%?;![0B M>:B%HE7P<4E`D\(HLW2J$C<_'6;G3[0^..6]_M96X2D=!)QMFSPEK\=;9[E` M:88"'GHG^/\WOKQ7-,+K>]U'ODBB"F+-79ZW+5-CV_!J>2"Q[E4 M[1J0;`^?TLMP/I?0W0H^2A9N[1D*`E;4#(FY<%<.?G+=6850$ MENUA5%[17+;GTGP58`1>+M[C=QL&CZXCG#>S+V`%;GQ=MM+C2XFJ6Y>KN618 MP?FKA7R->HS.^5P:;4W0=5EZT!O^=^J&`L:`M^+9K8>W=?L.7MH[&6=O;*Q` M^Q>?N5J8RVW5810 M#53UX5H^5]1N=],9AT-#>1,E=VBXKF.>:UG>[``N/MP?*3^UZG5;,5T%T)6F M]%G:P)>$D!()6',*JI/W9ZHFV?P,Z\%0`0NN!H5L=P04>Q^$[X+I(!Y-/17@ M;\&-7CC7IG"5)];EG#==&+CYG`@1.DF]UI!.SQO/^9&.<*<8X8CL\NGK&:F!<(\IN9M+$Y4'MA_>V[_Y%SL[;P*?> M[/0!XII;OE7>9E,NXTG;^P3?"(KED_X<\/0G]]YW1^X0,W2LL4$>;F&\(42> MNB='T<7Y>:-6(SOJ8?+9O1>A]1_K-^%@[ZR&!9W@)4>W2%Z/#P;0A)-!*ZO^Q"3"-?7O&_BT M\(()=1;W'<3]J\#UM1Z`'MC7!D$$]A!6*&"%08"9Z:P_`]>/Y601O1O!*#`_ M<,V]`4B4W^AF>VO5BRP'V'<*4N%8`T#N"5'&E7",0$`2DNZ&)!*)(7YH6$\" M[S&`WZ>A=9=&&9'\!$@*ZYW+S@Q,-0V16CC\?Z=V&`,;"-^!\L$X MB`5-S-R*7Z'FB9A.\(PB8AH0#%S(F=FAB=LLO358_,E%Z+TH@"6WQ*/M3!2MINI.)F`U*#Z=27C3B/X`\%Q47^#:=IF;Z:"S;;R)]-#J`9H.;V5ZE;\ MRO"\?=?_[166+D5HG))YZ(49_[LC:T%0H?B8<%6NEFIHH[8K\P?"9@^E14&I M@M5SL'*`JN(DAZ&0VAZ:"E:H#P(4#S=J>Y>]_;`AN[6!3@)Y%6B10M"PCC4" M5LBT8I,-(JV1XE;`4;&K'#]^L,$4P9<-DF=XGT#0S247P9L,Z?IDYTAWIIO! M67F]YG`6I;]0][%MB-QOUA@(_Q"Q#2`@YE]D`FC4)UB3$;(&1R*'#IE;TL^V M%COL.@>@3C"PO.=.)N`-P.]B$O.[",L7G]`E>2:P>Z"P08`)DL1=^7+ZZ=3Z MI=>[37P1UG]X.M@=+Z`+PJ[MBJOL(IHPL`$0UH^!WT[^18_UL,>H)ZS+DV8' MP;@3]U./I0XA^73RGU-P;6@@]#TDU1-3UP`O`M@C'PYI,&'Q4>4[?TY9L9/E MBES@)*``V$$1178X([QL:V2[:+@,Z9?]^]*\EDRH,EW8_(]@08Y1W*7,-RP+ M##GU8K8C:#JL$3@<;$WHM0GM&43@`,R],I+FD,G)E.?'B)2A$Z+VBQ37W\#=\N^)M<9NA*ZB$2U\NGZ;"!ZY,N"9)'_UIY M'EXI#VN^:Y_A"N[4&[M-Y`YD*077T2 M:%C@]`M/IAMN?#]XM#E$SB0_C,?,W`8HR)-_^N`:??CPUG@:ODZ>XF:^H)+` M+#Q2TN`_$_R8?D7]:"K-'MC^*(E/V(!*M6;%H>U'MG1.$MTN/'<,I(EUM)PP M7MUF<&>MEM<*.ZN4.K/5YV*-5&@G.MJI&C-!LA*8CBJL,"_V?:L_C`-T%2[( M(P!7-^U\)!&!UA1O`CMT**@$%Q;>#B-*GCM\7]1DBN[Z`)N%QRY[?J`HX&F7 M@D7*T$\G[)[;GFS7+;]W!*@04!`\$GA9#\)S]*/6DY`NJ9N<96CDYJSH!X15 MY[#H6BM=62O!R214=5K-PPSCRU3J.)V()"A4"M((X502=OE8Z0QFQA'546^& MIG%")@E]#DAY^5&#V.APCSEN&8BA/06GUX6PW74HK"$U'4U'(\PN87XR"+]2 MJL&>N#':)`H_(6C&AZF>D;.30TSO8:A%("2F#_PC<(8Q-PT!>C"]?Z`%P'QB M",@-8F4E,0GN8B(=`D<<EHYN>58!&A,&\\X3++ M2(`V>Z/Z`D/DP!W/)7&I!B^38!@]L,-.0R9#* M5OL'*!Z4K^3,!>HDE"*8`R6`73A%_783DT2^#["%E.V0TV($C<^@/WAJO4OV M*,HDJ]+<)4F`:Q*C>&4I@7O]WL`).7[ MF&4+N>DW9V9\[:2N2CH:P2UND&A#7+=\FMH3H?8$(\EZ(Y]O4YH<`V1:@);> M-<(QF=Y#N4]/"2Y.F^@52>^-9$@^1B^?1>E%ZZS1O3S'=5$)6%"H!`,"'+I( M6US'J\;5>9.6;^)-(TL9O)E,2EJXO4(8O6@WKIJ7>M$7V+NYMUJ-BQ:]=6J] MYX2ORV`PM`U\HM6]HG%1Y3N"TG%"YA_Q,HYH&`9/H"8$:Q#36L=/P@-9E[XXC66R:<<,WO,5$F)6$Q#R6Z3VK(^81U*\,&S4:W?6&R M02AD;C32R7/Q#=.,6J',LU_P*$+Y6QB2@/(DZA4)#6^FPJ*?-9J\I#LPG#U8 M4\\J:C4=TI]T&^DJ`^K%(!^WO+T)4$'<"HZ*]0YXYPGSM1AP(M4]>71OIK;E M36.+8YB!IKYJ@AV=1:17DUUZP\):+X'DT[&TL:@H*%6/J6SP MG47TH]10TTCFX,G#F5-)OFJQC3;"Q2(1FN**HYVHTVVX]= M&%<#(X`W&+JVM@C$]H/@4?KHYN;.4KRD5&2Q8H$=05'C:(3-"2M4SKH=;( M1(>IUX=!"'BC)$=3JH"2"(*C8]GZ(&%#DT?=LU?QBFL"@8=_T2Q"(@(D0Z:U M5W]=$DEE,$^F(D*Q'@>U&IWS\QP"$2AR]R>GG-!0JJ%0IFB>=H,IN!KHX+M^ M-`U1=38L#S2]IW>(Y2[Y2`A936!X(TG)G4*<+EGTA],%!05[GJ?>28Y]Q5&V M[.Y&=DOD2R3ZH^LH=L=4@5#KWL>7B#Q)/?LA+\C[O#*)9459NGH*9(V:6!`L M1ITNB,+8_HI^A%HRP:7F;;^"&M)HQR9GZ)"F4H%`*?"I38O4Q>Q`_8L:YAEB(:!2J2%6UH`2A^4(50$B6D6-1?5. M7)WZ9ND>;%J)S+>2(!Y!LWKONSLO'%%73AKP'/+*&`GCO^OL-^=B(BFC,LFN M?M/5L6J#!F%9G$$Q`BTBV%_LKE!(Q='<0*`X1>KX"6:^^/2!2E?1RW84^/8` MDTP1UN4YSU@>5G+\JJZA.Q40O+5,'GA^B6>V?[0`+(O@.N0EHWZHE&N1ZO^E M1\A-U*W;R*:8(J`^K8.9A;[MODT@#0NX!!0-%0,H; M29;@TVA2H]#&/9[)1.4P-Z4+HDV;W--)8-QU#N_P'>B!]%S`<*O;S4^MC\%B M7$P(B#*9"E,FD\XX4\V!)'!"3JFFGA[`PML<*Y,.7'"2R@CN!S.]_BIKKHH. MX+L9@83)\Q.-P3/6:BN4U,(KIG:JS*0BHVO-#GEI;K3+*B5!^KMR+V#J.W(? MC1S:E+\_L\8"?%&'8W[5M=/P?N>C@U"8UEYE(.0&9LS-6"((6P3YX78!B)^$]*P71!C9K3]R6L0WE_K*+021@Q(W--(:!!GZ_9%Y$C$Y M9<'I'Y]0Y_0PT,&5\P.2H)+PC$51"HW!I4%'A@V%)7R;"Q+@K9#"%GUB`C7V M9.)1$0C\3'1BW2]+P73Q.QU`4%MU&#X`B3";%,Y25%5)&37Z@-?KD?8@L5!* MQ+$'+A:EP3SWJ_#\F*3'@B]EDJ"5!-K2Q,T<3U)/RA*1P MN*Z*-^?E:0P5IF4\1RJ#<:9#(8];R7%9S29C8W48OCD.0HD`5B?8/M5M<=R+ M6Y6`*4H%A9C)F:L<8"G+A._RL0T-ITP;&3P/!,BGK_8) MA>^H^7$A7[-YXBU2N<`0N2\&L9$03U83*0*F0E?*]FK!-HPY'9U(CJK,^>MV M>@P9JR,)Y=HSL["/H:IGYL&<%P4TNR:BFOW3(.`.HGE$'U@2P^6P3" MI"NKJ`#ID+6W6=6CA"8R"^@I1TIZ?,A'F^ADMI&H(%C2Y$1Q77@Z1Y>A1NCW M4+)EI431VNDC:R0R`^3:"`&2,BH=.YM*X/$Q638$^BT,)B'FAG$8DHHIJ#!Y MG&E`5XQR"8T=ZNU.R7J*54)G.69LP=[K'0<37L(S%!)+73^`V.6AK!\P<5?@ MS*'>P)T^\PE9:90LR*GU.V_:@YYWAZCA&V:VW%57O-*&.W"WIQ4+E0TJ[-/E MLP^J4)5;-^M=?SH3J%E%Z\Z$%'FG35_JLV$_HM3/[:^>YOE\BYRX^1S/T`-T MZ1Q%J0B@CIW,@PYQ)UP1Q.`PNA4$@9^@+:6/)"/0?R' MB'M.,"EQZU1E-@YY+8',2H-VR`OZV2QX#`E1BF&B:?:PO8FQ+B@@0$RG:28X M38KK)!V\3,1,%M2V<,,J1"=35=AEG4_E4S7T1E_J>$##DM6O!`)U;7C&DK66 ME,QWOY-!Y2=,"?/59CT.%?[*R%0OZH^HVQV(4J=E=+M;<"$:MSY/=[Q;-MGF MH,TW"ZP1M+Z1UM^$;"N`,J:I`*K"%"L/%74V>.^XP[=LES^0#>[[;\!.ZOMP M\`9'LL$WB0DN!F>FQ2+H]7:7EW3MB5.02P6&3[V1MO[&_XR6WASGFDP\#X/F MO)#(6^"-OM6W" MXYW,Y6*50[<3]`L+T\&A_PMM#M[X?%M"^9ZMJY5*M1#.X8^:ZH8<&#XXR8\Q M6/2C'.9:;I)N!\?24%2]CM??)J[TE?9Y,7/`K)H2_Q81>$-X.Y5T0S\'^-5^ MRWE1H*MG&^)'S*-60)5VI\@5L!M`MT7E_[NL.^EQV8D2U-N0V_,6L(A+;A`^ M;7>V8A.6`;U'M"IU+?1SH%7:9FV57%NSM'722PU^<"0K!7C55'L?A"/A8JU( MQ)8C:UH+4W'CJ]RKH^A&2.52>+`:F$%I]7&GCB&^#3`%2C7JGT4X;A6S%7]@ M#%F MN.RE\BM#KWZZ]U0;C;VS%&O#GMX`L:,'3>T;_YJ+-A9C]W_ID_KJ>/YO M5->V"O7%,ZX'D_2EUX=)W<]6$#"\OROJZ0K#W]WX(?\`^,9W`!OT*CQI=:"6 MNL(7]^1:9PD9=P!OJ:OD=D[:XC?*`:@7YZU-27M+S3CP5&'=K%MNYHJ!+LO$ MK=:%H0QV"OJZ_+QK>I?B[%;G_'Q3>NM"4CYN?9>V3;)M`W:B^C9^P;>>V.:Q]U;Q,($O-71JJZCBK*%3J6GD, M2%0_RUK(UKIH79IV)!^,36"MCIAKP$I-]#`T>6NV>KV3':3?S)+&U5LF\UGW MTK#7!<&J$)4*5V'7J%2L6?=@+>I'`!__57B."M1[,>KR[8M!2UZ6O@2(]>&L MD,>W"F=%#%P7%;<(W<;9/"YFZH\JK7QO=ZXNSRJIOEH$7F7XTS^8N-25DH6/ M^-QV_Z@`PWD`*L/MO>V&E'+M)1T$=;:VPFQ]JXJ57@5L952YIMM\;DBMT=&5 M/AZ5__Q@^S*S_3&@.[^%4T$98O>B>]ZJ8M^H+-0[(%=F$X5*N-[9L=`KN_D6 MW-E9K:1/D91]JUG^]&;66JS[P[QV=%QXQXV M,!G+^X',?EZJ\W/N+=?<&H;[@_`AU;D.9/BG+YL:IQKC#X07/.WR/!VW-!H* MSXLF-M[RA2:9/D]LQU&?2X/QY#KQ`S[:_.%OR:0X7Z@&>\0;X(:V=V)[[CU` M/`CB.!B_M@;V\.M]&$Q]YV08>$'X"KL%Q2(9!EF0AG+44,@A:AAJ^YZ'?.P< M1ZAA!.21$VXEB&OJ.:\M'IMO6+_B+6DH=6#< MP%TYD19NGV1ZCXCW_$;-\/Y!L;Z"71?:/&_)+;F@JF`KGR9'0_PL1U6KKX+. M@Q((!;Q1J'E0\&^7*KKP\M`%>D"W;)\P##"&!T!8K=,NQ-UTD]MK:PWJR&S/ M<^67K=",,E*[I]A6Q0,B'*5"#UW%T`CT]RO+C0&B877+ M>!QV*\/N0W:OWA'6$*=E4K-,T,R>7G8\WSMX7<0ZEUVZ'KI6&B]#],6Z`#1/ MVYU]8!4\JOT,R'FR3=<5`MG\I(@:KPZJCH!P%Y;D*2B946'@'R9IRU#YMHR#A MM;_>0B(>PXKJPXK6,:S8T)W:GLCOQ^JLVX6W^`%-ZLDN\$CF,AQ_ MAK_/3K!=8T?UW:D3M%IO=%AQZG;C[OJGE9QF7@^3]*5O4^(^[M'%=U;W_8^" MNB-$JQF_:&N+Q5+1[*I;X`I`D@(=D3)Z/LVU_BD#Z<^JST1+-8S(&7V3V?.: M5_RLVW"L>\B4\,`DBV^N/#?.D.F,^0`:IMMM3LMB^>'X$J[/+T/`FT M<7NI=ELV>'M69-FXK]5>D`6>NZ:+O_LC?K'@7'7X&^O"5COB97V-[GES]<(? M#/95>QD'@WA9#Z.699==\L)PAG=.T+W4_5$OBD0`]W]^^C8(/?<5_@L?_Q]02P,$%`````@`C70*03=&WRR4"@```G(``!4` M'`!C9&]M+3(P,3(P-C,P7V-A;"YX;6Q55`D``ZI4)5"J5"50=7@+``$$)0X` M``0Y`0``[5UM<^(X$OY^5?9V9GLY+8(D!GN&.`PV=OYM*78 M(E&-L5C9SLN_OY:-'3"6+?-F477YD`!1M_OII]5JR;+X_.OSPD&/A'N4N5>U MYD6CAHAK,9NZ]U>U6]/HF-W!H(8\'[LV=IA+KFHNJ_WZS[_^!<'/Y[\9!KJA MQ+$O48]9QL"=LU_0""_()?I"7,*QS_@OZ#?L!.(3]OOU=`AOH\M=HO9%^PX9 MAH*RWXAK,WX['23*'GQ_>5FO/ST]7;CL$3\Q_L.[L)B:.I,%W"*)KFYO_`W] M*W#)WUN]=@-^M1K-UL7S'$SO81\:B/?UQL=ZX\.LT;I\U[Y\UU"\D(_]P$LN MU'ANK'XB\<\.=7]/7M76X#VU+QB_K[<:C6;]]V]#TWH@ M"VQ05W!BD5HL);1DR34_??I4#_\;-]UJ^7S'G?@:[7IL3J(9_DMSVJ]9XM%+ M+S1OR"SLAR%5>!DD;2'>&7$S0WQD-%M&NWGQ[-FUV/FA!SESR)3,D?@+09)< MU<+<9@MB4PL[$!R+NFA0!Y*"!7']CFOW79_Z+X(QO@@-!A"AQ@=.YEPM,ML>&%QQQJ0S3:U]@1[C8? M"/&](GO5-9S2Z@GFX,,'X@O!_2%DJCLR'M&SB8@$;SP?+T6F@PC8C8Y\52?$ MT<7>PXW#GO:'L:7I<"A&S"=-PPP6"\Q?QG.3WKMT#DV@3UH6"Z!3NO<3L,FB MI!#'+KH.BZ1EF`\0O=>0X>P)?A'N4S$Z1^RP]K4-TV?6CP?FV#!J]_\,(.6I M&)@G=S@+U9A3C8;=M!T039K2&;YS%,S.%SN/9(> M\3%U"LTMI^6@V<\"YT37@PS%H8$_I=Z/L@!**SIPA!CK7(>];+P4IG0LN#9T M,T48N^@Z8JRGG=TNK6WU:TC6+V5BL6,]PO`#E/'PL=`#$ZXF,E`LL?X2YK4H$D<;\D/S*_]_LR,ITDQ#H=9&[8[8I[& M^";_*]/#R=@<>W?AC"SPC'N,ES`S:S;KQ/&]^!,1*4VCT5Q-S'Y:??Q'Q_/6 M<#CXCCCA]?X0L^WXG_7J[!,E*H2.^"-"^A$[HG3M^%V([!<8[\,IN\1\1=DT MNK4HZG`+,0[]Z:K6;#3BRV!N;43/]IQXU:+NB5I%*#(H1$0L/^=LL>WDE4-9 M:?O7F8`+U]`3H?E%@$X@T*U!'Q\\G*%U%CJ7UZEE20:D?/A),EIG;_>2F& M)0BML?]`>`0RGR4E236RWIV>K!*XM>-L2/$==:B_-A=-<;/10H/.#R6OZ`_@ M9OB$P_QOS4"U7*"DH>)A-X.7K/Q0PAG:A9Y\;2?%6U;#*FL^ME@P-S0JM[S; M:E9Q2.6LI;$\LS4-GXYM4X$8.Q-(O@.WBY?4?UVY3_=]6>N*"S4U4@JP:L?- M5,SG76+W,7=A)N!!<@H6PJO$[I$YM:B\MBX6K+AH4V-,W0/:D9>Q3L-\8@9W MGL5IN+"W5I8JI^Q<'167=FJ4[N27#'8-;2H^*!N4!^%B,7TJIEQ&2B=4&VTJ3LD%CL\$I%\QL$HZ M[OW`A4Q%AH!)XOW,EA4'?X[UZUQD4:5;!X@VNCIB(<=>4)=Z?G1G=+6H*,N= M15(5=Q)5@M3`Z]=]7F'=`.YNM",%X+Z.Y==DSCB)VLWP,_'ZSP`._$Y=S%\& MX#EOQ%RQEP6\@DGGFS\.>H5*^[.)_#F>M3E!:=NZ2'&$9FZZA?R*D7> MO.*$<&**B]RF(<]%_MDY+YQ!]\ZF\/@1HV<4`)95Q%[#^"B?0$E;:]_7Y7Q+ ML>M7`T`Z*2R>4VTJ[HB9%I?K<]IVGA\5#**^Z8A?P?UHG:Q$NVDN='0CD5%=^Q*MG?U1RB':OQG;8)X?'^ M:&K!E+)'G(;*70\_BEEK^LY7)S:;WN]QLZG;,K^AF./YOE3>;Q!Y9 MP#7A[)&"OZY?;L$#`S=9Z%D]D"3?ZUA&P?^G'.5*D)+,K'?4[`)&M_R<+I!I M]&@?8`:4TGT5A5+53Q;V8$[1)]IQ&>[@%JM&`#T*/=EML8R&U9?[>S`F1Z[? MTDL(49P"<\-XCP5W_CQPXIW1$K[R12K>A[8?T*ZCO3[*VF4+L>"W\>1E M>O.%I+$:;>_UI"W?`]H1!CF!$["V1Z*_`W?[627Y-$-!5(W,#WJ26<8[9T"M M>#;0A:O)*^8"&34R?SX7,C/\<08LAD/Z:_RI4[DMJ,;GQW/A4^:9,R!U]=!A MC\P)YR3[X4-EHM64J9'_Z5S(+^/!,PB(T.I79Y0+@&QAY46#,V$\ST5GP+#* M0Y^E2Z]\98H1H.FZT7XNU"XB),Z(#G#88WDS4T&5T_KH4"-OQCK6GP'E)%XN MFC@X.JD'/ETN/PD7.VU`X&6Y%8E*H)Z+JVJ]E9ESYS+T'-#7>Q:>PP] MF0HT"5[Q=&]<*"B$[&9S/8>5'+YD@9KE!>W"UH-AA]09/Q<-`=],TC/_5?=,QZ@N7G3"SA<:U?.],^ MNNZ(#5B3SG>QX^H$1N<>O9Y8_3'3ZO`XAMFX^^^OXV&O/S7_@?K_N1W,OA_9 M[!U/7D_`?$J#62E$;([65*)7G2A6AM[$KXY]C$31.>TQFF9C"XV01*$H6LFB M-Y'TL8TN>5I[@J&9QK"N"+UJ0F\276_1FY6ZMSMM1,PXJ1TR[1\SYF-')%NQ MGQ*2;73AZ,Z1R+SBUCUV97N\E*5W*L4D)F_,,(%%Z5%-V^TJKI)*.CM]WD4F MZ`-.623^CN\-OYB0,Z6+5AMM*B[#]O!S)MCC^SA>WEQ?VIW:FGL_$$"3.S?.S4X1)8F[1EPQ,W,_I3K01BI( M.[PD^N_W-`)!I0D0,-ZJS0<#Y)S3SW/.Z=,OM/GVVVIAHV?B>A9U+EKRB=1" MQ#&H:3F/%ZT[75#TWF#00IZ/'1/;U"$7+8>V?OO7W_^&X.?;/P0!75G$-KNH M3PUAX,SHKVB$%Z2+KHE#7.Q3]U?T.[8#]H3^>3D9PNVFN2[JG'0>D"`4,/8[ M<4SJWDT&B;&Y[R^[HOCR\G+BT&?\0MTG[\2@QVXCB%SG:I329DAMAOR*>D M50.[)ET0TS*P#7FT$)F`"/$,%L3Q%<=4'=_RURRX[B($#"1"BW.7S"Y:!F@+ M+$^D+QV)-?M3$5U_O80>Y5F+I0U.$=^!M$<=DS@>,>'"H[9E0N*:E]AF[M;G MA/C>6WB+6S@DZC%VP8=SXC/%]U/(--)9P&@)G31`O M3=ABX"Q$-@<3KA$\$,&TP)U>.`V/&DI[)K%B.;X(HF(D(V8::!YWTI@`SL96 M2=#[V@=`'+8D+,CB@;@EX6ZK-H\5VW8YA*%"\[@2)!D)*-9(7V+'1!MU MM*7?)/(2:_($?QM`)PLLN.YIH[XZTM4^N]*UX:"O3.'F4ADJHYZ*]!M5G>H? M32-[79YPZE3AA#YM6?W\`1S?6*\G_$Z+\=.G\.M6'0$W[0II8W6B3`<@\,', M]I?P";&S*L1ZBGZ#KH;:'PT3J[2F3ZA]8<4!5B@V]0*7P,U(FZJ(50_][O96 MF7QG5/3!]6AP->@IHRE2>CWM;C0=C*[1&)CW!NH!^.4M_Q,JOV12"0O)C3)1 MH5^QB(V5[RQ$S6/.W1%(0'_-!!U6BJG6^\^--NRK$_UGI/[W;C#]WBSJBOL! M"9?S72Z1041G*&42O=I$L3&H`F3,%D6B>U[\1.VZ)(%28[>`.T^(MS)'0+M[7W%'<&'DTY2PXK]_,<[LLU)!MJAVV!G-E\I@N MG#.7+O(]&7F-\K&G_0H06HBZ4.PN6K+TB@*RCY@7+=\-,L@>,#@#!SH421BD M)VXPI59,,_0YME][C'>YAILE];!][=)@Z8$).V!OE;-[I+*R>(EZJ,9K3:;, MK8+FQ:EQ9S7U!D5?PE2K4"PR)._/?NP8 M\"CQ?']6L_/9D;BQ2TW(`3;CU6&5SJN4^Y+W\MX'R M5V`MPR,`?(_RQ(_9N?F8>7X^K=?/4^ICF^VFLYUVRXS&`QAT"8RVYN6Z1Q=+ M[*PY;B^H?DSUV_W(`\]S[2]WN==TU-*XLV+L#;:9X'O&]G/K-5SAN M1^>CYGG[ZT?O3>RO`*[!(T/J>5?@AGCEH,TR12_)C+IDLX:?XA5_SZ+.5HXY M#1JARLN=\^/+'<"LSF;$@!ZP(5&0=YG,J=K&#Y5ZON:=D:O`#UP2(=@,Q1JKI6&?'A/72+W>VG%P$=5C=GMQ_-Q@I'9$ MOHD[U*#MIV8/CY;\"E1R"*N]>PAKRQ8[&K>QAI@YSDFLYD_$E?U>5$*ODWE, M3M@Y)A=:1!N3*+9Y6(;%OCF5\#HM=/PO(UI(_F@V[7TV9Y79M)MF4_R;5@F; MO3/+:2,_HXV9O*X4E0_VP?[5`CSY'U!+`P04````"`"-=`I!*>A<;%\E``"G M`0(`%0`<`&-D;VTM,C`Q,C`V,S!?;&%B+GAM;%54"0`#JE0E4*I4)5!U>`L` M`00E#@``!#D!``#E77MSXS:2__^J[CO@9O[);]FM3NQ?+8G MV51J*T61D,T+12H`Z;'RZ0\/DN(#($%*!%M.JN*QI>Y&-_!#H]%X_>5O+\L` M/6-"_2C\^LW)N^,W"(=NY/GAX]=O/MT?3NXOIM,WB,9.Z#E!%.*OWX31F[_] M]3__`['__O)?AX?HVL>!]QY=1N[A-%Q$?T8WSA*_1Q]PB(D31^3/Z%LG2/@G MT;_.[SZR/V5Q[]'9N[,Y.CPT$/8M#KV(?+J;YL*>XGCU_NCH\^?/[\+HV?D< MD9_H.SR8*I?.C$CX'\? M'?_IZ/@/#\>G[W]W]OYWQX8%Q4ZCT^/CDZ-_??/QWGW"2^?0#WF;N/A-QL6EJ/A.OOKJ MJR/Q;49:HWR9DR`KX^PH4R>7S+[U&^@+FE#_/17J?8Q<)Q:0:BT&:2GX7X<9 MV2'_Z/#D]/#LY-T+]=YDE2]JD$0!OL,+),Q\'Z]7#*;47ZX"KI3X[(G@A5J9 M@)`CSG\4XD?6V!XOZ"M>T,D?>$&_23_^Z,QQ\`9Q2@9#K5U?E62E3$>VE;W% MQ(^\J["?UE7ND=1G?8?$6QA0Y+=NPD,4.T$OY8N\G'G^`]GQ\)>/DK]>(?=B/E;DKBQ_XPO_6>?#Z7?X.4=K]L>>V^PI4)GN]V5 M:E8!4"("A0259EI(2&(60GAB060,=$R8(AY7YCIP'A5V5;ZWA0:E6AD*2E^" M:'V51M56SVD0)QJCK2\20KB.;!;L!-]CA^B=@9[4%@+:E,W`H*,#@8L6Y:H0 M2<853G((.5[W`0_#.,/H?WV*%1B+TII4DMB6%`;S><;%&['%9JB$&` MR$3#6@J-9A-3!W'.PY\X*\IXD63^VWB@^C8*DC!VR/K:#S"IYK`;Z.R"2*-F M&3P5(D"@46O6!):<`PF6$1&2.L,[O(I([(>/J<*:!UG8N3JMN-1]7(P2!I#;MM'FY=/Z=IN<$ MR_BHX=D`,\P4*,=!3$U5-5YR,H!HJ>K6AA61J]DY4OIO/D!$_89-"-U8;6[[ZF),<=.6"=_HV.NA;&U;2\:*H@7*F5'&C7[(^+?>X[0; M<$XHQ3%M@6&5R";@U`H6H56F``,BI5JUE0A!!`D*:7[`"!$U6OO`T*A;QT>% M$!A,U-KI%B4<0*BY<.C3)/3X/U<_)_ZS$S`-Z22^<`A9LQA?G`O3V&[(:Q-5 MG-$J;Z'78QZQ;S`-_@N!EU MS2Q61U0#Y4L#:P,]&(`9*%D+RE(61'*>`Q1B$=([01!]%@<@%A%!7I3,XT42 M("=C822_/?W]L?"/OSW]XY\.F!"ZPN)(5+#3''M_D-X2O')\[^IEA4.*69^; MQ4^8E`(1364:<=J$;`=3BL@U8`,#8'-=JSA..1&6K%2`,N+4!:;QN MF8":L]M$3%>CBI@RY07CF#HJ7(5D@5TXIJ*`+Y`4`0ZJ9MF1)H:1X&B0)]%3 M0X1`L#BK<*&XX:5P]J9%87"C1*EM8$*C1@P*)1K!8]R?U;5.[? M^NWQN^/C$S9`D6?.''#R9@-CL_V(34IXPX_<2(D8L+B%$;Y/023P_QMZ7@OX2N^(>"71V M(BA.8(!T<^O)K>-[T_#"6?G,1>L"!!VUU<"L6>52$*8F!0/@9OUJP=7FAAJ> M$#OT0^1*!AA8JOONFRC&]\F#-6'5 MZJ>>MU*PL98<^RPVP\&:H;6O61,PHX*)QDNTNN([(9;JWH+Z! MH24OW$V&U0E('_-*TY(N`L",MGVT-MB3TK87I0G2^Y!9.[7:@,^8S*/\LNRN M*;;3#DFV]S!\32$'=.N0&1$G%SR1#KK%1!S6:\\>Z3E'RL6UF:))S^G8P/@0 M+9(5=*ZUA*- MW:%*H5YY;"H0@`&"2JOZZ$/%J2(""0X?2$3I+8D6VO6Z$H5-*"A4*P*A\#6L M]'5=L2H2!`5:"1(@,!"OFP;BC:&E'XKW$_@IMO0@DL[2-BZK<#$SH02A9A8P MWL5,SQK*))?<7%SB`[;'.'T1*GR4T=1'UCDT%:&DM`FR!E6+P%*0P?)1>@5K M)W>XJQ);4*+\X2X8L)F&,6:5$TL3TKZ@CW'UY'9G2LU*EZ=*:EHP?JE%P?ID M29(C7\Z:WJ9NZ$MQX!H*J++^<,W:[4*^6L?ZR>;5NG.\B`B6=`_."Z97+\RM M1L3S0X>LIVP>2&\8#A@GJ[]`=#%I=N.$B)AD.)@^>KA#=7[ M?##^T5R4EW7CV'GAL2R\!V!95:0^Z9R%0OH9CI;:?N_1JEQ'?HT4T+#0 MI%_]XH(4.F)CPP934*+3]N[7N]]"\\_]W.R^>`GC6^6 MFK#9>[+4W(C-BZ7M/*,[M(Z*UNZJ+3Y[7!@^WXH=_B=?PO!O2OL^.'[(.\0L MS)YUGBV4A"S:GRV8J]?TQET)M^DG=ULA15^Z&\FC=XM!S*EEKYB<].B+$V"> M-_>*W>D.L]]9[TO$95OR3I'2(],TO\4+>DBA<3#-':N;B/'"##/C]`%',S^8 MKM!#:9-$V^N"/:N`U@QOA<8F<)7J%9%9(H`5]:I4JYTKQ)O,6\#(@,0?V;&T M;&=KRWX7/;E-K+0I782-CA:,\VI1L!5'F]W%0':[5PTZ=ZCO3D+OT@^2&'L= M$:;E'A-P+28UX4_#"A:.S?I6T2FHQ<#H27H8D&Q/2S!S*Y8V'A=0JKWD.LD8/QHD:*-GX M_*-X*$MP@3L#QM_`8=J)C38>]L[7GRCVIF&^!WC"%Q/D=3O-$.PCR'(&OZ>A ME31_1RE@0-Q;=>6S;PN!YN*2%+_%-12,GR(?:4/D5B2='WQU-;&OH=H-RYG^&+M7LIKIQ++M_L.6R:8 M_F7)T/I]PWFQ*([XE5VR,+$.SSLP_Y3_+E[03%@IK'\K'2J0V55U!X^X37FV M8#7%=-9>DMC*9?4LH)D)I;.`S2Q@4&ZFIW)S210B9\ZF0E&8!:VKE$M,D/B% M92O^#0P8BI?OLHXL>JVF1E2$5L\$:A4M'0FL44&[NUJKH7)K'K]')=V8U[XI M"0:B\I,&BJL9-772S&+W\S`MIG?2E0+L741+ M?@9&+#KI,@\:8JLIG4:%2\D<)2481#6JI[RPDX5BG`2Y!7H8*&).F&!FRB66 M_Q:BT_0)C/:[H8P%6%X0[VA89=W;D!L,*CNK7,O'/+&_^)5XI9F#>.%5C+>% M6Z^!S"+J)M=O03:N+17KN(#5&],,U3H?8)!JE36XL!HJ"J?A,YOB1$3_H&$+ MS[BX4ZC?#+@"`V"DU;6L7QZ14T"%EIA`;?J*.;[JC"./QAI#6D;A"A=@N&E4 MK>T=2]+7ER8D9M!Y@0J\6X+Y4V>7>($)P5YZ['X2>L+.\LOVK75C)FQ<@'8Q MN!FT)I*@[8S8RHKZ]0N"-;\23#[;R-F0F[ZG+>-,J.`7)F[2]MW`KF8&X'TU M!AEXX`HG="^L5K>*4D$*'(@F[X)W#KV;A<&8`YD8;#8K:I($WPMWL&*/7X0W MWV.R]285J+N'MMLU!&M_>V>]51M66I>V04.73RWI+C;"-0H"`&4#0PT@W2`% M3+#16_6VC7!^)@$_K%N,Z"+"Z M\MG9L-(ZJ#$WM/7XSIK7IG9,J2>'S^F`;_6HAU)WK),1WV4UQ#N@<01691LW M/E8;T1P)EWF@0=)0WUH>+25';_U4P)<\4"`YKP@@8&"1=3(78T^<0^7/>XBM M59[^V'3NCN8`[6*`@`G`T,-8!U@Q0P_KFW MZFUSL$4F`1RXBT,2O^0U2P4:C&!E\K$"!972NO"@2`L&="T*-H<"(6?(4K`P M$'6'5^DT<+8P0)2>W":BVI0N(DI'"VWJTZ)G#5@I,8\L`<+*W#=O[=RACKK; MC;9[$43J]6Y-XL,=8[FADU"D&W@"[)E-W_B:&R9^Y%7S$YKJZB;"ZO.7/8PK MO8[9@1\6A'MHK@2QV"C-$=R64K+>BA/61PE9LS[UK1-H'C[ M"MSB&OT@H@D1R5XW2RFPD2(7!^;DC'R<[=;Q=3=`EDG&>+^RJ)SJS4K^/1@8 M*932ODW)-\-"P4'^GE\C%"I4HSQ:5U91^5B=)`&$"95>=5AL'M'8"30TSX") MC,)#E$[8G""_6DR7!3?FLO8(F+D)^1M@[2RCPZ6;GK49BG?T;WG[[Y9G+W/9I=H_OIAYOI]?1BGF*H!\)U4+G+>6 M:ON9NAU40?5]NBU$@ND9N[%#V65.-UWF[Y.[*W0^N;^Z1+>3[[^YNGF`T3?$ MK19/4>!A0OE4/E[S86A3)ZU.W9S?[JVS'2]J"Q,8@)EJ6L5A@@.2"-U`8R^#_SJ<_F2_& MF+%:SC88&U/).K3R@0%QQ,O6NG?HNXIRVJ:8AMS2VF+/H+`0'H;[15^%E>6#DHR M!EHUJ*W9/XC;>YNVR+6R6%LC,%0^7QIHH1\=5QV4K*U$<2XDV%#*AR0C#`=Y M[SYA+^$WBJB?$Y&/#T^2^"DB_B_8^Q1Z;&+$%^QGHG_Q"YKH^?KJ!1/7I_B6 M^"Z^X^>26K=>6"C8ZIX-:Q59VNPQ>*FC=S[KIC8M)HM7=*0\E)XT70/IR-DR M^D/#F?DJT2A/:3_HSL>7*>``3Z66_H'L'P09D/>P<[4^^B$6;X2V&5D@'`4= M-465",FIX*&DJEH#4C@I$K1;PT431EZRLM*KPGAA]U%0G=WHR:R%BPU*YB&B M@F;TIF]1K+9`RBB1E]ZPAB@C'&KN4+PACBNE#&?K1/;F!SH%-S."*@6,QM:I M5>OCZ45[*TF)F*"MUP$TC9T]%K36]>T*@;5&5BJ6-W#I6QB-JU))]S33>LC^ MFUU^6[SW5M>Z>EIK#=VF;M[F.D(8S=^BG>(Z+<4EPT/"XB%*CX;S[5Z^EVZP MD4\[\8MP^&3(":N/EG=CM0::CL;D&#+D@W'A2P^-JS`3W/(,OUOD3Y\?E%=@ MQD\8I6(&PA[7_^\X\*;A%64-_'D2\R%.9:Z.TAJRFE7-@:0F@^&*&G537AGY MQ*CY34!8T",G%G?]#@B&.[QT?+Y1(M-19X>"T"H4M(J6D%"C@@,$G6I*')", M>`.&P4`@+\N9+/FZR&PAKZ'6A2E-U!;AT*9R`1,Z4BC`:-&OC@[)@!S!P2^HXK><,H)5Q!S;;*$D/<>+B.!\GXUN<7#7I8R^#WW[ M*FK=L=Z_B-'[R[!V5?L9%XAX>B?-`.3YGKE@9VYY<\L*X%['#+Q:++#+7(NT MV+"2NM1]_S)&[W';5D]K?^M;`.S>MJ55^AN+LG<#53VOL9N-Y:IG88O)-YA5 M4A\/;2S9\MV:!L],[M@NI6LNO8/B%8\LY7@Y0"$6`=(N?75#JIZRX"UR?7Y= MQW=^_*0^@Z7+1ALR6TWM=S*HE/(WXAS=Q_525[5$0'D,G@I`GYF$,B*CG1VB MTR::,0,W[UU](=A5@L6D=!_3"JGJ+NPP$-E+9\4;Z7P\#9@46^#F$:.T$ M\3H]]:498:I$5L\E*!4L'4HH48P.JD:U:MMD)1'*7H[(\],#N:[K)$X(3DN5 M@>",AP#"K=YBXM8?_^S`9\U-=3$C=TXF3*.CIZNF54!)5D127*6Q&(OO>7#& M`S@6IZVDA*$RG,73#;.%/-O`CS;<.(1_^(POF:_T@\9-V3V$V,N']C5PDR;M M*@$&+/NJW7S^958Z_X)R62@5-I0G]'SW(B%$;#U;^C&;*9T[X4_I@07>R_B? M8OV`QGZ<*-(T6\BQYRFW,'/C.7L(@0'9+32O>=;+Z05RI2P4"&'=RUBD_D4E(NWNR"+^XO#`;&=V!!W4,+D1+<\U0H7QN-N=@*YG$F66RH\*7X=,%L MJ/P//U`PKQUEV)Q:R`X9&(0:_679RPYM:>XF6=13$`R@;ZF]\HS98?F,F?*D MRJXBD1V=35`>XYFPJ"E\%!ODS]>U,W>3SP[QI%5TEL0T=D+>86^2Y1R32E4/ M6([5DQ%#55/I8,6N"X'X;M=01E;[8X&.[\2ZQ"[FU.CLY`#QOO`ZNM\'1ABS M`5J^6S=0E5<+V:>.IZZ@7?:Z<@FCCVV#FE5;S>-$VZ<7=W@/_932!'N7">'W M#$B/)(ZD%L9UFIT^U?:7'H*LWTS?R]#:%?6=I$![(KFW!548Y]\#`?*67??J M9>6GRT(#CPS*DO9I>&BHJEV.$8IB7LU`H;>MEO.*R`+[+>,%8+",%,2/\?QN MR^.MPQG9$L;_(PDQ.CL6(?PI>IN$3N)Q1&W];@`,S_TMILP8?OCM985=]NM# MQ#^R-.Y&'CL61"*\[%M^9' MLAP4;0HZ0'/\Z(?B\&NZTOLZO$(Y'3J"8^BBP#[YANX5.USR'HR'L)?8']8S M/,KU`>2)]"R2CN]U.(2LIL;T"1UUV">WT*MZ!XC_S11X-)E=U,(67F>1 MK4,=()?/4(*`'Z4C/./HDZZ^"##Z]V#:_;K7MHQ,W]7$&\M%LEA&%XDA0X@0/F"Q/FMK0MB;6 M'<,X55US$G;5@!5/C&)[J\_87(?K;B2@F(E`;_T0K;%#Z)>::0T@5V(S6-/5 M.91@4J_?/L4C.V^64>&#A@>?OD$UJK;:`%G')AKZ:'MUE8 M[O%2E_>0I]]ZNM;5[O=J8A&F5?C*[:M@5Z^ M9#]F$UODG`HQ5KG6ADJD-A6X3_G2]HK;95I47QJL_CVDB;TZ\`X#=]W-=56G M5;T[]:3QKKH.W/9NI^MLTN8^.F/6T8';3U_EG7-(2,COG*O=>(OV_:HK>39Q MMA#?TDD2/T7$_T5_>\_NR]F+R+&MFG82$>H*&;U##6V9LNM1M'0\C)QGUL_$ MZ=@D]#!)_;\\_#+6PT>_@KVC9_L/NIX6URY)*0"NLD5CSWV_R9DU\>4EB\6N M'9\,F7OHK,5>C!O;5;&UPYAU%5Y-]^]G=^M"@W0''I^D+!CO9GZ2GYL)I0FR_RB/YG['&!9O[V\O>APIM6VD^[75MC^=T9#"S5=$^?G"G?>.S7I MN"OF"Y;\UMK-`<<[L230\!9:.X^UU)NI^GG"K8UA=`1VT5*'HHP[.S8J'D1C M'P@T[>CQLY&]_=7/B<^?AJ,Q2?B'=!8_8?+PY(1IA'H3A7(U:IAKZ;J7OQ>C M0=]JW'>OV:/%'O9(]T,Y5DKWB, M5;JM(1><^RRTFU>)N`X$\TK0KIG:4\#NLK?MBBVOG-LJ??3^/9K)^EZ^V/(#\4WH9/-W(&L?8H"-G>ATK-U>5B]"[?=]TT[F51^ MT=2(%8A3Z*IO#74%`4A*V/V;Z;N9O]XR69@0[`F=#3>#M3'9G/.9&5!T=&`B[?"1IT.=5'B&AMQ"A/:(%=@`8VYNIZMH)N99>D& M;*,+D5HT=@D-Y/!"(!-E%8_%\U1K)Z.$D0(]%P_QZI6C_ZSMP/_-C'RKHM?`VH@E5:56NY0#/63*H>$T8Q MOD_FU"6^S%#<81?[SWP)0SG!ZB(`4//TT[LI(OXB#XDCOMY;$H4VLL`TM%EK M@FZR;NTRB6/BSY-8K,;%$;IE@T;S:KP=GS8)/;/6:>,!U%;&JC:X1'&859*/ MU$@?2$3I+8D6?JQJC\+7@*I>I57]*79&@R312'4[6V&>..#W*;C1$G]D"JGJ M6$$&J*Z;M*MO$4IID21&;SEYXSMX`U;_1N%K]CF_G<8/$Z9O<3$B0B;_CAD/8WQDB]>B&MIHB"0%V-@5L'*KC)@<8#@8,/**JQ* M8$*\D=&F8+0I&89"L?OLL"A4L_2&)U+J.%!5!KFFI:>SDUY4.,4:8T#I#@%8%0RCU2 M@U6VGF3G7U.EC)*%'44`:M"^FNL.7:%4$-KL'JQG&`]&;G&Q48&/!`Y]DDY& M&9[5J`"U6X-RM>",DZ*4-ATCQQOO"'8HOL3RWVEX2_#*\;W+-!U])==XF4<1 M6NN3COTD`6K`+0U0C)5"#'J;"?R2;\M/9:)4F/"V$@]2'A@<3%PW2L*8WCIK M/HHSJ]DG),%>2X*TGR30..AD@"$.,IDH%2J`D(I%XZ=J;W!\P9P3F[0_^Q[V MSM>?*/:F83ZMG+BQ_ZS%@#DWH';OH71M@SZ.$9>!,B%HOD9ON1S6Y%^BS:1\ M(VND]DVW6=&':.+^G/@$,XV9=O'ZEAD4\^ODV*>K9>5H57=N0.W;0^G:(FTJ M@D]I4B$HDW*`A)R#/)$H1(%QYW=L3DU\?CR1`]3,<9=Y`#6EL:J&SGC#+;HO M+)\[#=.3W+U\KH(;4$/V4+JCS\U%C>]S[UCD)_W';,&7[;)X0M6:.EI`;=>J M8K6E-@Q\$BI8LN@'5H^[]D,G=/OV.`4WH%;KH73''I>+&K_'<2W9P,[_X2/R MLQ-P],G+,ZICB')+4P=^0&W<2^W:;B?>PCR6$;\4Y!P@*0DI!E/+[2QV&C]$ ML1-P)2^BD#(XRARTW`/!`<[WN#MA:8V["Q^`=NVE;K4]#?E!';+H=4_=`"?6 M=86\SHO^*K8U'0H1)1Z@M,R#<@I:ECOFEJ4II0GV+L4C MZ]+)R52Y^+)\(;/F]M+.4@"XEQTH/R1&LM*H2)_N\ZOWA;N\AW-2M4(@(6PP MVRP`D);X58+5R&)K$*ZM#&?ZH-NV>WF'BN'YS@,Z6]RR-F3J M"S-OH\!WU_+G`WZ)SP,V`-6">%/&'[W(M88J5I8X?U\Z*%R,Y3MJ70OEGS#R M?.H&$>57?O&[?F+V$5/""?U?)$BBA?ALSDOB?ZP*9?&_%W*6[@2(!6"Q`!-] M-T;3\TL(;DGD)6[\T0_Q?11XM596T,!J4+V"U;;CE*)E5I(<,5D848>O`#X2 M+'LU;UGLC=(<%PXA:YX'6O+ER=E"KDHK6T5/"JMQ6O6L'_2B,>\CCCR7%&+Y ME\O*20)QX9Z'67]BO4?T)LHD*9JJ^!$#Q4_LX^PC]H/[:_;)_P-02P,$%``` M``@`C70*01J^RIA)%P``>%X!`!4`'`!C9&]M+3(P,3(P-C,P7W!R92YX;6Q5 M5`D``ZI4)5"J5"50=7@+``$$)0X```0Y`0``[5U;E]HZLGX_:YW_X-.SSIK, M`^E;=F8GLW-FT4`GG-V!'B#)Y"G+;0OPQ%B,;/=E__HIV08,6+;D"R4ZR4.' MIG6IJJ\DE4JETF]_?URXQCUAOD.]=R?G+\].#.)9U':\V;N33^-6>]SI]T\, M/S`]VW2I1]Z=>/3D[__WW_]EP+_?_J?5,JX=XMIOC2ZU6GUO2O]F#,P%>6N\ M)QYA9D#9WXS/IAOR;^@_KT8W\&O.G1>_.!LN_^2XO*-3>F(;/(NJU.=_C1^/_0(_][T;T\@Q\79^<7 M+Q^G0'K7#*``__WT[-?3L]>3LXNWKR[?OCJ3["@P@]!?=W3V>);\BZO_YCK> M][?\QYWI$P.P\/RWC[[S[B3%WL/E2\IFIQ=G9^>G__QX,[;F9&&V'(]C8I&3 M52W>2E:]\S=OWIQ&?UT5W2OY>,?<51^7IRMRUBW#7YV<\BE*?.>M'Y%W0RTS MB%2JL!M#6(+_UEH5:_&O6N<7K%SC!$T>,+2*"@8FHQ3DCTW\6[_)%,W>%K",/&=Q=(%H9Q6H+1#/9MX/K'A@T]=QP9MM*],EXM[/"]SZMJP:O?^'<*4 M)T-@7KWZ*)1#3E8;RK56(S>[D$[,.U>"[/QJ]='7=7R+%=ZZL]L(6#DCU166J+QJ@>F\F5E5Y^1;RJ%XRX@/'T;BY M@2^VJI#'`/9XQ%XUQ"FOP8Z'KWD[L.,Z-UK&JD;Z(VQLC;BZD:Z?4+ZBW:76 M%KDNW^!05CA7P,[R6QZ=[3L?9A)KO7J[YAUQH^:_\;IR54_+$)N(-MIR^<1Z M.:/WIS9Q8.MU?LX_<$;.6V?GR8;K3_#5MYB&$9DYO&NNO`LBH#R[Z"ZE:95H M,\N@#%0,X%HU:C)K2Q'V-XE)B=-EM`=H67/'7>O0E-&%JBP3N=$B3M+R!1H. M#D(G6H+V4E83C7$`N.1,`L%-&4O"OM!)\ M)I\8`N^$C/-X#1LGT_U*3):O_.+BDC#\HA4,1=SC+<%?B.O^[M$';TQ,GWK$ M[OM^2%CN4BRL(XG-:ZVPD9(#'D"?J1N""-G3M>/"SB47F+VRDH#\54-`!'PC M&JOQ&!Z1)67N8YU[5)3Y`G(*">]B]-0_AD,(TY/=+&@7N3DBOQS_C`,HH@' M&*3YDU1N15E\M-QF2X@$'1P"]7[9OVH-,SQA]ZO,!9PZ,$.H[$HYVN:J5!U1YWMJ^#Q@5<+%;"-/=K@+&EMLE MD]$Z9[6J("1VO!06>V51?<#5,!'PK0]>_@JBB5+.!8@)U43U?LL MC9N"$/1`+0F-\D?$(J!F=RX9D"`?KOPJJ.YI:9QDV-8#H%M&EJ9C]QZ7W/`# MC1H&<\*V&!7@)%43U6,M#9>"$/1`+28MUZA`=DY7LR(RI`W43PE`8=_$W`II MC`@,:&"Z44E4G&X<\\YQ@6GB@U;M1T@5F(?RU5&]K&6Q5I6.'F,O1;6,JPTT M(./PSK>8$]V%2>WTI2>VW#9D,6PFAD4-PU+B45_9WL0KFT=F_%@*?VT;\5LM M'K%[)O,<;^:#`14N0I<3UR53QW+$#LGBBK+X-[6C4\%?7A"Z#F?I,:MP-J,! M,$77:X_7KBQR'91TJ,C#V]2&7`5>62'4"K:><0G9V1W600J798(4C!=;K?[E M9]#"D9^7:[4M/(+C\K;KT@<^QJXIZ]+P+IB&[O[)5H$#3:T-U$N'\L=[902C M!Z88#IEF?&L'\<>HK9?WA-U1G^";1RDW!ZQA0Q;)RHX\'K>$1<&ZQ>X=<4W4 M8(G2#I\B2>@Q0/>"JMMA,*?,^6-C,8DAVZ^!&B]1&BH1YYI"%-UEDX9G51HU M-J(B--L<:PI+\0V-6NYFZ.!&+7D50YO-7$%ZN_5&[I7<1FX\@?\^]@:PB1M> M&\/;WJ@]Z4,!Q"U^*%/)Q-9"_NEL+4=^_970J].1OE4"-VE>0 M>`9;Q^X.CO-(NSR*Q5XX7I2$B2<>2R(Z1>@5U4+=WZH@*L>^'J,J6=Z]6"9[ZH,@_`'U>.95D*$;Z6[, M>*Z5VE"/J-MC)>5H7.S'/V$DK"=#YPK6*[%1)2R-NA]7U@@AN\],@) M>&H=N_A#4)0P-CM%-D]67Y0O5J8FZH42!005Q*#'N,LD^+WI>%P+AQ[\>4E] MTQU.,PN"T3&3KA%H3R/F(RB%? M1DIZX`M4%6Z#=\K@WC)2F)HS>3MV4W85X[HZ/"Y8:\7%96%$=V04<:S'0-JE M\LKT':OMV5W'#0-B*\(DK(U[!:D0BAS8"@2B!XK%]CBPL\-)7C1+A?9P;S6I MHJ>TIRF0H8ZJD+^F5U&*DBWCWK&J33TJR54/12F01;D9'_L"5@6`)>5Q[(;8 M%^+,YEP4]Z"U,S((%W>$#:=[T2\%*[]Z,[@7@!0,M[(2TF-8"ZA/ST,2`5[* MK>#>_RD-63'L18*K.>A9R\BR_1='UX%EOY0)+.NTQQ^,ZYOA%TT2FJ[YD[\3 ME%$%UQW"";IE]-X![*^>/@&:?6]]EIX\.<@OO.5S6*8A36X1"4'<\:V4%)0> MLWN#?J]&\*D@;P6/&&KJB7^%22))?A8-O$;GTA,Z(K!!L)PH@^&&^`FM9YPV MWRUJ5%X]:G,H;/30Q-T3F^A"UW`*_``'PIO=A;5P$_,>"D&J(!&=0(\2;JY$ M$\E!%!.841`W=R\"M&)I'7]6E4@T/B"7<;=6H!/Y57`S!B-HAXP$]1CUFX>N M.W3!0Z4B4$2;%D%AW!3#"/CF2TT/9(%E1H#$+HG_3S&99/@JO@`EW0!J7""& M!JA+5U>MV,^:(*T/656QXPY54RHPUKQRY"& MKL!%!N5&S^31VZ^(&SI8-X8BP>@*9/*203#Q MYXD1*/S&'%%3F.S*Z`&+]<\(`@'I.BO()'M7MKOR&\/-N]Z4*28CP..?%>2] MUI5/W[#C8&L[UU$4V+%'WP@XCI\CJ^&@-KO?HBXT0ZYE$CN7D*F(FY*_)KF!FD!Z3'Y MRW-=>7W'CJRM!V!U@3U34S#)R5O=%,QM2%9E&G\JNXHI*"$J/6:#].S%+^6N M]L,2D_IV<5G8FO$.5(!!,)5G"4,/R$9DF9BCPZD$9.+BLI`==)^N"%F1,([? M`).74^5)6%XEF@FMJ43<(<:N_N5`1*HM:$ MK)HTXZZI1TW*".UY*DH;Q,G8$T@N]Y5(N;JRJG%0=T\MJB$04VF=6$:J!@8G M"WX`S?AV(:\;!_7\-*$;G-E:M*/G:6"!C,/ETHTV1::[VA3UO2EE"U/FM2K9 MVM+A_%IL_!2%HL?6896%DC_,*O3?IHO(8M+0VWF*,L[([YKF5!<,UDE#<\XO'GSY^;(^^\BO%X_[[0?^ZWVD/)D:[ MTQE^&DSZ@_?&[?"FW^GWRMTS%F20C';`$[I^/&MS4[K(42=1$7,%RH-E`K!? M0>??10N09&7,R\+RP&VM04IBT6C$7;0V-QZ2L]7]P?77S,%UP0?7A_:H9URU M^5W^V_97?GG_YRB2RU,:"Q-LG-0]DQ&)'G;FSW;X>[@4#J_*K1[?N*M)D!H- MR,M6SEO#ZQ'Y:^:(C%[BG0P[OW\8WG1[H_&?C=X_/O4G7W\.R3)O=W*"-S(N M7-ODZQ_?,%,6CB8#2LZ:%%N5;W:'6=*@0:=&JDECTZ:Q:LQXL?I4[FWK'VSX M#=G,])P_(N0W&8;X@/#LVY16I-ZCW7"P@8@_U5[%0CT\&<1D9*`' M6ME94N5@DZR+FIZF_,9&6BIZ`/G)ATU8SP^",$$X)J^'VTU\EY?RRB'FO2D[*PGX%8/,,`RM8"%V*(9 M.?YW>1^;7%74/">EK75IF>B!8I?X%G.6\3Y_0!Y2^W=&/?AHD21M4_"5!&V; M+L7/!91L"S<92DFSOHK8='&J[IZG3+:SMZR\I^=G>]Y37M.(JAI)7>-%7+M6 M)ZF`PJ+PJ*):F*<3UIS8(;_2EIV@+LX\WPZ#.67.'\3^!)BRR&L_C)2-WX[U MKYYZCX19CD]NF6.1D>G-BH\U#M`Q:FYP.579.@PY&!::#'C!.S8FXY_N29<$ MIN-FC/_SW?&?;LC8M&2\6+?U%^-%TERM$X(=A4V@GJ8F2Q&DYSK2+N% MBH;AGD[6/QK+X;1]4KG-5-H(T`$0&(\DRF%9!$JJH`;`9"M4IN!3A*?CA-$W MZ&L"KTR8@"TRGA/"$T:T;3MR#9GN9JZ"Z7GUHNU[1L.E#TVX(7_1)5M#VX]. M_HO>S7=^%$IR*&&D+[/C'FW(4SXP%Z1+%Z8CRM%)R;C)2Q: M4E!DEGQ>"&2RN#K=J5OR79@1DBPMW'`84U?H);\<:J2#G#R%W#4DS56FZ:<J+WG:1KH\8`R`&@ M*`F\/`(")#GI'XAK][V>#Y)Y:`=\PA,=B`D*HQ[YR^&4SV=#PX1W.B+<\`'; M:-5SCFPSRJ(>TLN+5LAE8Y*-+]VW%_P\:SB-\^WES/)Y%5`/W65E7,2O)N>T M61N`U>MUR2/UT<:!/V*<4?2*3"DCZS`/%==XE5Y0S_`E[?IF)*NQV@"5O>F4 M6*#NFS>7)#A549KR?>"&`U30F:IBU5AC=I_)%/(R(,!]R?E%H7'4 M!8GY8$*.>\*']9):#K^C^\4)YMENJARWA61]W-=1Y/T92N)H;)=.`O.1*UD% M;%0;P7W)1'9+7T8P>LS*(_IDNL%3$@@O.E[8*83[:H@<*-F,-30TKL,@9"3I M,EZCAWRFC8;N+6$\=E,@6[FJLA+'=*RH"$&3P*6ML-KAM`-KGQ/P\-KBV*6+ MW=BEK;;X_>^X-8,WUWP`DS0G!3%,)=JI=2`!0)V0L4C7%DX`]LR5Z7U?OP!% M&/\U\EKX@$68LWLHUQ1FJ&%I#+=&804)-N7ZB3VJO-_D7-_O>Y,Y"#9-6>^1 M)_2."8,19<>.$Z&:5FD2]5"P%I3K$*DFI[VX MZO8#J$?,DC\,`S\P/:ZZ@S`OV*+^?E!CS2NJ3O$[]35`\#R2*%<5SWLH&,"< M&R3!A7%\YGX,*OS<+O')>&/?DXH_^I0NBO?/7+LG#X* MK8K8\YA,$T.&WXQJ5"$S^D&.!M1'\X08_)Q(M]:9+\29S?D8O2?,G)&MF^K- MVP#YO2/'7^JCS(IX_?3K['L6$/1^Z21#4N")-V,'%^NAU+>`^#ST_"HM9P9?66-BS M/MJK(+2?.T-YAPV"^EM+PQWJ18B%ICLA;'&>I^^'I@3[=D+-NH\#Y/.8K957+I%< M=+%1Q/1AWQ#19\:O'?3G,1;$"^&!E;X,(;+:_4,=4?Z0:IP:QGU@T_%\Q_IL MNL*[BPWV)ZN4/]118S8HST/WBE>6]FS&HC#2@^AF!7ID=??YGQU6!E4CW:ZP M5TBM*]ML-K6WR^M05CN/Y)2P45ATNL:7'F.[UQDW!*\O[[V2>O\EX^JT<=[L MFPYHT\)6IP+W_AZJF)1$[7H63U7;V_"]T:1QR,_>UEQ-=Q;;96PE)7)D8]__@P!3]C&W]3A7_K#8$[8 M9&YZRO^X]]5PYH>R*/TPRGEP&[U6TG!OK>FNT@>SYO,< MA&6\N/(L1H'RA#-5M[^]'`VX=\NJ*^2AT3H6-_PF<'WMAO^EM!O^XK!N^(NJ M;O@+C=WP2LN3Y@[Q/:"*UXO*`;C9^>A1QB`_*9Q3%P#PXRFE.)WPZ[TQF&KD MST;<3/-IA(M)ETE7*=D`XA"\7:E61*_DL591)?34D4K`[62PEQ"''EN)+%I3 M1Q0*V&W5PL^M6"MZ&1+1`SZ8\Q=),(7DL,NM@9_PL#1L$I(XV&*8_(7_X%8Q M?/,?4$L#!!0````(`(UT"D&G4/'[H0@``%D_```1`!P`8V1O;2TR,#$R,#8S M,"YX5.T_ M(*I*[>2!IBXSWEBQDY)U&6LCBUI13C)/*8B$+)1)0`.`MO3W:?`F2B)E2O%D M5+']8)-$]V$W#KK1(.#+GY>^AQZ)D)2SJTKMK%I!A#GS^JG)G&RV[W>]7 MT,\__?L;!#^7WQH&ZE'BN4W4X8[19S/^(QIBGS311\*(P(J+']&OV`OT$_[[ M]7@`MQ%^$S7.&E-D&"7`?B7,Y>)NW$_!YDHMFJ;Y]/1TQO@C?N+B09XYO!R< MS0/AD!2KW;%NT?\"1KZK=QI5^%6OUNIGRQF8WL$*!/2]6?W!K)Y/JO7F^T;S M?;7DBQ16@4Q?5%U6XY](_5(Z<^)C!+W.Y%4EX]-3XXR+>[->K=;,WV\'=BA7 MB02;2X^RASSQVL7%A1FV)J([DLNI\!+HAJF;IUB2%!E:Z1YYRJ3"S-F0=U6J MD!7^8$:-&Z(T5_0\$J6)J$NVY"1QSN[YHPD-(%^K&=6:T:@EXH$T[C%>I"HS M+*:5,!3-"/9:YQ84N.=7H\ MI@H.%B[WB4L=[,$`][5\O7K>T*'I$9\PU>/"[Y`9#CQ@XG.`/3JCQ*T@A<4] M47H@R@5V2`G$9$1CQCB,7`C2^(E^MEA0&-GPX%^7>M@T!??(!#Q`^@)"LQA? M"Y@0&H&VML7<+E-4K72<"#]\2P51]ZJR5T*_%ZP(W^R2&64T-`]"J88,E*AF M+S%S482#,D"7YC9$!CB0Q+783^'U0A`),*'2`![$BK%(@1)X[`3>83IK4W)5 MX@=);Q_=_VW.7,(`%BXD]Z@+FCKVQKT.^T)G!SW1JTANTNLF^ZW8G]1DEA5X^P`(?G1&G%LOQL*A63 MU3B&+/1N`_[[-_*R/*3=*:V9M=#U#YBQ+[`*%(I)>U^.-'L"?VZ[0R#,ZB%K MU!VW)GT0>*.KJ/?;6,Y['G\JR]9:OIBL#\>0U6[9-Z@WL'Y[O60-N2(UPPY\ M'XN5-;/I/8.:QL%0&S@.#V!29_MN..D//Z(1\-GN=U\W:W7#GL/\ M<`UK"G>$5WKNYK<7=_D-NMX>UPL1J_W)C#3K=L?T?U/W_77_RZ=7V>[E4 MLYFD#M0IYNABFZ,8&?$9RF"C-3A*4*%^BZ]>;^FVDX4F>.JE)!4T%K)1J^ZP MH2%0B(%B$/0N@GF]G:Y[B.NQ&`!R6ND.L=!7CZ1#%*9>S$%)V6)*:MN49!'1 M&A*]2T&_1^]BW-?+$=2Z#O@3=0Z4N`($U)C*AWR:RHL7,U7?9FH#5">T"!9I MW#>Z=O.8D,N9 M?[;CI58P%>W*%7/TOM2LE!-/J/;&3&&/UTLR4]_#S(>CF:F_8F9VUC#YX)C,D/A7F)3[U-=523U%Y[>^0N?S069754< M8,I(MH_^`-?.EKZ7B&CH/7N)(:W;O1&_.('`PME!V=GK!!`.%9V"-8V9&)\` M**JT^BCS&J3?`Z/%?`F7/3P]U&50(=X7]'6@\5_421V(!SJY-6"_D*OM]5M> MU&$(G4,=WHRV+^1O)WU)UMUX@]9<[]#&]]N[N)?@.!<*L9TMX7T[_=$9A0%W M0J@]*OK.2/0,_/MUU2_PI$970X*O*,S+4\_37L:L*2.B*J$F%1$-GG@PV9L\#T_*:O;O&^ MPS(MP!3848D+Y61Q?)7X=+B/D02@4';_$B[F?P74.WT['I81/3D'M7URPGN4 MP8Q)L;?>7M[VKXSDR;D'"UHJK5FV]@[W'E;1[PE9JFL/UE>)DP?('QM^*L%X MB9R1OU&P3=VS8B?'6[FO[R5#L%#K]-R&D!H)[L(#D-!_1QU#:-#I;!`BG\"K_9]3YGP*I8 MO8`7?:@ZF.)BE>WV[8P9BTIB9+9$-LK<:H4 MZ1$DP5(.-9TB[F]4S?.GT6Q.+ZMPLG$&!9["RP&7![E^L-;)^M\+5"#(F*^P MIY=B#O>)Q88DS"=R1(03'IJ+O"XI>V@IHFOA1:3]$M%9]AS`=LUXA.+)E8T] MESKM0.@S\0/J4R4M=HW90WST2G.D;\,LF[X@9?JKJ<3$C-$SF<-MG6WF^A-S7S?$A"SM#L`5, ML/M0]'JU%HF):CUAX4:;YOWPZV_TKQ-J3L1DCEDT=.60AU^JV] M0?W?^-(36=$_>[CDX!"IGW"(/']B(S<=EM3XBNY>FM'>"US^"5!+`0(>`Q0` M```(`(UT"D$L:!%!Y#L``/S<`0`1`!@```````$```"D@0````!C9&]M+3(P M,3(P-C,P+GAM;%54!0`#JE0E4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`(UT"D$W1M\LE`H```)R```5`!@```````$```"D@2\\``!C9&]M+3(P,3(P M-C,P7V-A;"YX;6Q55`4``ZI4)5!U>`L``00E#@``!#D!``!02P$"'@,4```` M"`"-=`I!PU-_R2D(``!#1```%0`8```````!````I($21P``8V1O;2TR,#$R M,#8S,%]D968N>&UL550%``.J5"50=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`C70*02GH7&Q?)0``IP$"`!4`&````````0```*2!BD\``&-D;VTM,C`Q M,C`V,S!?;&%B+GAM;%54!0`#JE0E4'5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`(UT"D$:OLJ821<``'A>`0`5`!@```````$```"D@3AU``!C9&]M+3(P M,3(P-C,P7W!R92YX;6Q55`4``ZI4)5!U>`L``00E#@``!#D!``!02P$"'@,4 M````"`"-=`I!IU#Q^Z$(``!9/P``$0`8```````!````I('0C```8V1O;2TR M,#$R,#8S,"YX`L``00E#@``!#D!``!02P4&``````8` ,!@`:`@``O)4````` ` end